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ABSTRACT 
The present study entailed the development (Phase I), pilot (Phase II) and 
randomised controlled trial (RCT) (Phase III) of a psychosexual information booklet 
for women undergoing pelvic radiation therapy (PRT) for gynaecological or anorectal 
cancer. This was undertaken due to the high prevalence of psychosexual morbidity 
following PRT, and the lack of existing resources to facilitate recovery and reduce 
distress.  
The psychosexual information booklet was developed based on the literature, input 
from an expert multi-disciplinary advisory group, and published standards in 
developing information materials for cancer consumers.  
After the booklet development, a mainly qualitative retrospective pilot study was 
conducted which explored: a) women’s experiences and rehabilitation informational 
needs following PRT; b) the feasibility and acceptability of providing women with an 
information booklet about radiation-induced side effects potentially affecting 
recovery, and especially sexual functioning/vaginal changes; and c) assessed the 
acceptability of a measurement protocol that would be used in a later RCT. The pilot 
highlighted many challenges to quality of life faced by women after PRT, and 
revealed diverse informational needs, particularly regarding sexual rehabilitation. 
Overall, the pilot findings provided support for the provision of a psycho-educational 
resource to better support women in physical and psychosexual rehabilitation 
following PRT, as well as some guidance regarding improving the format of the 
booklet. The pilot booklet was revised based on participant feedback, as well as the 
recent Cochrane Review (Johnson & Miles, 2010) findings regarding vaginal dilator 
use. Given the high levels of acceptability of the pilot psychosexual booklet, its 
effectiveness was then prospectively evaluated in a multicentre randomised 
controlled trial (RCT). 
The longitudinal quantitative RCT assessed whether the psychosexual booklet 
improved adherence to recommended rehabilitation strategies (dilator use, vaginal 
lubrication and pelvic floor muscle exercises), improved knowledge, lowered levels of 
anxiety, depression and PRT-related psychological distress and improved sexual 
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activity, function and satisfaction post PRT. The RCT demonstrated that the 
psychosexual booklet improved knowledge and vaginal dilator use. Given that 
women in the pilot recognised dilator use as a difficult area for them, with many 
patient-clinician and patient-related barriers inhibiting use, this represents an 
important outcome.  
The clinical and psychosexual significance for women in implementing rehabilitation 
strategies is potentially far-reaching with regards to facilitating the detection of new 
and/or recurrent cancer (with dilator use), and to improving sexual and broader 
relationship outcomes for women, which in turn, could affect their physical and 
emotional wellbeing. However, the recent Cochrane Review (Miles et al., 2010) 
highlighted that there is a lack of evidence regarding the efficacy of dilator use which 
may alter dilator provision practices in the future. Further research is needed and is 
being undertaken in this area, which remains controversial.  
Furthermore, though levels of psychological distress and sexual dysfunction were 
low in the present study, the booklet failed to further lower levels of PRT-related 
psychological distress or anxiety and depression, or to improve sexual 
activity/function/satisfaction. Thus other strategies may be required to improve 
quality of life, and reduce psychological and sexual/psychosexual morbidity post 
PRT/treatment for gynaecological and anorectal cancer, particularly in the subset of 
women who suffer more morbidity in these areas.  
In summary, women experience a range of psychosexual challenges after PRT for 
gynaecological or anal/rectal cancer. The study psychosexual booklet appears to be 
useful for women in the gynaecological and anorectal post PRT setting. Women in 
the pilot found it to be helpful and useful and reported that it reduced distress. In the 
RCT it was shown to improve knowledge and vaginal dilator use. Future work is 
required to investigate ways in which the impact of the booklet could be enhanced to 
further improve women’s psychosexual outcomes.  
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CHAPTER 1 - Introduction 
1.1 Incidence, prognosis and treatment for 
gynaecological and female anorectal cancers 
In this chapter international and Australian statistics regarding aetiology, incidence 
and prevalence of female pelvic cancers (cervical, endometrial, vaginal, vulvar, rectal 
and anal) relevant to the current study will be presented. Following this section, the 
treatment of these cancers will be discussed, with presentation of major treatment 
side effects. 
1.2 Cancer in Australia 
An Australian Institute of Health and Welfare (AIHW, 2012) report identifies cancer 
as the most important cause of disease in Australia. In 2012, more than 120,700 
Australians were diagnosed with cancer, of which 40% were female. This excludes 
basal carcinoma and carcinomas of squamous cells of the skin. In females, the most 
frequent cancers reported were: 14560 cases of breast cancer, 7080 cases of bowel 
cancer, 5070 cases of melanoma of the skin, 4650 cases of  lung cancer and 2270 
cases of uterine cancer  (AIHW, 2012). Bowel and uterine cancers are of relevance 
to the current study.  
The number of Australians who died due to cancer was more than 42800 in 2010. 
Thus 3 out of every 10 deaths were due to cancer, making cancer the second-most 
common cause of death after cardiovascular diseases in Australia (AIHW, 2012).  
Cancer survival rates in Australia have improved over time. The 5-year survival rate 
for all cancers combined improved from 47% in 1982–1987 to 66% in 2006–2010. 
The survival outcome of Australians from cancer is generally better than people 
living in other countries and regions (AIHW, 2012). 
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1.3 Gynaecological and female anorectal 
cancers: Incidence, prevalence and aetiology 
The current study will focus on endometrial cancer (EC), cervical cancer (CC), 
vaginal cancer (VC) and vulvar cancer (VUC), which are forms of gynaecological 
cancer (GC). Additionally the study will focus on rectal cancer (RC) - a type of 
colorectal/bowel cancer (CRC) - and anal cancer (AC). Both RC and AC are cancers 
affecting the anorectal region and as such are termed anorectal cancers (ARC). 
These cancers can all be treated with pelvic radiation therapy (PRT). The above 
terminology will be used throughout the thesis. 
Detailed worldwide and Australian incidence, prevalence and aetiology data are 
presented in the next section for women with gynaecological and anorectal cancer.  
Data on age-standardised mortality and survival rates, 5-year survival rates, 
diagnosis by years and burden of disease are also presented.  
1.3.1 Gynaecological Cancer (GC) 
The term “Gynaecological Cancer“ (GCs) is a common term referring to all cancers 
of the female reproductive system. Specific names are given according to the organ 
or part of the body where they first develop. These may be ovary, uterus, cervix, 
vagina or vulvar. The causes of many GCs are not fully understood. However, there 
are a number of recognised risk factors linked with the development of one or more 
types of GC (Cancer Australia, 2014). These are discussed below in the sections on 
specific cancers. 
Comprehensive global cancer estimates are given in the International Agency for 
Research on Cancer reports. According to its latest report, in 2002, about 19% of the 
estimated 5.1 million new cancer cases were GCs, and about 13 million women were 
living with GC up to 5-years since diagnosis across the world (Sankaranarayanan & 
Ferlay, 2006). GC accounts for 9.4% (4,534) of all new cancers in Australian women 
(AIHW, 2012). Between 1982 and 2008, there was a 54% increase in new cases of 
gynaecological cancer in Australia (Cancer Australia, 2012). On average, twelve 
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women were diagnosed per day in 2008. 15,851 women were living following 
diagnosis in the last 5 years before 2008 (AIHW, 2012).  
GC accounts for 8.7% of all cancer deaths in Australian women. Between 1982 and 
2007 the mortality rate reduced by 34%; in 2007 risk of dying from GC before 85 
years was 1 in 63  which lowered from 1 in 43 in 1982 (Cancer Australia, 2012).  
Five-year relative survival from GC has also improved in Australia, from 59.6% in the 
period 1982 -1987 to 67.3% in the period 2006-2010, for pooled GCs.   
Cervical Cancer (CC) 
The lower, narrow part of the uterus connected with the top end of the vagina is 
called the cervix (American Society of Clinical Oncology, 2014).  
Human Papilloma viruses (HPVs) have been found to be a causal factor in 
developing anogenital carcinomas (cervical and anal cancers) (National Cancer 
Institute, 2013; Moore-Higgs, 2007). The main risk factors for CC include smoking, 
high parity representing 7 or more full-term pregnancies and long-standing use of 
oral contraceptives (National Cancer Institute, 2013). 
Globally, CC is the third most commonly identified GC and the fourth most common 
cause of female cancer deaths. About 9% (529, 800) of total new cancer cases and 
8% (275, 100) of overall cancer deaths of women in 2008 were CC cases according 
to GLOBALSCAN (GLOBOCAN 2008, cited in Jemal et al., 2008). In Australia, 778 
cases of CC were diagnosed in 2008.  CC accounted for 17.2% of all GCs and 1.6% 
of all cancers and was ranked as the 13th most commonly diagnosed cancer in 
women.  
The estimated figures for mortality from CC in developing countries were 242,000 
deaths in 2008. This is more than 85% of all CC cases in the world. This high figure 
is ascribed to lack of early detection and screening for pre-cancerous and early 
stage CC, lack of HPV testing and poor access to CC vaccine which can prevent 
70% of CCs (Jemal et al., 2011).   
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With 208 deaths in 2007, CC was the 3rd most common reason for all Australian GC 
deaths.  CC is also ranked 18th in terms of frequency across all cancer deaths among 
Australian women (Cancer Australia, 2012). 
In Australia, between 2006-2010, relative 5-year survival rates for CC were 72% 
(Cancer Australia, 2012). At the end of 2008, 2286 women suffered from CC over a 
five-year period (AIHW, 2012). 
Uterine / Endometrial Cancer (EC) 
Uterine cancer includes all cancers formed in the tissues of the uterus. Two types of 
uterine cancers occur. Endometrial cancer starts in the uterus linings and is the most 
common uterine cancer. Uterine sarcoma develops in the muscles or other tissues of 
the uterus and is a rare cancer. (National Cancer Institute, 2013). 
EC mostly affects postmenopausal women. The risk factors of EC are:  
postmenopausal oestrogen treatment, a high-fat diet, obesity, reproductive factors 
like nulliparity (never carried a pregnancy to term), polycystic ovarian syndrome, 
early menarche and late menopause and use of Tamoxifen. In contrast with the 
general population, markedly higher risk of EC is observed among women with 
hereditary nonpolyposis colorectal cancer syndrome (National Cancer Institute, 
2013). 
Estimated new cases worldwide in 2008 were 287,100 (American Cancer Society, 
2011). EC is the most common invasive GC in Australia, with the incidence rising 
with an aging population and growing rates of obesity (Cancer Australia, 2009). In 
2010, EC became the most frequently identified cancer in women with a mean of 6 
females diagnosed per day (Cancer Australia, 2012). In 2008, EC accounted for 
44.5% of all GCs and 4.2% of all cancers in women. (AIHW, 2012). Between 1982-
2008 new cases of EC more than doubled and the incidence grew by 22%, with the 
greatest rise in incidence being in women 50 years and older (ranging from 19-
26%)(Cancer Australia, 2012).  
With 338 deaths in 2007, EC was ranked the 2nd most common cause of GC death in 
Australia. Out of all GC deaths, 22.5% was due to EC. Causing 2% of all cancer 
deaths, EC occupied the 14th rank in all cancer deaths among Australian women.  
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Between 2006 -2010, relative 5-year survival rate for EC in Australia was 82%, which 
is the highest of all individual GC types (AIHW, 2012). Overall, improvement in 5-
year survival rate was 75% during 1982-1987 to 82% during 2006-2010 (AIHW, 
2012). An AIHW report (AIHW, 2012) reported that 7944 of all females living at the 
end of 2008 were diagnosed with EC in the preceding five years (AIHW, 2012). 
Vaginal Cancer (VC) 
Any kind of cancer that forms in the tissues of the vagina is considered vaginal 
cancer (National Cancer Institute, 2014). They are rare tumours as only about 1% of 
all GC cancers are vaginal cancer. (National Cancer Institute, 2014). There are two 
primary types of VC. They are squamous-cell carcinoma (85%) and adenocarcinoma 
(in women 30 years and younger) (5-10%) (National Cancer Institute, 2014). There is 
an uncommon form of adenocarcinoma, which is related to in utero exposure to Di-
Ethyl-Stilbestrol (DES).  
Given the rarity of vaginal cancer statistical information is limited. The current 
available worldwide and Australian data are presented below. 
In Australia, there were 70 cases of VC identified in 2008. VC ranked as the 38th 
most frequently diagnosed cancer in women, accounting for 1.5% of all GCs and 
.01% of all cancers in females (AIHW, 2012).  
VC was the 5th most common cause of Australian GC deaths, with 26 deaths in 2007 
(AIHW, 2012). VC is ranked 25th in frequency across all cancer deaths in Australian 
women (AIHW, 2012). 
In Australia, between 2006-2010, relative 5-year survival rates for VC were 45% 
(AIHW, 2012). At the end of 2008, the 5-year prevalence rate of VC in women was 
202 in Australia (AIHW, 2012). 
Vulvar Cancer (VUC) 
The immediately exterior area of vagina is the vulva. The vulva includes the tissues 
of the mons pubis, labia, clitoris, Bartholin glands, and perineum (“Vulva”, 2014). The 
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most common vulvar carcinoma is observed in the labia majora, accounting for about 
50% of cases. The less frequent occurrence in the labia minora accounts for about 
15-20% of vulvar carcinoma cases.  The least frequent sites are the clitoris and the 
Bartholin glands areas (Macnab et al., 1986). Squamous cell cancers are observed 
in about 90% of vulvar carcinomas (Eifel et al., 1997). The precursors of invasive 
squamous cell cancers could be some Vulvar Intra-epithelial Neoplasias (VIN) as 
reported by the National Cancer Institute (2014). 
Risk factors for VUC include the following. In many cases VUC is preceded by 
condyloma (genital warts) or squamous dysplasia (abnormality of development). 
According to the current evidence, Human Papilloma Virus (HPV) could be strongly 
associated as a factor for causing many genital tract carcinomas (Hampl et al., 
2006). Many common risk factors of cervical cancers are shared by these HPV-
linked cancers also.  These include: early age sexual intercourse, multiple sex 
partners, and history of abnormal Pap smears (Schiffman & Kjaer, 2003).  
As globally VUC is rare among women (Grulich et al., 2010), there is not much 
statistical data available. Below the current available worldwide and Australian data 
are presented. 
Developing countries report a higher percentage (approximately 60%) of VUC cases. 
About 66% of VUCs are reported among women of 70 years or more (Grulich et al., 
2010).  
In Australia, there were 282 cases of VUC identified in 2008 with VUC placed as the 
20th most commonly diagnosed cancer in women, accounting for 6.2% of all GCs 
and 0.6 % of all cancers (AIHW, 2012).  
VUC was the 4th most common cause of Australian GC deaths, with 65 deaths in 
2007. VUC in Australia is placed 36th in frequency across all cancer deaths in 
women (AIHW, 2012). 
In Australia, between 2006-2010 relative 5-year survival rates for VUC were 71% 
(AIHW, 2012). The 5-year prevalence rate at the end of 2008 for women with VUC 
was 1,034 in Australia (AIHW, 2012). 
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1.3.2 Female Anorectal Cancers (ARC)  
Colorectal Cancer (CRC) 
CRC (which is also known as colon cancer, rectal cancer or bowel cancer) develops 
in the colon or rectum (parts of the large intestine). Risk of CRC is doubled in cases 
where CRC was diagnosed in a first-degree relative, especially before 55 years of 
age. Another significant but weaker risk factor is inflammatory bowel disease. CRC 
can also occur in persons with genetic pre-disposition like familial adenomatous 
polyposis and hereditary nonpolyposis coli. However, this accounts for less than 5% 
of cases (National Cancer Institute, 2014). Other risk factors include: lack of physical 
activity, overweight, obesity, smoking, consumption of red and processed meat and 
excessive consumption of alcohol (Ferrari et al., 2007; Giovannucci, 2006 cited in 
Jemal et al., 2011).  
Globally, CRC is second among the most diagnosed cancers in females. The 
estimated female incidence of CRC is 570,100 or 9.4% of the total global new cancer 
cases as reported in 2008 (GLOBOCAN, 2008 cited in Jemal et al., 2011). In NSW 
alone, 3,000 new colon cancer cases and 1,670 rectal cancer cases are identified 
annually (Cancer Institute NSW, 2013).  
Worldwide, there were 288,100 estimated deaths in females from CRC in 2008. CRC 
death rates have declined in Western countries as a result of improved treatment, 
increased awareness and early detection/screening (Edwards et al., 2010; Mitry et 
al., 2002; Sant et al., 2001 cited in Jemal et al., 2011).  
In Australia, the one year survival rate for RC is 84% (Coleman, et al., 2011). The 5-
year prevalence of CRC in 2004 for females was 18,940 cases, which accounted for 
13.4% of all prevalent cases (AIHW and AACR, 2010). 
Rectal Cancer (RC) 
The rectum is the last section of the large intestine which is nearest to the anus 
(National Cancer Institute, 2013). RC is a type of colorectal cancer (CRC) that forms 
in these tissues of rectum.  
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There are many risk factors for RC. Patients with personal history of CRC, first 
degree family history and a personal history of ovarian/endometrial/breast cancer 
constitute the high risk groups accounting for 23% of all CRCs (Oncolink, 2006). 
Other risk factors for RC are the same as those for CRC described above (National 
Cancer Institute, 2014). 
In terms of international data, cancer of the rectum accounts for approximately 38% 
of CRCs diagnosed annually in the UK (O’Connor et al., 2010). Among women, CRC 
is the second most common cancer, of which about one-third occurs in the rectum. 
In 2006, there were 1,824 cases of RC in Australia, accounting for 4% of all female 
cancers (ACIM, 2012).  
In 2006, there were 541 RC deaths in Australia (ACIM, 2012).  
The 5-year survival rate estimated for women with RC for the period 2002-2008 was 
66.7% in the USA (Panjari et al., 2012). With improvements in treatment, the number 
of RC survivors is projected to increase (Roh et al., 2009). There are no Australian 
data on survival rates from RC, as distinct from CRC.  
Anal Cancer (AC) 
The anus is the opening of the rectum (i.e. last part of the large intestine) to the 
outside of the body. AC is formed in tissues of the anus.  (National Cancer Institute, 
2014).  
Human papilloma viruses (HPVs) have been found to be an important factor in 
developing anal cancers (National Cancer Institute, 2013; Moore-Higgs, 2007). A 
history of cervical cancer, vulvar or vaginal cancer and immunosuppression after 
organ transplant or immunosuppression related to human immunodeficiency virus 
(HIV) have also been linked to the development of AC (Holland, 2007) 
AC is a rare cancer in the general population, with annual age-adjusted incidence 
rates of all types combined of less than 2 per 100,000 worldwide. For reasons only 
partly understood, AC incidence has been increasing over the past three decades in 
a number of countries (Aggarwal et al., 2013).  
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In 2009/2010, 194 females were diagnosed with AC in Australia, accounting for 0.4% 
of all cancers in females. The Australian incidence of AC has increased significantly, 
from less than 1 in 100,000 in 1982 to 1.5 in 100,000 in 2005 (Simpson et al., 2012).  
There were 37 female deaths from AC in Australia in 2009/2010 (AIHW & AACR, 
2012).  
Australian 5-year survival rates range from 20% in the case of metastatic disease to 
80% in the case of localised anal cancer (Grulich et al., 2010).The five-year relative 
survival rate increased by nearly 10% from 58.9% to 63.3% over the last 20 years 
(Jin et al., 2011). 
1.4 Treatment for cancers in the pelvic region 
This section describes common treatments administered for endometrial (EC), 
cervical (CC), vaginal (VC), and vulvar cancer (VC) and female anal (AC) and rectal 
cancer (RC) patients, with a focus on pelvic radiation therapy (PRT) which is the 
target treatment in the current study. Side effects of the treatments will be discussed 
in conjunction with the descriptions of the treatments below. Physical vaginal 
changes/sexual/psychosexual effects and adjustment/recovery post PRT, which are 
related to the target treatment for this study, will be the major focus in this section. 
Gynaecological (GC) and anorectal cancers (ARC) are primarily treated with surgery, 
radiotherapy and chemotherapy and with various combinations thereof, for example, 
surgery and radiotherapy, radiotherapy and chemotherapy (called chemoradiation), 
or radiation alone. Neoadjuvant therapy may be given before, and adjuvant 
treatment may be offered after, the primary treatment (e.g. surgery), to target any 
microscopic disease that cannot be detected by eyesight or scans (Moore-Higgs 
2007), in order to improve the outcome of patients at high risk of relapse.  
The image below (Figure 1) illustrates the areas of the female reproductive system 
which are in the pelvic region and can be affected by PRT treatment.  Areas like the 
bladder and rectum are also affected as they lie within the pelvic radiation field area.   
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Figure 1: The female reproductive system 
Reproduced with permission by Cancer Council Victoria from the booklet ‘Sexuality 
and Cancer’, 2007, p. 9, with illustrations by Con Stamatis. 
1.4.1 Surgery for GC (CC, VC, VUC and EC) and its side effects 
Surgical treatment is often the primary treatment offered to GC patients (Audette & 
Waterman, 2010). The treatment for CC consists of hysterectomy (removal of the 
whole uterus including part of the vagina) with removal of the lymph nodes if the 
tumour is found to be invasive. If pathological investigations reveal high risk 
characteristics in surgery-treated patients, radiation therapy is also done to reduce 
the risk of relapse (National Cancer Institute, 2013). 
EC is a localized disease that can be cured usually by hysterectomy and bilateral 
salpingo-oophorectomy. Best results are achieved with either of the two standard 
treatments: hysterectomy or hysterectomy with adjuvant radiation therapy (National 
Cancer Institute, 2014).  
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Surgery alone or surgery combined with pelvic radiation is typically used to treat VC 
(National Cancer Institute, 2014). Stage of tumour is the determining factor of VC 
treatment options. In early stages, surgery and radiation therapy are more effective, 
but in more advanced stages, radiation therapy is the main treatment (National 
Cancer Institute, 2014).  
Although the standard primary treatment for VUC is surgery (National Cancer 
Institute, 2014), high post-surgery complication rates such as wound healing 
problems, lymphoedema, and functional deficits have, since the 1980’s, driven the 
tendency towards more restricted surgery, sometimes combined with radiation 
therapy (Eifel et al., 1997, cited in National Cancer Institute, 2014). More commonly, 
radiation is an adjuvant to surgery in patients in stages III or IV of the disease 
(Hacker et al., 1993 cited in National Cancer Institute, 2014).   
Side effects of hysterectomy and radical hysterectomy following GC include adverse 
vaginal changes (Brotto et al., 2008; Bergmark et al., 1999, Audette & Waterman, 
2010, Carter et al., 2013) including: shortening of the upper vagina (Corney et al., 
1993, Bodurka & Sun, 2006) and damage to pelvic nerves (Andersen et al., 1994; 
Carter et al., 2013). Sexual short and long-term effects of hysterectomy have been 
reported by many women (Cull et al., 1993; Lamb, 1990; Pieterse et al., 2006; Carter 
et al., 2013) and have been found to include: loss of sensitivity and difficulty 
achieving orgasm (Andersen et al., 1994), dyspareunia and vaginal bleeding (Corney 
et al., 1993), diminished sexual desire and interest (Greenwald et al., 2008), difficulty 
becoming sexually stimulated (Weijmar Schultz et al., 1991), reduced vaginal 
lubrication (Kylstra et al., 1991), diminished sexual satisfaction (Bukovic et al., 2008), 
and sudden and early menopause (Carter et al., 2011). Patients and partners 
undergo psychological and physical distress due to post-radical hysterectomy 
discomfort, which can negatively impact sexual function even though there may not 
be any effect on the ability to have an orgasm for women (Audette & Waterman, 
2010). Infertility is also a consequence of radical hysterectomy (Stead et al., 2007).  
Any cancer treatment that damages ovarian function and/or leads to the removal of 
the ovaries can have adverse effects on vaginal/sexual health due to hormonal 
deficiency (Carter et al., 2011; 2013; Schover, 2005; Tierney, 2008). Surgical 
menopause is distressing to deal with, firstly because it is instantaneous and often 
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difficult to manage hormonally since oestrogen is contraindicated especially for EC 
patients (with ovarian removal common since it is a hormone dependant cancer) 
(Quinn, 2007). The sudden onset of treatment-induced menopause (also applicable 
for radiation and chemotherapy patients who lose ovarian function) induces many 
side effects. The significant effects are hot flushes, labile mood, tiredness, changes 
in body image, disappearance of desire for sexual acts and enjoyment, vaginal 
dryness, infertility and scarring (Audette & Waterman, 2010; Carter et al., 2013; 
Hughes, 2008).  
Apart from hysterectomy, the possible other procedures for GC patients are: 
vulvectomy, pelvic exenteration alone or in combination with radical hysterectomy 
(Bodurka & Sun, 2006, Audette & Waterman, 2010). Each has its own sexual 
dysfunction effects.  Sexual function is affected post vulvectomy due to the extraction 
of skin and subcutaneous fat of the labia majora and minora, clitoris, and perineal 
body and the regional and femoral lymph nodes (Audette & Waterman, 2010; Carter 
et al., 2013).  
Pelvic exenteration, often used to treat recurrent disease such as cervical and 
vaginal cancers, includes hysterectomy, removal of the bladder, vagina, urethra and 
rectum and salpingo-oophorectomy, requiring ostomies for bowel and bladder 
function (Audette & Waterman, 2010, Carter et al., 2013). The surgery related 
resultant negative sexual affects include striking changes to a woman’s appearance 
also affecting, for instance, body-image and psychosocial functioning with a long 
journey to physical and psychological recovery, although often the vagina is 
reconstructed and the intactness of clitoris and vulva is maintained (Audette & 
Waterman, 2010).  
1.4.2 Chemotherapy for GC and its side effects 
GC tumours which are larger early stage or late stage are treated using radiation 
therapy as a pre-surgical or adjuvant treatment, or cisplatin-based chemotherapy 
plus hysterectomy (Quinn, 2007). Various types of chemotherapy are used in 
treating GC patients, both definitively and in combination with radiotherapy and 
surgery (Quinn, 2007). Although sometimes advocated, chemotherapy is not shown 
to be an effective curative method for advanced VC and there are currently no 
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routine medication schedules for it (National Cancer Institute, 2014). Newer 
integrated approaches are used with VUC. These include integration of surgery, 
radiation therapy, and chemotherapy, suitably combined depending upon clinical and 
pathologic conditions. However, there are varying patterns of practice in combining 
these treatments (National Cancer Institute, 2014; Shylasree et al., 2011).  
Fatigue is the most frequently reported and debilitating side effect of chemotherapy, 
as well as changes in skin, epilation (hair loss), dry mouth, taste alterations, nausea 
and vomiting. All these effects can play a part in later development of sexual 
dysfunction or sexual activity (Quinn, 2007). Other side effects of chemotherapy are 
anxiety, depression, awareness of changed body image and marital or partner 
difficulties (Carmack-Taylor et al., 2004).  
As discussed in section 1.4.1, premature menopause can be caused by GC 
treatments, including chemotherapy (Lo Presti et al., 2004; Jensen et al., 2007). 
Chemically-induced menopause experienced by women, like with surgery, can be 
more acute and extreme than naturally occurring menopause (Audette & Waterman, 
2010). Arousal and vaginal lubrication disruption (Stead et al., 2007) and both sexual 
desire and excitement problems (Andersen et al., 1992) are linked with premature 
menopause. These effects have been found to significantly diminish women’s 
Quality of Life (QOL) (Carter et al., 2011; 2013). Infertility can also be a 
consequence of chemotherapy treatment if premature menopause occurs 
(Molassiotis et al., 2002). 
1.4.3 Surgery for RC and AC and its side effects 
For localized RC (i.e. cancer that has not spread), the preferred treatment is 
complete surgical removal of the tumour with adequate margins, with the attempt of 
achieving a cure, although radiation and chemotherapy will often be given before or 
after surgery (National Cancer Institute, 2014). The surgical approach to treatment 
varies according to the location, stage and presence of high-risk features (e.g. 
positive margins). Where possible, attempts are made to preserve nerve and 
sphincter function; however this is not possible for all patients, leaving them with 
end-colostomy (permanent stoma/bag). 
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In abdominoperineal resection (APR), incisions are made in the abdomen and 
perineum and the rectum and part of the sigmoid colon along with the associated 
(regional) lymph nodes are removed. The last part of the remaining sigmoid colon is 
brought permanently to the surface of the abdomen as an opening, called a 
colostomy. As the quality of life generally worsens after APR, the less invasive lower 
anterior resection (LAR) (“Abdominoperinial resection”, 2014) is generally preferred 
for RC depending on its surgically feasibility. 
Surgery is no longer the treatment of choice for AC (National Cancer Institute, 2014) 
unless there is recurrence.  
1.4.4 Chemotherapy for RC and AC and its side effects 
In RC, chemotherapy may be used in addition to surgery in certain cases as 
neoadjunct (before surgery) or adjuvant (after surgery) therapy (“Colorectal cancer”, 
2014; National Cancer Institute, 2014). More recently, oncologists are increasingly 
using an approach combining chemotherapy and radiation treatments, to reduce the 
necessity of performing the incapacitating AC surgery. This combined approach has 
increased the preservation of an intact anal sphincter helping to improve the quality 
of life after definitive treatment for AC patients (National Cancer Institute, 2014; “Anal 
cancer”, 2014).  
There are many side effects of chemotherapy for rectal and anal cancer, including 
anaemia, bruising and bleeding, tiredness, lowered resistance to infection 
(neutropenia), nausea and vomiting, sore mouth, hair loss, sore/numb and/or tingling 
hands and feet, and diarrhea.  
1.4.5 Pelvic radiation therapy (PRT) and its side effects  
In radiation therapy, ionising radiation is used to damage the DNA of the exposed 
tissue resulting in the death of the cells (“Radiation therapy”, 2014). The success of 
radiation therapy depends on administering an adequate dose to the entire tumour 
without causing serious damage to the surrounding tissues, with the goal of 
achieving the highest probability of local tumour management with the least chance 
of side effects/toxicity (Moore-Higgs, 2007). Radiation therapy can be delivered with 
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curative or palliative intent (Moore-Higgs, 2007), the former being the focus of the 
current study.  
With particular relevance for the current study, combined treatment modalities (e.g. 
radiotherapy and chemotherapy) have been associated with not only improved 
survival rates, but also increases in toxicities which result in significant morbidity 
(Vogel, 2007; Creutzberg et al., 2000; Greimel et al., 2009).  
Provision of information about PRT-induced vaginal changes, sexual acute and late 
effects/toxicities and available rehabilitation options represents the focus of the 
current thesis.  
1.4.5.1 Types of PRTs 
External Beam Radiation Therapy (EBRT) 
The most common method of radiation therapy is EBRT. Ionising radiation is 
delivered either using a radioactive source or using an electromagnetic energy from 
a machine. This is placed at some distance from the tissue to be treated (see Figure 
2). It is differentiated from brachytherapy where radioactive sources are implanted or 
placed internally (i.e. administered internally) (Moore-Higgs, 2007). EBRT equipment 
is classified according to energy produced and depth of penetration within the 
intended area (Moore-Higgs, 2007).  
In EBRT, the first step is the planning or simulation session. In this session, marks 
are placed on the body and measurements are taken to direct the radiation beam in 
the correct position for each treatment. This is followed by a schedule of daily 
treatment.  The patient is placed on a treatment couch and then radiation doses are 
applied from multiple directions to the pelvis. This allows EBRT to be done on an 
outpatient basis. Usually, the treatment is delivered five days a week for 4 to 6 
weeks. Small amounts of radiation are administered daily rather than using fewer 
large doses. This enables reduction of tissue damage surrounding the tumour. 
Normal cells can recover during weekend rests.  
42 
 
 
Figure 2: EBRT of the pelvis 
(“External beam radiotherapy”, 2014; Health Sciences North, 2013) 
Intensity-modulated Radiation Therapy (IMRT) 
IMRT is a newer EBRT technique which uses numerous intensity levels via intensity-
modulated beams (D’Souza et al., 2012). In these intensity-modulated beams, the 
direction off any single beam or placement of any single source can be varied 
(D’Souza et al., 2012). This enables achievement of narrow margins of both dose 
distributions and dose gradients. This is difficult with conventional and 3-D modes 
(D’Souza et al., 2012, Light, 2007). Flexibility in dose administration is achievable 
with IMRT and is seen as a major advance in radiation therapy since it permits 
higher doses to be given whilst sparing normal tissues (Light, 2007). Intensity of 
beams is equal irrespective of tumour thickness in conventional therapy. In IMRT, 
the intensity of the beam can be varied along the treatment field based on the 
tumour thickness. The beam is stronger where the tumour is thicker and lighter 
where the tumour is thinner. Thus unnecessary radiation is eliminated (Life Bridge 
Health, 2014).  
The course of treatment in IMRT lasts five to eight weeks at the frequency of five 
days a week. The patient is in the treatment room for 15-30 minutes for each 
radiation session. Both EBRT and IMRT are painless (UCFS Medical Centre, 2014). 
Further studies are evaluating IMRT for treating gynaecological cancers (D’Souza et 
al., 2012). IMRT is also used to treat rectal (Ng et al., 2012; Brooks et al., 2013) and 
anal cancers (Menkarios et al., 2007; Bazan et al., 2011). 
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Vaginal Brachytherapy (Internal Radiation Therapy) 
Brachytherapy (brachy=Greek for short distance), also referred to as internal 
radiation or implant therapy, refers to the temporary or permanent placing of a 
radioactive source very close to or in contact with the targeted tissue (Moore-Higgs, 
2007). Brachytherapy works by providing a high dose of radiation to a specific 
tumour volume with a quick decline in dose to bordering normal tissues (Moore-
Higgs, 2007).  
Brachytherapy can be combined with EBRT, surgery, or chemotherapy if required. It 
is used for enhancing control of local disease, and to treat high risk tumour 
recurrence areas, improve comfort with recurrent disease, safeguard vital organ 
function, and save normal surrounding tissue from damage (Moore-Higgs, 2007).  
Either a High Dose Rate (HDR) or a Low Dose Rate (HDR) is possible in 
Brachytherapy/internal radiation. The radiation can be delivered with a vaginal 
cylinder applicator (see Figure 3 below and Figures 5, 6 and 7) or an applicator that 
treats the cervix and the uterus independently (Oncolink, 2006).  
 
 
Figure 3: Vaginal cylinder applicator 
(Oncolink, 2006) 
For the vaginal brachytherapy, women are treated in a lead-lined room. After 
positioning the cylinder properly, the radiation technician takes x-ray images or CT 
scans to verify the placement of the cylinder (Oncolink, 2006) (see figure 4). On 
calculation of the radiation dose by the physicist and radiation therapy technician the 
treatment machine directs the radioactive sources to the applicators for the required 
duration. During the process, women may feel vaginal pressure and experience 
marginal discomfort. If tandems and ovoids (see figures 4, 5 and 6) are used gauze 
packing is inserted in the vaginal vault to prevent movement of the applicators. In 
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some cases, contrast (barium) may be inserted in the rectum using a small tube. The 
use of a Foley catheter and the rectal contrast facilitates x-ray examination so that 
the absorbed radiation dose by the bladder and rectum can be established.  
Radiation exposure to others is averted by not allowing anyone into the treatment 
room. During this time, video cameras and two-way microphones assist monitoring 
the treatment. The duration of treatment time can vary from 5 to 20 minutes. After 
achievement of the treatment dose, the source is extracted into the HDR machine. A 
physicist then checks to ensure that no radioactivity exists in the woman’s body or 
outside the machine. Then the applicator is removed by the physician (Oncolink, 
2006).  
 
Figure 4: Side view of tandem and ovoids placed in a patient 
(Nucletron B.V., 2014) 
If HDR is not appropriate, low dose rate (LDR) brachytherapy may be recommended. 
In LDR brachytherapy, the patient is anesthetised before the insertion of the 
radioactive material as in the case of HDR. However, this procedure is done under 
in-patient conditions varying from 2 to 3 days. During the time the radioactive source 
is placed vaginally, friends and family are not allowed to visit, to avoid their radiation 
exposure. The duty times of the nurses are also controlled for the same reason 
(Oncolink, 2006).  
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Figure 5: Radiation applicators 
(Varian Medical Systems, 2014) 
 
 
Figure 6: Radiation applicators 
(Mayo Clinic Health Library, 2014) 
 
Figure 7: X-ray of inserted radiation application rods 
(UC San Diego Moores Cancer Center, 2014) 
1.4.5.2 General side effects of PRT 
Although radiation therapy by itself is painless, varying degrees of acute side effects 
are caused by higher radiation doses, usually restricted to the area of treatment. 
These symptoms may appear during treatment or immediately after, during the first 
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few months or years after the treatment (the long-term or late side effects) or 
following the re-treatment (cumulative side effects) (Vogel, 2007). These side effects 
vary in their type, gravity, and permanence depending on the organs receiving the 
radiation, and treatment and patient factors. The radiation considerations are: type of 
radiation used, total dose applied and its fractionation and concurrent chemotherapy 
if used. These side effects can be expected and predicted.  
Acute Side Effects of PRT  
The main acute side effects of PRT include fatigue and skin irritation. The skin 
irritation is similar to moderate sunburn in some instances. The irritated skin heals, 
but in some instances is not as supple as before (“Radiation therapy”, 2014). The 
fatigue often starts during the course of treatment itself and it can last for weeks, 
even after the end of the treatment.  
Damage to the epithelial surfaces   
The area being treated may determine any damage to epithelial surfaces, such as 
mucosa of the skin and vagina (Incrocci & Jensen, 2013; Johnson & Miles, 2010), 
bowel and ureter. The renewal rate of epithelial cells determines the speed of 
damage and time taken for recovery. In typical situations, the skin starts to get 
painful and go pink many weeks after PRT treatment (“Radiation therapy”, 2014). 
The effect may reach its zenith during the first week after the end of radiation therapy 
and lasts another week leading to possible break down of the skin. In spite of the 
thinning and weeping of skin (moist desquamation) becoming uncomfortable, 
recovery is usually fast (“Radiation therapy”, 2014). In areas of the skin where there 
are normal creases in the skin (e.g. the groin), these reactions are worse. Swelling of 
soft tissues (edema or oedema) is a common inflammation condition. This 
sometimes causes problems during radiation therapy (“Radiation therapy”, 2014). 
Enteritis  
Almost all patients show signs of acute enteritis after radiation therapy to any one of 
abdomen, pelvis, or rectum (National Cancer Institute 2014 – Gastrointestinal 
complications Health Professional Version: Radiation Enteritis). Enteritis is the term 
for inflammation of the small intestine and the symptoms include abdominal pain, 
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cramping, diarrhoea, dehydration and fever (Dugdale & Longretch, 2009; 
MedlinePlus Medical Encyclopedia cited in “Enteritis”, 2014; National Cancer 
Institute 2014). 
Intestinal discomfort 
Typical intestinal symptoms with radiation treatment to the lower bowel (e.g. in the 
rectal and anal cancer radiation field) and pelvic structures (e.g. female genital tract)) 
include diarrhoea, soreness, and nausea (“Radiation therapy”, 2014). 
Infertility 
The sensitivity of gonads (ovaries and testicles) to radiation is very high. In women, 
direct exposure to most commonly applied radiation doses reduces or even stops the 
capacity of the ovaries to produce ovum (eggs). Therefore, in the design of treatment 
planning, dose to gonads is excluded or at least minimised if they are not the main 
treatment areas (“Radiation therapy”, 2014). Saving at least one gonad from 
radiation can avoid infertility (“Radiation therapy”, 2014). 
Late (Post-treatment) Side Effects of PRT 
Areas that have been treated may exhibit side effects for periods lasting months to 
years after treatment, but these side effects are usually limited to the area that has 
been treated. Such late side effects are mostly attributable to damage caused to 
blood vessels and to connective tissue cells (“Radiation therapy”, 2014). 
Fractionating treatment into smaller parts reduces many late effects (“Radiation 
therapy”, 2014). 
Fibrosis 
Tissues treated with radiation show diffuse scarring which makes the tissues less 
supple over time (“Radiation therapy”, 2014). 
Epilation (hair loss) 
High doses of radiation above 1 Gy can cause epilation on any hair bearing skin 
(“Radiation therapy”, 2014). The absorbed dose is the energy absorbed per unit 
weight of the organ or the tissue. The unit of expression for this is gray (Gy). 
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Permanent hair loss can be caused by a single dose of 10 Gy; but if the dose is 
fractionated, permanent hair loss is delayed till the total dose exceeds 45 Gy 
(“Radiation therapy”, 2014). 
Enteritis 
Months to years after the completion of treatment, chronic radiation enteritis may be 
detected.  It may also begin as acute enteritis and may continue after treatment 
ends. The probability of persons treated with radiation to the abdomen developing 
chronic problems is about 5% to 15% (National Cancer Institute, 2014). 
Vaginal dryness 
After pelvic radiation, the naturally moist vaginal mucosa may become dry 
(“Radiation therapy”, 2014). 
Lymphoedema 
In lymphoedema, localized fluid retention and tissue swelling occur and are 
manifested in the radiation area with PRT in the form of swollen legs (see Figure 8). 
Damage to the lymphatic system during the radiation treatment can lead to this 
symptom (“Radiation therapy”, 2014). 
 
Figure 8: Lymphoedema post ovarian cancer surgery and lymph node resection 
(Lymphedema Therapy, 2014) 
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Radiation proctitis 
Radiation therapy to pelvic organs may lead to long-term effects on the rectum such 
as bowel urgency, bleeding and diarrhoea (“Radiation therapy”, 2014). Cystitis 
(bladder infection) is also known to occur as a result of pelvic radiation therapy when 
the bladder is affected (“Radiation therapy”, 2014). 
1.5 Summary 
In summary, the cancers which are the focus of this study (GC’s, especially EC and 
CC (VC and VUC relatively rare) and female RC (AC is rare)) are relatively prevalent 
conditions, with serious consequences, and for which treatment induces serious 
side-effects.  Whilst the overall and general side effects of PRT and other treatments 
have been briefly described above, the main focus of the current study is on the 
development and evaluation of a study-designed psychoeducational psychosexual 
PRT rehabilitation booklet which deals with post PRT physical vaginal and sexual 
changes for women. Hence an in-depth discussion of the physical and then sexual 
changes post PRT follows below in Chapter 2.  
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CHAPTER 2 - Vaginal changes and 
sexual side effects following PRT for 
gynaecological and female anorectal 
cancer patients; Psychosexual 
Information and support needs 
2.1 Introduction 
To inform this chapter, databases were searched including Medline, Web of Science, 
Science Direct, CINAHL, MEDLINE (PubMed) and PsycINFO. The search terms 
used were: vulvar cancer, vaginal cancer, cervical cancer, endometrial cancer, 
female anal and rectal cancers, pelvic radiation treatment, prevalence, incidence, 
vaginal dilators, sexual side effects, anxiety, depression, posttraumatic stress 
disorder, psychological adaptation/adjustment, health related quality of life, 
supportive care needs, and information needs. Other resources were searched such 
as reference lists of identified papers, reference lists of radiation/oncology books for 
the relevant cancers, conference abstracts, and the ‘related articles’ feature in 
databases such as PubMed. 
In this chapter, the vaginal and sexual side effects of PRT, which are integral to the 
present research, will be outlined, along with their impact on quality of life. Leading 
on from this, the main strategies for addressing the physical side effects of PRT to 
improve sexual functioning will be presented. The next section will present evidence 
of women’s psychosexual/ information and supportive care needs, and barriers to 
effective doctor-patient communication on this topic. The final section of the chapter 
will discuss the latest research with regards to information resource development 
and provision in this area. The study aims and hypotheses will conclude this chapter. 
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Kotronoulas et al., (2009) note that all people have a sexual facet which persists 
through different stages of their cancer passage. As discussed previously, for 
women with the pelvic cancers being examined in the current study (cervical, 
endometrial, vaginal, vulvar, rectal and anal), treatment can involve radical pelvic 
surgery (not current practice for anal cancer) often in conjunction with primary and/or 
adjuvant radiotherapy and chemotherapy (Schover, 2005; Breukink et al., 2009; 
Hassan & Cima, 2007). As a result of these invasive therapies, in particular PRT, 
profound physical changes in the areas of the body with which a woman defines 
herself sexually can occur. These effects have particular implications for sexual 
functioning and adjustment post PRT. 
The following sections will provide a more detailed overview of: i)  post-PRT (a) 
physical changes, (b) post PRT sexual changes and (c) quality of life and 
psychological outcomes of sexual dysfunction; ii) physical interventions to improve 
physical/vaginal and sexual functioning; iii) sexual information needs for women with 
gynaecological and anorectal cancer; iv) barriers to doctor-patient communication; v) 
potential interventions/resources to improve psycho-educational information and 
support to patients, and their barriers/facilitators.  
2.2.1 Physical changes after pelvic radiation therapy (PRT) 
Radiation to the female pelvis can affect sexual function in two ways: damage to the 
epithelium of the vaginal canal and premature ovarian failure (Shell, 2007). 
Implications of PRT physical vaginal changes will be discussed separately below 
only in the instance where they may vary by cancer type. 
Epithelium line surfaces and cavities of structures throughout the body. Its function is 
to protect, secrete, selectively absorb, and for transcellular transport and for 
detection of sensation. (“Epithelium”, 2014). 
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2.2.1.1 Main radiation physical damage to the vaginal canal in 
gynaecological and female anorectal patients: vaginal toxicity and 
stenosis  
Vaginal Toxicity 
Radiation toxicity refers to the health consequences of exposure to high amounts of 
ionising radiation appearing within 24 hours. The symptoms can begin within one or 
two hours of radiation and can last for several months (Donnelly et al., 2010; Xiao & 
Whitnall, 2009). As per its definition, radiation toxicity refers to acute medical 
problems and does not include the symptoms that evolve after a prolonged period. 
But similar symptoms may appear within months to years after radiation treatment 
(Reeves & Ainsworth, 1995). The exact onset and type of symptoms are dependent 
on the radiation exposure (“Acute radiation syndrome”, 2014).  
Vaginal Stenosis  
As noted previously, external pelvic radiotherapy (EBRT) and internal 
vault/intracavitary brachytherapy can result in significant vaginal changes such as 
stenosis (narrowing) and agglutination (“glue-like” adhesions resulting from internal 
scar tissue). If adhesions are not regularly broken down skin tightening and, 
shortening, narrowing and for some women, entire destruction of the vagina might 
transpire (Decruze et al., 1999; Gosselin et al., 2000). Vaginal stenosis can prevent 
adequate pelvic examinations, potentially affecting the ability to detect new cancer 
and/or recurrence, as well as potentially leading to sexual dysfunction and lowered 
quality of life (Johnson & Miles, 2010; Bahng et al., 2012; Bergmark et al., 2002). 
Though vaginal stenosis is a common side effect of PRT for women with 
gynaecological and colorectal cancer there has been little focus on it in the literature 
necessitating further study (Wolf, 2006). Wolf (2006) further argues that colorectal 
patients have received little attention in this regard compared to 
cervical/gynaecological cancer patients. Wolf (2006) notes this may be as a 
consequence of PRT being a treatment option for longer in cervical/gynaecological 
cancer (60 years versus 30 years) and female colorectal patients not being treated 
by gynaecologists who may focus to a greater degree on sexual/vaginal changes. As 
will be discussed later in this chapter, whilst this may be the case, the focus on post 
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PRT vaginal/sexual changes is also often not optimal for women with gynaecological 
cancer either (Bahng et al., 2012, Carter, 2011; 2013). 
Although no consensus exists with regards to the definition or a measurement tool 
for vaginal stenosis (Miles et al., 2012), the International Guidelines for Vaginal 
Dilation after Pelvic Radiotherapy recommend the following “grade 1-3 in which 
grade 3 incorporates vaginal narrowing or shortening that interferes with inserting 
tampons, with sexual activity or physical examination” (Miles et al., 2012, p. 7).   
The incidence of vaginal stenosis as a side effect of PRT is reported to range from 
1.2% to 88% in gynaecological cancer patients, with a substantial variability due to 
factors such as type (internal or external and/or combination of both), dose and 
volume of radiation administered and surgery (Miles et al., 2012, Brand et al., 2006; 
Sorbe et al., 2012; Nout et al., 2012; Bahng et al., 2012). As noted in the paragraph 
above there is no consensus on the standards and guidelines for assessing stenosis. 
The variability in the assessment methods might explain the large variability in the 
rates of stenosis. By contrast to the above reporting of the incidence of stenosis in 
gynaecological cancer patients, the number of anal and rectal patients developing 
post PRT vaginal stenosis is not well documented (Miles et al., 2012). Furthermore, 
Miles et al. (2012) highlight that there have been extensive modifications in the 
treatment of rectal and anal cancers, such as, radiation type and dose which 
potentially confound the measurement and prevalence of vaginal stenosis.  
Women’s experiences of vaginal stenosis following PRT are inconsistently reported 
in the literature. For instance, Nori et al.’s (1994, cited in Miles et al., 2012) study 
investigated the impact of vaginal stenosis on QOL and reported it being a ‘minor 
complication’, whilst Andersen et al. (1991, cited in Miles et al., 2012) reported 
women finding shortening of the vagina to be devastating. Many studies suggest a 
link between vaginal stenosis, dyspareunia severity and sexual dysfunction (Miles et 
al., 2012). Miles et al. (2012) note that this is a subjective issue since some women 
appear to be less disturbed by significant damage to their vagina whilst others are 
substantially impacted and experience longstanding psychosocial and sexuality-
related bereavement from relatively minor damage/vaginal change. Thus, the 
psychosexual effects of vaginal stenosis/vaginal changes are complex and 
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multifaceted as will be discussed later. Physical changes may not be the only cause 
of sexual dysfunction for women post PRT for gynaecological and anorectal cancer.  
2.2.2 Sexual changes after pelvic radiation therapy (PRT) 
Radiation-induced Sexual Dysfunction  
Radiation-induced sexual dysfunction should be contextualised with in sexual 
dysfunction in women in the general population, which is deemed common (Shifren 
et al., 2008; Najman et al., 2003).  Prevalence rates estimates of 43% have been 
reported in the U.S. (Addis et al., 2006; Bancroft et al., 2003) and the United 
Kingdom (Nazareth et al., 2003; Dunn et al., 1998). Prevalence rates of 41% were 
found in Australia (Dunn et al., 2000). Najman et al.’s (2003) study 60.5% of 
Australian women reported a symptom of sexual difficulty within the last year, with 
19.7% of women reporting more serious sexual dysfunction. In another Australian 
population based study Richters et al., (2003) found that for women lack of sexual 
interest and anorgasmia were the most frequent sexual problems. The 
aforementioned rates of sexual dysfunction in the general population need to be 
taken into account when discussing the rates of radiation-induced sexual 
dysfunction, discussed below.  
I. Radiation-induced sexual dysfunction in gynaecological cancer patients 
In the gynaecological cancer setting, radiation-induced effects contribute to the 
development of sexual dysfunction in a reported 49-79% of affected women (Munro 
et al., 1996). Many studies have reported major changes to levels of sexual 
desire/activity, anorgasmia, and decreased overall satisfaction with sexual life in the 
months and years following radiotherapy (Frumovitz et al., 2005; Jensen et al., 
2004b; Juraskova, 2009; Lindau et al., 2007). In view of upwards of 40% of 
gynaecological cancer patients reporting chronic post-treatment sexual difficulties, it 
is likely that sexual and relationship dysfunction persists when other areas of 
adjustment such as mental health have normalised (Katz, 2005; 2009; Schover, 
2005; Wolf, 2006; White, 2008).  
For women who are treated for cervical cancer, the effects of PRT have a specific 
effect on sexuality (Chase et al., 2008). Cervical cancer patients may experience 
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some of these effects to a greater degree, compared to other women undergoing 
PRT since they are generally younger and premenopausal (Bruheim, 2010a). 
Jensen et al. (2003) found sexual dysfunction and adverse vaginal changes two 
years post radiotherapy for cervical cancer. In their findings, more serious sexual 
dysfunction was observed among women only treated with radiation therapy in 
contrast to surgery-only patients during a follow-up of 2 years. The effects ranged 
from 85% of irradiated women reporting no interest in sex, 55% exhibiting 
dyspareunia, and another 50% exhibiting vaginal shortening. These sexual 
difficulties were statistically worse compared to women’s pre-treatment sexual 
function and to age-matched controls (Jensen et al., 2003). Similarly, Frumovitz et al. 
(2005) found more sexual dysfunction and vaginal problems five years post radiation 
treatment than in women who had radical hysterectomy and lymph node dissection, 
in cervical cancer patients. On the other hand, Bergmark et al. (1999) found no 
differences on the prevalence of vaginal shortness, inelasticity, or lubrication post 
PRT (internal or external) compared to surgery in early stage cervical cancer 
patients.  
For women with endometrial cancer, high dose brachytherapy can result in extensive 
sexual problems (Friedman et al., 2011; Greimel et al., 2009; Bahng et al., 2012; 
Onujiogu et al., 2011), with over a third (Cochran et al., 1987) to a half of patients 
(Friedman et al., 2011) not resuming sexual activity after treatment. Those who 
remain sexually active report decreased vaginal lubrication, pain, bleeding and 
difficulty reaching orgasm, with many women finding intercourse troubling as their 
vaginas were too reduced in size (Friedman et al., 2011). Of concern, sexual 
dysfunction in these women may be underreported (Goncalves, 2007), with some 
finding that these rates are closer to 80% (Damast et al., 2012). Therefore, 
endometrial cancer survivors, commonly thought to have a low risk, may, in reality 
suffer from ‘severe’ sexual dysfunction (Onujiogu et al., 2011, p. 356). 
Furthermore, PRT combined with surgery has been found to have a greater impact 
on sexual function than only surgery (Frumovitz et al., 2005, Greimel et al., 2009). In 
a longitudinal study of postoperative PRT in endometrial carcinoma (PORTEC-1), it 
was noted that in women who had pelvic EBRT after total abdominal hysterectomy, 
long-term symptoms of bowel and bladder, reduction in sexual enjoyment and 
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increased vaginal dryness and a negative Health Related Quality Of Life (HRQOL) 
were observed in comparison to those who had only surgery (Nout et al., 2011).   
As vaginal cancer cases are rare, most studies were done with small samples 
(Hiniker et al., 2013; Tran et al., 2007). Little data are available on late radiation 
toxicities of the different radiation treatments in this context (Lian et al., 2008; Tran et 
al., 2007). Lian et al. (2008) found that 68% of women in their study (n=68) had late 
radiation toxicity of vaginal morbidity, but minimal bladder (4.6%) and bowel toxicity 
(4.6%). The most frequent vaginal symptom was vaginal stenosis. Of those with 
stenosis, 30.9% had grade 1, 21.8% grade 2, 5.5% had grade 3 (meaning severely 
shortened vagina) and 5.5% had grade 4 toxicity (involving either vesico-vaginal 
fistula or recto-vaginal fistula). In this study vaginal morbidity was highest in the 
group undergoing both EBRT and brachytherapy (82.1%) and lowest in the 
brachytherapy alone group (0%). Higher doses of radiation were correlated with 
more frequent vaginal toxicity in Lian et al.’s (2008) study. Dixit et al.’s study, (1993, 
cited in Lian et al., 2008) gave some support to these findings with a higher risk of 
vaginal toxicity, though not statistically significant, in patients undergoing both EBRT 
and brachytherapy.  
Vulvar cancer is relatively rare; as such there is a significant lack of literature on 
treatment-related side effects (Aerts et al., 2014) and psychosexual outcomes for 
women (Barlow et al., 2014; Pilger et al., 2012). However, Weijmar Schultz et al. 
(1990) examined psychosexual functioning longitudinally post radiation treatment for 
vulvar cancer and found a high risk for vaginal stenosis at the vaginal opening with 
considerable reduction in genital feeling throughout arousal and orgasm with no 
symptom diminishment over time. Moreover, Hazewinkel et al. (2012) observed a 
negative correlation of sexual function of women (n=120), treated for vulvar cancer 
with age and with adjuvant inguinal (lymph node) radiotherapy. The effect of age 
was manifested in the decrease of “arousal” and “desire”. However, having a partner 
had a positive effect on ‘satisfaction’. These authors pointed out that when fibrosis 
results from adjuvant treatment, there is an increase in local morbidity (Hazewinkel 
et al., 2012). From multivariate analysis, a negative relationship between adjuvant 
radiotherapy and orgasm was observed (Hazewinkel et al., 2012). Aerts et al. (2014) 
citing a van Doorn et al.’s (2006) Cochrane Review, contend that, although vulvar 
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cancer treatment has become more personalised and less extreme, the iatrogenic 
effects of surgery, such as the impact on nerves and blood vessels related to anal, 
urinary and sexual function may be more pronounced when combined with 
radiotherapy. Women with vulvar cancer are at high risk for sexual morbidity given 
the condition and its treatments (Jefferies & Clifford, 2012; Hazewinkel et al., 2012; 
Aerts et al., 2014).  
II. Radiation-induced sexual dysfunction in anorectal cancer patients 
Anal and rectal patients also report significant sexual dysfunction post PRT (Incrocci 
& Jensen, 2013, Wolf, 2006). Lange et al. (2009) found that 62% of women with 
rectal cancers noted new or aggravated sexual problems post treatment, whilst rates 
of sexual activity among these women dropped from 51% pre-treatment to 33% 
three months post treatment, with a further reduction to 18% two-years post 
treatment. The only risk factor found for sexual dysfunction was preoperative 
radiotherapy (Lange et al., 2009). Gervaz et al. (2008) suggest that sexual function 
in rectal patients does not improve but stabilises over time ranging from 6 months to 
2 years (Gervaz et al., 2008). Admittedly, little is known about sexual dysfunction for 
women with rectal cancer with further research needed in this area (Ho et al., 2011; 
Incrocci & Jensen, 2013). 
In 55% of women with anal cancer, poor sexual function scores were found with 
respect to inadequate sexual interest, arousal difficulties, incapability to relax and 
enjoy sex and difficulty in reaching orgasm in Das et al.’s (2010) study. These 
authors contend that further research is required in female patients with anal cancers 
for better understanding of the sexual changes that are consequent on radiation to 
the internal and external genitalia (Das et al., 2010).  
Clinicians are inclined to under report anal cancer survivor’s sexuality-related 
symptoms (Vistad et al., 2008), however, Bentzen et al. (2013) contend that a large 
number of patients may experience post PRT effects, since the radiation dose is 
high and the sexual organs and anal sphincter are in the vicinity of the target volume 
of radiation for patients with anal cancers. Increased awareness of side effects is 
needed for better management of late effects for anal cancer survivors (Bentzen et 
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al., 2013), who remain a neglected cohort with regards to late PRT effects, and 
sexual dysfunction in particular (Aggarwal et al., 2013).  
Additionally, there is limited understanding of the effects of PRT on sexuality for 
endometrial cancer patients with rates of sexual dysfunction underestimated and 
understudied, and similarly for anal cancer patients (Incrocci & Jensen, 2013), which 
reflects a paucity of research in this area.  
Body image, identity disturbance and relationship effects with regards to sexuality 
post PRT for women with gynaecological cancer and anorectal cancer  
Gynaecological and anorectal cancer and its treatment are known to have an 
extensive impact on body image and sexual self-perception (Incrocci & Jensen, 
2013, Carpenter et al., 2009). Some of the factors linked with  psychological 
adaptation and QOL both immediately post-treatment and during survivorship 
include sexuality and body view issues (Ashing-Giwa et al., 2010, Lindau et al., 
2007).  
A review of the relevant literature indicates a growing disgruntlement that post 
cancer sexuality research focuses on the physical effects of gynaecological and 
female anorectal cancer treatment. Post-treatment effects are experienced not only 
at a physical but also a psychological level as sexuality is multidimensional; women 
treated for gynaecological and anorectal cancer experience anxiety, depression 
(Petersen & Quinlivan, 2002; Dunn et al., 2012), psychological distress (Dunn et al., 
2012; Philip et al., 2013), low self-worth (Holmes et al., 2005; Baumann et al., 2013) 
self-representation, identity and body view breakdown (Carpenter et al., 2009; 
Gilbert et al., 2011). Furthermore, certain effects may extend beyond the individual 
patient to involve their partner. These effects may include fear of pain during 
intercourse; fear that sexual activity will cause recurrence, anxiety relating to bladder 
and bowel dysfunction whilst having sexual activity, and breakdown in couple 
communications about sexual closeness (Juraskova et al., 2003; Philip et al., 2013; 
Gilbert et al., 2011). 
Often women find it difficult to perceive themselves to be sexually attractive during 
the treatment and after. Gynaecological cancer patients have reported a feeling of no 
longer being a woman, for instance, due to treatment-induced ovarian 
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failure/infertility (Gilbert et al., 2011; Stead et al., 2007). Therefore, the goals of care 
and rehabilitation should include detection and inclusion of body-image disruption 
factors (Pilger et al., 2012). Psychological effects of gynaecological cancer and its 
treatment are primarily related to a range of sexual symptoms. These symptoms 
include disfavoured body image associated with gaining weight, scars and marking 
from EBRT radiation beam placement (Gilbert et al., 2011; Burns et al., 2007; Lamb 
& Sheldon, 1993; Butler et al., 1998), loss of feeling womanlike (Juraskova et al., 
2003; Rasmusson et al., 2008), and feeling unattractive (with one woman reporting 
feeling a ‘monster’) as a result of hair loss (Stead et al., 2007).  
Similarly, Panjari et al. (2012) also cited disfavoured body view as a factor affecting 
sexual dysfunction in female rectal cancer patients along with fatigue, depression, 
loss of independence, and relationship changes. For instance, couples often 
experience changes of social roles during treatment which can jeopardise each 
person’s sense of individuality and worth (National Cancer Institute, 2013). Partner 
participation in physical care can have negative impact on sexuality. Such effects 
have been reported in the case of stoma care in colorectal cancer patients (National 
Cancer Institute, 2013). Younger couples affected by female rectal and anal cancer 
have been found to be more at risk of problems related to change or new domestic 
roles associated with treatment. They also report having more concerns about the 
effects of these on their intimacy and sexual relationship (Das et al., 2010).  
There are contradictory findings on the effects due to gynaecological cancer and its 
treatment in women and their psychosexual/sexual relationships. Some couples 
report a positive effect on their relationship (Lamb & Sheldon, 1993; Butler et al., 
1998) whilst others find that women’s sexual difficulties caused deterioration in the 
couple’s relationship (Burns et al., 2007; Bergmark et al., 1999). Some negative 
effects include blaming partners for their cancer, experiencing physical and 
psychological trauma and emotional detachment related to sexual activity, fear of 
cancer transmission, and concern of the partner about hurting the woman being 
translated as rejection or lack of interest (Juraskova et al., 2003).  
A major issue with regards to sexual difficulties of post gynaecological cancer cases 
is communication in couples (Stead et al., 2007; Juraskova et al., 2003). Resumption 
of intercourse does not necessarily imply satisfaction/enjoyment and may occur 
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without couples explicitly communicating their desire (or non-desire) for resuming 
intercourse. Some women feel, for instance, a pressure to continue sexual activity to 
maintain the relationship driven by fear of losing their partners or by feeling markedly 
dependant on them (Gilbert et al., 2011). Silencing themselves has been noted as a 
coping mechanism among women and their partners. This may further exacerbate 
their difficulties particularly due to lack of sexual information and support from 
clinicians (Stead et al., 2003). Based on this, researchers argue that prioritising 
sexuality in this setting would legitimise women’s and their partners’ difficulties and 
improve couples’ communication (Stilos et al., 2008; Weijmar & Schultz et al., 1992).  
In summary, this section drew attention to the psychosexual aspects of post PRT 
recovery, highlighting that PRT not only impacts on physical sexual functioning, but 
can affect body image and relationship dynamics. The section below will present 
data broadly on the effect of sexual difficulties on quality of life and on psychological 
well-being.   
2.2.3 Psychological and quality of life (QOL) sequelae of sexual 
dysfunction post PRT  
Women’s psychosexual wellbeing, that is, their perception about their own sexuality, 
has been found to have a bearing on how they cope with treatment side effects. 
Further, sexual difficulty is found to be associated with lowered psychological 
adjustment and QOL (Carter et al., 2013; Carpenter et al., 2010; Levin et al., 2010) 
during and after treatment (Le et al., 2009 cited in Carter et al., 2013) and in the 
survivorship literature (Ashing-Giwa et al., 2010; Lindau et al., 2007). In 
gynaecological cancer patients, controlling for younger age, fewer years of 
education, and greater fatigue and sexual morbidity co-varied with greater 
depression and anxiety of body changes in conjunction with reduced psychological 
adjustment (Levin et al., 2010). 
For example, treatment induced menopausal symptoms such as vaginal dryness is 
correlated with depression and elevated distress (Carter et al., 2010; 2013). 
Similarly, Health Related Quality Of Life (HRQOL) among patients who have rectal 
cancer and received PRT was found to be affected by sexual dysfunction 
postoperatively, although no serious effect was found on global QOL (Marijnen et al., 
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2005). In another study (Levin et al., 2010) conducted with 186 partnered women 
(mean age 55 years), there was positive and moderate correlation of sexual 
morbidity with traumatic stress (r = 0.30) depression (r=0.34) and body image (r = 
0.25). In the Medical Outcomes Study - Short Form 12, moderate correlations 
emerged for correlations with physical health (r = 0.34) and with mental health (r = 
0.25). It was also found that 48% of the depression variance, 26% of the stress due 
to body change variance and 31% of the psychological quality of life variance was 
accounted for by the sexual morbidity.  Thus it appears that sexual morbidity may be 
an additional psychological worry for women with gynaecological and anorectal 
cancer. Addressing sexual morbidity may therefore substantially improve 
psychological health (Levin et al., 2010). 
Furthermore, sexual dysfunction continues to impact on quality of life long-term, after 
other quality of life impacts of cancer treatment have resolved. Allal et al.’s (2005) 
found that although one year after combined treatment for locally advanced rectal 
cancer (cancer had grown outside the organ from where it started but not spread to 
distant parts of the body yet and may or may not be curable) some aspects of QOL 
had improved, but there was a decrease in sexual function and body image (Allal et 
al., 2005). Similarly in their study addressing long-term QOL after PRT for anal 
cancer, Das et al., (2010) found that patients had high median global QOL scores 
suggestive of a better QOL as measured by the FACT-C (higher scores indicate a 
better QOL), except for those pertaining to sexual function.  
Emotional morbidity may both be cause and effect of reduced sexual functioning. 
Anxiety and depression, the two most common forms of emotional morbidity after 
cancer had detrimental effects on sexual functioning (Carpenter et al., 2010; Levin et 
al., 2010; Le et al., 2009). Psychotropic medications used to treat 
psychiatric/psychological effects of having cancer may further impact on sexual 
function.  
In summary, PRT has an extensive impact on sexual functioning in gynaecological 
and anorectal cancer patients. The prevention and treatment of sexual morbidity has 
the potential to facilitate enhanced psychological adjustment and QOL for 
gynaecological and anorectal cancer patients. Improving sexual outcomes should be 
a focus of supportive care. The following section reviews the most common physical 
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intervention strategies that have been developed to improve sexual outcomes. 
Subsequent sections will explore informational and psycho-sexual interventions.  
2.3 Rehabilitation strategies: Vaginal dilators, 
lubricants and pelvic floor exercises 
2.3.1 Vaginal dilators 
Vaginal health is imperative for all women whether sexually active or not (Carter et 
al., 2013). Vaginal dryness, discomfort, and stenosis can inhibit sexual activity, and 
promote anxiety about gynaecological appointments, which in turn gives rise to 
painful pelvic exams and potential noncompliance with follow-up care (Carter et al., 
2013). Vaginal dilators and sexual intercourse may avert shortening of vaginal length 
and impairment of sexual functioning after brachytherapy (Jeffries et al., 2006). The 
basis for this thinking is that, after PRT, with scheduled dilation, the vagina can 
maintain its patency whilst healing, in turn allowing for successful pelvic vaginal 
examinations and maintaining/preserving optimal sexual function (Bahng et al., 
2012). According to the current International Guidelines for Vaginal Dilation after 
Pelvic Radiotherapy (Miles et al., 2012, p. 7) the current rationale for dilator use is to: 
 Assist sexual intercourse recommencement after PRT 
 Avert adhesions advancement to fibrosis and stenosis largely one year post 
PRT if women are not having penetrative intercourse and wish to maintain a 
patent vagina 
 Allow ongoing clinical follow-up pelvic examinations and/or for clinician cancer 
surveillance and detection of potentially treatable recurrence  
 Possibly lower sexual problems such as dyspareunia 
 Afford the opportunity for the communication of sexual 
difficulties/fears/mistaken beliefs about PRT 
 Lessen harm to tissues 
 Assist psychological welfare enhancement  
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Dilator use may be particularly important for postmenopausal, older women, with the 
thinning of vaginal mucosa making them more susceptible to toxicity (Bahng et al., 
2012).  
Evidence for the efficacy of vaginal dilators is mixed. Johnson & Miles (2010) 
conducted a Cochrane Review on vagina dilator use for women undergoing PRT. 
Johnson & Miles (2010) conducted a systematic review of vaginal dilation to prevent 
damage from PRT (Johnson and Miles, 2010). Both reviews concluded that good 
quality evidence was lacking to support acute radiation phase post-treatment dilation 
therapy. However, Level 2+ and Level 3 evidence (as defined by the International 
Guidelines, see below in Table 1) suggests that using vaginal dilators post the acute 
inflammatory phase (Johnson & Miles, 2010, p.7) could treat vaginal stenosis after it 
had happened. There is also no evidence that quality of life is enhanced by dilator 
use facilitating more comfortable pelvic examinations and hence providing life-
prolonging treatment (Miles et al., 2012).  Bahng et al. (2012) found that vaginal 
dilator use at least two to three times per week was significantly linked with a 
decreased risk of vaginal stenosis in endometrial cancer patients. Thus, while using 
vaginal dilators post PRT may lessen the (potentially irreversible) physical damage 
to the vagina; further evidence regarding their efficacy is needed.   
Table 1: International Guidelines on Levels of Evidence for Vaginal Dilation after 
Pelvic Radiotherapy  
(Miles et al., 2012, p. 5) 
Level 2++ Evidence is defined as systematic reviews of high quality case control and cohort studies. 
Level 2+ 
Evidence is defined as case control or cohort studies which are well 
carried out with a low risk of confounding or bias and with a 
moderate possibility causal relationship. 
Level 2- 
Evidence is defined as case control or cohort studies with a high 
risk of confounding or bias and a significant risk of relationship not 
being causal. 
Level 3 Evidence is defined as non-analytic studies like case reports and case series. 
Bahng et al. (2012, p. 671) note that although there is little empirical data to support 
dilator use, there is the “common wisdom” amongst clinicians of PRT vaginal/sexual 
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side effects and the benefits of vaginal dilator use (Oncolink, 2006); hence they are 
commonly recommended in guidelines such as those published by the American 
Cancer Society (2014), Sydney Gynaecology Group Sydney Cancer Centre 
Oncology Group (2014), Australian Government Cancer Australia (2012). For 
instance, the American Cancer Society (2014) advocates using vaginal dilators post 
PRT for prevention of vaginal stenosis as does the UK National Forum of 
Gynaecological Oncology Nurses, 2005 (cited in Punt, 2011). Dilator provision is 
common in Australia, however information on their use is not standardised (Bonner 
et al., 2012; Lancaster, 2004).  
Currently most recommendations on using dilators entail inserting a dilator two to 
three times per week to split up adhesions (Bahng, et al, 2012; Lancaster, 2004; 
American Cancer Society (2014); UK National Forum of Gynaecological Oncology 
Nurses 2005 cited in Punt, 2011; Miles et al., 2012). There is however a paucity of 
studies on optimal vaginal dilator-use frequency and length of time, and research is 
required to inform dilator instruction on long-term use (Punt, 2011). 
The International Guidelines for Vaginal Dilation after Pelvic Radiotherapy (Miles et 
al., 2012, p. 11) suggest that women should be presented with vaginal dilation 
information to establish whether they would like to use it, since dilation may assist 
post-PRT sexual activity for those who would like to maintain or resume it. The 
authors of these guidelines argue that women who do not desire to maintain vaginal 
patency may choose not to undertake dilator use. They further suggest that vaginal 
dilation might be recommended to thwart adhesions forming between clinician 
follow-up visits in patients where adhesions have occurred in the past. This may be 
appropriate for any cancer treated with PRT that includes the vagina as in the case 
of endometrial, cervical, vulval, low rectal, anal and urological cancers. According to 
Miles at al., (2012) PRT dose and volume of the vagina treated may affect the 
gravity of possible vaginal stenosis, and might determine shape of the dilator to be 
selected. 
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2.3.1.1 Adherence to use of vaginal dilators 
Despite guidelines recommending their use, the organised supply of dilators along 
with adequate information about their use is limited, and compliance is very low 
(Lancaster, 2004; Bonner et al., 2012).  
For example, Law et al. (2013) examined vaginal stenosis as a late effect of external 
PRT and brachytherapy. Law et al.’s (2013) prospective study aimed to ascertain 
adherence and efficacy of vaginal dilator use as measured by the ability to return to 
pre-treatment vaginal dilator size at 12 months (Oncolink, 2006). Women with rectal 
(n=28), anal (n=35), endometrial (n= 45) and cervical (n=1) cancers were followed-
up for one-year post PRT. Clinicians gave structured teaching to use dilators three 
times a week, regardless of frequency of sexual intercourse. Women kept monthly 
diaries of dilator size use and vaginal symptoms. At pre-PRT, 1, 6 and 12 months 
post-PRT, clinicians graded vaginal stenosis using CTCAE v3. Adherence was 
measured as the percentage of times patients used the dilator out of the number of 
times they were directed (3x/week X 52 weeks=156). Law et al. (2013) found that 
among 109 participants, aged 28-81 years (median = 58), over a 12-month period, 
the mean adherence with vaginal dilator use was 42%. Adherence was highest in the 
first quarter (58%), but fell to 25% by the fourth quarter. Predictors of adherence 
were disease type, treatment sequence and chemotherapy all at p<0.05. Rectal 
cancer patients were less prone to adhere to dilator use than anal and endometrial 
patients. Eighty-two percent of all patients returned to pre-PRT size at 12 months; of 
the 49% who reported a decrease in dilator size from pre-PRT to 1 month post-PRT, 
71% were able to return to pre-PRT size at 12 months. Anal cancer patients were 
most prone to report a decrease in vaginal dilator size at 1 month post-PRT (77%), 
but 68% of these patients returned to baseline at 12 months. Disease type and 
greater adherence to dilator use at 6 months were associated with returning to pre-
PRT size at 12months (both p <0.05). Thus, based on this prospective study, vaginal 
dilator use is an effective strategy in minimizing vaginal stenosis, but adherence at 
12 months was poor. The author argues that further studies are needed to evaluate 
methods of enhancing adherence to use of dilator and to determine the required 
optimal frequency and optimum duration of dilator use .  
66 
 
Dilator compliance also appears to diminish the further from treatment patients are, 
which is of concern since PRT effect can occur 2 and more years post treatment 
(Punt, 2011; Bahng et al., 2012). 
2.3.1.2 Barriers to vaginal dilator use post PRT  
Despite the potential advantages of using dilators, women report specific 
impediments to using them post PRT (Cullen et al., 2013; Punt, 2011; White & 
Faithfull, 2006; Lancaster, 2004).  Receiving limited or untimely information on the 
clinical and sexual importance of using dilators, uncertainty as a result of conflicting 
information provided, perception of use of dilators as boring and time consuming, not 
remembering to use dilators whenever required, negative experience perception 
about their use, embarrassment, the need for discretion with, for example, children 
around, and discomfort, anxiety, bleeding or pain in using the dilators are common 
barriers cited by women (Lancaster, 2004; Bonner et al., 2012, Friedman et al., 
2011, Greimel et al., 2009; Wolf, 2006). Further obstructions to adherence include 
inconsistency in vaginal dilator use information within and between treatment 
centres; modesty, association with “sex toys”, attitudes that dilators are ‘not natural’, 
fear of injuring the vagina, treatment invasion reliving/reminder, emotional avoidance 
of thinking of cancer and treatment, aversion/fear of dilator, psychological turning 
away from dilator use as being unfamiliar and/or strange and/or repugnant, not front 
of mind with regards recovery, lack of interest in sex, and feeling no motivating  
reason to pursue/continue dilator use, and being provided dilators once stenosis had 
already occurred (Friedman et al., 2011; Cullen et al., 2012; Lancaster, 2004; Carter 
et al., 2011; Juraskova et al., 2003, Bonner et al., 2012).  
As seen in the above list, attitudes to dilators, whether cultural or other, and values 
and beliefs affect vaginal dilator use (Cullen et al., 2012; 2013). Age has also been 
found to be a barrier with regards to vaginal dilator use compliance (Punt, 2011). 
There has been little research in to understanding low compliance and barriers to 
vaginal dilator use for women post treatment (Cullen et al., 2012; McCallum et al., 
2012; Friedman et al., 2011). Bonner et al. (2012) (and others) are attempting to 
address this gap in the literature and have developed a model for reducing barriers 
to dilator use which will be discussed in the section below.  
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2.3.1.3 Reducing barriers to using dilators 
A recent Cochrane Review highlighted that a lack of evidence and controversy on 
the efficacy of dilator use may alter dilator provision practices in the future (see 
section 2.3.1 for Johnson & Miles, 2010). It is claimed that Australian health 
professionals are inconsistent in advising the recommended use of dilators for post-
radiation rehabilitation and are often averse to provide any additional written 
information (Lancaster, 2004). Thus clear evidence to support use and training of 
clinicians in optimal communication about dilators may be one effective strategy to 
reduce barriers to using dilators.  
Knowing about the clinical importance of using dilators to enable pelvic vaginal 
examinations to detect cancer recurrence was helpful for women in persevering with 
using dilators and in using them more frequently in an ongoing manner (Robinson et 
al., 1999; Cullen et al., 2012; 2013; Punt, 2011). Thus good information about the 
rationale for dilator use is helpful. Viewing dilator use as a continuation of treatment 
and as a facet of recovery helped reduce barriers to their use for some women and 
‘fear of not using’ it once knowing about potential consequences such as vaginal 
stenosis and painful pelvic examinations encouraged their use (Cullen et al., 2012). 
Bonner et al. (2012) concurred and added the following strategies for reducing 
barriers found in their study: improving the belief of dilator efficacy, stenosis 
reminders and apprehension, coming to terms with routine and medical care use of 
dilators and highlighting the beneficial aspects allowed for their use. 
However, many women were still not using dilators after knowing about the clinical 
importance thereof, either because they did not have a partner, they were no longer 
sexually active or their partner had physical difficulties. In Friedman et al.’s (2011) 
study adherers were more likely to be concerned about their sex life than non-
adherers.  
As a result of barriers reported by women in their study and their barrier reduction 
findings noted above, Bonner et al. (2012) developed a dilator use model. They used 
a widely used theory in conceptualising health behaviours, namely the Health Belief 
Model (Rosenstock, 1974; Janz & Becker, 1984) (see Figure 9 below). Bonner et al. 
(2012, p. 2311) designed the model with the view to it informing future research and 
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interventions focusing on vaginal dilator use. The model is further intended to act as 
a foundation for helping women maintain their motivation to use dilators in an 
ongoing manner. The five main factors of this model are: action cues, modifying 
factors like demographics, specific health behaviour, perceived susceptibility and 
threats, benefits and barriers (Bonner et al., 2012, p.2312). They expound on each 
dimension as follows: 
 Cues to action: early information provision and continued dilator use follow-
up, stenosis discussion before PRT, additional explanation at dilator provision 
ideally all would take place in prioritised nurse-led session with supporting 
written information to minimise information overload and ongoing medical 
examination examining and encouraging dilator use. 
 Benefits of dilator use: individualised according to women’s need, for instance 
sexual function or pelvic examination. Follow-up consultations can assess 
stenosis and frequency of use discussed with empathy and without judgement 
to foster open communication and minimise guilt/blame if stenosis has 
developed.  
 Barriers to dilator use: via various methods such as information provision, 
vignettes of others women’s positive experiences and helpful ways they 
included dilator practice in their daily lives may invite consistent use. Discrete 
and attractive packaging may improve acceptance and comfort of dilators. 
 Demographic and clinical factors: pretreatment relationship status and sexual 
occurrence had some relationship to dilator motivation and use frequency. 
Use of dilators declined after PRT and between follow-up visits even in 
women motivated for dilator use. This suggests the importance of medical 
consultations as an important discussion arena to continue using dilators 
when it is clinically important and is desired by women.   
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Figure 9: Post- PRT Dilator use Determinants based on the Health Behaviour Model  
(Bonner et al., 2012, p. 2311) 
Cullen et al.’s (2013) model corroborates Bonner et al.’s (2012) model and there are 
some additional factors they include in their version to reduce barriers to dilator use: 
introduce dilators early and in an open approach as a facet of an extensive treatment 
plan; provide the basis for their use stressing vaginal health safeguarding rather than 
sexual focus; clinician initiated conversations about dilator values, beliefs and 
emotional response to their use. Furthermore these authors argue that improving 
dilator accessibility and provision of psychoeducational resource supporting dilator 
use might reduce what might be frightening in their acquisition and improve 
adherence (Cullen et al., 2013; Friedman et al., 2011; Brand et al., 2012). Lastly, 
with regards to reducing vaginal dilator use barriers, Cullen et al. (2013) contend that 
standardising rehabilitative vaginal dilator use within healthcare units would 
guarantee the reception of consistent messages reinforcing their use across 
women’s healthcare teams. 
Concluding this section, while vaginal dilation is commonly recommended after 
pelvic radiotherapy/brachytherapy to reduce the risk of vaginal stenosis/scarring, this 
recommendation is not routinely communicated or implemented in a standardised 
manner (Bahng, et al., 2012; Lancaster, 2004).  
   
70 
 
2.3.2 Other Rehabilitation Strategies: Vaginal Moisturisers, 
Lubricants and Pelvic Floor Muscle Exercises (Kegel)  
Whilst vaginal dilator use as a rehabilitation strategy is the main focus of the current 
study due to the potential clinical (surveillance/detecting new or recurrent cancer and 
vaginal health care by enabling pelvic examination) and sexual impact of vaginal 
stenosis post PRT, additional and important strategies to facilitate recovery will be 
briefly discussed below, namely lubricants/moisturisers and pelvic floor muscle 
exercises.  
2.3.2.1 Lubricants and moisturisers 
A significant number of women with gynaecological and anorectal cancer experience 
PRT-, chemotherapy- and/or surgery-induced premature menopause. Furthermore, 
women commonly experience an ongoing lack of interest in sexual relations and lack 
of lubrication post PRT which can be as a result of treatment induced menopausal 
symptoms (Jensen et al., 2004b; Schover, 2005; Sekse et al., 2010; 2013; Stilos et 
al., 2008; Bodurka & Sun, 2006). Low levels of oestrogen are linked with vaginal 
dryness and sexual adverse effects such as, pain, atrophy and itching which in turn 
can result in dyspareunia and bleeding during penetrative sexual intercourse and to 
lack of inclination for intercourse (Bodurka & Sun, 2006; Schover, 2005; 2008; Stilos 
et al., 2008; Audette & Waterman, 2010). Damast et al. (2012) found that sexual 
dysfunction was present in 80% of the endometrial cancer patients after high dose 
brachytherapy with lack of vaginal lubricant use found to be a contributing factor.  
Improving vaginal dryness and discomfort has been found to enhance sexual 
interest; perceptions of arousal and ability to achieve orgasm (Carter et al., 2010).  
Hormonal replacements can be prescribed by clinicians however women with 
hormone-receptive cancers (e.g. endometrial cancer patients) cannot be prescribed 
such treatment (Carter et al., 2013). Nonhormonal moisturisers and lubricants are 
commonly recommended for women with vaginal atrophy occurring as a result of 
PRT induced menopausal symptoms (Carter et al., 2010; 2013, Schover, 2005; 
Audette & Waterman, 2010), to re-establish lubrication and natural pH balance to the 
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vagina and vulva (Carter et al., 2011). Vaginal moisturisers and lubricants are 
distinct from each other and have different functions which will be discussed below. 
Vaginal Moisturisers 
Vaginal moisturisers are over-the-counter non-hormonal products (e.g. Replens, see 
Figure 10 below), prescribed for vaginal health whether the woman is sexually active 
or not. They are used for hydration of the vaginal mucosa and restore/maintain pH 
balance several times per week. Vaginal moisturisers improve water balance for 
dehydrated tissues, delivering nutrients and in doing so assisting tissue elasticity 
(Carter et al., 2013). There is growing clinician and patient recognition of the benefits 
of these products for menopausal women (Carter et al., 2013). Loprinzi et al. (1997) 
and Caswell and Kane (2002) did not find any benefit of using Replens over using 
water or pectin-based lubricants. Replens did provide the same symptom relief as 
vaginal oestrogens in Nachtigall (1994) and Bygdeman and Swahn’s (1996) small 
trials. Carter et al. (2011) contend that regular use of vaginal moisturisers may be 
effective as opposed to the differences in product ingredients. 
It is not unusual for women in this setting to require using moisturisers 3-5 times per 
week. For best absorption women are recommended to insert tampon shaped 
applicators or vaginal suppository moisturisers at night when going to sleep (Carter 
et al., 2011).  
 
Figure 10: Replens, an example of a vaginal moisturiser 
(Amazon, 2014) 
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Vaginal Lubricants 
Women post gynaecological cancer treatments often require the use of both 
moisturisers and lubricants to prevent pelvic examination and sexual activity 
discomfort. The purpose of vaginal lubricants is for their liquid or gel to be dispensed 
in the areas of clitoris and labia minora and inside the entrance of vagina to reduce 
pain and dryness during penetrative sexual intercourse and for greater effect on the 
penis/vibrator to reduce friction and irritation (Carter et al., 2011). Water and/or 
silicone based treatments such as Sylk (see Figure 11 below) are recommended 
above chemically based products which may irritate sensitive skin affected by 
radiation and lack of oestrogen. Petroleum based products are not advocated since 
they have been known to cause infection. 
Vaginal lubricants dispensed regularly and correctly have been found to inhibit post 
sexual activity irritation and mucosal tears which are also implicated in vaginal 
urinary tract infections (Carter et al., 2011).  
 
Figure 11: Sylk an example of personal lubricant 
(My Health Specials, 2014) 
2.3.2.2 Pelvic floor muscle exercises (Kegel) 
PRT is associated with numerous long-term side effects on pelvic organs (such as 
the sexual organs, bladder and bowel) however there has been little research on the 
adverse effects on pelvic floor function in the gynaecological (Hazewinkel et al., 
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2010a; 2010b; Tan et al., 2008) and anorectal cancer treatment setting (Andreyev et 
al., 2005; Ooi et al., 1999; Allgayer et al., 2005; Loos et al., 2013).  
Studies (Rosenbaum, 2007; Goldfinger et al., 2009) have found that consciousness 
and control of pelvic muscles is a successful interventional aspect of vaginal pain. If, 
during sexual intercourse, women are able to keep these muscles relaxed (Tu et al., 
2008) and on pelvic examination, they are less likely to experience pain from PRT 
treatment related vaginal degeneration (Carter et al., 2011). Carter et al. (2011) cited 
studies showing that increased blood flow to the pelvic floor by relaxing pelvic floor 
muscles has been found to have additional benefits, such as better sexual 
functioning (Lowenstein et al., 2010). Moreover, improved blood supply to the clitoral 
and genital area may have rehabilitation (Schroder et al., 2005) and improved 
arousal effects (Schover, 2005). Pelvic muscle control around the vaginal entrance 
can be achieved by using Kegel exercises. Physiotherapists can aid patients who 
have difficulty with these exercises by using biofeedback.  
Vaginal dilators are ranked in size. These can also be used to increase vaginal 
comfort and to gain control over pelvic floor muscles (Carter et al., 2011). Women 
often reflexively tense pelvic floor muscles when they experience vaginal pain. This 
causes more pain and inhibits insertion leading to resistance, acute pain, tissue 
inflammation and exacerbation of vaginal atrophy. Vaginal dilators can provide 
feedback in learning to control tensing and for relaxing the pelvic floor muscles and 
thus minimise these problems (Schover, 1997 cited in Carter et al., 2011).  
2.3.3 Evidence regarding the impact of dilator use 
Unfortunately, there is a paucity of prospective, retrospective and longitudinal 
studies explicitly exploring the use of vaginal dilators, measuring physical 
changes/vaginal stenosis, and the potential clinical and psychosexual significance of 
dilator use for women of undergoing PRT for gynaecological and anorectal cancer 
(n=30) (Lancaster, 2004; Friedman et al., 2011; Bahng et al., 2012; Wolf, 2006; 
Brand et al., 2012). Thus a strong evidence-base for recommending dilators is 
lacking. In a recent Cochrane Review on vaginal dilator use for women undergoing 
PRT Johnson and Miles (2010) concluded that routine dilation during or after PRT 
may be harmful. Though this is rare, there is evidence of traumatic rectovaginal 
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fistulae being associated with  dilation (Hoffman et al., 2003 cited in Johnson et al., 
2010) with resultant psychological effects (Hull et al., 2008; Miles, 2008 cited in 
Johnson et al., 2010b). As such, this potentially serious effect has to be recognised. 
Falk and Dizon (2013) note that although the efficacy of vaginal dilation has not been 
proven, with concerns raised by investigators, such as Johnson & Miles’ (2010), 
regarding the risk of genital tract fistula, they contend that there is currently no 
alternative to dilator use, besides surgery, for vaginal fibrosis/vaginal stenosis. Falk 
and Dizon (2013) note that fistula is a rare complication which may occur as a result 
of PRT even when dilators are not used. 
Johnson & Miles (2010) found no reliable evidence showing that routine and regular 
dilator use prevents PRT-related late effects or QOL citing, for instance, study 
methodological flaws, small sample sizes and a lack of randomised controlled trials. 
They did conclude that gentle vaginal exploration might allow for the parting of the 
vaginal walls prior to them sticking together and that some women may benefit from 
using dilators once the inflammatory period had settled (2-8 weeks after radiation 
therapy), however, they found no good quality comparative data (Johnson & Miles, 
2010). According to Johnson et al. (2010), although dilation might treat late effects of 
radiotherapy, its applicability to acute toxicity phase cannot always be assumed. 
Also, there is lack of good evidence for routine dilator use during treatment. 
Furthermore these authors contend that imposing dilator use could cause 
psychological distress (Johnson & Miles, 2010).  
Surveillance, however, for new and recurrent cancer, has been strongly 
recommended as seen by the following below. Jin et al. (2011) found that the rate of 
squamous cell carcinoma of the anal region has steadily increased for both men and 
women in Australia since the mid-1980s. About 90% of these were linked to the HPV 
infection. Besides other risk factors women who have had anogenital (e.g. cervical 
cancer) disease have higher odds of developing anal cancer. In Young et al.’s 
(2009) review of 120 anal cancer patients study, 26% of women had related cervical, 
vulval or vaginal intraepithelial neoplasia or cervical cancer reflecting the 
documented link between anal cancer and HPV. In addition, women with anal cancer 
have a greater likelihood of previous cervical, vulvar and vaginal cancer thus follow-
up of patients with gynaecological malignancies need close surveillance of 
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neighbouring anatomical structures (Bjorge et al., 2002; Frisch et al., 1997 cited in 
Young et al., 2009). Invasive and pre-invasive neoplasms of the vulva could be HPV-
induced and the carcinogenic effect could also be widely prevalent in the vulvar 
epithelium. Hence, regular follow-up of patients should be done to check for 
symptoms or signs of recurrence (National Cancer Institute, 2014). 
2.4 Information and supportive care needs after 
PRT 
It was highlighted above that women should be informed of the potential physical 
and sexual effects of PRT before and after their treatment. Adequate information is 
critical to prepare patients for what potentially could occur in regards to their sexual 
functioning in the short and long-term (Cleary et al., 2012). This section will focus on 
literature relating to an important and neglected facet of supportive care post PRT, 
both clinically and psychologically, namely, physical and sexual 
recovery/rehabilitation information provision, and the benefit thereof for women.  
Husson et al. (2011) argue that among the most critical factors of supportive care for 
cancer patients across the cancer trajectory, provision of information is the most 
important aspect. The author reasoned it on the basis that “(t)he goal of providing 
information is to prepare patients for their treatment, to increase adherence to 
therapy, to increase their abilities to cope with the illness and to promote recovery 
(van der Meulen et al., 2008)” (Husson et al., 2011, p. 761).  
Information seeking itself often acts as a method of coping with the after-effects 
(Power et al., 2008). Cancer patients want information. For example, 80% of women 
with gynaecological cancer want detailed information about their disease, its 
treatment and self-care concerns (Bourgeois-Law & Lotocki, 1999). They also want 
to discuss various points related to intimacy and issues on sexuality and of fertility 
after cancer treatment (Katz, 2009; Friedman et al., 2011; Stead et al., 2003; Park et 
al., 2009; Bober et al., 2013; Schover, 2005), as do women with anorectal cancer 
(Wolf, 2006; Greimel et al., 2009; Phillip et al., 2013). Women want to play a role in 
decision making and in their recovery, and need adequate information about 
rehabilitation options to aid this (White, 2008; Bourgeois-Law & Lotocki, 1999).   
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Moreover, the imparting and tailoring of sufficient information regarding radiation 
side effects and dilator use has important implications for women’s physical and 
psychological recovery and wellbeing post PRT treatment. It has been found that 
sufficiently informed women exhibit better: coping skills with side effects; 
engagement with and adherence to post-radiation rehabilitation; a reduction in being 
scared to engage in intercourse and dilator use following treatment; and fewer 
intimate and sexual partner disruptions (Robinson et al., 1999; Juraskova et al., 
2003; Klee et al., 2000). Some studies have demonstrated that when cancer patients 
were satisfied with the information they received greater health related quality of life, 
lower levels of depression and reduced levels of anxiety were shown (Husson et al., 
2011). Conversely, patients who were not informed about possible side effects 
frequently felt disappointed, fearful, and in some instances, angry (Cassileth et al., 
1980). Moreover, many women have erroneous beliefs (e.g. their vagina being 
radioactive post-treatment), and incorrect ideas and improbable expectations with 
regards to their treatment and recovery (Carter et al., 2013), thus information to 
correct misconceptions is vital. 
However, despite the demonstrated need for information and support concerning 
post PRT sexual functioning, care in this area appears to be sub-optimal.  
2.4.1 Unmet needs for information and support 
Many studies (Sekse et al., 2010; Rasmusson et al., 2008; Burns et al., 2007) have 
shown that women are unprepared to deal with and cope with sexual difficulties post 
gynaecological and colorectal cancer treatment (Wolf, 2006). Research shows that 
sexual information needs of gynaecological (Cleary et al., 2012; Faithfull & White, 
2008), and more so anorectal cancer patients (Breukink and Donovan 2013; Cornish 
et al., 2007; O’Connor et al., 2010), are frequently unmet. In a systematic review, 
Husson et al. (2011) found that in the studies that they reviewed ranges of 6-93% of 
cancer patients reported unmet information provision needs. A NSW Cancer Council 
survey (2007) (Heading, 2008) found that a major failure of care reported by 
outpatients was about not receiving enough information about possible changes in 
sexual activity and in the relationship with spouse or partner. These survey findings 
are corroborated by other studies showing gynaecological and female anorectal 
patients receive little or no sexuality information (Incrocci & Jensen, 2013; Katz, 
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2005, Stead et al., 2006; Juraskova et al., 2003; Wolf, 2006). For example, research 
suggests that only 10-28% of gynaecological cancer patients are provided with 
information regarding sexual function from their treatment team prior to starting their 
treatment (Tsai et al., 2011; Stead et al., 2003; Lammerink et al., 2012). When they 
do receive information, patients are often dissatisfied, disappointed and discontented 
with the information made available (Steele & Fitch, 2008, Cleary & Hegarty, 2011). 
Similarly, in Nicolaije et al.’s (2012) study, most endometrial cancer patients said 
they were either not, or were a little informed about potential treatment side effects. 
Women in this study received the least information on topics related to post-
treatment care including what to anticipate psychosocially and what to expect about 
their sexual life, where to go for help, for rehabilitation or psychological support, how 
to cope with matters after discharge and things to implement to aid their health. 
Importantly, they reported that the aftercare related issues, named above, was 
where women desired receiving more information. O’Connor et al. (2010) also found 
that whilst women with rectal cancer were satisfied with treatment- related 
information they received they were less satisfied with information about the long-
term physical, psychological and social consequences of the disease.  
2.4.2 Factors impacting on information provision 
As noted above, maximum possible information is desired by the majority of cancer 
patients (Jenkins et al., 2001, Rutten et al., 2005 cited in Nicolaije et al., 2012). 
However, the extent of information desired may be affected by factors such as: 
gender, age, education point, cultural upbringing, cancer type, coping manner, 
illness stage with regards to diagnosis, treatment and follow-up (O’Connor et al., 
2010). For example, O’Connor et al.’s (2010) study on rectal patients’ informational 
needs showed that younger patients had significantly higher information needs. They 
were more concerned about whether the treatment would change the way they 
appeared or whether it would affect their sex life or relationships. Further to these 
challenges, older women often ask fewer questions than their younger counterparts 
and as a consequence might receive less information (Nicolaije et al., 2012). To 
compound this, studies have also shown that clinicians may be biased towards 
providing older patients with less information (Mayer et al., 2007 cited in Nicolaije et 
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al., 2012). Therefore, these older patients rely more on information from their 
healthcare practitioners (Rutten et al., 2005). 
On a similar note, less educated patients might show more certainty (Galloway et al., 
1996 cited in Nicolaije et al., 2012), seek less information (Rutten et al., 2005) and 
be less likely to question information that is not meeting their needs (Nicolaije et al., 
2012). Thus they may obtain less relevant information than higher educated patients 
(Nicolaije et al., 2012). Practitioners may also provide more information to their 
higher educated patients (Nicolaije et al., 2012).  
Patients with less comorbidity were noted to be receiving more information and 
deriving greater satisfaction with the information. This suggests, patients with more 
problems have a greater need for more specific information and standard information 
have limitations in providing the required information (Nicolaije et al., 2012).  
These are challenges that need to be considered in the advancement of 
personalised, patient-centred, accurately-timed information for those in need 
(Nicolaije et al., 2012). Additionally, the challenge with all the cancers in the current 
study is to know which, when and how much information to provide. For instance, 
colorectal patients require information that is not overwhelming at a time of immense 
uncertainty as to their treatment road (e.g. requiring a stoma, if so temporary or 
permanent stoma, radiotherapy, chemotherapy) (O’Connor et al., 2010). Similarly, 
with regards to the timing of sexual health information for gynaecological cancer 
patients the literature appears to deduce that there is no one time period to provide 
education on sexuality; rather information should be provided to address issues 
across the trajectory of diagnosis, treatment and recovery, with personalised needs 
guiding timing (Bourgeois- Law & Lotocki, 1999, Gamel et al., 2000, Rasmusson & 
Thome, 2008). Bruheim et al. (2013b) suggest that providing information about 
possible side effects prior to treatment will ease the difficulty for cancer patients in 
identifying or raising these issues/problems should they present at a later stage. 
However they may not be ready to consider these issues at that time. A still existing 
challenge within supportive care in radiotherapy practice is the determination of the 
optimal time, context and strategy to convey sensitive information (Faithfull & White, 
2008). This has been an area identified for further research as has the need for, and 
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relationship between, written materials and clinical discussions (Faithful & White, 
2008; Katz, 2005; Wolf, 2006; Bodurka & Sun, 2006).  
As can be seen, addressing information needs and providing information to cancer 
patients is a complex and multifaceted issue (King et al., 2010; Hill et al., 2011; 
McCallum et al., 2012). Along the cancer care and treatment trajectory, there are 
numerous junctures where obtaining care and information can be lacking and/or 
inadequate in meeting patients’ needs (Porter et al., 2005). Similarly treatment 
pathways are specialised for patients being treated for different cancers. 
Furthermore cancer patients express varying needs with some ignoring or avoiding 
information as a coping mechanism (Leydon et al., 2000) and some others searching 
to know as much about their treatment as they can (Cox et al., 2006). King et al. 
(2010) found that clinicians are encouraged to tailor the information to be provided 
according to the readiness of their patients to receive it and depending on the phase 
of their disease. However, it has been shown that clinicians, at diagnosis, often 
underestimate their patient’s desire for information (Frojd & Von Essen, 2006 cited in 
King et al., 2010). Furthermore, Cox et al., 2006 cited in King et al. (2010) argue that 
the patients who wish for resources are often disadvantaged by materials or 
discussion not being available to them at diagnosis.  
Thus the above literature review section highlights the importance and complexities 
of meeting supportive care and informational needs for women and issues to 
consider in doing so. Breukink and Donovan (2013) argue that there should be a 
discussion and documentation of sexual dysfunction as a post cancer treatment 
complication. However, the prevention and treatment of sexual morbidity are often 
not ideal in clinical practice for a host of reasons (Levin et al., 2010). Potential 
barriers to clinician and patient sexual morbidity discussions and interventions will be 
discussed below. 
2.5 Patient-clinician communication about PRT 
treatment-related sexual issues 
Patient-centred communication may provide a means of overcoming issues such as 
dissatisfaction and unmet information needs. Onujiogu et al. (2011, p. 359) stressed 
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the importance of this communication going as far as to say that “…it’s paramount 
that clinicians make an effort to communicate with gynaecologic cancer patients 
about the risks and modes of management of sexual dysfunction”. However, despite 
such assertions, discussions of post-treatment sexual adjustment issues commonly 
remains a taboo within the clinical setting (Hill et al., 2011; Lindau et al., 2007; Wolf, 
2006; Falk and Dizon, 2013). Only 25% of doctors and 20% of nurses reported 
discussing sexual function with their patients in Stead et al.’s ovarian cancer study 
(2003). Hendren et al. (2005) found that only 9% of female and 39% of male rectal 
cancer patients recall discussion about the effects of the treatment on their sexual 
function preoperatively. Chorost et al. (2000) found a similar result with regards to no 
mention of possible sexual dysfunction in the informed consent process in a 
multimodality colorectal treatment study.  Thus, it has been found that many 
clinicians prefer to concentrate on tackling the disease (Quinn et al., 2008;  Hordern 
et al., 2007) and rarely raise sexual issues (Stead et al., 2003; Wang et al., 2013). 
Moreover, discussions of sexual issues are often not raised despite the fact that 
healthcare professionals are well aware that these post-treatment issues exist 
(Wang et al., 2013). In Stead et al.’s (2003) ovarian cancer study, most healthcare 
professionals reported knowing that women would experience sexual problems.   
Research has shown that doctors feel uncomfortable when discussing these aspects 
with patients. Doctors often assume that women have an adequate understanding of 
female reproductive anatomy. This assumption has implications on effective 
information provision. Further reported reasons for health care professionals not 
discussing sexual function with gynaecological cancer patients are: feeling that it is 
not their responsibility, lacking time, training, knowledge and experience, 
embarrassment discussing sexual issues and lack of resources to provide additional 
support if needed (Bodurka & Sun, 2006, Park et al., 2009; Hordern & Street, 2007; 
Bober et al., 2013). Onujiogu et al. (2011) and others (Bonner et al., 2012; White, 
2008; Cullen et al., 2012) cite additional clinician barriers over and above those 
mentioned above, namely, opposite gender consultations, privacy constraints and 
practitioner discomfort discussing sexual issues. Additionally, some practitioners 
perceive sexual dysfunction to be a low priority (White, 2008).  
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Many women note that they found it difficult to raise the issue of their sexual 
changes with their doctors, not knowing if it was their doctor’s role, with some 
women feeling it was a taboo topic (Hill et al., 2011). Hill et al. (2011) established 
that out of 40-68% of gynaecological and breast cancer patients who believed that it 
would be beneficial to speak to a sexual health professional, only 7-10% really did 
so. Moreover, women report not being referred to clinicians to discuss treatment-
related sexual health (Juraskova, 2009). Further, sexual adjustment may be a 
particularly difficult topic to discuss for older women, couples and those with cultural 
or religious constraints (Juraskova et al., 2003), even though these issues are of 
concern to them (Stead et al., 2003). 
When discussions do occur, patients are frequently unhappy with the quality of 
discussions and amount of time spent by their medical team to discuss sexual health 
issues (Lindau at el., 2007; Duffy et al., 2009). This may explain why few patients 
recall the mention or discussion of sexual risks before treatment or treatment options 
for sexual function post treatment (Park et al., 2009). Lindau et al. (2007) found that 
conversations about cancer/treatment sexual effects were linked with significantly 
lower complex issues of sexual morbidity among patients who suffer vaginal and 
cervical cancer over a very long period.  
A graphic example of the sorts of problems described above comes from an open 
letter from a woman who had endometrial cancer to her oncologist. This was 
published by the members of the Macmillan Late Effects Working Group in the 
Clinical Oncology Journal to motivate oncologists to discuss and debate this 
important issue (Vicary et al., 2007, p. 746-747). 
“Dear Doctor 
I have been coming to your clinic for nearly 6 years now. Last week, I was seen by 
your registrar, who informed me that everything was fine. He said that it would be 
very unlikely for the cancer ever to return, and there was no longer any need for me 
to come back for follow-up. 
I was sorry that I didn't see you, though. You were right about the cancer not coming 
back, that is a relief and I am grateful. But you know, we never had a proper 
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conversation about it all, and what it has really been like. Perhaps you would be 
surprised to know how my life is. 
Everybody says how well I look, and I guess I am cured now. So, as your registrar 
says, I can put it all behind me. Funny, it feels a bit like when I was first diagnosed 
with endometrial cancer. First the hysterectomy, then the radiotherapy with internal 
treatments. ‘Just get through the tiredness and diarrhoea, it's all to be expected, then 
everything will be normal again’. But, it's never been the same, never my ‘normal’ as 
I once was. 
At first, I would ask how long I would be a bit loose, or having to rush to the loo. I 
didn't like to tell you I was having accidents, how embarrassing. You did ask me 
once if we were managing intercourse. I know I said yes, but I couldn't tell you how 
sore and uncomfortable it was. My husband gave up after a while, he could see he 
was just hurting me. I used the dilator just as the nurse instructed, but it has never 
been the same. I wanted to know if everyone was like me, but I never had the 
courage to ask. 
There's another thing, my bladder. In the first year I kept getting cystitis. After this, I 
couldn't last for more than an hour. Everything now needs careful planning. I kept 
going back to my GP who gave me antibiotics, but they made little difference. A 
couple of years later, I had some bleeding from the back passage – that really 
alarmed me. You sent me to the specialist who carried out a colonoscopy. It was 
very uncomfortable, but at least he had an answer. He told me the radiotherapy had 
damaged the bowel and that surgery might be needed if the bleeding didn't stop. 
Fortunately, it did. I eventually understood that this was the problem with my bladder, 
too. It had just shrunk. 
Perhaps you did tell me at the beginning, before the treatment. I don't think I took it 
in, and when I did learn about radiotherapy damage, it was hard to find answers. 
There is so much I still don't know. Will it get worse? What will happen to me? 
I think I was quite angry with you at this time, but I eventually realised that my 
problems weren't caused by bad treatment, they just happen to some people. I just 
didn't understand, but that made it harder to keep bringing the subject up when you 
saw me in clinic. ‘How was I?’ you asked. On a good day uncomfortable, using pads, 
83 
 
and planning carefully every time I went out of the house. On a bad day, I'd rather 
not eat than embarrass myself in front of family and friends and I sleep in a separate 
room now. 
My GP says he has not seen anyone like me before. For a long time, he said he 
didn't know what was going on. He admits he has little experience in looking after 
people with different types of cancer and especially in dealing with the after effects. I 
often have thought that it would have made a difference to talk to other people who 
had similar experiences to me. That's been the worst thing – at times I have felt that I 
was making a fuss. Eventually, finding out that all this was late effects on my bowel 
and bladder almost came as a relief. At least there was an explanation. 
I don't mean to grumble. I just want specialists like yourself to realise that it is not just 
the big problems like bleeding, it is all the little things put together that wear us down. 
We don't expect you to have the answers – by now I realise there aren't easy ones – 
but it helps to be able to talk about them without embarrassment. If you can put in 
our notes that there is no sign of cancer, isn't it important to write down what else we 
are living with, if only so that other doctors and nurses will understand too and we 
can judge if things are changing or getting worse. 
With hindsight, I think I needed to be more prepared for this at the very beginning – 
that life would be different rather than expecting everything to be the same. More 
information. This would have helped, as well as getting information when problems 
begin. When they do happen, it is so important that our symptoms are recognised 
and acknowledged as part of the treatment effects. At least that gives them a label 
and an explanation. Even so, it is hard to qualify for benefits, and GPs and other 
people simply don't understand what I am talking about. 
So, from now on, no more visits – it is all behind me. Yet you and your team are the 
only people who really understand about me and the problems I live with. Frankly, 
I'm scared of losing contact. I feel strongly that I will continue to need the support of 
your clinic and team. I don't need to be seen regularly, but I do need to see you if 
something else happens. I'd like to think that you will still be there to advise and refer 
me on, if I need help from others. 
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Finally, I would like to challenge you to think what you can do for other people like 
me, perhaps the ones just starting treatment now. For all of us, patients, doctors and 
nurses alike, our hearts are set on improving the results and more people being 
cured. It is a tribute to your hard work that more and more of us survive our cancers. 
That means more people like me who have to adapt to a different ‘normal’ and a life 
that has changed. You know, my husband had a heart attack 3 months ago. What 
struck me was how the Heart Specialist Team talked to us together and explained 
that this would now affect all aspects of our lives that things would be different, 
including sex, and they gave us some advice on what to expect and how we were 
going to cope. It made me wonder if something similar would really help people 
going through treatment for cancer. 
I guess I'm an expert too, now – I've lived with problems of surgery and radiotherapy 
for 6 years now. I understand that I don't need regular cancer checks, but I do need 
to know that I can contact you somehow – perhaps through your nurse specialist. I 
would really appreciate that. 
I also know from a friend who was treated for breast cancer that her oncologist sees 
patients affected by late effects through a dedicated clinic and everyone is seen 
once a year. I was wondering if something like this might be set up for those for other 
types of cancer? 
I would like to thank you and your team for the help you have given me over the past 
few years, which is deeply appreciated, and in anticipation of your help in the future 
should I need it. 
Yours sincerely” 
In light of the problems in doctor-patient communication about late pelvic radiation 
effects, particularly sexuality, when opportunities do present for discussions 
regarding post-treatment sexual function, medical personnel evidently need 
guidance and resources in order to intervene optimally (Carter et al., 2013). Many 
authors argue that clinicians require additional training in order to discuss and deal 
with sexual dysfunction with their patients undergoing cancer treatments which can 
cause sexual dysfunction (Park et al., 2009; Bober et al., 2013). Despite this, 
clinicians receive limited communication training, thereby impeding their developing 
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proficiency in key communication areas. Online training may improve this in the 
future. For instance, an online program with learning modules has been developed in 
Australia to impart required knowledge and skills among health professionals to 
render support for women and their partners who experience psychosexual concerns 
after gynaecological cancer post-treatment (Cancer Australia, 2014). Encouragingly, 
Jensen et al. (2003) note that the demand for discussion between healthcare 
professionals and patients on all dimensions of adverse effects post treatment is on 
the rise reflecting a greater acknowledgement of sexual difficulties post cancer and 
it’s treatment.  
Thus to conclude this section, clinician and patient barriers to communication about 
sexual issues post PRT abound and need to be addressed. One way of addressing 
issues in doctor-patient communication is to support or supplement this interaction 
with external resources.  
The following and final sections of the literature review will examine 
psychoeducational interventions/resources for improving communication and 
facilitating post PRT psychosexual recovery.  
2.6 Psychoeducational psychosexual 
interventions and resources 
It has been found that psychoeducational interventions can reduce the fear about 
sexual activity, increase knowledge of related issues and increase adherence with 
using vaginal dilators and improve sexual desire, arousal, orgasm and satisfaction 
(Robinson et al., 1999; Jeffries et al., 2006; Brotto et al., 2008). However, there is a 
significant lack of development and implementation of intervention studies aimed at 
evaluating and treating sexual dysfunction post treatment in the gynaecological and 
anorectal cancer setting (McCallum et al., 2012; Philip et al., 2013; Wolf, 2006; Park 
et al., 2009; Bober et al., 2012). For instance, Gervaz et al., (2008) call for the 
development of effective interventions for the unmet sexual needs of rectal and anal 
(Philip et al., 2013) cancer patients. Flynn et al. (2009) cite a Cochrane Review 
(2009) calling for methodologically sound interventions to address sexual concerns 
for this important patient cohort. Indeed, health professionals report having 
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inadequate knowledge and access to materials that would assist them in 
communicating about post-treatment psychosexual changes (Bourgeois-Law & 
Lotocki, 1999; Cull et al., 1993; Corney et al., 1993). More specifically, there is a lack 
of resources for patients and healthcare professionals working with women 
undergoing pelvic radiation (Faithfull & White, 2008; Bonner et al., 2012; O’Connor et 
al., 2014). 
2.6.1 Printed materials 
In providing information to cancer patients, it has been suggested that verbal 
informing/teaching should go together with additional educational methods to 
guarantee positive outcomes (Treacy & Mayer, 2000). Information provision involves 
new and oftentimes frightening concepts. Thus patients can have difficulty 
comprehending and retaining verbal information, and this can be exacerbated by 
shock, disbelief and information overload. Patients also sometimes perceive 
information as irrelevant at particular times during their cancer diagnosis and 
treatment continuum though needing/desiring the information at a later stage (Cleary 
et al., 2012). Additionally, many women report that they prefer not to discuss sexual 
matters though they would still like to access information.  
Printed education materials can be referred back to as and when is needed, serving 
as a lasting reminder of verbal material (Mills & Sullivan, 1999). There exists a 
tremendous benefit in written information if patients want to retain them as they can 
serve as enduring documents providing reminders from memory and treating 
mistaken beliefs. Such information also helps to enlighten families and community 
clinicians. Thus everyone concerned is aware of the facts and advice that patients 
have been given (Mills & Sullivan, 1999, p. 635). Thus printed materials form an 
important adjunct to doctor-patient communication in this area. 
Furthermore, patients appear to have a strong desire for and benefit from printed 
materials. Whilst Bourgeois-Law and Lotocki (1999) found that 60.3% (n=35) of 
gynaecological cancer patients would prefer a one-on-one consultation with a 
healthcare professional to meet their information needs regarding sexuality, this was 
followed by a pamphlet as a preference (44.8%, n=26). Endometrial cancer patients 
were found to be more satisfied and reported receiving more information upon 
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provision of written information than those who were not in Nicolaije et al.’s (2012) 
study. These authors argue that this is consistent with other studies that found that 
patients who received written information had better recall, knowledge and 
satisfaction with information (Johnson et al., 2003, Smith et al., 2011 cited in 
Nicolaije et al., 2012). Communication/decision aid/psychoeducational resources 
have also been shown to increase knowledge, reduce conflicts of decisions, and 
increase participation in making decisions without undue anxiety (O’Connor et al, 
1999).  
Moreover written material can encourage and promote further discussion and 
questioning (Dennison, 1997 cited in Mills & Sullivan, 1999). Griffiths and Leek 
(1994, cited in Mills & Sullivan, 1999) examined various modes of imparting 
information and found that patients and nurses deemed written resources more 
effective than alternate methods. Taken together, these findings emphasise a need 
to adjoin verbal information with written information (Cleary et al., 2012). 
To be trusted and incorporated into patient care by clinicians, printed materials need 
to be evidence-based and of a high quality (Cleary et al., 2012). Printed materials 
should also address the kind of information women need with regards to sexual 
functioning, tailored to their current knowledge rather than clinician assumed patient 
needs (Aggarwal et al., 2013). Thus patient-reported outcomes and viewpoints are a 
recognised element in the literature on intervention/education material development 
and design (Carter et al., 2013; Campbell et al., 2007). This is to ensure needs-
based, relevant and targeted resources (Cleary et al., 2012).  
The current study aimed to fill the identified gap in information for women following 
PRT, by developing, piloting and trialing a psychoeducational-psychosexual recovery 
booklet for women post PRT, based on evidence, and consumer input.  
To conclude this background chapter the study aims, hypotheses and an explication 
of the study undertakings will be provided below.  
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Aims 
Phase I 
The first phase of the study focused on the development of a psychoeducational 
information booklet to improve information delivery about radiation-induced side 
effects potentially affecting post-treatment recovery, and especially sexual 
functioning, for women with gynaecological and anorectal cancer. The booklet aimed 
to provide information on sexual/psychosexual side effects of PRT and rehabilitation 
options and evidence-based self-care strategies, such as the use of vaginal dilators, 
to prevent/minimise treatment-related vaginal changes. 
Phase II 
The second phase of the study piloted the information booklet. The aims of the pilot 
were to explore women’s views about sexuality and rehabilitation informational 
needs following PRT; investigate the feasibility and acceptability of providing women 
undergoing PRT with an information booklet (developed in Phase I of the study) 
about radiation-induced side effects potentially affecting recovery, and especially 
sexual functioning/vaginal changes, and assess the acceptability of a measurement 
protocol that will be used in a later randomised controlled trial (RCT) of the booklet 
(Phase III).  
Phase III 
The third phase was the conduct of a randomised controlled trial (RCT) of the 
information booklet. The RCT aimed: to evaluate the effectiveness of an Information 
Booklet in improving knowledge, use of dilators and sexual outcomes and reducing 
anxiety depression and stress, through information delivery about: the clinical 
importance of the use of dilators to maintain vaginal patency and minimise stenosis 
for adequate pelvic examinations to detect new or recurrence of cancer, radiation-
induced side effects potentially effecting post-treatment physical and sexual 
functioning, rehabilitation options and self-care strategies, such as the use of vaginal 
dilators, to prevent/minimise vaginal changes. 
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Hypotheses 
In the RCT it was anticipated that compared to the control group (standard care and 
general “Understanding Radiotherapy” Cancer Council booklet), patients in the 
intervention group (who receive standard care plus the study Information Booklet) 
would report:  
1. Greater and more consistent use of vaginal dilators, lubricants and Pelvic 
Floor Muscle exercises;  
2. Greater knowledge regarding post-treatment physical and sexual side-effects 
and rehabilitation options;  
3. Lower levels of anxiety, depression and PRT-related posttraumatic stress 
symptoms; and  
4. Greater improvements in sexual functioning and sexual satisfaction (at 3 and 
6 months post-treatment). 
This study addresses a previously neglected but important component of post-
treatment care for women receiving pelvic radiotherapy by introducing a novel, 
simple and much needed resource. If shown to be effective for women in a 
gynaecological and anorectal cancer setting, the proposed resource is potentially 
transferable to a range of treatment settings for women requiring pelvic-radiotherapy, 
such as bladder cancer.  
The information booklet development chapter will follow here. Following this the pilot 
method and results and the trial (RCT) method and results (at Baseline, 3 and 6 
months) and the overall discussion, clinical implications and study limitations will be 
presented. 
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CHAPTER 3 - Phase I: The 
development of a pelvic radiation 
therapy psychosexual rehabilitation 
information booklet for women with 
gynaecological and anorectal cancer 
3.1 Introduction 
As noted earlier, the need for an information booklet on pelvic radiation therapy 
psychosexual rehabilitation was established from previous research of reported need 
in women, who noted that they received little information on the debilitating and 
highly distressing vaginal and sexual/psychosexual side effects post pelvic radiation 
treatment (Flynn et al., 2012). Clinicians also reported a lack of psychosexual 
resources to support raising sexual issues with their patients (Bodurka and Sun, 
2006, White, 2008).  
Over and above the literature review, expert clinician input, and consumer input we 
conducted a rapid review of existing resources concerning post-radiation care in this 
setting in order to assess what was available, relevant, validated, evidence based 
and/or missing for the study population (n= 25), to determine if a new resource was 
required. Resources identified and examined included leaflets and booklets from 
Australian Cancer Councils (e.g. Sexuality and Cancer of The Cancer Council 
Victoria, 2007); Understanding Radiotherapy (The Cancer Council New South 
Wales, 2007); Understanding Cervical Cancer (The Cancer Council, New South 
Wales, 2005); Understanding Bowel Cancer (The Cancer Council, New South 
Wales, 2008); Understanding Cancer of the Uterus (The Cancer Council, New South 
Wales, 2005), and from other sources such as companies producing dilators for use 
in this population, as well as general support services see Table 2. Clinician and 
consumer input were elicited to assess these resources and identify any gaps or 
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deficiencies in them. Though many of the resources noted in Table 2 contained 
material which partially addressed identified needs in our population, there was no 
single resource found for women undergoing pelvic radiotherapy and which focused 
exclusively on the physical, sexual and psychosexual affects. No resource found 
included detailed information on physical and sexual side effects, psychosexual 
information and support and recommended rehabilitation strategies, especially 
vaginal dilator use. Thus this study attempted to address this gap by developing and 
evaluating an informational booklet on this topic.  
Relevant information from the booklets listed in Table 2 was drawn upon and 
amalgamated. The ticked boxes linked to each resource in Table 2 highlight that 
information was extracted from the resources though reformulated and/or further 
elaborated upon and extended where necessary in order to create the relevant 
sections. What was found lacking and missing was written by the expert panel and 
research team. 
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Table 2:  Identified published resources (see reference list) 
Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
Female anatomy 
(diagrams and 
information) 
      
Pelvic radiation therapy 
(PRT)       
PRT general and 
female reproductive 
system acute and late 
effects 
      
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Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
PRT sexual effects       
Myths about cancer, 
treatment and sexuality 
after PRT 
      
Coping with sexual 
difficulties after PRT       
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Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
Rehabilitation strategy 
1. Vaginal dilators       
Rehabilitation strategy 
2: vaginal lubricants 
and moisturisers 
      
Rehabilitation strategy 
3. Pelvic floor muscle 
exercises and other 
exercises  
      
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Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
Psychological/emotional 
effects of PRT       
Vignettes of women 
with cervical, 
endometrial and anal 
cancer 
      
Sources of 
sexual/relationship 
information and support 
      
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Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
Contacts and resources 
(e.g. books/booklets, 
websites, Helpline, 
Lifeline) 
      
Glossary of terms       
Questions to ask 
clinicians – general 
cancer/treatment 
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Resources -> 
Criteria 
Booklets (x 2): 
Understanding 
Radiotherapy; 
Understanding 
radiation therapy 
 
Booklets (x7): 
Understanding 
Cancer of the 
uterus, vagina; 
bladder; cervix; 
vulva; vaginal; 
bowel cancer 
Booklets (x 2): 
Sexuality and 
Cancer; Sexuality 
for Women with 
Cancer, 
Vaginal dilator use 
leaflets (x3), pelvic 
floor muscle 
exercise leaflets 
(x1), Amielle Care 
Brochure (Amielle 
Dilators company) 
Booklets and 
leaflets (x 6)  
Helping women 
face cancer with 
confidence (Look 
good… feel 
better); The 
Double whammy 
(cancer and 
depression; 
Cancer -How are 
you travelling?; 
Emotions and 
Cancer;  
Lymphoedema – 
what you need to 
know; Sexuality 
for people who 
have a stoma Life 
after Cancer; 
Support Services: 
Cancer Council 
Helpline 
Telephone and 
other Support 
Services; Support 
groups; 
Psychologist 
services at cancer 
centres; 
Multilingual 
cancer 
information 
contacts 
Questions to ask – 
sexual health, vaginal 
dilators 
      
Recovery Diary       
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3.2 Booklet development 
3.2.1 Steps in developing and evaluating the booklet 
The well established and rigorously developed Ottawa guidelines (O’Connor & 
Jacobsen, 2003, p. 5) for developing and evaluating decision aids (DAs) were 
adapted for this study. While not a DA per se, psychoeducational resources can be a 
form of DA (O’Connor & Jacobsen, 2003), hence these criteria were deemed 
appropriate for the study booklet development. The guidelines, with the way in which 
they were addressed in the current study, are listed below.  
3.2.1.1 Assess need 
O’Connor & Jacobsen (2003) note that the number of consumers affected by a 
health issue, the severity of the problem, current practice and preference differences, 
availability and demand for aids all require consideration, using primary and 
secondary sources. For best results, need for the aid should be delineated by all 
potential users, namely patients and clinicians. For the current study the literature 
was searched to establish prevalence and severity of post-radiation psychosexual 
difficulties (see chapter 2). Interviews were undertaken with oncology professionals, 
researchers and experts with regards to the perceived need for the information 
booklet. The majority of those interviewed, namely, gynaecological and radiation 
oncologists, gynaecological and colorectal clinical nurse consultants, cancer care 
and radiation nurses, clinical and health psychologists and a physiotherapist working 
in the field, all strongly endorsed the need for a resource for women based on their 
clinical observations and/or research they had undertaken or were/had been 
involved in. Many clinicians reported their own experience of helplessness with 
regards to being able to assist their patients and provide them with evidence-based 
resources and/or information to deal with the physical and psychosexual effects of 
PRT. Consumer need for the booklet was demonstrated by interviews as above. The 
lack of a relevant resource was established also by searching the literature (see 
chapter 2).  
 
99 
 
3.2.1.2 Assess feasibility 
O’Connor & Jacobson (2003) suggest that with regards to assessing feasibility, 
important interviews with informers, discussions with focus groups and/or results of 
surveys can be used to explore common roles and practices in decision-making, 
facilitators and barriers to access or obtain support for information, and decisions 
and potential strategies available for overcoming barriers. In this study, the clinician 
interviews described above also assessed the feasibility of providing women with a 
psychosexual resource post PRT. Clinicians interviewed endorsed the feasibility of 
providing the booklet as part of routine clinical care, and did not feel there were 
major barriers to implementation.  
3.2.1.3 Defining the objectives of the aid 
The objectives related to the psycho-educational information booklet were carefully 
defined by the research team. These were to facilitate information delivery and 
communication about pelvic radiation-induced side effects potentially affecting post-
treatment recovery, and especially sexual functioning. It was hoped the booklet 
would improve knowledge, use of dilators and sexual outcomes and reduce anxiety 
depression and stress, through information delivery about:  
 The clinical importance of the use of dilators to maintain vaginal patency and      
minimise stenosis for adequate pelvic examinations to detect new or 
recurrence of cancer.  
 Radiation-induced side effects potentially effecting post-treatment sexual 
functioning.  
 Rehabilitation options and self-care strategies, such as the use of vaginal 
dilators, lubricants and pelvic floor muscles relaxation exercises to 
prevent/minimise vaginal changes.  
3.2.1.4 Identify the framework of decision support 
The framework deemed most appropriate for the study booklet was that of a 
psychoeducational resource, which would allow patients to make choices based on 
the information provided and on their values and needs (see section 2.6 in Chapter 2 
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and section 3.3 in this Chapter). Knowledge/information is a form of supportive care 
known to reduce psychological morbidity post cancer treatment (Husson et al., 2011; 
Juraskova et al., 2003).  
3.2.1.5 Select the methods of decision support to be used in the 
aid. 
The method of decision support was primarily information supplemented by 
directions to useful contacts, books and websites for women. Women were advised 
to discuss, clarify and confirm any decisions made with their healthcare team and/or 
to address any concerns that they had at any point prior to using the recommended 
rehabilitation strategies. 
3.2.1.6 Select the designs and measures to evaluate the aid 
Though some quantitative data was gathered, a mainly qualitative methodology was 
employed in the pilot of the study information booklet (n=20).  The aim of the booklet 
pilot was to retrospectively (i) explore women’s views about sexuality and 
rehabilitation informational needs following PRT; (ii) investigate the feasibility and 
acceptability of providing women undergoing PRT with the information booklet 
(developed in Phase I of the study) about radiation-induced side effects potentially 
affecting recovery, and especially sexual functioning/vaginal changes, and (iii) 
assess the acceptability of a measurement protocol that would be used in a later 
randomised controlled trial (RCT) of the booklet (Phase III) (See Chapter 5 
onwards). Standardised outcome measures used were: psychological status scales 
(HADS, IES-R) and sexual function and satisfaction scales (SAQ, SFAGIS, FSFI 
subscale). Purpose-designed scales utilised to assess the outcomes of acceptability 
and need and usefulness of the study booklet were measured using the Knowledge 
Scale and the Feedback Scales (KS, FS), and demographic and clinical 
characteristics of the sample were obtained. Further outcome measures 
implemented included inviting women to comment on the booklet using open-ended 
questions in the study questionnaires, and in 30-45 minute semi-structured 
telephone interviews.  
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Following women’s positive booklet endorsement/feedback in the pilot, the booklet 
was revised and evaluated in a randomised controlled trial (RCT) (n=82) (see 
Chapter 5 onwards). The feasibility of the measurement protocol was assessed and 
revised for the RCT (See pilot chapter 4).  
The RCT study employed a quantitative, prospective (baseline, 3 and 6 months 
follow-up post PRT), multi-centre, randomised controlled trial (RCT) design aimed to 
evaluate the effectiveness of the psychoeducational information booklet, utilising 
most of the same outcome measures as used in the pilot (with some variations, see 
Chapter 4).  
3.2.1.7 Plan dissemination 
Following the RCT, on the basis of positive outcomes, the researcher met with 
clinicians and researchers and cancer community organisations, to explore optimal 
methods for booklet publication and dissemination to women at oncology centres 
post evaluation, by mail and online in Australia. Several clinicians and the Cancer 
Council NSW agreed to disseminate the booklet.  
3.3 Booklet development  
In conjunction with the literature and relevant available resource reviews, an expert 
advisory group comprising clinicians involved in women’s post-radiation care and 
consumers, was established to provide input into the development of the booklet. 
Recommended expert clinicians and academics were recruited from three major 
tertiary hospitals in NSW, Australia, and included gynaecological oncologists, 
radiation oncologists, specialist cancer nurses in gynaecological and anorectal 
oncology, radiation oncology nurses, a physiotherapist and a clinical psychologist 
working in the area. An initial draft was prepared by the candidate, based on the 
literature and principles described below. The expert advisory group and three 
consumers reviewed the study booklet, providing recommendations which were 
included in the booklet development. 
The booklet was based on the literature and analysis of existing resources as 
discussed above (all listed in Table 2). Furthermore, based on a previous, large 
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scale study on psychosexual adjustment following treatment for gynaecological 
cancer (early stage endometrial and cervical cancer), by Juraskova (2003), the 
following elements were proposed in order to facilitate effective post-treatment 
sexual adjustment (see Table 3), which were all incorporated in to the current study 
booklet. 
Table 3: Proposed components to facilitate effective post-treatment sexual 
adjustment  
(Juraskova, 2003, p. 117) 
Advocate coping in an active and positive way  
Promote positive perception on sexual self-concept/intimate relating 
Target on the communication skills of the couple 
Encourage sensuous activities different from intercourse  
Provide information on any physical changes which can be potentially treatment-
induced and possible side effects 
Elicit feedback regarding information given and as understood by them 
Provide opportunities of tackling difficulties due to late-presenting 
physiological/psychological problems 
Educate irradiated gynaecological patients about the importance of using the 
dilators 
The above study (Juraskova, 2003), also provided practical suggestions, with 
regards to written and verbal information for women, to facilitate positive adjustment 
post-treatment, which were also considered for the current study booklet and where 
relevant implemented (see Table 4). 
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Table 4: Practical suggestions to facilitate positive adjustment  
(Juraskova, 2003, p. 135) 
Provide information in simple and non-judgemental language 
Discuss the content of written information to maximise understanding (women 
encouraged to discuss any concerns with their clinicians in current study booklet) 
Provide clear explanations, using diagrams and visual aids (diagrams in current 
study booklet) 
Encourage patients to ask questions (prompt list in current study booklet)  
Invite partner or friend to be present at consultation (and colposcopy) women 
encouraged to speak to their partners, families, friends for support in current study 
booklet) 
Explain the advantages of watching colposcopy on video (n/a for current study) 
Normalise and generalise the condition (physical and sexual side effects, 
concerns/needs and psychological affects normalised and generalised in current 
study booklet) 
Raise potential concerns related to cancer and fertility (discussed in current study 
booklet) 
Promote an active and positive coping style (promoted in current study booklet) 
Make the option of further counselling available at any time (offered in the current 
booklet in many instances) 
Include personal quotes from treated patients in pamphlets (included in current study 
booklet) 
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Initial and later drafts of the booklet were reviewed using an iterative process 
involving discussion between the research team and the expert advisory group. The 
final draft was also reviewed by an independent group of clinical oncology 
consultants (oncologists, specialist cancer nurses, radiation nurses) involved in 
women’s post-radiation care to check the clinical relevance and accuracy of the 
information.  
As a result of clinicians’ and researchers’ input, women with anal and rectal cancer 
were targeted as well as women with gynaecological cancers. The advisory group 
also provided and reviewed medical, sexual side effects and psychosexual 
information, vignettes of patients’ experiences and contacts for women. A clinical 
psychologist working exclusively with women treated for cancer including 
gynaecological and anorectal cancer gave input with regards to the psychological 
effect of the treatment and specifically with regards to sexual dysfunction.  
The draft information booklet was professionally designed by a graphic designer and 
professionally printed. The draft booklet was then piloted and then revised based on 
patient feedback (see Appendix 2.1), updated information by experts in the field and 
current evidence. The booklet was then redesigned by the graphic designer and 
reprinted for the randomised controlled trial (see Appendix 2.2).  
The final content of the booklet incorporated information on: PRT, PRT side effects 
(including diagrams of female reproductive organs), general PRT acute and late 
effects, description of and coping with sexual difficulties after radiation, practical 
strategies to maximise vaginal health after radiation treatment (e.g. using vaginal 
dilators), psychological/emotional effects of pelvic radiation therapy, how and where 
to access information and help, and a question prompt list.   
The full content list is presented in Table 5 and some exemplar pages in Figure 12. 
The final booklet (RCT) is provided in the appendices (Appendix 2.2).  
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Table 5: Structure and Content of the Information Booklet 
Content of the Information Booklet 
 Internal and external pelvic radiation therapy 
 Pelvic radiation therapy general acute and late side effects and (includes 
diagrams of female reproductive organs) 
 Sexuality during and after pelvic radiation therapy (e.g., common sexual 
problems pain during intercourse, reduced vaginal flexibility and size), dispels 
myths about treatment and sexuality 
 Coping with sexual difficulties after radiation 
 Practical strategies to maximise vaginal health after radiation treatment- 
Vaginal dilators, Lubricators, Pelvic Floor Muscle (PFM) Exercises 
 Psychological/emotional effects of pelvic radiation therapy 
 Where you can get information, support contacts and resources 
 References and Glossary of terms 
 Asking Questions can Help: lists prompt questions to ask health professionals 
 Useful health care team contacts: section to list name, number and email 
 My Recovery Diary: lubricant use, sexual activity, dilator use, any difficulties 
(removed from RCT booklet) 
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Figure 12: Examples of booklet pages 
3.5 Tailoring and acknowledging the sensitivity 
of the content 
The literature has highlighted challenges in providing information catering for women 
differing in information preferences, age, culture, cancer type and stage and 
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response to potentially sensitive and distressing issues (Nicolaije et al., 2012; 
O’Connor et al., 2010; King et al., 2010; Hill et al., 2011; McCallum et al., 2012). 
Thus these issues were carefully considered in developing the booklet. For instance, 
the booklet audience was considered with regards to women’s varied ages, cultural 
backgrounds, cancer types, relationship status, sexual orientation, information needs 
and preferences for timing of information provision.  
Messages in the booklet acknowledged that some women may prefer not to read 
about or address sexuality; however it was emphasised that some information 
contained in the booklet has significance for all women whose vaginal health post 
PRT is affected. These messages were conveyed, for instance, in the booklet’s 
opening pages (see completed booklet in Appendix 2.2). 
An attempt was made to make information relevant to all women, whether sexually 
active, heterosexual or lesbian, in a relationship or not. Further, should women’s 
sexuality be of concern and importance to them, the messages in the booklet were 
supporting and validating of their needs for their sex life to be acknowledged and 
maintained and for them to have ways to adjust and ensure this. Following the pilot 
study (see Chapter 4) the booklet was further revised based on the pilot and current 
literature, for the RCT of the resource (see chapter 5 onwards). Those revisions are 
described at the end of the pilot chapter (section 4.4). 
3.4 Ensuring rigour and quality of the booklet 
The widely accepted C.R.E.D.I.B.L.E. Criteria (O’Connor et al., 2003, p. 327) were 
utilised to ensure that the developed study booklet was rigorous and of high quality. 
The development of C.R.E.D.I.B.L.E Criteria was done as part of the Cochrane 
Systematic Review of Patient Decision Aids (O’Connor et al., 2003). These 
C.R.E.D.I.B.L.E Criteria provide key indicators that provide confidence in resource 
credibility, which are listed in Table 6. The ways in which the booklet addresses each 
criterion are also listed.     
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Table 6: The C.R.E.D.I.B.L.E. criteria (O’Connor et al., 2003, p. 327) 
C 
Competently 
developed 
Are the essential components that promote quality 
decision-making included?  
Information is provided in the booklet; as this resource 
was not a decision aid, values clarification exercises 
were not included.   
Are the credentials of developers included in the decision 
aid or supporting materials?  
The developers are listed on the Acknowledgements 
page. 
Is the development process adequate? A complete 
development process includes a needs assessment and 
review by a panel of experts and a panel of potential 
users.  
As noted above, a comprehensive needs assessment 
was undertaken, via the literature, structured interviewers 
with professional stakeholders.   
R Recently updated 
Does the developer have an update policy or evidence 
review process that is continuous or at least every two 
years?  
An update policy is currently being negotiated with 
relevant bodies that may be disseminating the booklet, 
post evaluation.  
E Evidence-based 
Is there a link to an evidence review group or is the 
process that was used to identify and appraise evidence 
described?  
The information was based on a thorough literature 
review (see below) and an expert panel review group 
although that is not outlined in the booklet.   
Are references to scientific studies or systematic 
overviews used to support statements describing 
benefits/harms?  
References are provided in the booklet.  
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DI 
Disclosure of 
conflicts of interest 
Is there disclosure of sponsorship and conflict of 
interest?  
There was neither sponsorship nor any known conflict of 
interest in developing the booklet for women.    
BL 
Balanced 
presentation of 
options, benefits, 
and harms 
Is there a balanced presentation of potential harms and 
benefits?  
Benefits and potential difficulties of dilator use are 
presented. Women are advised to check with their 
treating clinicians before following any post treatment 
rehabilitation recommendations. Women are advised to 
only use vaginal dilators once the acute inflammatory 
phase has settled after their treatment and their use is 
only upon their clinician’s recommendation.  
Do the majority of users find it balanced?  
Perceived balance of the booklet was assessed during 
the randomized controlled trial (see Chapter 5).  
E 
Decision aid is 
Efficacious at 
improving decision 
making 
Do evaluations show that the decision aid improves 
knowledge?  
See chapter 5 and 6 onwards for booklet pilot and RCT 
findings respectively 
Do evaluations show that the decision aid is acceptable 
to users?  
See chapter 5 and 6 onwards for booklet pilot and  RCT 
findings respectively 
Do evaluations show other benefits?  
No other benefits were evaluated.   
Do evaluations show that it was free from adverse 
effects?    
See chapter 4 and 5 onwards for booklet pilot and RCT 
findings respectively 
Do evaluations include a randomized controlled trial? 
Yes – see chapter 5 onwards. 
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3.6 Summary 
The first phase of the current study, namely, the development of the study 
psychoeducational PRT recovery information booklet was presented in this chapter. 
The following chapters focus on evaluating the booklet, in line with the study aims 
and outcomes measured in phase II and III respectively, namely, the pilot and trial of 
this psychosexual information resource for women who have undergone pelvic 
radiation therapy.  
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CHAPTER 4 - Phase II:  The pilot of 
the study developed pelvic radiation 
therapy psychosexual rehabilitation 
information booklet for women with 
gynaecological and anorectal cancer 
4.1 Aims 
As noted in Chapters I and II, women undertaking pelvic radiation treatment (PRT) 
appear to have unmet needs for psychosexual rehabilitation/recovery information 
and resources (Onujiogu et al., 2011; Damast et al., 2012; Bodurka & Sun, 2006; 
Heading, 2008; Lancaster, 2004; Juraskova, 2003; Wolf, 2006; Katz, 2005; Friedman 
et al., 2011; Schover, 2005; White & Faithfull, 2011; Faithfull & White, 2008). In order 
to better meet these needs, a booklet was developed, as reported in Chapter 3. The 
booklet provides information on sexual/vaginal changes side effects following PRT, 
rehabilitation options and evidence-based self-care strategies, such as the use of 
vaginal dilators, which may prevent or minimise treatment-related vaginal changes.  
The aims of the pilot study were to:  
(i) further explore women’s views about sexuality and rehabilitation informational 
needs following PRT;  
(ii) investigate the feasibility and acceptability of providing women undergoing PRT 
with an information booklet (developed in Phase I of the study) about radiation-
induced side effects potentially affecting recovery, and especially sexual 
functioning/vaginal changes, and  
iii) assess the acceptability of a measurement protocol that will be used in a later 
randomised controlled trial (RCT) of the booklet (Phase III).  
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4.2 Method 
4.2.1 Design 
To improve our understanding of patients’ psychosexual recovery needs post PRT 
treatment and to assess women’s responses to the psychosexual rehabilitation 
information booklet, we employed mainly qualitative methodology for this pilot study. 
This was deemed most appropriate for this new area of enquiry, as it would avoid 
pre-empting responses to the booklet (Casebeer & Verhoef, 1997), and would best 
facilitate the elicitation of specific, in-depth, holistic data on the post-treatment sexual 
needs of women, and their views on the information booklet. Quantitative methods 
were used for sample description and characterisation of women recruited in the pilot 
study and for the purpose of pilot aim iii.  
4.2.2 Sample 
Women who had previously undergone definitive or adjuvant treatment (i.e. not 
palliative treatment) at a tertiary cancer centre were approached to participate in this 
pilot study. Patients were eligible to participate if they: (i) had undergone PRT for 
cervical, endometrial, anal or rectal cancers (i.e. cancers found in the pelvic region), 
(ii) were less than 5 years post-treatment, (iii) had been given vaginal dilators as part 
of their post-treatment care, (iv) were 18 years or more of age, (v) were English 
speaking, and (vi) had no concurrent psychiatric or cognitive disability (screened by 
recruiters).  
The pilot study followed purposive sampling procedures in selecting particular 
categories of participants: type of cancer (gynaecological versus anorectal), time 
since treatment (immediately post-PRT versus 4-5 years post PRT), and types of 
clinical setting (follow-up clinics and database), which were meaningful to the 
exploration of the phenomenon and aims of this study, and would ensure that all 
relevant views were heard.  
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4.2.3 Procedures 
Two recruitment pathways were employed for this phase of the study; (i) at the clinic 
(face-to-face recruitment) and (ii) via mail-out.  
Eligible patients were identified by participating clinicians (oncologists or specialist 
cancer nurses) either from the clinic database or at the patient’s follow-up clinic visit.  
Eligible participants who were attending their follow-up visit were approached by 
clinic staff and provided with study packs if they were interested in participating (see 
recruitment pathway 1 in Figure 13). Participants selected from the clinic database 
were mailed packs with the study materials and a letter requesting them to 
participate in this study (see recruitment pathway 2 in Figure 13). The following 
database selection criteria were used: a) participants who in previous studies had 
offered to participate in further research in this area and were eligible, or, b) 
potentially eligible participants selected by the gynaecological and anorectal 
oncology healthcare team. Patients selected retrospectively from the database who 
were mailed study packs and did not wish to participate were given the option to 
return or dispose of the study materials.  
The study packs contained: invitation letters from a doctor/nurse and the 
researchers, a consent form and study information sheet, the information booklet, 
the study questionnaire, and a reply paid envelope (materials available in Appendix 
1). Participants were asked to read the materials and then return the completed 
questionnaire and signed consent form to the research team within two weeks of 
receipt.  
Following return of the questionnaire, semi-structured telephone interviews lasting 
45-60 minutes were conducted to elicit thoughts and feelings about sexuality and 
informational needs post PRT, and feedback about the format, content, clarity and 
usefulness of the booklet, the relevance of the sections, and any suggestions for 
improvement. Participants were provided with the option of withdrawing from the 
study at any time without any adverse consequences on their treatment or 
relationship with their treatment team.  
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Pathway 1:  Clinic Recruitment  
 
Pathway 2:  Mail-out Recruitment  
 
Figure 13: The Two Recruitment Pathways for the Pilot of the Information Booklet 
(Phase II of the study) 
4.2.4 Ethics 
Ethical approvals for the study were obtained from the South West Area Health 
Service, Sydney and from Human Ethics Committee of the University of Sydney (see 
Appendix 1).  
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Due to the sensitive nature of this study, ethical considerations were addressed 
directly from early stages of its development. Protection of vulnerable participants 
was implemented initially through the establishment of rigorous inclusion and 
exclusion criteria. During audit of the clinic database, clinicians familiar with the 
patients being recruited excluded those where there were any concerns about a 
patient’s suitability to be approached prior to any invitation into the study in person or 
invitation letter being sent. 
Women who had agreed to participate in the study and who asked for further 
information about their medical management or expressed distress during the 
interview were offered the contact names of relevant members of their treatment 
team (normally the clinical nurse specialist (CNS) or medical consultant) to approach 
for further information and/or support and onward referral was provided by the 
researcher when offered and/or desire expressed for referral. The researcher, as a 
clinical psychologist, provided specialist information about routes of referral for 
counselling services regarding sexual and relationship concerns. The researcher 
also used her clinical judgement (as a clinical psychologist) of patient cues to identify 
potential distress in participants. The researcher acknowledged the distress within 
the interview, making supportive and empathic comments and offering additional 
support and/or referral in the future. The overt acknowledgement of distress or 
concern expressed during an interview appeared to create greater rapport with some 
participants. 
4.2.5 Measures  
To characterize the sample and obtain quantitative feedback on the booklet, the 
study questionnaires included the following standardized or purpose-designed 
measures:  
4.2.5.1 Hospital Anxiety and Depression Scale (HADS) (Zigmond & 
Snaith, 1983) 
Levels of anxiety and depression were assessed using the validated Hospital Anxiety 
and Depression Scale (HADS) (Zigmond & Snaith, 1983) which consisted of 14 
items. This is a self-assessment evaluation designed to estimate and discriminate 
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between states and severity of anxiety (7 items) and depression (7 items) among 
physically ill patients.  
Each item is presented with Likert scale with a five-point scoring system ranging 
from 0-4 for varying response categories, which apply to the previous week. Each 
item is scored from 0-3. The possible range on anxiety and depression subscales 
scores is 0-21. Summed scores of less than or equal to 7 are indicative of a ‘non-
case’. Summed scores in the range of 8-10 are a ‘doubtful’ case and those above 11 
are a ‘case’ of ‘probable’ presence of psychological distress (possible range on 
anxiety and depression subscales 0-21). If borderline scores (i.e. 8, 9, or 10) are 
found on both subscales individuals are considered at risk for psychological distress. 
High scores reflect high degrees of anxiety or depression symptoms. 
The HADS is a reliable and valid measure and both subscales have good internal 
reliability, with the following mean Cronbach’s alpha found over 15 studies: anxiety: 
0.83; depression: 0.82 (Bjelland et al., 2002). Bjelland et al., (2002, p. 75) found that 
the HADS had “good” to very good” concurrent validity. The HADS has also been 
found to be useful in assessing cancer patients before and after treatment as well as 
for assessment of long-term mental health in long-term survivors (Hopwood et al., 
2000; Hammerlid et al., 1999; Ibbotson et al., 1994 cited in Fossa et al., 2002). The 
inventory has been found to be sensitive to changes both during the course of the 
disease and in response to psychotherapeutic and pharmacological interventions 
(Herrmann, 1997). The HADS has been found to best identify affective disorders in 
those who are disease free and those with stable disease. Furthermore, in its ability 
to detect anxiety and depression in the oncology setting, the HADS, when compared 
with other scales commonly used with the cancer population, namely the General 
Health Questionnaire (GHQ 28) and the Rotterdam Symptom Checklist (RSCL) 
performed best in the sample (Ibbotson et al., 1994). It was found that the sensitivity 
was 80%, specificity was 76% and the positive predictive value was 41%. 
The HADS is deemed one of the most efficient and extensively used screening 
instruments for assessing anxiety and depression levels in a medical scenario and 
also in the general population (Bjelland et al., 2002). Annunziata et al. (2011) noted 
that, in oncology settings, one of the most frequently used scales is the HADS. This 
is because the HADS is specific in assessing patients with organic diseases. The 
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scale does not consider somatic symptoms which are due to emotional distress like 
weight loss, headache or insomnia. In a recent review of methods used in screening 
for emotional distress of cancer patients, Vodermeir et al.’s (2009) reported that the 
HADS had the most extensive validation  data and this was observed across disease 
types, stages, languages and cultures.  We used the HADS to determine the 
psychological profile of the pilot sample with regards to anxiety and depression 
levels and to evaluate the feasibility of using the scale as a measure for later use in a 
randomized controlled trial of the information booklet. 
4.2.5.2 The Impact of Event Scale-Revised (IES-R) (Weiss & Marmar, 
1997) 
Levels of post-traumatic stress were evaluated with the aid of the Impact of Event 
Scale-Revised (IES-R). This scale is a self-report method used to assess 
psychological responses to traumatic stressors such as cancer diagnosis and 
radiation treatment (Elliot & Briere, 1995; Joseph, 2000). It is a very widely used 
method for this purpose. The initial 15-item IES questionnaire  (Horowitz, 1976) 
focused on intrusion and avoidance symptoms; the revised 22-item IES-R (Weiss & 
Marmar, 1997) includes items on hyper-arousal and flashback symptoms which 
more closely relates to the DSM-IV criteria for PTSD (Pratt et al., 2006). This  uses a 
5-point Likert scale of range 0-4 to evaluate the response in a format of equal 
intervals for assessing “how distressed or bothered” they were by each symptom 
during the past week since a traumatic event.  Scoring of the IES-R yields sub-
scores for the individual subsets (intrusion, avoidance, and increased arousal) can 
be obtained as well as a total scale score ranging from 0-88 that indicates subjective 
distress. The mean total stress score indicates posttraumatic stress symptomatology 
with high scores reflecting high levels of posttraumatic stress symptoms. 
Alternatively a cut-off score of 33 (maximum total score 88) identifies patients with 
symptoms in the clinical range. In the current pilot study mean cut-offs were used 
where clinical cases are drawn with a score greater than 1.5 since the authors of the 
IES-R, namely Weiss and Marmar (1997), suggest that the mean of the non-missing 
items should be used instead of summing the item scores (Creamer et al., 2003).   
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Creamer et al. (2003) reported high internal consistency for the total scale of the 
psychometric properties measured by the IES-R as reflected by Cronbach’s alpha 
value of 0.96. It was also consistent for the three subscales. The Cronbach’s alpha 
values were 0.94 for intrusion, 0.87 for avoidance and 0.91 for hyperarousal 
respectively. Branstrom et al. (2010) also reported high internal consistency with 
Cronbach’s values of 0.88 for intrusion, 0.85 for avoidance and 0.80 for 
hyperarousal. The original IES was found to be sensitive to discrimination between 
different populations experiencing different life events (Horowitz et al., 1979). The 
scale is short, easy to administer and individuals of various educational, cultural and 
socioeconomic backgrounds have been able to use it. We used the IES-R to 
determine the psychological profile of the pilot sample with regards to levels of 
posttraumatic stress and to assess the scale’s feasibility as a measure for later use 
in a randomized controlled trial of the information booklet. 
To obtain levels of intrusion and avoidance symptoms on the IES subscales (no cut-
offs have been provided for the subscales on the IES-R and hence the newly added 
hyperarousal scale) the following method can be used (Weiss & Marmar, 1997). The 
levels for the seven intrusion items can be computed with values ranging from 0 to 
35. Also levels for the eight items of avoidance, values of which range between 0 
and 40 are computable. Horowitz (1979) identified three threshold values related to 
low, medium and high symptom levels corresponding to clinical concerns. These 
values were < 8.5 for low, 8.6 to 19.0 for medium and high >19 for high. Scoring of 
the IES-R yields subscores for the individual response sets (intrusion, avoidance, 
increased arousal), as well as a total score that indicates total subjective distress. 
The mean total stress score on the initial administration of the IES was 39.5, with 
mean intrusion being 21.4, and avoidance 18.2 (Horowitz et al., 1979). Although no 
formal PTSD cut-offs have been specified, these original Horowitz et al. (1979) 
scores are generally accepted as a yardstick against which other populations are 
measured. 
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4.2.5.3 Sexual Function Measures 
4.2.5.3.1 The Female Sexual Function Index (FSFI) (Rosen et al., 2000) - 
the Satisfaction Subscale 
In the current study a Satisfaction subscale, consisting of 3 items (14, 15, and 16) 
drawn from the 19 items were drawn from the Female Sexual Function Index (FSFI) 
was used. This subscale is only comprised of items that measure and load 
statistically the global satisfaction of sexual and relationship aspects and therefore, 
according to its authors, this subscale can be regarded as the “quality of life” domain 
of the FSFI (Rosen et al., 2000, p. 198). Respondents rate their overall satisfaction 
with respect to the extent of emotional closeness during sexual activity, extent of 
satisfaction due to their sexual relationship with their partner, and their overall 
satisfaction in sexual life on a 5-point Likert scale over the past 4-weeks.  
Only the satisfaction subscale was used in the current study to avoid 
repetition/duplication and to shorten the questionnaire for women as the topics of 
other subscales were covered by the other sexual function/satisfaction scales 
employed, namely, the SAQ and the SFAGIS (both described below).  
The individual domain scores are used for estimating the subscale scores of FSFI. 
The scores of the individual items comprising the domain are added and the sum is 
multiplied by the factor of the domain concerned. A domain score of zero indicates 
that there was no sexual activity during the past month. Scores range from 0-5 or 1-5 
since the ranges items are: 14=0-5, 15 and 16=1-5. Less than 5.04 on the 
satisfaction subscale were found to be the cut-off score determining difficulty/low 
satisfaction in that domain (Weigel et al., 2005). 
The FSFI has norms based on a sample of women who are diagnosed with Female 
Sexual Arousal Disorder. It discriminates well between clinical and non-clinical 
populations (Rosen et al., 2000). The Satisfaction subscale demonstrates high 
internal consistency denoted by Cronbach’s alpha value of 0.82 (Dargis et al., 2012) 
and test-retest reliability (r value of 0.83) (Rosen et al., 2000).  
Donovan et al. (2010) confirm that the psychometric properties of the FSFI have 
been demonstrated in numerous studies including those that have evaluated sexual 
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function in colorectal cancer survivors (e.g. da Silva et al., 2008 who examined the 
effect of colorectal surgery on sexual function for female cancer patients; and Jayne 
et al., 2005 and Hendren et al., 2005, where the scale was used to assess sexual 
function in rectal cancer post-surgery women. Baser et al. (2012) found that the FSFI 
showed strong psychometric properties supporting its ongoing use in assessing 
women’s cancer-related sexual function. The current study included rectal and anal 
patients since this is an understudied and under included patient population with 
regards to the sexual side effects of PRT though the PRT sexual side effects mimic 
those of the gynaecological setting (Wolf, 2006). Hence this appeared to be a well 
validated and reliable scale for the current study where gynaecological and female 
anorectal cancer women’s post PRT cancer-related post PRT sexual function was 
being assessed. 
4.2.5.3.2 The Sexual Activity Questionnaire (SAQ) (Thirlaway et al., 1996) 
The 14-item scale Sexual Activity Questionnaire (SAQ) was used in the assessment 
of various facets related to sexual function. The SAQ consists of three sections: 
hormonal status and status of women as sexually active, sexual inactivity reasons 
and sexual functioning. The first part of hormonal status, whether women are active 
sexually or not and reasons for sexual inactivity including issues related to partner, 
fatigue, lack of interest in sexual activity and  difficult or uncomfortable sexual 
relations due to physical problems. The format gives space for participants to add 
reasons not listed. Sexually active women then complete the second section of the 
scale, assessing aspects of sexual functioning. The time frame for SAQ sexual 
function section is the previous one month. It has 10 items with three subscales 
related to pleasure, discomfort and habit. A four-point Likert scale is used for rating 
of items 1–7 of the SAQ sexual function section ranging from ‘not at all’ (0) to ‘very 
much’ (3). The SAQ—Discomfort items are expressed in three ways related to 
‘dryness of the vagina’ and ‘pain and discomfort at penetration’. There are five items 
related to SAQ—Pleasure component. These are: ‘sex is important’, ‘do enjoy sexual 
activity’, ‘do desire to have sex’, ‘feel satisfied with sex’ and ‘satisfied or not with 
frequency of sexual activity’. Accordingly, high scores of SAQ pleasure and 
discomfort together means simultaneous high pleasure and high discomfort. There 
are seven items in pleasure subscale with its scores ranging from 0-18. In the 
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discomfort subscale, there are two items with scores ranging from 0-6. The habit 
subscale has only one item with the range of scores from 0-3 (Metcalfe et al., 2004). 
Normative data of the SAQ based on studies on Norwegian women registered high 
internal consistency and high test-retest reliability for the scale according to Vistad et 
al. (2007). Liavaag et al. (2008) obtained the internal consistency values of α = 0.93, 
0.81 and 0.93 for SAQ—Pleasure, for SAQ—Discomfort and among NORM 
corresponding values respectively. The test-retest reliability estimates of Pearson’s r 
for the individual items ranged from 0.68 to 1.00 (Carmack Taylor et al., 2004). The 
SAQ distinguishes between groups expected to differ on sexuality as in the case of 
pre- and postmenopausal women and has been used in breast (Ganz et al., 2002) in 
gynaecological cancer (Carmack Taylor et al., 2004) and in rectal cancer populations 
(Movsas et al., 1998). The SAQ has been found to be non-offensive and feasible. 
Findings demonstrate that the SAQ can be used for sexual function evaluation in 
women with different gynaecological diseases and other conditions affecting their 
sexuality (Vistad et al., 2007). The SAQ has been shown to be acceptable to both 
younger and older women and is recommended for use in clinical trials (Stead et al., 
1999). 
4.2.5.3.3 The Sexual Functioning After Gynaecological Illness Scale 
(SFAGIS) (Bransfield, Horiot, & Nabid, 1984)  
This scale was included in order to assess clinically important elements of post-
treatment rehabilitation such as sexual health, side effects of radiation treatment and 
use of vaginal dilators. The SFAGIS (original form) is self-report measure containing 
30 items. Each item is assessed on a 4-point Likert-type scale. An extensive review 
of the literature on sexual functioning and gynaecological cancer led to the 
conception of the SFAGIS and its main themes (Bruner & Boyd, 1999).  The themes 
were identified and integrated into 15 item pools of sexual desire, availability of a 
partner, patient's fear of sexual activity, sexual satisfaction, initiation of sexual 
activity, affectionate behaviour, frequency of sexual intercourse, frequency of 
orgasm, vaginal dimensions and mucousal conditions, potential for vaginal 
lubrication, desire for information on sexual matters, changes in sexual activity after 
therapy, compliance with a recommendation for a dilator use and intervention of a 
health care provider. Though the SFAGIS has a satisfactory face validity (Juraskova, 
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2003), a  value of 0.80 for split-half reliability coefficient and internal consistency 
reliability alpha (based on Kuder-Richardson formula) of 0.756 and a reliability alpha 
of 0.70, Bruner and Boyd (1999) found it focuses more on narrow aspects of sexual 
function and not the broader issue of sexuality. However, despite the SFAGIS’s 
limitations particular items were relevant with regards to narrower aspects of sexual 
function since at the time of the pilot study it was the only scale we are aware of that 
included a combination of items such as the use of vaginal dilators and post-
treatment mucosal changes. We used additional scales and subscales (i.e. the FSFI 
and SAQ) to make up for and include broader function and satisfaction dimensions 
of sexuality. In order to reduce the burden for participants, items of the SFAGIS that 
overlap with the SAQ and FSFI items were excluded from the scale, leaving an 
adapted 22-item version of the scale (see Appendix 3.1).  
4.2.5.4 Knowledge Scale 
The 15-item purpose-designed Knowledge Scale was used to assess women’s 
knowledge and understanding of the content of the booklet (e.g. side-effects of PRT, 
sexual difficulties post PRT and recommended post-treatment rehabilitation options - 
see Appendix 3.1). Response options were either true/false or ‘don’t know’. A total 
score (0-15) was calculated by summing items. High scores reflect good 
understanding of the booklet content.  
4.2.5.5 Feedback Scale  
General views of participants on the presentation of the study booklet and its content 
were evaluated with a purpose-designed Feedback Scale of 19 items which 
assessed participants’ perceptions of: the format, clarity, sensitivity and utility of the 
booklet, their confidence in using and awareness of the potential importance of using 
rehabilitation strategies, and their comfort with the information in the booklet (see 
Appendix 3.1). Response options used a 5-point Likert scale, which ranged from 
‘Strongly Disagree’ to ‘Strongly agree’ and a ‘Not sure’ option. High scores reflect 
positive feedback on the booklet. 
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4.2.6 Demographic and Clinical information  
Demographic and clinical information was also collected (see Appendix 3.1). These 
included patients’ age and age at diagnosis, relationship status, number of children, 
occupation and highest qualification level. Clinical data concerning cancer type, 
types of treatment received and time since diagnosis were also obtained via the 
questionnaires.  
4.2.7 Semi- structured Telephone Interview 
The researcher conducted telephone interviews with all participants who returned 
their questionnaires and agreed to the telephone interview as part of the study 
protocol. The interviews lasted on average from 30 to 45 minutes in duration. The 
interviewer, who is a trained clinical psychologist, probed for greater detail where 
appropriate. Questions initially addressed general information and support needs 
after PRT. Questions relating to the pilot aims were then asked with regards to the 
format, content and utility of the booklet. Women were asked semi-structured and 
open-ended questions about what they liked, disliked and how to improve the 
booklet overall and more specifically about each chapter and section of the booklet. 
Women were asked to note if they found any aspects of the booklet distressing or 
offensive. The researcher wrote down women’s replies verbatim and transcribed 
their interviews on to a spreadsheet under each question/code which had been 
chosen a priori. Themes that later emerged were given a new category as discussed 
above with regards to the content analysis of the data (see Appendix 1 for 
questionnaires and telephone script). 
4.2.8 Sample size 
Previous pilot studies of communication aids have shown that about 20 patients are 
adequate to achieve theoretical qualitative feedback saturation, and to provide clear 
quantitative trends (Marshall, 1996). Sampling continued until no new themes 
emerged (theoretical saturation (Morse, 2004)) in three consecutive interviews, and 
this was achieved with twenty respondents.  
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4.2.9 Data analysis 
4.2.9.1 Qualitative data 
We utilised a qualitative content analysis approach. Krippendorf (1980) (cited in Elo 
& Kyngas, 2008, p 108) described this approach as a research method useful in 
making valid and replicable conclusions from data as related to their contexts. This 
method serves to represent facts, to gain knowledge and new insights all leading to 
a practical guide for action. 
Thus it appeared to be extremely well suited as a method for analyzing the sensitive 
and multifaceted psychosexual/vaginal changes experienced by women post PRT 
for gynaecological and anorectal cancer. Rosenthal & Rosnow (1991) defined 
content analysis as a method of categorizing information using frequency of 
occurrences. According to Stemler (2001, p1), content analysis is a systematic 
replicable method in which many words of the text can be compressed into fewer 
categories using explicit rules and coding. The approach is considered to be at the 
juncture of qualitative and quantitative techniques, allowing for quantitative 
examination of ostensibly qualitative data to access both manifest and latent 
meaning from the text (Kondracki et al., 2002; Elo & Kyngas, 2008). Quantitatively, 
message elements are counted to identify foreground themes and emphasis in 
certain areas. Qualitatively, the manifest and latent/inferred meanings of the 
messages under inspection can be elaborated on, leading to the development of 
hypotheses or theories based on knowledge and evidence drawn from the study 
(Kondracki et al., 2002).  
Furthermore, content analysis can be applied both inductively and deductively; these 
options are not mutually exclusive but rather are considered useful when combined 
(Berg, 2004). In other words, in content analysis the coding scheme can be decided 
a priori (White and Marsh, 2006; Stemler, 2001) or once emergent themes are 
evident. Thus, as noted above, a directed (deductive) content analysis can be 
undertaken, as with the current study, when incomplete information exists on a 
phenomenon from prior research or requires elaboration (Hsieh & Shannon, 2005) 
because it affords the focusing of questions. With this method, a more structured 
process guides the coding (or categorising) scheme, which helps to identify key 
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concepts and/or variables to be used as initial coding categories (Hseih & Shannon, 
2005). This is of a higher standard than traditional content analysis where codes are 
derived after data collection in an inductive approach. Data collected through 
interviews, as in the current study, used open ended questions which were followed 
by targeted questions on predetermined categories. However, as was the case in the 
current study, text can also later be given a new code/category based on analysis of 
inductive/latent/emergent meanings over and above the initial deductive/a priori 
codes/categories.  
The summing of responses, that is the quantitative aspect of this method, can also 
extend further than the manifest meaning of the data (Hseih & Shannon, 2005) and 
allow for interpretation of the content. Here, as noted above, underlying meaning is 
discovered, such that it is inferred from the data rather than directly addressed at the 
onset. Examples from the current study of non a priori format, content and utility of 
booklet categories that emerged post data collection were: acceptability of the 
booklet rehabilitation strategies, booklet validating sexuality; experiences of care in 
the healthcare setting. However, frequencies of response occurrences held equal 
importance in this content analysis, making it a versatile and relevant research 
method for assessing the feasibility of a psychosexual/vaginal changes rehabilitation 
booklet to women undergoing PRT for cancers in the pelvic region. Thus, both 
inductive and deductive content analyses were utilized: the former where there are 
no prior studies or information is disjointed on an experience and the latter used for 
testing a previous theory in a different type of setting or for comparing different 
groupings at different time periods (Elo & Kyngas, 2008).  
Furthermore, in accordance with pilot aim ii) the quantification of responses was 
highly relevant, as noted above, to inform clinicians in supporting and participating in 
the later RCT. In health sciences, content analysis is accepted and widely used as a 
standard qualitative research method (Hsieh & Shannon, 2005). It is particularly well-
suited to studies involving the practice and education of nurses and other helping 
professionals because of its focus on communication (Downe-Wamboldt, 1992). 
Thus content analysis appears well-suited for clinical practice and patient education 
in the healthcare setting, which was pertinent to the current study.  
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Based on existing theory and specialised/expert colleagues’ consensus regarding 
categories, the current study initially used a priori coding. Here, the coding is applied 
to the data with revisions made as required to ensure mutual exclusivity and 
exhaustiveness (Stemler, 2001; Weber, 1990). Each question from the telephone 
interviews and the study questionnaire was entered into a spreadsheet and 
frequencies of response occurrence were recorded. Responses that fell into broader 
emergent categories were later allocated to those new categories.  
Other qualitative methods, such as thematic analysis, were considered but later 
excluded because they did not appear to meet the pilot study research 
questions/aims, taking account of their different foci (Harper, 2012, p. 85). For 
example, a thematic analysis – which aims to map out the range of concepts or 
summarize unstructured data in thematic categories – was excluded because unlike 
content analysis, it does not examine frequencies of responses. This was needed to 
meet the study objectives to determine how many participants liked the booklet 
format and content and found it helpful (utility) and thus its feasibility for women post 
PRT treatment. Other qualitative methodologies excluded were Grounded Theory, 
Phenomenology and Narrative approach because again content analysis appeared 
to relate to the research aims best. 
4.2.9.2 Trustworthiness 
A major advantage of content analysis is the fact that validity and reliability can be 
tested and maintained, since it is replicable and systematic (Potter & Levine-
Donnerstein, 1999; Stemler, 2001). A content analysis categorises data according to 
a coding scheme which includes rules of data analysis that are logical and scientific. 
This systematic approach is central to trustworthiness (Hsieh & Shannon, 2005) and 
made content analysis an appealing, dependable and relevant research method for 
the present study. 
However, results will not be correct if faulty definitions and non-mutually exclusive 
and exhaustive categories are used (Stemler, 2001). Thus, the following measures 
were put in place to ensure trustworthiness in the present study: 
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Reliability is aided by the demonstration of the data and the analysis, since the 
interpretations and findings can be easily reproduced by others examining the data 
and the process and procedure of the chosen examination (Elo & Kyngis, 2008). In 
the current study, bona fida citations (i.e., patient quotes) were liberally included, in 
accordance with Patton (1990) and Sandelowski (1993) s’ assertion that they 
increase the trustworthiness, reliability, and validity of the analysis by exemplifying 
how categories arose from the original data. Confidentiality/non-identification of the 
participants was observed (Ford & Reutter, 1990).  
Numerous other strategies were also implemented in the current study to ensure 
rigour, validity and reliability of the qualitative approach, most notably an a priori 
coding scheme that guides coders, test-re-test procedures, and multiple coders. 
Emergent categories were subject to the same scrutiny and processes. Further, to 
ensure face, criterion and construct validity, and reliability, the coding scheme had 
definitions which were clear, instructions which were easy to follow, and clear 
examples. Doing this allows for methodical and reproducible analysis of the data and 
ensures inter-coder and intra-coder reliability (White and Marsh, 2006). 
4.2.9.3 Quantitative data 
The quantitative data on demographic and disease characteristics, from the 
standardised measures and regarding perceptions of the booklet, were entered into 
SPSS (IBM SPSS Statistics Premium, Version 19.0) and analysed using frequencies 
and descriptive statistics.  
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4.3 Results 
4.3.1 Sample characteristics 
Of the 66 women invited for participation in the study, 20 (30%) responded. The low 
rate of response was expected given the psychosexual nature of the study and is 
consistent with similar studies (Bonner et al., 2012; Cullen et al., 2012), possibly due 
to reluctance to discuss sensitive and personal issues, as well as the time since 
treatment (up to 5 years post treatment).  
The characteristics of the final sample are presented in Table 7. The average age at 
the time of the study was 55 years, the majority (55%) were married and almost half 
the women (45%) had a university education. In the current study sample, 14 women 
were treated for gynaecological cancer (70%) and 6 (30%) for anorectal cancer. Six 
women were treated with surgery, radiotherapy and chemotherapy (30%), 5 
radiotherapy and surgery (25%), 8 radiotherapy and chemotherapy (40%) and one 
woman had radiotherapy only (5%). Nine women had been diagnosed one year prior 
to the pilot study (45%), 3 were 1-2 years (15%), 1 was 3-4 years (5%) and 7 were 
five years (35%) since diagnosis.    
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Table 7: Demographic and clinical characteristics and descriptive statistics of the 
Sample (N = 20) 
Variable Value 
Age- Years 
   Mean 55.2 
   SD 11.92 
   Range 38-82 
Age at diagnosis- Years 
   Mean 52.65 
   SD 11.89 
   Range 37-81 
Relationship Status 
   Single 4   (20%) 
   Married/de facto 11   (55%) 
   Separated/Divorced 2   (10%) 
   Widowed 3   (15%) 
Education 
   High school 3   (15%) 
   TAFE certificate, diploma, business college 4   (20%) 
   Bachelor’s degree 4   (20%) 
   Postgraduate degree 9   (45%) 
Presently working 
   Yes 14   (70%) 
   No 6   (30%) 
Type of Cancer 
   Gynaecological 14   (70%) 
   Anorectal 6   (30%) 
Type of Treatment 
   Surgery, Radiotherapy, & Chemotherapy 6   (30%) 
   Surgery and Radiotherapy 5   (25%) 
   Radiotherapy and Chemotherapy 8   (40%) 
   Radiotherapy only 1     (5%) 
Time since diagnosis 
   0-1 years 9 (45%) 
   1-2 years 3 (15%) 
   3-4 years 1 (5%) 
   5 years  7 (35%) 
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4.3.1.1 Psychological Characteristics 
On the Hospital Anxiety and Depression Scale (HADS) most women fell within the 
‘normal’ range (n=16). Two women scored in the subclinical and two in the clinical 
range for anxiety and two women fell in the subclinical range for depression (see 
Table 8 for descriptive statistics).  
With respect to the Impact of Events-Revised Scale (IES-R) most women fell within 
normal levels (n=18) with two women reporting clinical levels of post-traumatic stress 
symptoms (Descriptive statistics in Table 8). 
Table 8: Descriptive statistics of the Sample (N = 20) on the HADS and IES-R 
Scale Mean SD 
HADS Anxiety (max score 21)  5.30 4.40 
HADS Depression (max score 21) 3.55 2.87 
IES-R Avoidance (max score 4) 0.89 0.85 
IES-R Intrusions (max score 4) 0.79 0.71 
IES-R Hyperarousal (max score 4) 0.57 0.64 
IES-R Total (max score12) 0.75 0.63 
HADS = Hospital Anxiety and Depression Scale; IES-R = Impact of Events Scale-
Revised  
4.3.1.2 Sexual Function and Satisfaction Outcomes 
On the FSFI, only a minority of women reported being ‘moderately’ or ‘very satisfied’ 
with the extent of emotional closeness during sexual activity in the past month (n = 
7), their sexual relationship with their partner (n=3) or their overall sex life (n=3) (See 
Table 9 below for descriptive statistics on the Satisfaction subscale used from the 
FSFI). The most common reasons given on the SAQ for not being sexually active 
were not having a partner (n=9) and no interest in sex (n=3), with others indicating 
the barriers as being too tired, partner not being interested or a physical problem in 
themselves or their partner. Only the first section of the SAQ, which elicited sexually 
active condition and sexual inactivity reasons (e.g. lack of interest, fatigue), were 
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analysed and included since too few participants in the sample reported being 
sexually active (n=7).  
The majority of women (n=16) indicated on the SFAGIS, that they would have liked 
their doctors to speak to them about sexual matters. There was no consistency in the 
time that patients reported being given their vaginal dilators following treatment.  
Most women (n=19) felt they had been given sufficient explanation on dilator use, 
however one participant used it ‘not at all even though it was prescribed’, 13 
participants used it ‘less often than I should’ and only  six women  ‘used it as often as 
the doctor or nurse told me to’.  
Table 9: Descriptive statistics of the Sample (N = 20) on the FSFI  
Scale Mean SD 
FSFI Satisfaction (max score 6) 2.60 1.64 
FSFI = Female Sexual Function Index. 
4.3.1.3 Knowledge/Understanding 
Responses on the Knowledge Scale are presented in Table 10 below. All of the 
women answered 8/15 or more items correctly, with a median score of 13/15, 
showing good overall understanding of the content of the booklet. The least 
understood items related to the likely occurrence of vaginal changes post-treatment, 
with only 13 patients answering the item correctly. The item asking about dilator care 
appeared to have been ambiguously worded and was hence answered incorrectly 
(12 women answered correctly) and has since been revised. 
The format and utility of the booklet 
On the Feedback Scale all of the women (100%) found the booklet format easy to 
read and understand. The booklet was found to be helpful and useful by the majority 
of women (see Table 11 below). 
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Table 10: Women’s Knowledge of Information Contained in the Booklet on the 
Knowledge Scale 
Items 
Correct 
(n) 
Incorrect 
(n) 
% 
Correct 
The term vaginal stenosis means the 
narrowing of the vaginal walls (True) 18 2 90 
The use of vaginal dilators is recommended 
3-5 times per week (T) 19 1 95 
Dilators need to be used for 5-10 minutes at a 
time (T) 18 2 90 
Dilators need to be used for no longer than for 
one year after your treatment (F) 15 5 75 
Using vaginal dilators can help in making 
sexual intercourse less painful (T) 19 1 95 
It is not important to use vaginal dilators for 
pelvic examinations by your oncologists (F) 17 3 85 
Cancer treatment can affect your emotions 
(T) 18 2 90 
All women receiving Pelvic Radiation Therapy 
will experience sexual difficulties (F) 17 3 85 
There are people to talk to about your sexual 
life if you need help after your treatment (T) 19 1 95 
Sexual intercourse can spread cancer (F) 20 0 100 
Pelvic radiation therapy can make you 
"radioactive". Therefore, it is important to be 
careful that this is not transferred to your 
partner (F) 
20 0 100 
All vaginal changes from Pelvic Radiation 
Therapy will happen in the first few months 
after treatment (F) 
13 7 65 
It is advised that you use lubricant when using 
the dilator (T) 20 0 100 
Dilators require special procedures to keep 
them hygienically sterilised after each use (F) 12 8 60 
 
   
133 
 
Table 11: Women’s Feedback on the Information Booklet on the Feedback Scale 
Item Strongly 
Disagree/ 
Disagree 
n (%) 
Neutral 
n (%) 
Strongly 
Agree/ 
Agree 
n (%) 
Easy to read 0 (0) 0 (0) 20 (100) 
Easy to understand 0 (0) 0 (0) 20 (100) 
Information was confusing 19 (95) 0 (0) 1 (5) 
Booklet made me anxious 17 (85) 0 (0) 3 (15) 
Too long 19 (95) 0 (0) 1 (5) 
Too detailed 19 (95) 0 (0) 1 (5) 
I liked the overall format 1 (5) 1 (5) 18 (90) 
I know which options are available to me 1 (5) 0 (0) 19 (95) 
I have acquired new information 1 (5) 0 (0) 19 (95) 
After reading the booklet, I feel confident using 
vaginal dilators 2 (10) 0 (0) 17 (85) 
Booklet provided additional information to that 
provided so far 3 (15) 0 (0) 17 (85) 
I felt uncomfortable with the personal nature of the 
information 16 (80) 2 (10) 2 (10) 
Research team handled my care in an appropriate 
and sensitive way 2 (10) 1 (5) 17 (85) 
Booklet was helpful 2 (10) 0 (0) 18 (90) 
Booklet gave me information I needed 2 (10) 2 (10) 16 (80) 
Booklet gave me information I did not have 4 (20) 1 (5) 14 (70) 
I know why it is important to use vaginal dilators 1 (5) 0 (0) 19 (95) 
I found it easy to find the information I wanted 1 (5) 2 (10) 16 (80) 
I like the way the booklet looked 2 (10) 1 (5) 17 (85) 
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4.3.2 Qualitative results 
Overall, the pilot study qualitative data supported the quantitative data and was in 
line with previous and current literature. Women described sexuality as a hidden 
topic, endorsed the importance of information about sexuality and sexual 
rehabilitation post pelvic radiation treatment and gave strongly positive feedback 
about the content, format and utility of the booklet. The data below includes the study 
questionnaires general comments (free text) and the telephone interview responses. 
Data relating to women’s experience and needs post PRT, and their feedback on the 
format, content and utility of the booklet are described within themes, namely: 
1) Women’s experiences of Care in their healthcare setting with regards to sexual 
difficulties/vaginal changes post PRT. 
2) Booklet content validating sexual difficulties/vaginal changes post PRT.  
3) Booklet useful over the cancer journey with regards to sexual difficulties/vaginal 
changes. 
4) Acceptability of the booklet format and content for women post PRT. 
5) Suggestions for improvement of the booklet. 
The themes identified were pertinent to assessing the need for, and the feasibility of 
providing, a psychosexual rehabilitation resource for women post PRT in line with 
pilot aims (i) and (ii). Participant quotes illustrating each theme are shown below.  
4.3.2.1 Pilot aims i) and ii) results: 
4.3.2.1.1 Experiences of care in their healthcare setting for women with 
regards to sexuality post PRT 
Overall, many women reported that their experience of care concerning sexuality 
had not been optimal. Women described sexuality as something hidden, avoided 
and ignored, and had a perception that their health care team were uncomfortable 
raising these issues. Women also reported being unsure as to whether it was their 
doctors’ role to discuss sexual/vaginal changes matters. 
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“I would have liked to have spoken to someone, I was scared, you are brave enough 
in the room to talk to but with probably 3-4 doctors, it may not be his role. I couldn’t 
talk about sexual issues; maybe it guards doctors of being accused of something (if 
they raise sexual matters)? (I) felt with the doctor this is woman’s stuff- talk to a 
woman was the prevailing idea. Vaginal changes did not enter into these 
conversations. I had a feeling of failure, and of shortcomings, that I was not 
delivering for my partner.”   
“...due to some physical and emotional circumstances, my sexual activity since 
surgery/treatment is not the same ....I find this very regrettable. My doctor was 
fantastic but I got the general gist after radiotherapy that the less is said (about 
sexual issues) the better ... It was frustrating. It’s important to validate sexuality 
issues and to know I’m not alone.” 
“...the dilator situation is all very much hidden and not discussed much, sometimes 
male doctors do not like to discuss much, I found the dilators, after all the treatment, 
very intrusive.” 
Most women (n=17) responded extremely positively to the side effects section of the 
booklet with regards to sexual difficulties post PRT and at times felt this was not 
discussed at length by their healthcare team, or commented on their inability to 
process information at the time or commented on the lack of information, which the 
pilot study had brought to the fore,  
“I thought that was the stuff on scar tissue was useful (in the booklet). I hadn't had 
that described to me in detail before. I found it upsetting that it hadn't been explained 
and that it could be a permanent problem. This was probably the most useful part of 
the whole book for me. It would have been good to know this from the beginning.” 
“Knowing what to expect helps, I can't recall it being discussed too much, all a bit of 
a blur initially, I got online, wasn't an awful lot other than scary. Stuff like numbers.  
Sometimes feel (the healthcare team) overload you, especially with the radiation. I 
wasn't told that could have an adverse reaction, happened to me, I blistered, I spoke 
to radiation oncologist who said 'you poor thing' – I assumed it was the norm.”  
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“The book was able to answer many questions that I felt was too insignificant to take 
to a health care professional.  Thank you for providing this excellent resource.” 
Patients (n=2) who found the side-effect section of the booklet less helpful said “it 
was too late” for them now as they were many years post-treatment and had not had 
the information at the time of their treatment. 
4.3.2.1.2 Booklet content validating sexuality for women post PRT 
Women highlighted many sexual difficulties/vaginal change side effects post PRT 
treatment, their unmet needs with regards to help for these, and the resultant 
physical and psychological distress they experienced.  Many women (n=17) reported 
that the booklet validated, made sense of and alleviated their sexual concerns to 
some degree and that information on sexual issues was highly beneficial, as 
highlighted in the quotes below.  
“(it was) spot on, I felt jubilant finally, thank you, some validation, confirmation, put in 
writing, I felt so alone, I realised what didn't correspond, my sexual activity has never 
gone back to what it was before.” 
“It (the booklet) openly addresses issues on sexuality which is a welcome move 
forward.”  
 “I thought to myself I am so glad I’ve got this (booklet) because I’ve just been given 
the dilators and (that) was a struggle in itself. It was a good bible to use, I referred 
back often, I was glad I had it. A couple of things stood out which reassured me.” 
Most women felt particularly comforted by having a booklet specific to them, which 
addressed sexuality. This was particularly reported by those with anal cancer, 
reflecting the stigma they could feel about these issues, such as the link to the HPV 
with anal cancer.  Woman also highlighted how the booklet gave them confidence 
and permission to address their sexuality and have more control over what was 
happening to them and that this was empowering for them.   
“I felt that I had little support on my journey with anal cancer, there was no booklet 
for me, I was so relieved to see this – it was so comforting and empowering that my 
sexual life was being addressed, you feel so powerless, it’s only through clear and 
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consistent information that you can feel some control over what’s happening. You're 
so desperate, because with anal cancer you don't fit into other categories and so 
much is linked with the HPV virus. Both anal cancer and talking about sexual issues 
have seemed like taboo subjects.” 
 “...the booklet gave me confidence to resume sexual activity.  Giving me information 
helped me to take control, confidence to go for it.  Information is power - let's give it a 
go. It made me feel confident to have sex.” 
“...If you follow this it will help you afterwards. I felt conveyer-belted – I had sense of 
powerlessness - knowledge is power – it gives you more control in the process.  It 
ensures better control of your health long-term.” 
Many women expressed gratitude and relief that the resource was being developed 
since that in itself was acknowledgement, normalisation and recognition of vaginal 
changes and sexual difficulties post PRT. Additionally, the booklet content was found 
to be valuable with regards to sexuality and the effects of PRT on relationships. The 
results revealed the distress, fear, pain and anxiety experienced by women 
themselves and their further distress that their sexual difficulties were having, or 
might have, on their intimate-partner relationships.  
“Even before opening the booklet it was great, just the fact that there is a booklet on 
this. I felt informed and comfortable that the information was there.” 
“The fact that the survey is being done acknowledged what can happen to younger 
women.  How many cases, with diagnosis and treatment, relationships do break up.” 
“I trust deeper layers, and other things take the place of the sexual but I still have 
doubts as to whether he is still faithful. I wonder am I able to keep up my end of the 
deal sexually? I am worried that my partner will stray. I am worried about the role in 
what will keep couples together, sexual pleasure was what keeps you together.”  
“I am quite anxious about this.  I'm experiencing dryness, pain and fear which leads 
to more anxiety. I feel a loss of desire but I want to be close.  I'm very sad a lot of the 
time so I don't feel attractive.  I want to get that area physically functioning again. It 
was interesting to read that section to keep doing the dilators.” 
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Many women reported wanting information about sexual side effects and 
rehabilitation strategies post PRT and that having such information could have 
potentially improved their recovery and could have reduced the late effects some 
were still enduring many years post-treatment. Many women noted how the booklet 
information had helped them overcome some barriers to using the rehabilitation 
strategies and to persevere through difficult phases during and after their treatment 
and how this was significantly helpful for them over their cancer journey whether they 
were sexually active or not, 
“If this booklet had been available to me at the time of treatment I may have reduced 
the scarring in my vagina and not have so much discomfort when having pelvic 
vaginal examinations done.” 
“...I used the words of the booklet like a mantra after I was struggling with the 
narrowing of my vagina after my treatment for rectal cancer, I persevered with the 
dilators and I succeeded, I was so grateful to have the booklet.”  
“The importance of using vaginal dilators (was conveyed in the booklet).  I was not 
really aware of this because as I am not in sexual relationship.  You really need to 
look after your vaginal health for yourself.” 
In validating and recognising sexual side effects and providing rehabilitation 
strategies post PRT, women found the booklet gave them permission to discuss 
concerns and sexual rehabilitation options with others, both by themselves and with 
their partners. Such discussions, and using the recommended rehabilitation 
strategies/vaginal dilators, could potentially, have important potential clinical and 
psychosexual consequences (i.e. using dilators to potentially prevent/reduce vaginal 
stenosis and allow adequate pelvic examination to detect cancer occurrence 
(gynaecological cancer for anal/rectal patients) or recurrence (gynaecological and 
anorectal) and its relevance for ongoing psychosexual wellbeing and rehabilitation. 
“I think the booklet is essential, it should be widely distributed to many other areas 
not only pelvic cancer, it should be generalised, others should be made aware of the 
symptoms, it showed that you should not to be afraid to follow through on any 
suspicions. To know the symptoms and to ask doctors what you're concerned 
about.”  
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“Yes it is helpful in that the way is open for discussion; it’s not embarrassing for me. 
It is ok to talk about it.”  
“oh yes, I would find it easier rather than having to explain, here are some 
words/diagrams that I would have difficulty saying and it’s in black and white.”  
 “...yes, it helped to discuss it with my partner and we are considering seeking out a 
sexual counsellor either together or on my own.” 
“...possibly (the booklet information would help to raise concerns with others) in the 
sense that it gives you a better understanding of your body and what it's been 
through.  It gives you more confidence in terms of knowledge. I feel more confident 
talking to my GP as well; she/he is not a bowel cancer specialist.”   
On the other hand some women felt the opposite,  
“no and I'd be embarrassed to give it to someone. I might be more comfortable if my 
husband and I were more sexually active.  It was private to me.  I let that booklet into 
my private body space.  I wouldn't want it splattered around.  It may be me being old 
fashioned.” 
4.3.2.1.3 Use of booklet over the cancer journey for women undergoing 
PRT 
The booklet was found to be useful over the cancer journey since it provided, 
“... a detailed explanation of reasons for using vaginal dilators and how to use them. 
It (and provided) a framework for thinking about my sexuality and how to prepare for 
the impacts on my sex life and my relationship with my husband.” 
Women on the whole (n=16) strongly felt that they would have liked to have had the 
booklet at the time of their treatment, to address concerns they had at that time.  
Furthermore, it was found to be helpful even after an extended period post-
treatment. This is in line with research and clinical evidence that side effects can 
present many years post-treatment. Woman also reflected that the booklet side 
effects information would be helpful over time, since at the time of consultation there 
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may be too much information to process or remember and hence having the booklet 
they could come back to it if need be, would be helpful. 
“The entire booklet was helpful even though I had been already given this 
information - 'chemo-brain' makes you forget so it's handy to have it in writing.  
Before treatment is best.” 
“I think the side effects section information is the most important, it was a really good 
section. You tend not to listen at the time (of the consultation) so you can look at it 
later (in the booklet) and know what to do.”  
“I have recovered (from gynaecological cancer) about 6 years now and I still found 
some of the information useful”. 
Women felt the booklet helped them to plan and think into the future. By being 
affirming, optimistic and positive, the booklet provided a sense that looking after your 
vaginal health could be beneficial at a later life stage even if it was not immediately 
relevant now, both for women who were or were not currently in a sexual 
relationship. Women commented on how having the diagnosis and treatment had 
changed them sexually and that having the information at the time of their treatment 
would have brought this in to the open and helped them in knowing what to expect. 
“There were things in the book I probably wouldn't have known.  Who knows if I get 
married again I can do so with confidence.  I think one's never too old and never too 
old to learn.” 
“I would feel like a VIP to have this booklet in the early days of treatment.  It helps to 
prepare for your new post cancer life, particularly for women in a relationship.” 
“The booklet should be introduced at beginning of your treatment because you are a 
different person different at the end, you should have a glance at it, you have no idea 
how it’s going to affect you, at the time of diagnosis you couldn’t care about sex or 
damage, afterwards then think how do I cope with getting everything back on track.  
What I got in the beginning saw in a different light at the end, it’s good to get at the 
beginning so there’s no mystery and you want to be reminded.” 
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A woman strongly reflected how indispensable she felt the booklet was for women 
over their cancer journey, 
“I think it would be really a helpful thing.  The sooner you could put it out for patients 
like me.  I would have really liked it during my treatment.  Thanks for the booklet.”  
In addition, the utility and timing of introducing/providing this resource across the 
cancer journey with regards to varying needs and for partners and family is evident 
from the quotes below. Women spoke about how having the booklet reduced and 
alleviated their fear. A woman with anal cancer summed up the usefulness of having 
the booklet over her cancer journey as having something to come back to, to orient 
herself when she felt isolated: 
“I suppose the best part was having a written tool to refer to at different parts of the 
journey. I referred to different sections at different times.  There's nothing on anal 
cancer - no booklets.  I love getting things to read.  This booklet is the only written 
material related to my experience it was a reference point.” 
“...I thought it was great; though wish I'd had it at the beginning of the process.  I was 
concerned early on about the effects of radiation, narrowing and tightening and 
menopause.... My sex life was an important consideration for me.” 
“It wasn’t only good for me but it was good for my partner and children, my husband 
tried to push the effects aside, the booklet can alleviate fear, having knowledge was 
very helpful.” 
Half of the sample (n=10) would have found it helpful if their doctor or nurse went 
through the information with them before they went home. However, half of the 
women (n=10) did not want to discuss the booklet, preferring to take it home and ask 
questions at a later stage should they wish/need to. Many patients reported that the 
booklet was useful to refer back to at various stages in their recovery process 
reducing their fear, distress, isolation and alienation,   
“Yes, absolutely…. I think sometimes it's scary, maybe I'll have diarrhoea …knowing 
that you don't necessarily have all those things (is helpful).  The Myths section is 
good. (It’s) good to go back to it too. (It’s) good to read up on dilators again – it’s a 
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long term thing.  I think there's benefit to have it early on (to) allay fears and go back 
to it.  Making sure using the REPLENS, because it is ages, I focused on different 
things, dilators, more surgery, have surgery. It’s good to get the booklet early on - 
because it’s knowledge - because you are overwhelmed by the information you are 
getting... You're entering a completely alien territory...like being on the 
moon...they've all been there all the time – there is lots of information to take in... 
(you) feel like you're OK but you're not ...(it was) months and months until I spoke to 
my clinical nurse consultant- rational – (It) would have been good to have the 
information to hand.  In lots of ways my husband was a big concern for me.  Intimacy 
(was the) last thing (I was) concerned about, (I was) not concerned about having lots 
of sex, (I was) concerned at the time about treatment.” 
4.3.2.1.4 Acceptability of the booklet content and format for women post 
PRT 
Women also described the general value the booklet had for them. 
“I was very impressed with the booklet, it was something new and fresh and it didn’t 
instil any fear...from talking to others my immediate reaction was I’m going to die and 
give up, some booklets are frightening and I chose not to read them but the best 
thing I could have done was to read this booklet.” 
“... the booklet is very useful and it’s written in a way that is easy to understand. The 
underlying feel to it is it’s here to help you not to distress you.”  
 “There was a wider dimension to the booklet than just words on a page.” 
Most women liked the overall format and the inclusion of inspirational quotes 
throughout the booklet,  
 “I like very much the size, spiral binding, typeface, colours and layout of the book.  
As well, I think the illustrations are excellent, especially the photographs of 
sculptures which are relevant and tasteful.  The information in the booklet is well 
written, very clear, and carefully worded.” 
“I did love the Christopher Robin quote it made me cry.” 
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“...the pictures, the little comments, humanised and ‘unmedicalised’ it (the treatment 
and side effects)” 
When commenting on different sections of the booklet most women (n=16) found the 
female anatomy diagrams in the “Understanding your body” section, and information 
about sexual side-effects were acceptable and helpful as educational tools, validated 
their experience and provided permission to discuss their needs. Furthermore, the 
content of the ‘Psychological/emotions’ chapter was found to be important by most 
participants since it again validated their experiences of the emotional/psychological 
and sexual/psychosexual effects of pelvic radiation treatment with women noting.  
“...it’s preferable to see the diagrams here "where's (in consultation with your doctor) 
that a patient might feel embarrassed showing ignorance.”  
“...I really liked the little emotional bits..., though all my healthcare team were 
excellent with treatment, you feel like a lump being pushed around for medical 
purposes.  (The booklet had a) touch of humanity and emotion, it made me feel I’m 
not just a body.” 
“I thought it was all important because there are those consequences, not only 
physical.  Having it (the sexual side effects) written down validates feelings and 
encourages you to talk if having problems.” 
Most women (n=17) also appreciated the ‘Vignettes’ sections of other woman’s 
experiences following PRT. A patient recovering from anal cancer also commented 
on how important the vignettes were for her in giving her a voice and reducing her 
feelings of being ostracised, again highlighting the stigma associated with this 
diagnosis, and the potential significance therefore of the booklet for this population.  
 “Yes, I thought it was very good, it makes it more personal you can relate better to 
someone else's story.  ”  
“I did appreciate the vignettes section …very much so. (I’d like) more, more, more.  
Again for empathy and you are not alone.” 
“I liked that, it could be useful to have that for anal, rectal cancer inclusiveness, anal 
cancer is such an ‘ostracising’ cancer, and you don't feel you are quite so alienated.  
144 
 
It’s not a cancer you can talk about.  I believe there will be more of it with the HPV 
virus.  At first I said that I had rectal cancer, and then I made a decision to be open, 
even if people made assumptions.  It gives others the courage to talk about it.” 
Most of the women (n=16) responded very positively to the ‘Asking Questions’ 
section being included in the booklet and many patients (n=13) liked the ‘Further 
Contacts/QPL’ section and would access sites if they needed to, since it gave 
women permission to ask questions and it gave encouragement, strength and hope 
in that it was discussing recovery after PRT. 
“I think I would have found it helpful because it gives me permission to ask questions 
in the first place. It could be at the end of each section.”  
“...It’s an excellent section.  I have the contacts in a folder - if I needed help I know 
I've got it there.  It gives me strength.  This is a resource book for recovering”.  
In summary, the booklet was found to be helpful, needed and useful for many 
women in the pilot study, providing information, reducing fear and distress and 
imparting support and care. This demonstrated a high degree of acceptability of this 
resource. Many women (n=17) expressed gratitude and relief for the booklet. They 
felt it was containing in reducing fear, and would help them to persevere through 
difficult and deeply distressing side effects post PRT treatment and with following the 
potential rehabilitation strategies such as using vaginal dilators, all emphasised in 
the quotes below: 
 “It has been extremely beneficial to have this booklet at my disposal.  I refer back to 
it time and again and am unsure how women before me went without it.  Thank you.” 
“The booklet has given me an element of safety and security.” 
“...reading the booklet at the most difficult time of treatment really gave me strength.” 
When asked specifically about the booklet content, nothing was found offensive by 
any of the patients. Privacy was found to be a barrier to dilator use, but the need for 
the booklet was strongly endorsed given women’s previous attempts to prevent the 
side effects, overcome barriers in using the dilators and find information on how to 
manage the vaginal health/sexual side effects of treatment. 
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“I found the booklet completely helpful, information on the brands of lubricants was 
really helpful, and at the time it I would have been trying to put in place using 
dilators. I needed private time from son, I was conscious of storing them in a place 
where my son could not find them and be confronted by them, it was helpful to 
include some information about how to keep them clean, where to store them to 
keep them dry, due to cleaners and children I suggest clearing a space for the 
dilators in a private area.” 
4.3.2.1.5 Suggested improvements of booklet  
Some suggested improvements from women in the pilot which were incorporated 
into a revised booklet were:  
 Clarifying that this is a psychosexual resource and providing links to other 
resources about more general radiotherapy rehabilitation,  
 Clarifying that the content was relevant to people not in a sexual relationship 
and is a resource for women in same-sex relationships, due to the clinical 
importance of maintaining a healthy vagina, and  
 Reassuring women that dilator use, and the extent to which it is inserted, can 
be gradually increased.   
“...perhaps explaining that for the first few times, when using a dilator, it is okay if it 
doesn't go all the way in.  Just try to get it in as far as it can go if you feel too anxious 
about it.  I felt very pressured to get it all the way in and it didn't happen for a few 
weeks until I felt completely relaxed about resuming my life - and that didn't happen 
for a few weeks after I'd been given the dilator.  I just know that I felt anxious and 
distressed about the dilator for the first few weeks until I was told to just take it as far 
as I could and leave it there until next time and they try a little bit each time to take it 
further.” 
Some healthcare professionals and clinicians (n=3) involved in the pilot felt that the 
diagrams might be too confrontational and alienate some women entirely from 
engaging with the resource, hence the diagrams were changed to 
drawings/illustrations (by the graphic designer) for the RCT based on this feedback.  
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Aspects of the booklet which were disliked, too confrontational or distressing were 
the following:  
A woman who did find the booklet distressing stated that,  
“...the information (about the dilators) - it's necessary / helpful information, but it is 
still confronting emotionally. A bit more introduction to this aspect may be useful 
...Just reading that much information about the effects of radiation was upsetting as it 
brought it all back. The question is when the appropriate time is to hand out the 
booklet - at the beginning of treatment it would be overwhelming so probably best 
done immediately at the conclusion.” 
Most women found that the booklet was not too sexual in nature (n=16). One woman 
did however find the booklet too sexual, 
“...the honest answer is yes. It is quite confronting to read about the mechanics of 
sexual nature.”  
Another woman who was not comfortable with the sexual content of the booklet and 
found it upsetting commented that:  
 “I felt somewhat alienated by the dominance of sexuality - uterine cancer and good 
health is a woman's primary concern I feel.”  
 Of the two women who did not respond favourably to the booklet’s sexual content, 
one found the concept (sexual rehabilitation and vaginal stenosis/dilator use) “a bit 
scary” and another would prefer to discuss the booklet content with their doctor or 
nurse prior to reading it. One woman found the booklet over emphasised sexual 
matters and another found the sexual nature of the booklet challenging and focused 
on those in a relationship,  
“...my relationship is non-sexual the last 7 years,  I’ve been together for 25 years with 
women, now it’s about maintaining my wellbeing, sexual relationships were very 
dominant, what I was looking for wasn’t there "health info".” 
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Another woman felt that “the booklet was quite confronting, I did not like the graphics 
... there is lots of emphasis on people in a sexual relationship, the booklet is not 
sensitive to people who are single.” 
Some women in the pilot (n=5) stated varying reasons why they did not feel the need 
or did not want to access internet sites in the ‘Contacts’ section since they were 
concerned that they would be overwhelmed or frightened by accessing some of the 
information available on the internet. Some reported (n=2) that they did not find the 
sites that helpful. 
Although the ‘Diary’ section of the booklet, where women could keep a record of their 
dilator, lubricant and PFME regime, was liked; the majority of women said that they 
would not use it. This was the case for both women many years post PRT treatment 
and those soon after their treatment. It appears that an element of the response to 
the diary section was related to not using the vaginal dilators/rehabilitation strategies 
and barriers to using them as evident by the quotes below. 
“I didn't know if I'd use it unless there was an issue, but there was not for me, it’s 
probably beneficial to keep a record.” 
“I probably wouldn't have used them (the diary section”.  I have two young children, (I 
had) no time to myself during the treatment.  It’s for someone older, who didn't have 
little children.  So I wouldn't discount it (the diary section).” 
“Not sure that I'm the kind of person who would have done that anyway.  I didn't feel 
the need to document it. (I) probably wouldn't have used it.” 
4.3.2.2 Pilot aim iii) results 
Feasibility of the assessment protocol for Phase III of the study – the randomised 
controlled trial (RCT) of the information booklet 
The pilot results assessing the feasibility of the assessment process for the later 
randomised controlled study of the pilot revealed the following: 
Items of the SFAGIS were found not to assess the broader dimensions of sexuality, 
and were replaced by the more reliable and valid Sexual and Vaginal Changes 
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Questionnaire (SVQ) (Jensen et al., 2004a). Further, it was felt that adherence to 
strategies such as dilators and lubricants were not adequately captured by the 
existing items, and a study purpose-designed Adherence Scale (AS) was developed. 
The FSFI satisfaction subscale and the SAQ (except for the sexual activity and 
reasons for inactivity subscales of the SAQ) were removed since they became 
redundant with the inclusion of the SVQ and AS. 
The standardised HADS, IES-R, and the purpose-designed Knowledge Scale and 
Feedback Scale were retained for the RCT, as they were all well accepted and 
completed by pilot participants. Some items on the Feedback scale were found to 
have ambiguous wording, and were amended for the trial questionnaires.  
4.4 Discussion 
This pilot study aimed to (i) explore women’s views about sexuality and rehabilitation 
informational needs following PRT; (ii) investigate the feasibility and acceptability of 
providing women undergoing PRT with the study developed information booklet and 
iii) assess the acceptability of a measurement protocol that would be used in a later 
randomised controlled trial (RCT) of the booklet (Phase III). The study findings will 
be discussed below. 
4.4.1 Pilot aims i) and ii)  
The qualitative findings revealed that there were many unmet needs for women with 
regards to the physical and psycho-sexual effects of their pelvic radiation treatment 
for gynaecological or anorectal cancer. Women emphasised the vaginal changes 
and sexual trauma they experienced following treatment, and the importance sex 
had in their lives. Some described feeling that they were failing their partner; this is in 
keeping with earlier research which found that some women who were sexually 
active prior to gynaecological cancer diagnosis and treatment never resume sexual 
relations post treatment (Stead et al., 2007). Cochran (1987) found that a third of 
endometrial cancer patients ended all sexual activity post treatment.  
Disturbingly, many women felt that their sexual concerns and need for information 
about sexual side effects were not validated by the health care team, and that in 
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general, sex was a hidden and avoided taboo topic. These findings are consistent 
with those found in other studies. For instance, some health care professionals’ 
reported reasons for not discussing sexual function with gynaecological cancer 
patients were: feeling that it is not their responsibility, lacking knowledge and 
experience, embarrassment discussing sexual issues and lack of back-up resources 
to provide additional support if need be (Bodurka & Sun, 2006).  In this study, most 
of the respondents/healthcare professionals knew that women would experience a 
sexual problem (after ovarian cancer in this case), but only 25% of physicians and 
20% of nurses reported actually discussing sexual function. Katz (2005) noted that in 
another study of gynaecological cancer patients up to 50% had received little or no 
information on sexuality and cancer, while 60% wanted more information. In a similar 
vein, a NSW Cancer Institute survey (Heading, 2008) found that one of the largest 
areas of failure of care for outpatients was receiving no or inadequate information 
about possible changes in sexual activity and receiving no or insufficient information 
about possible changes in relationship with spouse or partner. 
Many women noted that they found it difficult to raise the issue of their sexual 
changes with their doctors, not knowing if it was their doctor’s role and some felt that 
it seemed to be a taboo topic. These findings mirrored those of other studies. Stead 
et al. (2003) observed that discussion of their sexual concerns with the doctors was 
desired by women. However the topic was rarely raised. Wolf (2006), Katz (2005), 
Greimel et al. (2009), Friedman et al. (2011), Bodurka & Sun (2006) and Schover 
(2005) have described similar findings for gynaecological and colorectal cancer 
patients post PRT. Women are often not comfortable to raise issues themselves 
(Faithful & White, 2008).  
Rehabilitation strategies – barriers to dilator use 
Women also noted specific barriers to using dilators, such as little or lack of sufficient 
information on the clinical and sexual importance of using dilators, embarrassment, 
and the need for discretion with children around, and discomfort or pain in using the 
dilators. Similar findings have been reported in other studies (Lancaster, 2004; 
Bonner et al., 2012, Friedman et al., 2011, Greimel et al., 2009; Wolf, 2006). 
Knowing about the clinical importance of using dilators to enable pelvic examinations 
to detect recurrence was helpful for women in persevering with using dilators and in 
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using them more frequently in an ongoing manner. However, many said they still 
were not using dilators, either because they did not have a partner, they were no 
longer sexually active or their partner had physical difficulties. Many women 
commented that having the booklet reduced some of the barriers to using dilators 
such as knowing the importance of using them and how to use them and for how 
long. 
The role of the booklet and its acceptability 
With regards to informational needs women in the study did want to have information 
about and to talk about the sexual difficulties that they were having. Thus, the 
booklet piloted in this study was very well received, with most women indicating that 
it was helpful for them and that they liked the format and content. Women noted that 
their experiences and concerns were recognised and validated by the booklet, that 
the booklet provided clear evidence-based information about the importance of 
sexual rehabilitation strategies and that the booklet would facilitate communication 
with the health care team about these issues. 
Most women reported that the information contained in the booklet was not 
distressing and in fact the reverse was more common, with women reporting that the 
booklet alleviated their concerns and reduced their fear and anxiety. Though a few 
women found some of the information confronting they still felt it was important to 
have the information hence it appeared that an upsetting aspect of the booklet 
content relates to the distressing nature of the diagnosis, treatment and recovery 
from the treatment. A minority of women felt that the booklet was too focused on 
those who had a partner or who were currently in a sexual relationship.  The booklet 
was revised based on these findings, to emphasise that while the purpose of the 
booklet was as a psychosexual resource, an additional and critical component was 
vaginal health.   
Women reported that having the information on hand at various stages of their 
recovery process would be very helpful. As noted above, the study verified findings 
that many women experience sexual difficulties post PRT treatment and findings 
from previous studies that women wanted information about what to expect at 
different times during and after their treatment (Bourgeois-Law & Lotocki, 1999). In 
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addition, an important aspect of the pilot study related to assessing the timing of 
when the booklet should be given to patients. Most women in the study felt that the 
booklet should be given at the beginning of their treatment so that they knew what to 
expect.  
The study findings also confirmed that women want to play a role and have a choice 
in their recovery by having information about the rehabilitation options at their 
disposal in ensuring more control over their long-term health. Many women 
expressed relief at the booklet development and reported that had they had it at the 
time of their treatment they may have had reduced vaginal scarring and 
subsequently less sexual difficulties, and their fears would have been reduced or 
eliminated had they known about the side effects as opposed to suffering in silence 
and distress. Talking about sexual issues was seen as a welcome move forward 
since many women reported that their sex life was important to them.  
Even after an extended period of time post-treatment, women found the booklet 
useful to assist with dealing with the late effects of the treatment. The booklet was 
also found to be useful across different ages and varying individual needs, and its 
reach extended to partners and family. Anecdotally the healthcare professionals 
working in this area whom we consulted and those who participated in the pilot 
expressed a strong desire for the booklet to become available for their patients. 
Women in the pilot felt that the resource would benefit and help others – one such 
woman stated that,  
 “I’ve said all constructive criticisms of the booklet but I’m saying even if you don't 
change a single comma it is well worthwhile.” 
4.5 Limitations  
Given the small sample size the findings need to be interpreted cautiously. As the 
response rate of this study was low for this pilot study, it reflects in the hesitation of 
women to discuss sexual issues, vaginal changes and dilator use. Women with more 
conservative sexual attitudes and those who did experience adverse side effects 
may not have opted to participate in the study. All participants were recruited from 
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the same treatment centre. They were all English speaking and generally well 
educated. It may not be possible to extend these findings to other treatment centres 
where standard care practices are different and for women who belong to different 
cultural and socioeconomic groups and those in developing countries. Furthermore, 
this was a retrospective study with women up to 5 years post treatment. Thus there 
is a need to further evaluate the booklet in a larger, prospective randomised 
controlled trial.  
4.6 Conclusion 
Overall, the pilot findings provide support for the provision of psychoeducational 
resources such as the current booklet to better support women in rehabilitation 
following radiotherapy for gynaecological and anorectal cancer. The booklet appears 
to be the first of its kind and the pilot results suggest women would welcome, 
appreciate and highly value such a resource as a facet of their post treatment care 
and recovery. Women also felt the booklet would facilitate self-care and being able to 
play a role in their own rehabilitation, which they would like to do.  
The booklet was revised based on the feedback from the study participants and 
current Cochrane Review (Johnson & Miles, 2010) findings. The changes to the pilot 
information booklet and questionnaires are listed in Appendix 2 and 3. Given the 
high levels of acceptability of the booklet, its effectiveness was next prospectively 
evaluated in a multicentre RCT (see chapter 5 onwards).  
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CHAPTER 5 - Phase III:  The 
randomised controlled trial of the 
study developed pelvic radiation 
therapy psychosexual rehabilitation 
information booklet for women with 
gynaecological and anorectal cancer 
5.1 Aims and Research Design 
This multi-centre randomised controlled trial (RCT) aimed to investigate the 
effectiveness of a psychoeducational information booklet designed to facilitate 
information delivery and communication about pelvic radiation-induced side effects 
potentially affecting post-treatment recovery, and especially sexual functioning. 
Participants were randomly allocated to receive either the newly designed 
information booklet “Recovery after Pelvic Radiation Therapy: A Guide for Women” 
(intervention group) or the Cancer Council NSW “Understanding radiotherapy” 
booklet (control group). Adherence to rehabilitation strategies, knowledge about 
side-effects of pelvic cancer and rehabilitation options, feedback about the 
information booklet, levels of anxiety, depression and posttraumatic stress, as well 
as sexual activity, functioning and satisfaction were assessed at baseline 
(immediately after each participant’s first radiotherapy consultation) and at 3, and 6  
months post radiation treatment. These time frames were selected since longitudinal 
studies have shown they are critical times during recovery and the most favourable 
times for clinical interventions, should they be needed (Weijmar Schultz et al., 1992).  
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5.2 Hypotheses 
It was hypothesised that compared to the patients in the control group (who received 
standard care and the general ‘Understanding Radiotherapy’ Cancer Council 
booklet) patients in the intervention group (receiving standard care and the study 
booklet) would report: 
1. Primary outcome  
a. Greater and more consistent use of vaginal dilators, lubricants and 
Pelvic Floor Muscle exercises, as measured by the purpose-designed 
Adherence Scale (AS) at 3 and 6 months post PRT. 
2. Secondary outcomes 
a. Greater knowledge in regards to post-treatment side-effects and 
rehabilitation options as measured by the purpose-designed 
Knowledge Scale (KS) and Feedback Scale (FS) at 3 and 6 months 
post PRT. 
b. Lower levels of PRT-related posttraumatic stress as measured by the 
Impact of Event Scale – Revised (IES-R) at 3 and 6 months post PRT. 
c. Lower levels of anxiety and depression as measured by The Hospital 
Anxiety and Depression Scale (HADS) at 3 and 6 months post PRT.  
d. Greater improvements in sexual activity/function and satisfaction as 
measured by the SAQ, and SVQ 
5.3 Method 
5.3.1 Sample 
Eligibility criteria for the sample are described below.  
5.3.1.1 Participants Inclusion/Exclusion criteria 
Cancer patients scheduled for radiotherapy were targeted because the study booklet 
aimed to facilitate communication about the psychosexual effects of pelvic radiation 
therapy (PRT).  
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Women were included in the study whether they were sexually active or not 
because: 
 they may be interested in sexual activity whether or not they are in a 
relationship and previous definitions of sexuality have been criticised for being 
too limited and narrow with regards to sexual satisfaction and function 
(Juraskova, 2003; Cleary & Hegarty, 2011; Hordern, 2008),  
 for those women not currently in a relationship the booklet could be 
informative should this change at a later stage, and 
  PRT side effects can have both physical and sexual consequences for 
women.  
Moreover, in order to further the generalisability of the results, both heterosexual and 
homosexual women were included in the study.  
5.3.1.2 Recruitment procedure 
Inclusion criteria: 
 
Exclusion criteria: 
 
 Current or previous diagnosis 
of gynaecological cancer 
(GC) (cervical, endometrial, 
vaginal, vulvar) or anorectal 
cancer (ARC) (anal or rectal 
cancer)  
 Any cancer stage 
 Scheduled for radiotherapy 
(PRT)  
 Over 18 years of age  
 English speaking 
 Primary language not English 
 Psychiatric or intellectual 
impairment 
 Highly dependent on medical 
care 
 
Women were recruited from the following centres in NSW: Royal Prince Alfred 
Hospital, Royal Hospital for Women, Prince of Wales Hospital, Liverpool Hospital, St 
George Hospital, Genesis Care Radiation Centre at the Mater Hospital, and Royal 
North Shore Hospital.  
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Potentially eligible patients were identified and confirmed as eligible by their radiation 
oncologist or specialist cancer care nurse practitioner (see Figure 14). The recruiting 
clinician spoke to the women about the study at their first radiotherapy session. If 
women were interested in the study the recruiting clinician obtained verbal consent 
for their contact details to be sent to the research team and gave the woman a pre-
randomised study pack (see Appendix 1.2). The study pack included the study 
information sheet and consent form and the baseline questionnaire along with a self-
addressed reply paid envelope. Patients who later decided not to participate were 
requested to dispose of the study pack at their convenience. The recruiting clinician 
then faxed or emailed the woman’s contact details to the research team. The initials 
and reason for declining of those women who declined to participate were emailed or 
faxed to the research team by recruiters at this time also.  
Within one week of permission being obtained for research contact, a member of the 
research team followed up by telephone (see Appendix 1.14 for telephone welcome 
call script) to answer any questions, confirm participation and prompt questionnaire 
return.  
5.3.1.3. Study Procedure 
The study procedure is shown in Figure 14 below.   
In order to elicit baseline demographics, clinical characteristics and pre-treatment 
sexual function, levels of anxiety, depression and distress from participants, data 
were obtained for the baseline sample (via questionnaire) prior to radiotherapy 
commencing.  
Following the baseline assessment, women commenced their pelvic radiation 
therapy (PRT). Two weeks before the end of their PRT they were mailed the control 
or intervention booklet. For external radiotherapy (EBRT) patients this was two 
weeks before ending 5-6 weeks of treatment and for women undergoing 
brachytherapy/internal pelvic radiation this was within two weeks of their treatment, 
which can be only two weeks in duration. Women received a follow up call within one 
week of receiving their booklet to encourage reading of the booklet, and to clarify any 
queries about the study procedure and questionnaire.  
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Three and six months post radiotherapy, women were mailed self-addressed reply 
paid follow-up questionnaires (see Appendix 3.3). Participants were sent reminder 
letters and duplicate questionnaires if they had not returned their questionnaires 
within 3 weeks of receiving them, at all assessment points. 
 
Figure 14: Randomised Controlled Trial Procedure 
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5.3.2 Ethical considerations 
Ethics approval for the study was obtained from the Sydney Local Health District 
(Royal Prince Alfred Human Resources Ethics Committee) and from The University 
of Sydney Human Ethics Committee (see Appendix 1) prior to study 
commencement. Site specific (SSA) ethics approval was individually obtained from 
the seven sites in NSW, Australia, where the study was undertaken. 
Similarly to the pilot study procedure (Chapter 4), due to the sensitive nature of this 
study, ethical considerations were addressed directly from early stages of its 
development. Protection of vulnerable participants was implemented initially through 
the establishment of rigorous inclusion and exclusion criteria. During audit of the 
clinic database, clinicians familiar with the patients being recruited excluded those 
where there were any concerns about a patient’s suitability to be approached prior to 
any invitation into the study in person or invitation letter being sent. 
The participant invitation and information letters provided contact details of the 
principal investigator and the researcher (both clinical psychologists) to contact them 
for support and referral, should they experience distress during the study.  
5.3.3 Measures  
Chapter 4 of this thesis reported both the pilot study of the booklet and an 
assessment of the feasibility of the measures, some of which were removed or 
adapted for use in the RCT as a result of feedback during the pilot.  
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Table 12: Overview of pilot study, RCT baseline and follow up measures 
Measures Pilot study RCT Baseline RCT Follow ups 
Demographic 
characteristics ✔ ✔ ✔ 
HADS ✔ ✔ ✔ 
IES-R ✔ ✔ ✔ 
SAQ ✔ ✔ (habit subscale) 
✔ 
(habit subscale) 
FSFI ✔   
SFAGIS ✔  ✔ (selected items) 
SVQ  ✔ ✔ 
Adherence Scale   ✔ 
Knowledge Scale ✔  ✔ (2 items changed) 
Feedback Scale ✔  ✔ (2 items deleted) 
5.3.3.1 Demographic and clinical characteristics 
Demographic and clinical information were collected in the baseline questionnaire 
and included patients’ age and age at diagnosis, relationship status, primary 
language spoken, and number of children, occupation and highest qualification level. 
Clinical data concerning cancer type, types of treatment received, taking 
psychotropic medication and time since diagnosis were also obtained via the 
questionnaire.  
5.3.3.2 Primary Outcome Measure 
5.3.3.1.1 Background of the study purpose-designed scales scoring 
methods  
Three new scales were designed specifically for the purposes of this study by a team 
of experts comprising clinicians, researchers and clinical psychologists, based on the 
literature and clinical expertise. These were: the Adherence Scale (AS), the 
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Knowledge Scale (KS), and the Feedback Scale (FS). Preliminary psychometric 
analyses of these measures are described below.  
To ensure consistency, scale items were subjected to internal consistency tests 
utilizing the Cronbach’s Alpha as a measure. An alpha value of 0.7 or above was 
considered to demonstrate the set of items were internally consistent in measuring 
each construct. 
5.3.3.1.2 Adherence Scale (AS) 
The primary outcome, namely greater and more consistent use of vaginal dilators, 
lubricants and pelvic floor muscle exercises, that is, adherence to the recommended 
rehabilitation strategies post PRT, was measured by a purpose-designed 
questionnaire.  The scale was comprised of three subscales primarily using Likert 
scales, pertaining to (1) vaginal dilators (12 items); (2) vaginal moisturisers (5 items); 
and (3) pelvic floor muscle relaxation exercises (5 items). Three subscale scores 
were calculated summarising using a dilator, a moisturiser and pelvic floor muscle 
exercises. The computational details of these scores are provided in the table below. 
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Table 13: Computational details of scores derived from the Adherence Scale 
Variable Conceptual Definition 
Operational Definition 
Number 
of Items Computation Interpretation of Scores 
Use and frequency of use of Dilator 
Whether a 
person used a 
dilator and if so 
how many times 
2 
Combined responses 
from the questions 
‘Since treatment have 
you used a vaginal 
dilator’ and ‘How 
often do you use a 
dilator’ 
3 = High use (More than 5 
times/ week) 
2 = (3-5 times) 
1 = (1-2 times/week) 
0 = No use (Do not use) 
Use and frequency of use of Moisturiser 
Whether a 
person used a 
moisturiser and if 
so how many 
times 
2 
Combined responses 
from the questions 
‘Since treatment have 
you used a vaginal 
dilator’ and ‘How 
often do you use a 
moisturiser’ 
3 = High use (More than 5 
times/ week) 
2 = (3-5 times) 
1 = (1-2 times/week) 
0 = No use (Do not use) 
Use and frequency of use of PFME 
Whether a 
person used 
PFME and if so 
how many times 
2 
Combined responses 
from the questions 
‘Since treatment have 
you used PFME’ and 
‘How often do you 
use PFME’ 
3 = High use (More than 5 
times/ week) 
2 = (3-5 times) 
1 = (1-2 times/week) 
0 = No use (Do not use) 
At the baseline, first follow-up and second follow-up, the graphical presentation and accompanying K-S test of normality of the 
adherence scores indicated that the use and frequency of use of dilator score, the use and frequency of use of moisturiser score, 
and the use and frequency of use of PFME score were not normally distributed  (p<0.001). Therefore, the use of parametric 
statistics was not justified for any analysis using these scores.   
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5.3.3.2 Secondary outcome measures 
5.3.3.2.1 Perceived effectiveness of these rehabilitation strategies in 
aiding recovery (AS) 
Additional items in the Adherence Scale were purpose-developed to measure the 
perceived effectiveness of the above strategies, and subjected to an Exploratory 
Factor Analysis (EFA). Principal Component Analysis with Direct Oblimin Rotation 
and Kaiser Normalization was conducted. A solution was extracted with 4 factors, 
each with Eigenvalues > 1, explaining 87.39% of the variance (Table 14).  
On the basis of this 4 factor solution, three subscales were proposed. The 
conceptual and operational definitions of the three proposed subscales are 
summarized in Table 15. Factor 1 (Vaginal Dilator Aided Recovery - Positive) and 
Factor 2 (Vaginal Dilator Aided Recovery - Negative) were combined into one 
subscale (Vaginal Dilator Aided Recovery) by reverse scoring the items included 
within Factor 2 and then averaging all the items from Factor 1 and Factor 2. High 
scores indicate high levels of recovery.   
At the first and second follow-up phases, the frequency distribution for Subscale 1, 
Subscale 2 and Subscale 3 did not deviate significantly from a bell-shaped normal 
curve and the Kolmogorov-Smirnov Z statistics for these scores was not significant 
at p < .001. Vaginal Dilator Aided Recovery score, Vaginal Moisturiser Aided 
Recovery score, and PFME Aided Recovery score were all found to be normally 
distributed. Therefore, parametric statistics was justified for any analysis using these 
scores.  
A correlation matrix using Pearson’s Correlation Coefficients (Table 16) indicated 
that the three subscales were not significantly correlated with each other at p <.05.  
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Table 14: Structure of the Adherence Scale Extracted from the Pattern Matrix by Principal Component Analysis with Direct Oblimin 
Rotation and Kaiser Normalization 
    Loadings from the Pattern Matrix 
    Factor 1 Factor 2 Factor 3 Factor 4 
Percentage of Variance Explained by Each Factor 9.39% 21.53% 16.63% 39.84% 
Cumulative Percentage 9.39% 30.92% 47.55% 87.39% 
Eigenvalues 1.503 3.445 2.66 6.374 
Item FACTOR 1: Vaginal Dilator Aided Recovery - Positive         
5 I was given sufficient explanation on the purpose and use of the vaginal dilator as part of my post-treatment recovery. 0.894       
6 I am confident using the vaginal dilator. 0.744       
7 Using the vaginal dilator just prior to sexual intercourse makes intercourse easier. 0.616       
9 Using the vaginal dilator has been helpful. 0.795       
12 My partner is supportive about my dilator use. 0.798       
  FACTOR  2: Vaginal Dilator Aided Recovery - Negative         
8 I would have liked more opportunity to practice the use of vaginal dilator with a nurse.   0.84     
10 I have emotional difficulties using a vaginal dilator (e.g. feeling anxious).   0.961     
11 I have physical difficulties using a vaginal dilator (e.g. it is painful).   0.864     
  FACTOR 3: Vaginal Moisturiser Aided Recovery         
14 I was given sufficient explanation on the use of vaginal moisturisers as part of my post-treatment recovery.     0.544   
15 I am confident using vaginal moisturiser.     0.976   
16 Using vaginal moisturiser has been helpful.     0.968   
17 My partner is supportive about my vaginal moisturiser use.     0.922   
  FACTOR 4: Pelvic Floor Muscle Relaxation Exercises Aided Recovery         
19 I was given sufficient explanation on the use of pelvic floor muscle relaxation exercises as part of my post-treatment recovery.       0.803 
20 I am confident using pelvic floor muscle relaxation exercises.       0.869 
21 Using pelvic floor muscle relaxation exercises has been helpful.       0.867 
22 My partner is supportive about my use of pelvic floor muscle relaxation exercises.       0.867 
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Table 15: Conceptual and Operational Definitions of Three Proposed Subscales 
Variable Conceptual Definition 
Operational Definition 
Number 
of Items Computation Interpretation of Scores 
Subscale 1 Vaginal Dilator Aided Recovery 8 
5 minus average 
scores for items 5, 6, 
7, 9, 12, *8R, 10R and 
11R 
5= High levels of recovery 
1= Low levels of recovery 
Subscale 2 
Vaginal 
Moisturiser Aided 
Recovery 
4 
5 minus Average 
Score for items 14, 
15,16, and 17 
5= High levels of recovery 
1= Low levels of recovery 
Subscale 3 
Pelvic Floor 
Muscle 
Relaxation 
Exercises Aided 
Recovery 
4 
5 minus Average 
Score for items 19, 
20,21, and 22 
5= High levels of recovery 
1= Low levels of recovery 
*R= Reversed scored: The item has been reverse scored by transforming or re-coding the responses 
so that high “scores” on the item indicate high levels of the attribute being measured and low "scores" 
on the item indicate low levels of the attribute being measured 
Table 16: Pearson’s Correlation Matrix 
 
Subscale 1 Subscale 2 
Subscale 2 .110 
 
Subscale 3 -.586 .240 
5.3.3.2.2 Knowledge Scale (KS) 
The 14-item purpose-designed KS was used to assess women’s knowledge and 
understanding of the content of the booklet (e.g. side-effects of PRT, sexual 
difficulties post PRT and recommended post-treatment rehabilitation options – see 
Appendix 3.3). Response options were ‘true’, ’false’ or ‘don’t know’. A total score (0-
14) was calculated by summing items; the dimensional structure of the items was not 
assessed as it was not expected that the items would be correlated in any consistent 
way. High scores reflect good understanding of the booklet content. The 
computational details for the knowledge score are summarized in the table below. 
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Table 17: Computational details of the score derived from the Knowledge Scale 
Variable Conceptual Definition 
Operational Definition 
Number 
of Items Computation Interpretation of Scores 
Knowledge 
Score 
Knowledge of 
pelvic cancer 
and its impacts 
in general, 
vaginal dilators, 
vaginal 
moisturisers, and 
pelvic floor 
exercises  
14 
Total score for items 
1 to 14 (score of 1 for 
a correct answer (the 
correct answer for 
items 1, 2, 3, 5, 7, 9, 
and 14 is ‘true’ and 
the correct answer 
for balance of the 
questions is ‘false’) 
and 0 for an incorrect 
answer or a question 
to which a 
respondent does not 
know the answer) 
14 = High levels of 
knowledge 
0   = Low levels of 
knowledge 
At the first follow-up phase, the graphical presentation showed that this score is not 
normally distributed; this was supported by K-S test of normality (p<0.001). 
Therefore, use of parametric statistics was not justified for this score at the first 
follow-up phase. However, at the second follow-up phase, the graphical presentation 
showed that this score is normally distributed; this was supported by K-S test of 
normality (p>0.001). Therefore, use of parametric statistics was justified for this 
score at the second follow-up phase. 
5.3.3.2.3 Feedback Scale (FS) 
Participants’ general views on the presentation and content of the study booklet were 
assessed using the 17-item purpose-designed FS which assessed participants’ 
perceptions of: the format, clarity, sensitivity and utility of the booklet, their 
confidence in using and awareness of the potential importance of using rehabilitation 
strategies, and their comfort with the information in the booklet (see Appendix 3.3). 
Response options consisted of 5-points of a Likert scale, which ranged from 
‘Strongly Disagree’ to ‘Strongly agree’ with a ‘Not sure’ option. A total score (0-68) 
was calculated by summing items; the dimensional structure of the items was not 
assessed as it was not expected that the items would be correlated in any consistent 
way. High scores reflect positive feedback on the booklet. 
   
166 
 
Table 18: Computational details of the score derived from the Feedback Scale 
Variable Conceptual Definition 
Operational Definition 
Number 
of Items Computation Interpretation of Scores 
Feedback 
Score 
Feedback from 
the respondents 
about the 
information 
provided in the 
new booklet  
17 
Sum of scores for 
items 1 to 17 minus 
17 
68 = Positive feedback 
0 = Negative feedback 
At the first follow-up phase, the graphical presentation showed that this score was 
normally distributed; this was supported by K-S test of normality (p=0.033>0.001). 
Therefore, the use of parametric statistics was justified for this score. However, at 
the second follow-up phase, the graphical presentation showed that this score is not 
normally distributed; this was supported by K-S test of normality (p<0.001). 
Therefore, use of parametric statistics was not justified for this score at the second 
follow-up phase. 
5.3.3.2.4 Psychological status - Hospital Anxiety and Depression Scale 
(HADS) (Zigmond & Snaith, 1983) 
Levels of anxiety and depression were assessed using the 14-item HADS (Zigmond 
& Snaith, 1983). This self-assessment scale is designed to measure and 
discriminate between states and severity of anxiety (7 items) and depression (7 
items) among physically ill patients. The psychometric properties of this scale are 
described in detail in Chapter 4. The internal consistency of the anxiety and 
depression scales in the current sample were an alpha of .87 (all items) (Cronbach’s 
alpha = .86 (anxiety items) and .80 (depression items), respectively). Since the 
Cronbach’s alpha was greater than 0.7 the items from the scale and derived 
subscales were deemed fit (reliable) to be used in subsequent analysis. 
At the first baseline and the second follow-up phases, the graphical presentation 
showed that the anxiety score is normally distributed; this was supported by K-S test 
of normality (p>0.001). Therefore, use of parametric statistics was justified for this 
score at the baseline and second follow-up phases. However, at the first follow-up 
phase, the graphical presentation showed that this score is not normally distributed; 
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this was supported by K-S test of normality (p <0.001). Therefore, use of parametric 
statistics was not justified for this score at the first follow-up phase. 
Graphical presentations for the depression score across the three phases showed 
that this score is not normally distributed; this was supported by K-S test of normality 
(p<0.001). Therefore, use of parametric statistics was not justified for this score at 
the baseline, first and second follow-up phases.  
5.3.3.2.5 Psychological status - The Impact of event Scale-Revised (IES-
R) (Weiss & Marmar, 1997) 
The IES was used to reflect information processing formulation of Horowitz’s (1976) 
for stress response due to alternating phases of intrusion and avoidance. The 
psychometric properties of this scale are described in detail in Chapter4. The overall 
reliability coefficient for the IES-R scale in the current study was found to be an alpha 
of .94 (items=22). Since the Cronbach’s alpha was greater than 0.7 the items from 
the scale was deemed fit (reliable) to be used in subsequent analysis. 
Subscale scores (avoidance and intrusion) were also calculated. The cut-off scores 
for avoidance and intrusion were derived from the cut-off scores for total IES (PTSD 
cut-off), from avoidance and intrusion by Horowitz et al. (1979); and from cut-off 
scores for total IES-R (PTSD cut-off) by Creamer et al. (2003). A scaling factor was 
computed as the ratio of total IES (Horowitz et al., 1979) and total IES-R (Creamer et 
al., 2003) scores (33.0/39.5 or 0.84) and applied on the avoidance and intrusion cut-
off scores from Horowitz et al. (1979). The resultant cut-off scores of 15.2 and 17.9 
were used as criteria for clinical significance of avoidance and intrusion, respectively 
(Table 19). 
Graphical presentations for the IES-R and its three subscales across the three 
phases showed that these scores are not normally distributed; this was supported by 
K-S test of normality (p<0.001). Therefore, use of parametric statistics was not 
justified for these score at the baseline, first and second follow-up phases.  
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Table 19: Avoidance and Intrusion score estimation 
IES/IES-R Total Avoidance Intrusion 
39.5 18.2 21.4 
Horowitz et al. 
(1979) 
Horowitz et al. 
(1979) 
Horowitz et al. 
(1979) 
33.0 15.2 17.9 
Creamer et al. 
(2003) Estimated Estimated 
5.3.3.2.6 Sexual Function and Satisfaction - The Sexual Activity 
Questionnaire (SAQ) (Thirlaway et al., 1996) 
The 14-item scale Sexual Activity Questionnaire (SAQ) was used for assessing 
various facets of sexual activity. The SAQ consists of three sections; (1) hormonal 
status and sexual activeness of women (2) sexual inactivity reasons and (3) 
functioning of sexual activity. This questionnaire and its psychometric properties 
have been outlined in detail in Chapter 4. In the current study only part (1) and part 
(2) were used since the content of part (3) was measured by another scale in the 
study. 
Following the frequency distribution analysis, scores of only the seven items 
measuring reasons for sexual inactivity were used in subsequent statistical analyses 
(Partner Unavailability; Self Too Tired; Partner Too Tired; Self Lack of Interest; 
Partner Lack of Interest; Self Physical Problem; and Partner Physical Problem). The 
distributions of these items were found to be non-normal across the three phases. In 
view of this, non-parametric techniques were used to summarise and analyse these 
scores.  
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5.3.3.2.7 Sexual Function and Satisfaction - Sexual Vaginal Changes 
Questionnaire (SVQ) (Jensen et al., 2004a) 
The 27-item Sexual function-Vaginal changes Questionnaire (SVQ, Jensen et al, 
2004a), developed for using in the case of gynaecological cancer patients, 
comprises: three scales applicable to all patients (sexual interest, intimacy and 
global sexual satisfaction) and two scales applicable to sexually active respondents 
only (sexual functioning and vaginal changes). High internal consistency has been 
obtained for all five scales with alpha =0.76 to 0.83 (Jensen et al., 2004a) and 
sensitivity to change longitudinally (Jensen et al., 2003).  
The internal consistency of the scales in the current sample ranged from alphas of 
0.53 to 0.72. The overall internal consistency of the SVQ was 0.08 (N=23). This low 
value of Cronbach's alpha is primarily attributed to four questions (11, 11.1, 12 and 
12.1) relating to vaginal dryness and associated level of bother; and pain 
experienced during intercourse and associated level of bother. Excluding these 
questions in computing the internal consistency for the SVQ yields a Cronbach's 
alpha value of 0.69 (N=20). The low value of internal consistency is likely due to the 
small size of the sample that responded to the above-mentioned questions and the 
nature of the responses themselves. It was decided not to exclude these questions 
relating to  vaginal dryness and associated level of bother; and pain experienced 
during intercourse and associated level of bother as these are important for 
calculating the crucial ‘Symptoms scale on vaginal changes’ score.  
The following scores were computed using the responses from the SVQ: Intimacy 
score (2-8), Sexual interest score (1-4), Worries about sex life score (1-4), Sexual 
satisfaction score (1-7), Symptoms scale on vaginal changes score (4-16), Vaginal 
bleeding during intercourse score (2-8), Vaginal dimension score (1-4), and Sexual 
functioning score (3-12). The scores were calculated in accordance with the 
respective score definitions as suggested by Jensen et al. (2004a). 
The frequency distributions of the 8 scores were analysed to test for normality at the 
first and second follow-up phases. At the first follow-up phase, sexual interest, 
worries about sex life, sexual satisfaction, and vaginal dimension scores were found 
to be not normally distributed; and intimacy, symptoms scale on vaginal changes, 
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vaginal bleeding during intercourse, and sexual functioning scores were found to be 
normally distributed. At the second follow-up phase, intimacy, sexual interest, 
worries about sex life, and vaginal dimension scores were found to be not normally 
distributed; and sexual satisfaction, symptoms scale on vaginal changes, vaginal 
bleeding during intercourse, and sexual functioning score were found to be normally 
distributed. Parametric statistics and techniques were used to summarise and 
analyse scores which were found to be normally distributed and non-parametric 
statistics and techniques were used for the rest.  
5.3.3.2.8 Sexual Function and Satisfaction - The Sexual Functioning After 
Gynaecological Illness Scale (SFAGIS) (Bransfield, Horiot, & Nabid, 
1984).  
This scale was included in order to assess clinically important elements of post-treatment 
rehabilitation such as sexual health, side effects of radiation treatment and use of vaginal 
dilators. Though the SFAGIS has been found to have satisfactory face validity (Juraskova, 
2003), a split-half reliability coefficient of .80 (internal consistency reliability alpha (based on 
Kuder-Richardson formula) of 0.756) and achieved a reliability alpha of 0.70, Bruner and 
Boyd (1999) found its focus is on more narrow aspects of sexual function as opposed to the 
broader issue of sexuality. However, despite the SFAGIS’s limitations, particular items were 
relevant with regards to these narrower aspects of sexual function. Furthermore it remains 
the only scale we are aware of that includes a combination of items such as the use of 
vaginal dilators and post-treatment mucosal changes. Given the use of additional scales and 
subscales (i.e. the SAQ and SVQ) to include broader function and satisfaction dimensions of 
sexuality, and to reduce the burden for participants, items of the SFAGIS that overlap with 
the Sexual Activity Questionnaire (SAQ) were excluded from the scale, leaving an adapted 
8-item version (see Appendix 3.3). The frequencies of responses for each of the individual 
items were analysed for this scale.  
5.3.4 Data Analysis 
Sample size  
To achieve ≥80% power at a 5% significance level, the required total sample size at follow-
up was 132 patients. The following data was considered: since the Adherence Scale which 
measures the primary outcome of the study is a new primary outcome measure it has no 
previous results to base effect sizes on; therefore an effect size of 0.5, a medium effect, was 
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assumed. A sample size of 102 (n=51 per group) ensures 80% power and a 2-tailed alpha 
error of 0.05. There was an estimated response rate of 70%, therefore a sample size of 132 
was required. 
Statistical analyses were conducted using the Statistical Package for the Social 
Sciences Premium (SPSS, IBM) Version 21. The data was examined for data entry 
errors, plausibility of means and standard deviation, outliers and missing values. The 
missing data was random with no particular association with any of the demographic 
characteristics. Some components of the questionnaire were not applicable for all 
participants such as those without partners on items assessing sexual function and 
behaviour.  
5.3.4.1 Checking Assumptions and Choice of Statistics 
Prior to conducting statistical analyses the assumptions of parametric statistics was 
inspected. Visual inspection of the data using histograms with normal curves; 
overlaid; stem-and-leaf plots; box plots; P-P plots; Q-Q plots were conducted.  The 
data were examined for statistical skewness and kurtosis. The Kolmogorov-Smirnov 
(K-S) test was used to check the statistical significance of normal distribution of the 
variables. Some of the continuous scales used in the baseline assessment such as 
the Impact of Events Scale Revised (IES-R) were positively skewed at p<.001 and 
did not meet the assumptions of parametric statistics. Non-parametric statistics were 
used (e.g. median and IQR) where the variables were found to deviate significantly 
from a normal distribution. 
5.3.4.2 Data Analysis Aims - Baseline 
The main aims of the data analysis at the baseline were to: 
 compare the groups with respect to demographic and clinical characteristics, 
psychological status, IES-R, and sexual activity/function. It was hypothesised 
that, due to randomisation, there will be no differences between patients in the 
control group and patients in the intervention group with regard to 
demographic and clinical characteristics, psychological status, IES-R, and 
sexual activity/function; and 
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 identify potential confounding variables for subsequent multivariate analysis 
5.3.4.2.1 Confounding variables #1: Demographic and Clinical data 
Demographic and clinical data was summarised using frequencies, mean and 
standard deviation as appropriate. The distribution of age of the participants and the 
age of diagnosis were examined for intervention and control groups. The distribution 
of the age of the participants appeared normally distributed and was supported by a 
K-S test for both the control (p=0.200) and intervention group (p=0.137). Similarly the 
age of diagnosis also showed a normal distribution and the K-S test was not 
significant for both control (p=0.200) and intervention (p=0.088) groups. The 
variables were considered as normally distributed and included in the subsequent 
univariate and multivariate analyses. 
Group differences at baseline on the categorical demographic variables were 
assessed using chi-square tests. The following categorical variables were analysed 
(including collapsed categories with each variable, when required to satisfy the chi-
square’s assumption of expected frequencies): 
 Marital status (married, others) 
 Education (Year 12 or below, TAFE/ Business college, undergraduate/ higher) 
 Occupation (professional, non-professional, and non-working) 
 Language spoken (English, others) 
 No. of children (none, 1-2 children, 3 and higher) 
 Type of cancer (Gynaecological, Anorectal) 
 Taking antidepressants (No, Yes) 
 Treatment (Surgery, External Pelvic Radio, Internal Radio, Chemotherapy/ 
Combination treatments) 
All the demographic and clinical variables were considered as potential confounding 
variables in subsequent multivariate analysis. 
5.3.4.2.2 Confounding Variables #2: Psychological Variable (HADS) 
Distributions of baseline anxiety and depression scores were assessed for normality 
assumptions. The depression score was found to be positively skewed at p < .001. 
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Chi-square statistic was used for determining the difference between clinical and 
non-clinical cases for the anxiety and depression baseline scores. Parametric and 
non-parametric tests were used to investigate group differences in baseline levels of 
anxiety and depression, respectively. HADS data were considered in this study as 
potential confounding variables as well as outcome variables. 
5.3.4.2.3 Confounding Variables #3: Impact of Events Scale (IES-R) 
Similarly to the HADS data, IES-R subscales and total score were considered as 
potential confounders as well as outcome variables. Parametric or non-parametric 
tests were used to investigate the group differences in baseline scores of IES-R total 
score and sub-scale scores as appropriate.  
5.3.4.3 Data Analysis Aims - First Follow-up 
The main aims of the data analysis at the first follow up were to: 
 compare the groups with respect to adherence, knowledge, feedback about 
the booklet, sexual function and psychological status; 
 compare baseline and first follow-up scores; and 
 determine predictors of psychological status and sexual activity/function. 
It was hypothesised that, in comparison with patients in the control group, patients in 
the intervention group would report: 
 greater adherence to rehabilitation strategies; greater knowledge of 
rehabilitation strategies; and more positive feedback on the booklet they 
received; 
 lower levels of PRT-related psychological distress (including lower levels of 
avoidance, intrusion and hyperarousal), anxiety, and depression; and  
 better sexual functioning and satisfaction including enhanced interest in 
sexual activities, enhanced intimacy, and enhanced sexual functions. 
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Further, it was hypothesised that: 
 compared to baseline, at the first follow up there would be less prevalence of 
PRT-related psychological distress/PTSD; anxiety and depression; and less 
prevalence of sexual dysfunction & dissatisfaction. 
Finally, it was hypothesised on the basis of the literature that: 
 intervention group membership would predict psychological function 
controlling for demographic and clinical characteristics; and  
 intervention group membership would predict sexual activity/function, when 
controlling for demographic and clinical characteristics, psychological status. 
5.3.4.3.1 Analysis of clinical conditions - Baseline and First Follow Up  
Dichotomized scores were created for some of the variables which measured 
psychological status and sexual activity/function at both the baseline and first follow 
up stages. This step had the objective of determining the proportion of patients with 
or without a certain condition, and to see if there were significantly different between 
stages (baseline and first follow up) for both the groups (control and intervention) 
and overall sample. Some of the scores have established clinical significance cut-off 
score, and these cut-offs were used to dichotomize the respective scores. For 
anxiety and depression, the borderline and caseness cases were categorised into 
one class, and two categories each were created for IES-R, avoidance and intrusion 
based on established clinical significance cut-off scores. In the absence of any 
established clinical significance cut-off score, the scores were dichotomized using 
the respective variable mean/median as at the baseline. This was done to allow 
consistent analysis and reporting of the prevalence of the various clinical conditions. 
McNemar Test is known to be an appropriate technique for analyzing differences 
between repeated measure proportions or dichotomous items. McNemar test is a 
non-parametric statistical test and can be used with data sets and samples that are 
not normally distributed (Ciechalski, et al., 2002). Prevalence percentages, relative 
risk (RR) and corresponding 95% confidence intervals (95% CI) were estimated for 
each dichotomised score. 
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5.3.4.3.2 Multiple Linear Regression - Using Baseline and First Follow-up 
Phase Data  
A multiple linear regression based approach has been utilised to identify the 
predictors of measures drawn from the IES-R, SVQ, SAQ, and other secondary 
outcome measures. The models have taken into consideration sample demographic 
and clinical characteristics, and potential confounding variables.  These variables 
have been controlled for where appropriate. 
In this research, no statistically significant differences were obtained between the 
control and the intervention groups with respect to any demographic or clinical 
characteristics, and also for any measures of psychological status at baseline. 
Therefore, there were no pre-qualified confounding variables which could be 
controlled for in the regression models. However, some variables which have been 
known to have a confounding effect in other similar studies were identified and used 
in the regression models as potential confounders. These variables are age, marital 
status (1-Married or defacto, 0-Not married and other), Highest Qualification (1-
Higher than year 12, 0-Year 12 or less), and measures of psychological status 
(anxiety, depression, and IES-R). Furthermore, the baseline measures of length of 
relationship, number of children, language spoken at home (1-Engligh, 0-Other), 
occupation status of professional (1, 0), occupation status of non-professional (1, 0), 
occupation status of not working (1, 0), taking anti-depressant medication (1, 0), 
treatment at Royal Hospital for Women (RHW) / Prince of Wales Hospital (POWH) 
(1, 0), treatment at Royal North Shore Hospital (RNSH) (1, 0), treatment at Royal 
Prince Alfred Hospital (RPAH) (1, 0), treatment at Liverpool Hospital (1, 0), treatment 
at St George Hospital (1, 0), treatment at Genesis Care Mater Hospital (1, 0), 
Cervical cancer (1, 0), Endometrial cancer (1, 0), Anal cancer (1, 0), Rectal cancer 
(1, 0), Vaginal cancer (1, 0), Vulvar cancer (1, 0), treatment approach of Surgery (1, 
0), treatment approach of External pelvic radiotherapy (1, 0), treatment approach of 
Internal radiotherapy (1, 0), and treatment approach of Chemotherapy (1, 0) have 
been used as independent variables in the models. In addition to these, the 
independent variable of group membership (0-control; and 1-intervention) has been 
considered for inclusion in all the models.  
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Two sets of multiple linear regression models were developed, one for the measures 
drawn from the SVQ and SAQ; and the other for the measures of PTSD, anxiety, 
and depression. The independent variables for the former set of models include 
demographic and clinical characteristics, measures of psychological status (as 
potential confounders), and group membership. The independent variables for the 
latter set of models include only the demographic and clinical characteristics, and 
group membership variable. 
Two sets of models per measure have been reported where applicable, one showing 
the effect size of all the independent variables that were input; and the other showing 
the effect size of only the significant independent variables. The latter models were 
developed using a stepwise method and a .05 criterion of statistical significance. The 
same .05 criterion were used as a cut-off for the significance of the whole model, 
model intercept, and the predictors. This procedure shortlists predictor variable/s 
using the guiding principle of statistical significance and assumes linear relationship. 
Missing values in the dependent and independent variables were substituted by 
respective variable means for selected variables. It is recommended not to replace 
missing values for variables with greater than 25% missing values (Feng et al., 2010; 
Little et al., 1987; Little, 1988; Meng, 1994; Rubin, 1976; Schafer, 1997). Therefore, 
dependent and independent variables which had more than 25% of the values 
missing were ignored for this analysis. A summary of included and excluded 
variables is provided in Appendix 4.1.  
The assumptions related to multiple regression, which include, linearity of the 
relationship between dependent and independent variables, independence of errors, 
homoscedasticity and normality of errors were tested for and were met for all the 
significant models that have been reported.  
5.3.4.4 Data Analysis Aims - Second Follow-up 
The main aims of the data analysis at the second follow up were to: 
 compare the groups with respect to adherence, knowledge, feedback about 
the booklet, sexual function and psychological status; 
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 compare baseline and second follow-up scores; and 
 determine predictors of adherence, knowledge, feedback about booklet, 
psychological status  and sexual activity/function. 
It was hypothesised that, compared to the patients in the control group, those in 
the intervention group would report: 
 greater adherence to rehabilitation strategies; greater knowledge of 
rehabilitation strategies; and more positive feedback on the booklet they 
received; 
 lower levels of anxiety, depression and PRT-related psychological distress 
(including lower levels of avoidance, intrusion and hyperarousal); and  
 better sexual functioning and satisfaction including enhanced interest in 
sexual activities, enhanced intimacy, and enhanced sexual functions. 
Further, it was hypothesised that: 
 compared to baseline, at the second follow up there would be less prevalence 
of PRT-related psychological distress/PTSD; less prevalence of anxiety and 
depression; and less prevalence of sexual dysfunction and dissatisfaction. 
Finally, it was hypothesised on the basis of the literature that: 
 intervention group membership would predict adherence, knowledge, 
feedback about the booklet, sexual activity/function/satisfaction, controlling for 
demographic and clinical characteristics and psychological function. 
5.3.4.1.1 Analysis of clinical conditions - Baseline and Second Follow Up  
A similar approach was utilised to dichotomise the scores which measured 
psychological status and sexual activity/function at both the baseline and second 
follow up stages, as at the first follow-up phase. The prevalence percentages, 
relative risk (RR) and corresponding 95% confidence intervals (95% CI) were 
estimated for each dichotomised score. Statistical tests were conducted to determine 
if the prevalence percentages were significantly different between stages (baseline 
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and second follow up) for both the groups (control and intervention) and overall 
sample. 
5.3.4.1.2 Multiple Linear Regression - Using Baseline and Second 
Follow-up Phase Data  
The previously reported multiple linear regression models attempted to identify the 
predictors of measures drawn from the IES-R, SVQ, and SAQ using the baseline 
and first follow-up phase data. The same methodology was implemented except 
using the baseline and second follow-up data in the analysis. A summary of included 
and excluded variables is provided in Appendix 4.1.  
5.3.4.1.3 Multiple Linear Regression - Using First Follow-up and Second 
Follow-up Phase Data 
The effectiveness of the psychoeducational information booklet was assessed using 
measures drawn from the AS, KS, and FS and by utilising the data collected at the 
first and second follow-up phases. These scales were not used at the baseline 
phase and therefore, baseline phase data could not be utilised.  
A similar regression based approach as was used for the measures drawn from the 
SVQ and SAQ was utilised on the measures drawn from the AS, KS and FS. 
Dependent and independent variables which had more than 25% of the values 
missing were ignored for this analysis with the exception of the Use and frequency of 
use of Dilator score, Use and frequency of use of Moisturiser score, Use and 
frequency of use of PFME score, Knowledge score, Feedback score, Anxiety score, 
Depression score, and IES-R total score. The proportion of missing values for these 
scores is more than 25%. Despite this, regression modelling was done using these 
scores as some of these scores are of prime interest in this research. Missing values 
were not substituted by respective variable means, but the model excluded cases 
using a ‘listwise’ approach. Under this approach, only cases with valid values for all 
variables are included in the analyses. Degrees of freedom were based on the 
listwise N. The results from this analysis should be viewed with caution as this 
analysis is based on a subset of participants. A summary of the dependent and 
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independent variables selected for used in the multiple linear regression model is 
provided in Appendix 4.1.  
5.3.4.1.4 Multiple Linear Regression - Using Baseline, First Follow-up 
and Second Follow-up Phase Data 
The previously reported multiple linear regression models attempted to identify the 
predictors of measures drawn from the SVQ, SAQ, and IES-R scales using the 
baseline and first follow-up phase data. The same methodology was implemented 
using the baseline, first follow-up and second follow-up data. Once again, the 
measures drawn from the AS, KS and FS were not utilised in this analysis as these 
scales were not used at the baseline phase.   
Dependent and independent variables which had more than 25% of the values 
missing were ignored for this analysis. A summary of the dependent and 
independent variables that were selected to be used in the multiple linear regression 
models is provided in Appendix 4.1.  
5.3.4.5 Missing Value Handling 
Due to participants dropping out or not responding to certain items at the baseline, 
first and second follow-up, most of the measures utilised in this research have 
missing values. A summary of the proportion of values missing for each of the 
measures for all the phases of data collection combined is given in Appendix 4.1. 
In all the analysis except the multivariate analysis (i.e. multiple linear regressions), 
the missing values were ignored using a ‘pairwise exclusion’ method. In this method, 
those cases which had no missing values for variables in a group (cell) were 
included in the analysis of that group. However, there may be missing values for 
such cases for variables used in other groups. This allows for the maximum possible 
utilisation of the available data without substituting for missing values (which may 
introduce bias into the findings). The missing values were substituted by respective 
variable means in the multiple linear regression analyses undertaken in this 
research, unless otherwise indicated. 
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5.4. RESULTS 
5.4.1 Baseline 
Consecutive patients at the seven participating hospitals who fulfilled the study 
eligibility criteria were invited to participate in the study. As a result 109 women who 
were scheduled for internal (brachytherapy) and/or external (EBRT/IMRT) pelvic 
radiation therapy for gynaecological or anorectal cancer were approached (see 
Figure 15). Of the 109 eligible patients 5 (4%) women declined to participate at the 
outset. Of these women, one found the study too complicated, another felt too 
exhausted and stressed, one woman was too busy, another women did not want to 
be on a database and one woman gave no reason for declining. Of the remaining 
104 (94%) women, 21 women (21% of n=109) did not proceed beyond hospital 
recruitment, failing to complete baseline data (see Figure 15). These 21 women 
provided no reason for their non-participation and did not respond to follow-up calls 
or letters with attached reminder questionnaires.  Thus, the final sample of women 
consisted of 82 women corresponding to a response rate of 78% (n=109). Of these, 
63 women (60%) completed the 3-month follow up (follow-up 1) and 54 women 
completed the 6-month follow up (51%) (follow-up 2). 
To systematically assess for sample bias, patients who declined or failed to 
participate were compared to patients who decided to participate on demographic 
and clinical characteristics. De-indentified data on age and type of cancer from 
women who declined or failed to participate were obtained from radiation oncology 
clinicians participating in the study. The age of decliners/non-participators (M=61.25, 
SD=11.41) was not significantly different to that of the final set of participants 
(M=60.43, SD=12.09) (Age t(22.10)=0.26, p=0.80). Also, there were no statistically 
significant differences in the type of cancer (gynaecological vs. anorectal) between 
the decliners/non-participators and the final participant groups (χ2=0.067, p=0.80). 
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Figure 15: Recruitment sample and data collection overview 
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5.4.1.1 Differences between groups at baseline on demographic 
and clinical characteristics 
The overview of demographic and clinical characteristics obtained from participating 
patients (N=82) is shown in Table 20 and 21 respectively. The control and 
intervention groups did not differ in terms of age, age at the time of diagnosis, marital 
status, length of relationship, number of children, and sexual orientation.  
The proportion of participants in a relationship was statistically equivalent in the 
control group (60.5%) and the intervention group (52.3%). Further, the length of 
relationship between groups indicated no significant differences between groups.  
There was also no difference in the number of children for the participants in the 
control group and intervention group. In our sample, the majority of participants in 
the intervention group (90.9%) and control group (97.4%) had heterosexual 
orientation, with no significant difference between groups. 
The two groups of participants were not different in their level of education, language 
spoken at home or use of antidepressant or sedative medication (10.5% and 6.8% of 
women were currently taking antidepressant or sedative medication in the control 
and intervention group respectively).  
Nor did the groups differ in type of cancer or treatment type, with approximately half 
of the women having received external pelvic radiotherapy, internal radiotherapy or 
chemotherapy (see Table 21). Approximately two-thirds of the women reported 
surgery. Patients receiving combination treatment (one or more of Surgery, External 
Pelvic Radiotherapy, Internal Radiotherapy, or Chemotherapy) was reported in 
81.6% of the control group and 86.4% of the intervention group participants.  
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Table 20: Demographic Characteristics of Participants (N=82) 
 Control Intervention Overall 
t df p-valueCharacteristic Mean SD Mean SD Mean SD 
Participant Age 61.13 10.87 59.82 13.15 60.43 12.09 .50 79.86 .62 
Age at Diagnosis 61.54 10.51 59.66 13.04 60.52 11.92 .72 78.87 .47 
Length of 
Relationship 28.52 14.59 26.53 16.53 27.47 15.53 .47 52.99 .64 
 
Characteristic Category Control Intervention Overall Test Statistic df 
p-
value
Marital Status 
1= Single 5 13.16% 8 18.18% 13 15.85% 
0.62 1 0.43 
2 = Married or De Facto 23 60.53% 23 52.27% 46 56.10% 
3 = Relationship 1 2.63% 1 2.27% 2 2.44% 
4 = Separated/Divorced 6 15.79% 4 9.09% 10 12.20% 
5 =  Widowed 3 7.89% 8 18.18% 11 13.41% 
Sexual Orientation 
1 = Heterosexual 37 97.37% 40 90.91% 77 93.90% 
- - - 
2 = Homosexual 0 0.00% 1 2.27% 1 1.22% 
3 = Bisexual 1 2.63% 0 0.00% 1 1.22% 
4 = I prefer not to answer this question 0 0.00% 2 4.55% 2 2.44% 
9 = Missing 0 0.00% 1 2.27% 1 1.22% 
Number of Children 
0 = No Children 8 21.05% 10 22.73% 18 21.95% 
0.26 2 0.88 
1 =1 Child 9 23.68% 5 11.36% 14 17.07% 
2 = 2 Children 9 23.68% 14 31.82% 23 28.05% 
3 = 3 Children 4 10.53% 8 18.18% 12 14.63% 
4 = 4 Children 6 15.79% 6 13.64% 12 14.63% 
5 = 5 Children 0 0.00% 1 2.27% 1 1.22% 
6 = 6 Children 1 2.63% 0 0.00% 1 1.22% 
9 = Missing 1 2.63% 0 0.00% 1 1.22% 
Highest Qualification 
1 = Year 10 or below 9 23.68% 12 27.27% 21 25.61% 
0.51 2 0.77 2 = Year 12 – HSC 3 7.89% 5 11.36% 8 9.76% 
3 = TAFE certificate, diploma, business 
college 14 36.84% 11 25.00% 25 30.49% 
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Characteristic Category Control Intervention Overall Test Statistic df 
p-
value
4 = Bachelor’s degree 3 7.89% 6 13.64% 9 10.98% 
5 = Postgraduate degree 8 21.05% 7 15.91% 15 18.29% 
6 = Other 1 2.63% 3 6.82% 4 4.88% 
Current Occupation 
1 = Manager 4 10.53% 4 9.09% 8 9.76% 
0.96 2 0.95 
2 = Executive 5 13.16% 5 11.36% 10 12.20% 
3 = Blue collar 1 2.63% 3 6.82% 4 4.88% 
4 = Retired 1 2.63% 4 9.09% 5 6.10% 
5 = Housewife 3 7.89% 1 2.27% 4 4.88% 
6 = Professional 8 21.05% 11 25.00% 19 23.17% 
7 = Technical 6 15.79% 6 13.64% 12 14.63% 
8 = Administration 10 26.32% 8 18.18% 18 21.95% 
9 = Missing 0 0.00% 2 4.55% 2 2.44% 
Language Spoken at 
Home 
1 = English 29 76.32% 35 79.55% 64 78.05% 
0.12 1 0.73 2 = Other 9 23.68% 9 20.45% 18 21.95% 
Table 21: Clinical Characteristics of Participants (N=82) 
Characteristic Category Control Intervention Overall Test Statistic df p-value 
Taking antidepressant or 
Sedative 
1 = No 34 89.47% 41 93.18% 75 91.46% 
2.83 2 0.24 2 = Yes 4 10.53% 3 6.82% 7 8.54% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Type of Cancer 
1 = Cervical 5 13.16% 2 4.76% 7 8.54% 
0.67 1 0.41 
2 = 
Endometrial 21 55.26% 28 66.67% 49 59.76% 
3 = Anal 1 2.63% 5 11.90% 6 7.32% 
4 = Rectal 8 21.05% 9 21.43% 17 20.73% 
5 = Vaginal 2 5.26% 0 0.00% 2 2.44% 
6 = Vulvar 1 2.63% 0 0.00% 1 1.22% 
Treatment - Surgery 
1 = No 10 26.32% 15 34.09% 25 30.49% 
0.37 1 0.54 
2 = Yes 26 68.42% 29 65.91% 55 67.07% 
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Characteristic Category Control Intervention Overall Test Statistic df p-value 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Treatment - External Pelvic 
Radio 
1 = No 15 39.47% 19 43.18% 34 41.46% 
0.02 1 0.89 2 = Yes 21 55.26% 25 56.82% 46 56.10% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Treatment - Internal Radio 
1 = No 19 50.00% 23 52.27% 42 51.22% 
0 1 0.96 2 = Yes 17 44.74% 21 47.73% 38 46.34% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Treatment - Chemotherapy 
1 = No 19 50.00% 22 50.00% 41 50.00% 
0.61 1 0.81 2 = Yes 17 44.74% 22 50.00% 39 47.56% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Treatment - Other 
1 = No 36 94.74% 44 100.00% 80 97.56% 
- - - 2 = Yes 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
Treatment - Combination 
1 = No 5 13.16% 6 13.64% 11 13.41% 
0 1 0.97 2 = Yes 31 81.58% 38 86.36% 69 84.15% 
9 = Missing 2 5.26% 0 0.00% 2 2.44% 
 
5.4.1.2   Psychological Status - Baseline 
5.4.1.2.1 Hospital Depression and Anxiety Scale (HADS) - Differences between groups at baseline 
An independent sample t-test indicated no significant difference between the intervention and control groups on HADS anxiety 
scores at baseline (see Table 22).  
186 
 
In using the cut-off scores for caseness/clinical levels of anxiety symptomatology 
(from here on referred to as clinical anxiety level; normal/non-clinical levels <8, 
borderline clinical case 8-10, clinical case >11), 65.8% of women (n=25) had non-
clinical levels of anxiety, 23.7% (n=9) were borderline and 10.5% (n=4) were 
considered clinically anxious in the control group. In the intervention group, 79.5% of 
women scores fell within the normal range (n=35), 11.4% (n=5) were borderline and 
9.1% (n=4) were considered clinically anxious. There was no statistical difference 
between women in the control and intervention group on clinical anxiety caseness 
(χ2=2.383, p=0.30).  
Non-parametric statistics was conducted for depression, as HADS depression 
scores were not normally distributed. Mann-Whitney U test indicated no significant 
difference between the intervention and control groups (See Table 22).  The majority 
of women were considered non-clinical cases according to depression score cut-offs. 
Borderline clinical depression was seen in 10.5% (n=4) of control and 9.1% (n=4) of 
intervention participants with 2.3% (n=1) of women considered clinically depressed in 
the intervention group, while none fitted criteria for clinical depression in the control 
group.  
Table 22: HADS Scores 
 Control Intervention Overall Test Statistic  df p-value
Score Mean/ Median SD/IQR 
Mean/ 
Median SD/IQR
Mean/ 
Median SD/IQR
Anxiety1 5.39 3.91 5.05 3.40 5.21 3.63 0.428(t) 73.871 0.67 
Depression2 3.00 4.00 2.00 3.75 2.00 4.00 709.000 (U) 82 0.23 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
5.4.1.2.2 Impact of Event Scale Revised (IES-R) - Differences between 
groups at baseline 
The median total IES-R scores of patients in the control and intervention groups 
were (CON=15.00, IQR=22.00) and (INT=11.00, IQR=17.00) respectively (see Table 
23). Mann-Whitney U test indicated no significant difference between the intervention 
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and control groups for IES-R scores (U(76)= 684, p=0.79). Similarly, none of the 
subscales showed statistical difference between the control and intervention groups 
at baseline (Table 23). 
In using the cut-off scores for clinically significant symptomatology/cases 
posttraumatic stress/psychological distress (score > 33), 15.2% (n= 5) were 
considered clinical cases in the control group. In the intervention group 18.6% (n=8) 
were considered clinical cases of PRT-related psychological distress/posttraumatic 
stress. There was no statistical difference between control and intervention group on 
average psychological distress/posttraumatic stress ‘caseness’ (χ2=0.157, p=0.69).  
In using derived clinical cut off scores of 15.2 for avoidance and 17.9 for intrusion, 
12.1% (N=4) and 14% (N=6) had higher than cut-off scores for avoidance in the 
control and intervention groups, respectively. There was no statistical difference 
between control and intervention group (χ2=0.055, p=0.82). 0% and 7% (N=3) had 
higher than cut-off scores for intrusion in the control and intervention groups, 
respectively, with no statistical difference between control and intervention groups 
(χ2=2.397, p=0.12).  
Table 23: IES-R Scores 
 Control Intervention Overall Test 
Statistic 
(U) 
 
df p-valueScore Median IQR Median IQR Median IQR 
Mean Total 
IES-R 15.00 22.00 11.00 17.00 12.50 18.75 684.00 76 0.79 
Avoidance 5.00 11.00 6.00 9.00 6.00 10.00 674.50 76 0.71 
Intrusion 4.00 7.00 4.00 6.00 4.00 6.75 649.50 76 0.53 
Hyperarousal 2.00 5.00 1.00 4.00 2.00 5.00 619.00 76 0.33 
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5.4.1.3 Sexual Function  
5.4.1.3.1 Sexual Activity Questionnaire (SAQ) - Differences between 
groups at baseline 
The median scores for the various SAQ items were tested for group differences 
using the Mann-Whitney U test and the results indicated that there was no significant 
difference between the intervention and control groups. 
5.4.1.3.2 Overall group and sample SAQ response frequencies at 
baseline 
In the current study (see Table 24) overall 40.2% of women were not married or 
having an intimate relationship with someone, whilst 54.9% of women were. It was 
found that 89% of women had not changed their partner in the last 6 months and 
74.4% were not currently engaging in sexual activity whilst 19.5% of women were. 
With regards to the reasons for sexual inactivity, 54.1% of women did not have a 
current partner, 1.6% was too tired, 26.2% were not interested in sex, 4.9% of 
women reported their partner was not interested in sex, 19.7% of women reported a 
physical problem making sexual activity difficult or uncomfortable, 13.1% reported 
the aforementioned for their partner, 16.4% reported currently being sexually inactive 
for other reasons. An examination of sexual health of women over 50 years in the 
USA indicates that more than half of women in this cohort are sexually inactive  
(Schick et al., 2010). In comparison with this American study, this study sample is 
characterised by relatively low levels of sexual activity. The main reasons for this 
include lack of partner (54.1%) and higher average age of the sample (60 years).  
5.4.1.3.3 Sexual Vaginal Changes Questionnaire (SVQ) - Differences 
between groups at baseline 
Mann-Whitney U test indicated no significant difference between the intervention and 
control groups for Intimacy, Sexual interest, and Worries about sex life score (see 
Table 25). An independent sample t-test which examined for statistically significant 
differences between the control and intervention group responses did not find any 
significant differences for Sexual satisfaction or Sexual functioning. 
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Table 24: Sexual Activity Item Responses 
Item Category Control Intervention Overall 
Are you currently married or having an intimate relationship with 
someone? 
1 = No 13 34.21% 20 45.45% 33 40.24% 
2 = Yes 23 60.53% 22 50.00% 45 54.88% 
9 = Missing 2 5.26% 2 4.55% 4 4.88% 
Have you changed your sexual partner in the last 6 months? 
1 = No 33 86.84% 40 90.91% 73 89.02% 
2 = Yes 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 5 13.16% 4 9.09% 9 10.98% 
Do you engage in sexual activity with anyone at the moment?  
1 = No 28 73.68% 33 75.00% 61 74.39% 
2 = Yes 6 15.79% 10 22.73% 16 19.51% 
9 = Missing 4 10.53% 1 2.27% 5 6.10% 
I am not sexually active at the moment because - I do not have a 
partner at the moment 
1 = No 18 64.29% 15 45.45% 33 54.10% 
2 = Yes 10 35.71% 15 45.45% 25 40.98% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - I am too tired 
1 = No 28 100.00% 29 87.88% 57 93.44% 
2 = Yes 0 0.00% 1 3.03% 1 1.64% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - My partner is too 
tired 
1 = No 28 100.00% 30 90.91% 58 95.08% 
2 = Yes 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - I am not 
interested in sex 
1 = No 22 78.57% 20 60.61% 42 68.85% 
2 = Yes 6 21.43% 10 30.30% 16 26.23% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - My partner in not 
interested in sex 
1 = No 28 100.00% 27 81.82% 55 90.16% 
2 = Yes 0 0.00% 3 9.09% 3 4.92% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - I have a physical 
problem which makes sexual relations difficult or uncomfortable 
1 = No 21 75.00% 25 75.76% 46 75.41% 
2 = Yes 7 25.00% 5 15.15% 12 19.67% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - My partner has a 
physical problem which makes sexual relations difficult or 
uncomfortable 
1 = No 24 85.71% 26 78.79% 50 81.97% 
2 = Yes 4 14.29% 4 12.12% 8 13.11% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
I am not sexually active at the moment because - of other reasons 
1 = No 22 78.57% 26 78.79% 48 78.69% 
2 = Yes 6 21.43% 4 12.12% 10 16.39% 
9 = Missing 0 0.00% 3 9.09% 3 4.92% 
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Table 25: SVQ Scores by Group Membership 
 Control Intervention Overall Test 
Statistic df 
p-
valueScore Mean/Median SD/IQR Mean/Median SD/IQR Mean/Median SD/IQR
Intimacy score2 7.00 2.00 6.00 3.00 6.00 3.00 
501.00 
(U) 73 0.06 
Sexual interest 
score2 2.00 1.00 1.00 1.00 1.00 1.00 
609.50 
(U) 73 0.49 
Worries about sex 
life score2 1.00 1.00 1.00 1.00 1.00 1.00 
589.50 
(U) 70 0.77 
Sexual satisfaction 
score1 3.84 2.19 4.85 1.84 4.41 2.04 -1.86 (t) 46.50 0.07 
Symptoms scale 
on vaginal 
changes score1 
9.75 4.19 - - 9.00 4.00 - - - 
Vaginal bleeding 
during intercourse 
score1 
5.25 2.22 - - 5.40 1.95 - - - 
Vaginal  dimension 
score2 3.00 2.25 - - 1.00 2.00 - - - 
Sexual functioning 
score1 7.75 2.63 9.29 1.38 8.73 1.95 -1.09 (t) 3.97 0.34 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
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5.4.1.4 Correlation Analysis - Baseline 
The correlation matrix using Spearman's Rank Non-Parametric Correlation 
Coefficients is shown in Appendix 4.2. A number of significant correlations were 
observed at p < 0.05 and p < 0.01. These significant correlations were considered in 
the subsequent multivariate analysis to avoid the problem of multicollinearity. 
5.4.1.5 A summary of baseline results 
The analysis of baseline results indicates that the random allocation to the 
intervention and control groups was successful in ensuring the groups were equal 
with respect to demographic, clinical and psychological variables. Theoretical 
considerations were used to select an optimal set of covariates to consider in the 
follow-up analyses, and included; age, marital status, education level and 
occupational status. The potential confounding effects of anxiety, depression, and 
IES-R were also controlled in subsequent analyses, since levels of these measures 
were believed to influence patients’ responses on sexual function, adherence and 
feedback. 
5.4.2 First Follow-up 
5.4.2.1 Rehabilitation Strategies - First Follow-up 
5.4.2.1.1 Adherence Scale (AS) - First Follow-up 
The responses from the Adherence Scale are summarised in Table 26, Table 27 and 
Table 28. The responses indicate that out of vaginal dilator, vaginal moisturiser, and 
PFME, a relatively larger proportion of participants reported using a vaginal dilator 
after treatment (N=37, 45.12%), this was followed by the use of vaginal moisturiser 
(N=17, 20.73%) and PFME (N=10, 12.20%).   
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Table 26: Adherence Scale Responses - Vaginal Dilator Use - First Follow Up 
Item Category Control Intervention Overall
Prior to treatment did you use a 
cylinder/vibrator 
1= No 29 76.32% 27 61.36% 56 68.29% 
2 =Yes 0 0.00% 2 4.55% 2 2.44% 
9 = Missing 9 23.68% 15 34.09% 24 29.27% 
Have you been given a vaginal dilator 
1= No 7 18.42% 6 13.64% 13 15.85% 
2 =Yes 23 60.53% 24 54.55% 47 57.32% 
9 = Missing 8 21.05% 14 31.82% 22 26.83% 
Since treatment have you used a 
vaginal dilator 
1= No 12 31.58% 11 25.00% 23 28.05% 
2 =Yes 18 47.37% 19 43.18% 37 45.12% 
9 = Missing 8 21.05% 14 31.82% 22 26.83% 
How often do you use a dilator 
1 = More than recommended 2 11.11% 0 0.00% 2 5.41% 
2 = As often as recommended 7 38.89% 8 42.11% 15 40.54% 
3 = Less often than recommended 9 50.00% 11 57.89% 20 54.05% 
Please indicate how much you agree 
with the following statement: I was 
given sufficient explanation on the 
purpose and use of the vaginal dilator 
as part of my post-treatment recovery.  
1 = Strongly agree 12 31.58% 16 36.36% 28 34.15% 
2 = Agree 9 23.68% 8 18.18% 17 20.73%
3 = Neither 1 2.63% 1 2.27% 2 2.44% 
4 = Disagree 2 5.26% 2 4.55% 4 4.88% 
5 = Strongly disagree 1 2.63% 0 0.00% 1 1.22% 
9 = Missing 13 34.21% 17 38.64% 30 36.59% 
Please indicate how much you agree 
with the following statement: I am 
confident using the vaginal dilator. 
1 = Strongly agree 11 28.95% 11 25.00% 22 26.83% 
2 = Agree 6 15.79% 6 13.64% 12 14.63%
3 = Neither 1 2.63% 7 15.91% 8 9.76% 
4 = Disagree 2 5.26% 0 0.00% 2 2.44% 
5 = Strongly disagree 2 5.26% 2 4.55% 4 4.88% 
9 = Missing 16 42.11% 18 40.91% 34 41.46% 
Please indicate how much you agree 
with the following statement: Using the 
vaginal dilator just prior to sexual 
intercourse makes intercourse easier. 
1 = Strongly agree 1 2.63% 0 0.00% 1 1.22% 
2 = Agree 1 2.63% 1 2.27% 2 2.44%
3 = Neither 13 34.21% 18 40.91% 31 37.80% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 3 7.89% 1 2.27% 4 4.88% 
9 = Missing 20 52.63% 24 54.55% 44 53.66% 
Please indicate how much you agree 
with the following statement: I would 
have liked more opportunity to practice 
1 = Strongly agree 2 5.26% 1 2.27% 3 3.66% 
2 = Agree 1 2.63% 1 2.27% 2 2.44% 
3 = Neither 7 18.42% 3 6.82% 10 12.20% 
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Item Category Control Intervention Overall 
the use of vaginal dilator with a nurse. 4 = Disagree 5 13.16% 12 27.27% 17 20.73% 
5 = Strongly disagree 5 13.16% 8 18.18% 13 15.85% 
9 = Missing 18 47.37% 19 43.18% 37 45.12% 
Please indicate how much you agree 
with the following statement: Using the 
vaginal dilator has been helpful. 
1 = Strongly agree 2 5.26% 5 11.36% 7 8.54% 
2 = Agree 6 15.79% 7 15.91% 13 15.85% 
3 = Neither 10 26.32% 12 27.27% 22 26.83% 
4 = Disagree 1 2.63% 0 0.00% 1 1.22% 
5 = Strongly disagree 1 2.63% 2 4.55% 3 3.66% 
9 = Missing 18 47.37% 18 40.91% 36 43.90% 
Please indicate how much you agree 
with the following statement: I have 
emotional difficulties using a vaginal 
dilator (e.g. feeling anxious). 
1 = Strongly agree 0 0.00% 1 2.27% 1 1.22% 
2 = Agree 3 7.89% 2 4.55% 5 6.10% 
3 = Neither 6 15.79% 8 18.18% 14 17.07% 
4 = Disagree 7 18.42% 8 18.18% 15 18.29%
5 = Strongly disagree 5 13.16% 7 15.91% 12 14.63% 
9 = Missing 17 44.74% 18 40.91% 35 42.68% 
Please indicate how much you agree 
with the following statement: I have 
physical difficulties using a vaginal 
dilator (e.g. it is painful). 
1 = Strongly agree 1 2.63% 0 0.00% 1 1.22% 
2 = Agree 2 5.26% 1 2.27% 3 3.66% 
3 = Neither 4 10.53% 6 13.64% 10 12.20% 
4 = Disagree 7 18.42% 9 20.45% 16 19.51%
5 = Strongly disagree 6 15.79% 9 20.45% 15 18.29% 
9 = Missing 18 47.37% 19 43.18% 37 45.12% 
Please indicate how much you agree 
with the following statement: My partner 
is supportive about my dilator use. 
1 = Strongly agree 3 10.34% 6 19.35% 9 15.00% 
2 = Agree 3 10.34% 4 12.90% 7 11.67% 
3 = Neither 5 17.24% 3 9.68% 8 13.33% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00%
5 = Strongly disagree 2 6.90% 1 3.23% 3 5.00% 
9 = Missing 16 55.17% 17 54.84% 33 55.00% 
The above question is not applicable 
because: 
1 = I do not have a partner 7 77.78% 13 100.00% 20 90.91% 
2 = My partner is unaware of my vaginal dilator 
use 2 22.22% 0 0.00% 2 9.09% 
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Table 27: Adherence Scale Responses - Vaginal Moisturiser Use - First Follow Up  
Item Category Control Intervention Overall
Since treatment have you used a vaginal 
moisturiser 
1= No 20 52.63% 24 54.55% 44 53.66% 
2 =Yes 9 23.68% 8 18.18% 17 20.73% 
9 = Missing 9 23.68% 12 27.27% 21 25.61% 
How often do you use the moisturiser 
1 = More than recommended 4 44.44% 3 37.50% 7 41.18% 
2 = As often as recommended 2 22.22% 0 0.00% 2 11.76% 
3 = Less often than recommended 3 33.33% 5 62.50% 8 47.06% 
Please indicate how much you agree with 
the following statement: I was given 
sufficient explanation on the use of vaginal 
moisturisers as part of my post-treatment 
recovery. 
1 = Strongly agree 4 10.53% 3 6.82% 7 8.54% 
2 = Agree 6 15.79% 4 9.09% 10 12.20% 
3 = Neither 3 7.89% 5 11.36% 8 9.76% 
4 = Disagree 2 5.26% 4 9.09% 6 7.32% 
5 = Strongly disagree 4 10.53% 2 4.55% 6 7.32% 
9 = Missing 19 50.00% 26 59.09% 45 54.88% 
Please indicate how much you agree with 
the following statement: I am confident using 
vaginal moisturiser. 
1 = Strongly agree 3 7.89% 5 11.36% 8 9.76% 
2 = Agree 4 10.53% 4 9.09% 8 9.76% 
3 = Neither 5 13.16% 8 18.18% 13 15.85% 
4 = Disagree 3 7.89% 0 0.00% 3 3.66% 
5 = Strongly disagree 3 7.89% 0 0.00% 3 3.66% 
9 = Missing 20 52.63% 27 61.36% 47 57.32% 
Please indicate how much you agree with 
the following statement: Using vaginal 
moisturiser has been helpful. 
1 = Strongly agree 3 7.89% 3 6.82% 6 7.32% 
2 = Agree 3 7.89% 4 9.09% 7 8.54% 
3 = Neither 9 23.68% 8 18.18% 17 20.73% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 2 5.26% 1 2.27% 3 3.66% 
9 = Missing 21 55.26% 28 63.64% 49 59.76% 
Please indicate how much you agree with 
the following statement: My partner is 
supportive about my vaginal moisturiser use. 
1 = Strongly agree 4 12.50% 4 12.12% 8 12.31% 
2 = Agree 1 3.13% 1 3.03% 2 3.08% 
3 = Neither 6 18.75% 2 6.06% 8 12.31% 
4 = Disagree  0 0.00%  0 0.00% 0 0.00% 
5 = Strongly disagree 1 3.13% 0 0.00% 1 1.54% 
9 = Missing 20 62.50% 26 78.79% 46 70.77% 
The above question is not applicable 
because: 
1 = I do not have a partner 5 83.33% 10 90.91% 15 88.24% 
2 = My partner is unaware of my vaginal moisturiser 
use 1 16.67% 1 9.09% 2 11.76% 
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Table 28: Adherence Scale Responses - Pelvic Floor Muscle Relaxation Exercises Use - First Follow Up  
Item Category Control Intervention Overall 
Since treatment have you used pelvic floor 
muscle relaxation exercises 
1= No 23 60.53% 26 59.09% 49 59.76% 
2 =Yes 5 13.16% 5 11.36% 10 12.20% 
9 = Missing 10 26.32% 13 29.55% 23 28.05% 
How often (times/week) do you use pelvic 
floor muscle relaxation exercises 
  
1 = One 0 0.00% 1 20.00% 1 10.00% 
2 = Three 1 20.00% 0 0.00% 1 10.00% 
3 = Five 1 20.00% 0 0.00% 1 10.00% 
4 = Seven 1 20.00% 1 20.00% 2 20.00% 
5 = Ten 0 0.00% 1 20.00% 1 10.00% 
9 = Missing 2 40.00% 2 40.00% 4 40.00% 
Please indicate how much you agree with 
the following statement: I was given 
sufficient explanation on the use of pelvic 
floor muscle relaxation exercises as part of 
my post-treatment recovery. 
1 = Strongly agree 2 5.26% 2 4.55% 4 4.88% 
2 = Agree 3 7.89% 2 4.55% 5 6.10% 
3 = Neither 4 10.53% 8 18.18% 12 14.63% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 3 7.89% 8 18.18% 11 13.41% 
9 = Missing 26 68.42% 24 54.55% 50 60.98% 
Please indicate how much you agree with 
the following statement: I am confident using 
pelvic floor muscle relaxation exercises. 
1 = Strongly agree 2 5.26% 0 0.00% 2 2.44% 
2 = Agree 2 5.26% 4 9.09% 6 7.32% 
3 = Neither 5 13.16% 7 15.91% 12 14.63% 
4 = Disagree 1 2.63% 3 6.82% 4 4.88% 
5 = Strongly disagree 2 5.26% 2 4.55% 4 4.88% 
9 = Missing 26 68.42% 28 63.64% 54 65.85% 
Please indicate how much you agree with 
the following statement: Using pelvic floor 
muscle relaxation exercises has been 
helpful. 
1 = Strongly agree 2 5.26% 0 0.00% 2 2.44% 
2 = Agree 2 5.26% 1 2.27% 3 3.66% 
3 = Neither 5 13.16% 13 29.55% 18 21.95% 
4 = Disagree 0 0.00% 1 2.27% 1 1.22% 
5 = Strongly disagree 1 2.63% 1 2.27% 2 2.44% 
9 = Missing 28 73.68% 28 63.64% 56 68.29% 
Please indicate how much you agree with 
the following statement: My partner is 
supportive about my use of pelvic floor 
muscle relaxation exercises. 
1 = Strongly agree 2 6.45% 0 0.00% 2 3.23% 
2 = Agree 0 0.00% 0 0.00% 0 0.00% 
3 = Neither 2 6.45% 6 19.35% 8 12.90% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 0 0.00% 1 3.23% 1 1.61% 
9 = Missing 27 87.10% 24 77.42% 51 82.26% 
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Item Category Control Intervention Overall 
The above question is not applicable 
because: 
1 = I do not have a partner 5 71.43% 11 84.62% 16 80.00% 
2 = My partner is unaware of my use of pelvic 
floor muscle relaxation exercises 2 28.57% 2 15.38% 4 20.00% 
 The summary statistics for the six scores derived from the Adherence scale are provided in Table 29. There were no statistically 
significant differences between the control and intervention groups with respect to any of these scores. 
Table 29: Adherence Scale Scores - First Follow Up  
 Control Intervention Overall Test 
Statistic df 
p-
value Score Mean/Median SD/IQR Mean/Median SD/IQR Mean/Median SD/IQR
Use and frequency of use of Dilator2 2.00 3.00 2.00 3.00 2.00 3.00 413.5 (U) 60 0.57 
Use and frequency of use of Moisturiser2 0.00 1.00 0.00 0.75 0.00 1.00 443.5 (U) 61 0.71 
Use and frequency of use of PFME2 0.00 0.00 0.00 0.00 0.00 0.00 373.0 (U) 55 0.90 
Vaginal Dilator Aided Recovery1 3.04 0.60 3.22 0.66 3.13 0.62 -0.713 (t) 22.35 0.48 
Vaginal Moisturiser Aided Recovery1 2.46 1.19 3.18 0.98 2.72 1.15 -1.428 (t) 14.84 0.17 
PFME Aided Recovery1 3.06 1.09 1.57 0.84 2.11 1.16 2.370 (t) 5.09 0.06 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
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5.4.2.2 Knowledge Scale (KS) - First Follow-up 
The responses from the knowledge scale are summarised in Table 30. The 
responses for the control and intervention groups were similar with respect to the 
knowledge scale questions. The responses were either clustered at either the correct 
or the incorrect end of the scale. Some of the questions which attracted relatively 
larger proportion of incorrect response were related to sterilisation procedure for 
dilators (‘Dilators require special procedures to keep them hygienically sterilised after 
each use’) and the timing of vaginal changes after radiation (‘All vaginal changes 
from Pelvic Radiation Therapy will happen in the first few months after treatment’). 
Non-parametric statistics was conducted as the knowledge scale score was not 
normally distributed. Mann-Whitney U test indicated non-significant differences 
between the control and intervention groups (U=162, p=0.10) (Table 31). 
5.4.2.3 Feedback Scale (FS) - First Follow-up 
The responses from the Feedback Scale are summarised in Table 32. The feedback 
received through this scale was overwhelmingly positive and the general trend was 
for the respondents to be acquiescent since the majority either strongly agreed or 
disagreed with the items.  
At first follow up, the mean feedback score for the control group (meanCn=37.17, 
SD=6.87) was significantly less than the intervention group (meanIn=42.86, 
SD=5.07). Parametric statistics was conducted as the feedback score was normally 
distributed. Independent sample t-test indicated significant difference between the 
control and intervention groups for the feedback score (t (40) =-3.30, p=0.002<0.05) 
(Table 33) The feedback from the group which received the intervention was more 
positive compared to the control group. 
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Table 30: Knowledge Scale Responses - First Follow Up  
Item Group Incorrect Correct Don't 
Know 
Missing 
The term vaginal stenosis means the narrowing of the vaginal walls  
Control 3 12 14 9 7.89% 31.58% 36.84% 23.68% 
Intervention 0 23 6 15 0.00% 52.27% 13.64% 34.09% 
Overall 3 35 20 24 3.66% 42.68% 24.39% 29.27% 
The use of vaginal dilators is recommended 3-5 times per week     
Control 3 20 6 9 7.89% 52.63% 15.79% 23.68% 
Intervention 0 27 2 15 0.00% 61.36% 4.55% 34.09% 
Overall 3 47 8 24 3.66% 57.32% 9.76% 29.27% 
Dilator’s need to be used for 5-10 minutes at a time                   
Control 6 14 9 9 15.79% 36.84% 23.68% 23.68% 
Intervention 3 22 4 15 6.82% 50.00% 9.09% 34.09% 
Overall 9 36 13 24 10.98% 43.90% 15.85% 29.27% 
Dilators need to be used no longer than for one year after your treatment      
Control 4 13 11 10 10.53% 34.21% 28.95% 26.32% 
Intervention 2 16 11 15 4.55% 36.36% 25.00% 34.09% 
Overall 6 29 22 25 7.32% 35.37% 26.83% 30.49% 
Using vaginal dilators can help in making sexual intercourse less painful                     
Control 2 16 10 10 5.26% 42.11% 26.32% 26.32% 
Intervention 0 23 6 15 0.00% 52.27% 13.64% 34.09% 
Overall 2 39 16 25 2.44% 47.56% 19.51% 30.49% 
It is not important to use vaginal dilators for pelvic examinations by your oncologists                 Control 7 12 9 10 18.42% 31.58% 23.68% 26.32% 
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Item Group Incorrect Correct Don't 
Know 
Missing 
Intervention 4 21 4 15 9.09% 47.73% 9.09% 34.09% 
Overall 11 33 13 25 13.41% 40.24% 15.85% 30.49% 
Cancer treatment can affect your emotions   
Control 2 26 0 10 5.26% 68.42% 0.00% 26.32% 
Intervention 1 28 0 15 2.27% 63.64% 0.00% 34.09% 
Overall 3 54 0 25 3.66% 65.85% 0.00% 30.49% 
All women receiving Pelvic Radiation Therapy will experience sexual difficulties               
Control 3 17 8 10 7.89% 44.74% 21.05% 26.32% 
Intervention 2 11 16 15 4.55% 25.00% 36.36% 34.09% 
Overall 5 28 24 25 6.10% 34.15% 29.27% 30.49% 
There are family members and health professionals that you can you talk to about your sexual  life if you need 
help after your treatment        
Control 2 25 1 10 5.26% 65.79% 2.63% 26.32% 
Intervention 0 26 3 15 0.00% 59.09% 6.82% 34.09% 
Overall 2 51 4 25 2.44% 62.20% 4.88% 30.49% 
Sexual intercourse cannot spread cancer                        
Control 6 19 2 11 15.79% 50.00% 5.26% 28.95% 
Intervention 3 24 2 15 6.82% 54.55% 4.55% 34.09% 
Overall 9 43 4 26 10.98% 52.44% 4.88% 31.71% 
Pelvic radiation therapy can make you 'radioactive'. Therefore, it is important to be careful that the radiation is 
not transferred to your partner    
Control 4 20 4 10 10.53% 52.63% 10.53% 26.32% 
Intervention 2 24 3 15 4.55% 54.55% 6.82% 34.09% 
Overall 6 44 7 25 7.32% 53.66% 8.54% 30.49% 
All vaginal changes from Pelvic Radiation Therapy will happen in the first few months after treatment          Control 8 9 11 10 
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Item Group Incorrect Correct Don't 
Know 
Missing 
21.05% 23.68% 28.95% 26.32% 
Intervention 13 7 9 15 29.55% 15.91% 20.45% 34.09% 
Overall 21 16 20 25 25.61% 19.51% 24.39% 30.49% 
Is the use of lubrication necessary when using the dilator    
Control 1 19 8 10 2.63% 50.00% 21.05% 26.32% 
Intervention 0 25 4 15 0.00% 56.82% 9.09% 34.09% 
Overall 1 44 12 25 1.22% 53.66% 14.63% 30.49% 
Dilators require special procedures to keep them hygienically sterilised after each use   
Control 15 8 5 10 39.47% 21.05% 13.16% 26.32% 
Intervention 21 7 1 15 47.73% 15.91% 2.27% 34.09% 
Overall 36 15 6 25 43.90% 18.29% 7.32% 30.49% 
Table 31: Knowledge Scale Score - First Follow Up  
 Control Intervention Overall Test 
Statistic 
U 
df p-value Score Median IQR Median IQR Median IQR 
Knowledge Score 9.00 6.00 10.00 3.00 10.00 4.00 162 43 0.10 
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Table 32: Feedback Scale Responses - First Follow Up  
Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
The booklet was easy to read 
Control 1 0 1 18 8 10 2.63% 0.00% 2.63% 47.37% 21.05% 26.32% 
Intervention 0 0 0 12 17 15 0.00% 0.00% 0.00% 27.27% 38.64% 34.09% 
Overall 1 0 1 30 25 25 1.22% 0.00% 1.22% 36.59% 30.49% 30.49% 
The booklet was easy to understand 
Control 1 0 1 19 7 10 2.63% 0.00% 2.63% 50.00% 18.42% 26.32% 
Intervention 0 0 0 12 17 15 0.00% 0.00% 0.00% 27.27% 38.64% 34.09% 
Overall 1 0 1 31 24 25 1.22% 0.00% 1.22% 37.80% 29.27% 30.49% 
The information in booklet was confusing 
Control 5 19 3 1 0 10 13.16% 50.00% 7.89% 2.63% 0.00% 26.32% 
Intervention 10 19 0 0 0 15 22.73% 43.18% 0.00% 0.00% 0.00% 34.09% 
Overall 15 38 3 1 0 25 18.29% 46.34% 3.66% 1.22% 0.00% 30.49% 
The booklet made me anxious 
Control 5 18 4 1 0 10 13.16% 47.37% 10.53% 2.63% 0.00% 26.32% 
Intervention 11 13 3 2 0 15 25.00% 29.55% 6.82% 4.55% 0.00% 34.09% 
Overall 16 31 7 3 0 25 19.51% 37.80% 8.54% 3.66% 0.00% 30.49% 
The booklet was too long 
Control 4 22 1 0 1 10 10.53% 57.89% 2.63% 0.00% 2.63% 26.32% 
Intervention 11 12 2 4 0 15 25.00% 27.27% 4.55% 9.09% 0.00% 34.09% 
Overall 15 34 3 4 1 25 18.29% 41.46% 3.66% 4.88% 1.22% 30.49% 
The booklet was too detailed Control 
5 17 2 3 0 11 
13.16% 44.74% 5.26% 7.89% 0.00% 28.95% 
Intervention 11 13 3 2 0 15 
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Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
25.00% 29.55% 6.82% 4.55% 0.00% 34.09% 
Overall 16 30 5 5 0 26 19.51% 36.59% 6.10% 6.10% 0.00% 31.71% 
I liked the overall format of the booklet 
Control 1 2 3 15 7 10 2.63% 5.26% 7.89% 39.47% 18.42% 26.32% 
Intervention 0 0 3 15 11 15 0.00% 0.00% 6.82% 34.09% 25.00% 34.09% 
Overall 1 2 6 30 18 25 1.22% 2.44% 7.32% 36.59% 21.95% 30.49% 
I know which options are available to me 
Control 2 1 5 17 3 10 5.26% 2.63% 13.16% 44.74% 7.89% 26.32% 
Intervention 0 0 3 18 8 15 0.00% 0.00% 6.82% 40.91% 18.18% 34.09% 
Overall 2 1 8 35 11 25 2.44% 1.22% 9.76% 42.68% 13.41% 30.49% 
I have acquired new information in dealing with sexual difficulties following 
radiotherapy 
Control 1 6 10 10 0 11 2.63% 15.79% 26.32% 26.32% 0.00% 28.95% 
Intervention 2 1 2 17 6 16 4.55% 2.27% 4.55% 38.64% 13.64% 36.36% 
Overall 3 7 12 27 6 27 3.66% 8.54% 14.63% 32.93% 7.32% 32.93% 
After reading the booklet, I feel confident using vaginal dilators 
Control 2 7 3 14 1 11 5.26% 18.42% 7.89% 36.84% 2.63% 28.95% 
Intervention 0 2 5 10 12 15 0.00% 4.55% 11.36% 22.73% 27.27% 34.09% 
Overall 2 9 8 24 13 26 2.44% 10.98% 9.76% 29.27% 15.85% 31.71% 
The booklet provided additional information to that given to me by health 
professionals to date 
Control 1 4 3 15 2 13 2.63% 10.53% 7.89% 39.47% 5.26% 34.21% 
Intervention 0 5 4 12 8 15 0.00% 11.36% 9.09% 27.27% 18.18% 34.09% 
Overall 1 9 7 27 10 28 1.22% 10.98% 8.54% 32.93% 12.20% 34.15% 
I felt uncomfortable with the personal nature of information in the booklet Control 6 14 4 4 0 10 15.79% 36.84% 10.53% 10.53% 0.00% 26.32% 
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Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
Intervention 10 11 2 2 3 16 22.73% 25.00% 4.55% 4.55% 6.82% 36.36% 
Overall 16 25 6 6 3 26 19.51% 30.49% 7.32% 7.32% 3.66% 31.71% 
The booklet was helpful to me 
Control 2 2 2 14 7 11 5.26% 5.26% 5.26% 36.84% 18.42% 28.95% 
Intervention 0 1 3 16 9 15 0.00% 2.27% 6.82% 36.36% 20.45% 34.09% 
Overall 2 3 5 30 16 26 2.44% 3.66% 6.10% 36.59% 19.51% 31.71% 
The booklet gave me information that I needed 
Control 4 2 2 16 4 10 10.53% 5.26% 5.26% 42.11% 10.53% 26.32% 
Intervention 0 1 4 15 9 15 0.00% 2.27% 9.09% 34.09% 20.45% 34.09% 
Overall 4 3 6 31 13 25 4.88% 3.66% 7.32% 37.80% 15.85% 30.49% 
I know why it is important to use vaginal dilators 
Control 2 3 4 11 7 11 5.26% 7.89% 10.53% 28.95% 18.42% 28.95% 
Intervention 0 0 1 15 13 15 0.00% 0.00% 2.27% 34.09% 29.55% 34.09% 
Overall 2 3 5 26 20 26 2.44% 3.66% 6.10% 31.71% 24.39% 31.71% 
I found it easy to find the information I wanted in the booklet 
Control 3 2 1 18 4 10 7.89% 5.26% 2.63% 47.37% 10.53% 26.32% 
Intervention 0 1 3 17 8 15 0.00% 2.27% 6.82% 38.64% 18.18% 34.09% 
Overall 3 3 4 35 12 25 3.66% 3.66% 4.88% 42.68% 14.63% 30.49% 
I liked the way the booklet looked 
Control 2 1 3 19 3 10 5.26% 2.63% 7.89% 50.00% 7.89% 26.32% 
Intervention 0 0 3 18 8 15 0.00% 0.00% 6.82% 40.91% 18.18% 34.09% 
Overall 2 1 6 37 11 25 2.44% 1.22% 7.32% 45.12% 13.41% 30.49% 
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Table 33: Feedback Scale Score - First Follow Up  
 Control Intervention Overall Test 
Statistic 
t 
df p-value Score Mean SD Mean SD Mean SD 
Feedback 37.17 6.87 42.86 5.07 40.31 6.48 -3.30 40 .00 
5.4.2.4 Psychological Status - First Follow-up 
5.4.2.4.1 Hospital Depression and Anxiety Scale (HADS) - Differences 
between groups at first follow-up 
Table 34: HADS Scores - First Follow Up  
 Control Intervention Overall Test Statistic  
(U) df 
p-
valueScore Median IQR Median IQR Median IQR 
Anxiety 4.00 4.00 5.00 3.00 4.00 3.00 226.5 47 0.28 
Depression 2.00 2.00 2.00 2.75 2.00 2.00 268.0 47 0.86 
Mann-Whitney U test indicated no significant difference between the intervention and 
control groups for anxiety (U=226.5, p=0.28). 
In using the cut-off scores for caseness (normal <8, borderline 8-10, case >11), 
95.7% (N=22) had normal scores, and one person (4.3%, N=1) was considered a 
case for anxiety in the control group. In the intervention group, 79.2% (N=19) had 
normal scores, 16.7% (N=4) were borderline and one person (4.2%, N=1) was 
considered a case for anxiety. There was no statistical difference between control 
and intervention group on anxiety caseness (χ2=4.20, p=0.12). Overall, for the whole 
sample, 87.2% (N=41) were normal, 8.5% (N=4) were borderline and 4.3% (N=2) 
were considered a case for anxiety. 
Mann-Whitney U test indicated no significant difference between the intervention and 
control groups for depression (U=268, p=0.86). 
The majority were considered normal according to depression cut-offs. Borderline 
depression was observed in one person in the control group (4.3%, N=1), while none 
fitted the criteria for borderline depression in the intervention group. One person was 
considered a case in the control group (4.2%, N=1), while none fitted the criteria for 
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caseness in the intervention group. Overall, for the whole sample, 95.7% (N=45) 
were normal, and one person was borderline (2.1%, N=1), and one person (2.1%, 
N=1) was considered a case for depression. 
5.4.2.4.2 Impact of Event Scale Revised (IES-R) - Differences between 
groups at first follow-up 
Table 35: IES-R Scores - First Follow Up  
 Control Intervention Overall Test 
Statistic 
(U) 
df p-value 
Score Median IQR Median IQR Median IQR 
Mean Total IES-R 5.00 16.00 7.50 16.75 7.00 17.00 482 63 0.85 
Avoidance 3.00 9.00 4.00 9.75 4.00 9.00 471 63 0.73 
Intrusion 2.00 7.00 2.00 5.75 2.00 6.00 466 63 0.67 
Hyperarousal 1.00 5.00 1.00 2.00 1.00 3.00 412 63 0.23 
Mann-Whitney U test indicated no significant difference between the intervention and 
control groups for IES-R Scores or any of the subscales. 
In using the cut-off scores for caseness (PTSD/psychological distress > 33), 96.8% 
(N=30) had normal scores, and 3.2% (N=1) were considered a case for mean total 
IES-R score in the control group. In the intervention group 90.6% (N=29) had normal 
scores, and 9.4% (N=3) were considered a case for mean total IES-R score. There 
was no statistical difference between control and intervention group on mean total 
IES-R score caseness (χ2=1.001, p=0.32). Overall, for the whole sample, 93.7% 
(N=59) had normal scores, and 6.3% (N= 4) were considered a case for mean total 
IES-R scores.  
Using 15.2 and 17.9 cut-off scores as guidelines for caseness of avoidance and 
intrusion, respectively; the following results were obtained:  
88.9% (N=56) people had lower than cut-off scores for avoidance and the balance 
11.1% (N=7) of people had higher than cut-off scores for avoidance. Within the 
control group, 93.5% (N=29) people had lower than cut-off scores for avoidance and 
the balance 6.5% (N=2) had higher than cut-off scores for avoidance. Within the 
intervention group 84.4% (N=27) people had lower than cut-off scores for avoidance, 
and the balance 15.6% (N=5) had higher than cut-off scores for avoidance. There 
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was no statistical difference between control and intervention group (χ2=1.342, 
p=0.25). 
96.8% (N=61) people had lower than cut-off scores for intrusion and the balance 
3.2% (N=2) people had higher than cut-off scores for intrusion. Within the control 
group, 100% (N=31) of the people had lower than cut-off scores for intrusion. Within 
the intervention group 93.8% (N=30) people had lower than cut-off scores for 
intrusion, and the balance 6.3% (N=2) had higher than cut-off scores for intrusion. 
There was no statistical difference between control and intervention group (χ2=2.001, 
p=0.16). 
5.4.2.5 Sexual Function - First Follow-up 
5.4.2.5.1 Sexual Activity Questionnaire (SAQ) – Differences between 
groups at first follow-up 
The median scores for the various SAQ items were tested for group differences 
using the Mann-Whitney U test and the results indicated that there were significant 
differences between the intervention and control groups for self physical problems 
making sexual relations difficult or uncomfortable (U(46)=203, p=0.03). Whilst the 
median scores for self physical problems for the control and the intervention groups 
were the same, the mean score for the control group (M= 0.27, SD=0.46) was higher 
than the mean score for the intervention group (M=0.04, SD=0.20) for this score. 
This indicates that the intervention group reported fewer physical problems making 
sexual relations difficult or uncomfortable compared to the control group. 
5.4.2.3.2 Sexual Vaginal Changes Questionnaire (SVQ) - Differences 
between groups at first follow-up 
The various SVQ items were tested for group differences using appropriate 
parametric or non-parametric techniques and the results indicated that there were no 
significant differences between the intervention and control groups for any of the 
items. 
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Table 36: SVQ Scores - First Follow Up 
 Control Intervention Overall Test Statistic 
 
df p-value
Score Mean/Median SD/IQR Mean/Median SD/IQR Mean/Median SD/IQR
Intimacy score1 5.90 1.59 5.80 1.65 5.85 1.61 0.229 (t) 57 0.82 
Sexual interest score2 1.00 2.00 1.00 1.00 1.00 1.00 449.0 (U) 60 0.99 
Worries about sex life 
score2 1.00 1.00 1.00 0.00 1.00 0.50 367.0 (U) 57 0.42 
Sexual satisfaction 
score2 4.00 4.25 5.00 3.00 4.50 4.00 257.5 (U) 52 0.13 
Symptoms scale on 
vaginal changes score1 8.67 1.15 10.00 4.36 9.33 2.94 -0.512 (t) 2.28 0.65 
Vaginal bleeding during 
intercourse score1 3.00 1.00 2.25 0.50 2.57 0.79 1.192 (t) 2.76 0.33 
Vaginal  dimension 
score2 1.00 0.00 1.00 1.50 1.00 0.00 21.0 (U) 15 0.31 
Sexual functioning 
score1 10.44 2.24 9.14 2.48 9.88 2.36 1.086 (t) 12.32 0.30 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
5.4.2.5.3 The Sexual Functioning After Gynaecological Illness Scale (SFAGIS) - First follow-up 
The responses from the SFAGIS are summarised in Table 37.  
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Table 37: SFAGIS Item Responses - First Follow Up  
Item Category Control Intervention Overall
1. Because of my illness my 
partner 
1 = This does not concern me because I don't have a partner 10 26.32% 15 34.09% 25 30.49% 
2 = Can catch my illness even if I do not have sexual relations 1 2.63% 0 0.00% 1 1.22% 
3 = Can become sick or hurt if we have sexual relations 0 0.00% 0 0.00% 0 0.00% 
4 = Cannot be harmed provided we do not have sexual relations 1 2.63% 0 0.00% 1 1.22% 
5 = Cannot be harmed if we have sexual relations 16 42.11% 12 27.27% 28 34.15% 
9 = Missing 10 26.32% 17 38.64% 27 32.93% 
2. My doctor told me I could 
have sexual relations 
1 = He/she did not mention it 9 23.68% 10 22.73% 19 23.17% 
2 = Three months or more after end of treatment 8 21.05% 3 6.82% 11 13.41% 
3 = One month after the end of treatment 4 10.53% 4 9.09% 8 9.76%
4 = During and after my treatment 1 2.63% 1 2.27% 2 2.44% 
5 = Whenever my partner and I wanted to have them 5 13.16% 7 15.91% 12 14.63% 
9 = Missing 11 28.95% 19 43.18% 30 36.59% 
3. My doctor talked about 
my sex life 
1 = Not at all 10 26.32% 9 20.45% 19 23.17% 
2 = I do not remember if he/she talked about it 2 5.26% 6 13.64% 8 9.76% 
3 = After the end of my treatment 6 15.79% 6 13.64% 12 14.63%
4 = Before or during my treatment 3 7.89% 1 2.27% 4 4.88% 
5 = Before and after my treatment 7 18.42% 7 15.91% 14 17.07% 
9 = Missing 10 26.32% 15 34.09% 25 30.49% 
4. My partner 
1 = This does not concern me because I do not have a partner 10 26.32% 15 34.09% 25 30.49% 
2 = Is afraid that s/he will “catch” my illness 0 0.00% 0 0.00% 0 0.00% 
3 = Is afraid that my treatment will harm him/her 0 0.00% 1 2.27% 1 1.22%
4 = Does not know very much about my illness or its treatment 2 5.26% 1 2.27% 3 3.66% 
5 = Knows that neither my illness nor its treatment can harm 
him/her 17 44.74% 10 22.73% 27 32.93% 
9 = Missing 9 23.68% 17 38.64% 26 31.71% 
5. If I had a choice, I would 
like my doctor 
1 = Not to speak to me about sexual matters 4 10.53% 9 20.45% 13 15.85% 
2 = To speak to me about sexual matters 23 60.53% 18 40.91% 41 50.00% 
9 = Missing 11 28.95% 17 38.64% 28 34.15% 
6. If I had a partner, I would 
like my doctor 
1 = To speak to my partner and to myself about sexual matters 9 23.68% 4 9.09% 13 15.85% 
2 = To speak to both my partner and myself together about sexual 
matters 15 39.47% 20 45.45% 35 42.68% 
3 = To speak only to my partner about sexual matters 1 2.63% 0 0.00% 1 1.22% 
9 = Missing 13 34.21% 20 45.45% 33 40.24%
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Item Category Control Intervention Overall 
7. I would like to receive 
information about sexual 
expectations following 
treatment 
1 = Not at all 10 26.32% 13 29.55% 23 28.05% 
2 = Prior to the first treatment 12 31.58% 5 11.36% 17 20.73% 
3 = Immediately following the first treatment 1 2.63% 2 4.55% 3 3.66% 
4 = During my first follow-up consultation 2 5.26% 2 4.55% 4 4.88% 
5 = On my request when queries arise 4 10.53% 6 13.64% 10 12.20% 
9 = Missing 9 23.68% 16 36.36% 25 30.49% 
8. I would like to receive 
information about sexual 
expectations following 
treatment from 
1 = Nobody 10 26.32% 13 29.55% 23 28.05% 
2 = Another female 2 5.26% 7 15.91% 9 10.98% 
3 = A female doctor 2 5.26% 1 2.27% 3 3.66% 
4 = Male health worker 1 2.63% 0 0.00% 1 1.22% 
5 = Either a male or female 13 34.21% 6 13.64% 19 23.17% 
9 = Missing 10 26.32% 17 38.64% 27 32.93% 
5.4.2.6 Correlation Analysis 
Correlation matrix using Spearman's Rank Non-Parametric Correlation Coefficients is shown in Appendix 4.2. A number of 
significant correlations were observed at p < 0.05 and p < 0.01. These significant correlations were considered in the subsequent 
multivariate analysis to avoid the problem of multicollinearity. 
5.4.2.7 Analysis of clinical conditions - Baseline and First Follow Up 
The results from the analysis of psychological status and sexual function scores between the baseline and first follow up phases 
are summarised in Table 38 and Figure 16. 
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Table 38: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Overall Sample 
First Follow Up Baseline p 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 12.8% (6/47) 0.293 (0.031 - 2.756) 6.4% (3/47) 0.341 (0.056 - 2.064) 0.453 
Depression 4.3% (2/47) - - - - 
IES-R Total 6.9% (4/58) 0.173 (0.071 - 0.422) 17.2% (10/58) 0.069 (0.008 - 0.601) 0.070 
Avoidance 12.1% (7/58) 0.183 (0.051 - 0.653) 12.1% (7/58) 0.183 (0.051 - 0.653) 1.000 
Intrusion 3.4% (2/58) 0.036 (0.003 - 0.388) 3.4% (2/58) 0.036 (0.003 - 0.388) 1.000 
Hyperarousal 24.1% (14/58) 0.350 (0.190 - 0.644) 36.2% (21/58) 0.227 (0.081 - 0.635) 0.118 
Presence of Sexual Activity 24.6% (14/57) 0.109 (0.034 - 0.346) 21.1% (12/57) 0.148 (0.061 - 0.360) 0.727 
Partner Unavailability 52.5% (21/40) 0.058 (0.009 - 0.394) 50.0% (20/40) 0.105 (0.028 - 0.394) 1.000 
Self Too Tired 5.0% (2/40) - - - - 
Partner Too Tired 2.5% (1/40) - - - - 
Self Lack of Interest 35.0% (14/40) 0.337 (0.136 - 0.835) 32.5% (13/40) 0.361 (0.158 - 0.825) 1.000 
Partner Lack of Interest 15.0% (6/40) 0.176 (0.013 - 2.454) 5.0% (2/40) 0.263 (0.053 - 1.315) 0.219 
Self Physical Problem 15.0% (6/40) 0.071 (0.018 - 0.284) 17.5% (7/40) 0.042 (0.006 - 0.309) 1.000 
Partner Physical Problem 17.5% (7/40) 0.053 (0.007 - 0.405) 12.5% (5/40) 0.107 (0.033 - 0.344) 0.625 
Intimacy 32.1% (17/53) 0.405 (0.243 - 0.675) 49.1% (26/53) 0.206 (0.067 - 0.635) 0.035 
Sexual interest 45.3% (24/53) 0.218 (0.096 - 0.496) 45.3% (24/53) 0.218 (0.096 - 0.496) 1.000 
Worries about sex life 27.5% (14/51) 0.233 (0.124 - 0.437) 41.2% (21/51) 0.054 (0.008 - 0.381) 0.039 
Sexual satisfaction 52.5% (21/40) 0.340 (0.134 - 0.865) 42.5% (17/40) 0.455 (0.245 - 0.844) 0.388 
Symptoms scale on vaginal changes 100.0% (1/1) - - - - 
Vaginal bleeding during intercourse - - 100.0% (2/2) - - 
Vaginal  dimension 50.0% (2/4) - 25.0% (1/4) 0.033 (0.067 - 1.652) - 
Sexual functioning 75.0% (3/4) 1.500 (0.674 - 3.339) 75.0% (3/4) 1.500 (0.674 - 3.339) 1.000 
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Figure 16: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Overall Sample 
The results from the exact McNemar's test determined that there was a statistically 
significant difference in the proportion of people with above average levels of 
intimacy (p=0.03<0.05) and worries about sex life (p=0.04<0.05) between the 
baseline and first follow up. The proportion of participants reporting above average 
levels of intimacy increased from 32.1% (17/53) at baseline to 49.1% (26/53) at the 
first follow-up; and the proportion of participants reporting above average levels of 
worries about sex life increased from 27.5% (14/51) at baseline to 41.2% (21/51) at 
the first follow-up. However, similar results were not observed for other measures of 
psychological status and sexual function.  
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The results from the analysis of psychological status and sexual function scores for 
the control group between the baseline and first follow up phases are summarised in 
Table 39 and Figure 17. 
The results from the exact McNemar's test determined that there was a statistically 
significant difference in the proportion of people with above average levels of 
intimacy (p=0.01<0.05) in the control groups between the baseline and first follow 
up. The proportion of participants reporting above average levels of intimacy in the 
control group increased from 30.8% (8/26) at baseline to 65.4% (17/26) at the first 
follow-up. However, similar results were not observed for other measures of 
psychological status and sexual function.  
The results from the analysis of psychological status and sexual function scores for 
the intervention group between the baseline and first follow up phases are 
summarised in Table 40 and Figure 18. 
There were no statistically significant differences in the proportion of people with the 
different psychological or sexual function measures in the intervention group 
between the baseline and first follow up. 
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Table 39: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Control Group 
First Follow Up Baseline p 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 4.3% (1/23) - 8.7% (2/23) - 1.000 
Depression 4.3% (1/23) - - - - 
IES-R Total 3.8% (1/26) - 15.4% (4/26) - 0.375 
Avoidance 7.7% (2/26) 0.167 (0.024 - 1.135) 11.5% (3/26) 0.130 (0.011 - 1.584) 1.000 
Intrusion - - - - - 
Hyperarousal 30.8% (8/26) 0.296 (0.114 - 0.768) 38.5% (10/26) 0.208 (0.052 - 0.838) 0.688 
Presence of Sexual Activity 25.9% (7/27) 0.175 (0.041 - 0.756) 22.2% (6/27) 0.214 (0.065 - 0.705) 1.000 
Partner Unavailability 50% (10/20) - 45.0% (9/20) 0.091 (0.014 - 0.589) - 
Self Too Tired 10.0% (2/20) - - - - 
Partner Too Tired 5.0% (1/20) - - - - 
Self Lack of Interest 35.0% (7/20) 0.269 (0.065 - 1.122) 30.0% (6/20) 0.321 (0.102 - 1.017) 1.000 
Partner Lack of Interest 25.0% (5/20) - - - - 
Self Physical Problem 25.0% (5/20) 0.083 (0.012 - 0.582) 25.0% (5/20) 0.083 (0.012 - 0.582) 1.000 
Partner Physical Problem 20.0% (4/20) 0.250 (0.020 - 3.189) 10.0% (2/20) 0.333 (0.059 - 1.877) 0.625 
Intimacy 30.8% (8/26) 0.635 (0.389 - 1.036) 65.4% (17/26) 0.270 (0.039 - 1.865) 0.012 
Sexual interest 39.3% (11/28) 0.235 (0.100 - 0.554) 53.6% (15/28) - 0.125 
Worries about sex life 33.3% (9/27) 0.188 (0.065 - 0.540) 40.7% (11/27) 0.086 (0.012 - 0.593) 0.625 
Sexual satisfaction 47.4% (9/19) 0.450 (0.107 - 1.897) 31.6% (6/19) 0.577 (0.237 - 1.406) 0.453 
Symptoms scale on vaginal changes 100.0% (1/1) - - - - 
Vaginal bleeding during intercourse - - 100.0% (1/1) - - 
Vaginal  dimension 50.0% (1/2) - 50.0% (1/2) - - 
Sexual functioning 100.0% (2/2) - 100.0% (2/2) - - 
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Figure 17: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Control Group 
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Table 40: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Intervention Group 
First Follow Up Baseline p 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 20.8% (5/24) - 4.2% (1/24) 0.174 (0.071 - 0.424) 0.125 
Depression 4.2% (1/24) - - - - 
IES-R Total 9.4% (3/32) 0.103 (0.035 - 0.302) 18.8% (6/32) - 0.250 
Avoidance 15.6% (5/32) 0.185 (0.033 - 1.026) 12.5% (4/32) 0.214 (0.050 - 0.914) 1.000 
Intrusion 6.3% (2/32) 0.067 (0.006 - 0.716) 6.3% (2/32) 0.067 (0.006 - 0.716) 1.000 
Hyperarousal 18.8% (6/32) 0.404 (0.173 - 0.944) 34.4% (11/32) 0.262 (0.057 - 1.213) 0.180 
Presence of Sexual Activity 23.3% (7/30) 0.061 (0.008 - 0.438) 20.0% (6/30) 0.100 (0.025 - 0.395) 1.000 
Partner Unavailability 55.0% (11/20) 0.122 (0.019 - 0.783) 55.0% (11/20) 0.122 (0.019 - 0.783) 1.000 
Self Too Tired - - - - - 
Partner Too Tired - - - - - 
Self Lack of Interest 35.0% (7/20) 0.404 (0.124 - 1.317) 35.0% (7/20) 0.404 (0.124 - 1.317) 1.000 
Partner Lack of Interest 5.0% (1/20) 0.053 (0.008 - 0.355) 10.0% (2/20) - 1.000 
Self Physical Problem 5.0% (1/20) - 10.0% (2/20) - 1.000 
Partner Physical Problem 15.0% (3/20) - 15.0% (3/20) - 1.000 
Intimacy 33.3% (9/27) 0.143 (0.037 - 0.552) 33.3% (9/27) 0.143 (0.037 - 0.552) 1.000 
Sexual interest 52.0% (13/25) 0135 (0.020 - 0.928) 36.0% (9/25) 0.352 (0.164 - 0.754) 0.219 
Worries about sex life 20.8% (5/24) 0.263 (0.124 - 0.558) 41.7% (10/24) - 0.063 
Sexual satisfaction 57.1% (12/21) 0.296 (0.084 - 1.050) 52.4% (11/21) 0.367 (0.137 - 0.984) 1.000 
Symptoms scale on vaginal changes - - - - - 
Vaginal bleeding during intercourse - - 100.0% (1/1) - - 
Vaginal  dimension 50.0% (1/2) - - - - 
Sexual functioning 50.0% (1/2) - 50.0% (1/2) - - 
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Figure 18: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Intervention Group 
5.4.2.8 Multiple Linear Regression - Using Baseline and First 
Follow-up Phase Data 
Details of the multiple linear regression models with Intimacy, Sexual interest, 
Worries about sex life, Anxiety, Depression, and IES-R as the dependent variables 
are shown below.  
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5.4.2.8.1 Intimacy 
A multiple linear regression model was developed with intimacy score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, the hospitals where the 
participants are being treated, the type of cancers, and membership to the 
intervention group as independent variables.  
Table 41: Full Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 4.293 2.194 0.030
Anxiety -0.103 -1.361 0.176
Depression -0.029 -0.281 0.779
IES-R Total 0.020 0.927 0.355
Participant Age 0.015 0.608 0.544
Marital Status 1.167 2.286 0.024
Highest Qualification 1.235 2.193 0.030
Treatment at Royal North Shore Hospital (RNSH) -0.690 -1.069 0.287
Treatment at Royal Prince Alfred Hospital (RPAH) 0.218 0.273 0.785
Treatment at Liverpool Hospital 1.340 1.410 0.161
Treatment at St George Hospital -2.025 -1.427 0.156
Treatment at Genesis Care, Mater Hospital 0.144 0.140 0.889
Cancer Type - Cervical 1.902 2.007 0.047
Cancer Type - Anal 0.068 0.067 0.946
Cancer Type - Rectal -0.117 -0.151 0.880
Cancer Type - Vaginal 5.937 3.368 0.001
Cancer Type - Vulvar 1.588 0.727 0.468
Intervention Group Membership -0.344 -0.694 0.489
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
The results of the analysis indicate that the independent variables input in the model 
account for 20.2% (R2 = .202, F (17, 163) = 2.175, p = 0.007) of variance in intimacy 
score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
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Table 42: Final Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 4.828 10.262 <0.001 
Marital Status 1.243 2.539 0.012 
Highest Qualification 1.217 2.395 0.018 
Cancer Type - Vaginal 4.684 3.154 0.002 
The final model indicates that marital status, highest qualification attained, and 
vaginal cancer accounted for a significant proportion of the intimacy score, R2 = .129, 
F (3, 163) = 7.879, p < 0.001. 
Marital status, highest qualifications attained and vaginal cancer explain 
approximately 12.9% of the variance in the intimacy score. Being married or in a 
defacto relationship will translate to 1.243 units increase in the intimacy score when 
all the other independent variables are controlled; having attained an education level 
of year 12 or more will translate to 1.217 units increase in the intimacy score when 
all the other independent variables are controlled; and presence of vaginal cancer 
will translate to 4.684 units of increase in the intimacy score when all the other 
independent variables are controlled.  
5.4.2.8.2 Sexual Interest 
A multiple linear regression model was developed with sexual interest score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, the hospitals where the 
participants are being treated, the type of cancers, and membership to the 
intervention group as independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 34% (R2 = .34, F (17, 163) = 4.424, p < 0.001) of variance in sexual 
interest score. Some of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given in Table 44.  
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Table 43: Full Regression Model for Sexual Interest 
Intercept / Predictors β t Sig. 
Intercept 3.150 6.243 <0.001
Anxiety 0.019 0.994 0.322 
Depression -0.053 -1.971 0.051 
IES-R Total 0.005 0.842 0.401 
Participant Age -0.026 -3.996 <0.001
Marital Status 0.612 4.654 <0.001
Highest Qualification 0.291 2.005 0.047 
Treatment at Royal North Shore Hospital 
(RNSH) -0.113 -0.680 0.498 
Treatment at Royal Prince Alfred Hospital 
(RPAH) -0.083 -0.403 0.688 
Treatment at Liverpool Hospital -0.616 -2.517 0.013 
Treatment at St George Hospital -0.113 -0.309 0.757 
Treatment at Genesis Care, Mater Hospital -0.227 -0.856 0.393 
Cancer Type - Cervical -0.496 -2.032 0.044 
Cancer Type - Anal -0.520 -2.008 0.046 
Cancer Type - Rectal -0.492 -2.461 0.015 
Cancer Type - Vaginal -1.143 -2.515 0.013 
Cancer Type - Vulvar -0.020 -0.035 0.972 
Intervention Group Membership -0.115 -0.903 0.368 
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
Table 44: Final Regression Model for Sexual Interest  
Intercept / Predictors β t Sig. 
Intercept 2.480 6.569 <0.001 
Participant Age -0.025 -4.245 <0.001 
Marital Status 0.636 5.047 <0.001 
Highest Qualification 0.272 2.012 0.046 
Treatment at Liverpool 
Hospital -0.540 -2.353 0.020 
Cancer Type - Endometrial 0.506 3.747 <0.001 
The final model indicates that participant age, marital status, highest qualification 
attained, being treated at Liverpool hospital, and endometrial cancer accounted for a 
significant proportion of the sexual interest score, R2 = .299, F (5, 163) = 13.468, p < 
0.001. 
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Participant age, marital status, highest qualification attained, being treated at 
Liverpool hospital, and endometrial cancer explains approximately 29.9% of the 
variance in the sexual interest score. One unit increase in age will translate to 0.025 
units decline in the sexual interest score when all the other independent variables 
are controlled; being married or in a defacto relationship will translate to 0.636 units 
increase in the sexual interest score when all the other independent variables are 
controlled; education level of year 12 or more will translate to 0.272 units increase in 
the sexual interest score when all the other independent variables are controlled; 
being treated at Liverpool hospital will translate to 0.540 units decline in sexual 
interest score when all the other independent variables are controlled; and presence 
of endometrial cancer will translate to 0.506 units of increase in the sexual interest 
score when all the other independent variables are controlled.  
5.4.2.8.3 Worries about sex life 
A multiple linear regression model was developed with worries about sex life as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, the hospitals where the 
participants are being treated, the type of cancers, and membership to the 
intervention group as independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 36.1% (R2 = .361, F (17, 163) = 4.847, p < 0.001) of variance in worries 
about sex life score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given in Table 46.  
The final model indicates that participant age, highest qualification attained, IES-R 
score, and being treated at Royal North Shore hospital accounted for a significant 
proportion of the worries about sex life score, R2 = .33, F (4, 163) = 19.621, p < 
0.001. 
Participant age, highest qualification attained, IES-R total score, and being treated at 
Royal North Shore hospital explain approximately 33% of the variance in the sexual 
interest score. One unit increase in age will translate to 0.013 units decline in worries 
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about sex life score when all the other independent variables are controlled; having 
attained an education level of year 12 or more will translate to 0.185 units increase in 
the worries about sex life score when all the other independent variables are 
controlled; one unit increase in the IES-R score will translate to 0.013 units increase 
in worries about sex life score when all the other independent variables are 
controlled; and being treated at the Royal North Shore hospital will translate to 0.234 
units increase in worries about sex life score when all other independent variables 
are controlled.  
Table 45: Full Regression Model for Worries About Sex Life 
Intercept / Predictors β t Sig. 
Intercept 2.063 6.723 <0.001
Anxiety -0.004 -0.332 0.741 
Depression -0.008 -0.503 0.616 
IES-R Total 0.015 4.470 <0.001
Participant Age -0.015 -3.851 <0.001
Marital Status -0.083 -1.032 0.304 
Highest Qualification 0.148 1.670 0.097 
Treatment at Royal North Shore Hospital (RNSH) 0.245 2.419 0.017 
Treatment at Royal Prince Alfred Hospital (RPAH) -0.008 -0.063 0.950 
Treatment at Liverpool Hospital 0.006 0.042 0.967 
Treatment at St George Hospital -0.175 -0.785 0.434 
Treatment at Genesis Care, Mater Hospital 0.263 1.631 0.105 
Cancer Type - Cervical -0.051 -0.345 0.731 
Cancer Type - Anal -0.070 -0.443 0.659 
Cancer Type - Rectal -0.008 -0.066 0.947 
Cancer Type - Vaginal 0.004 0.013 0.990 
Cancer Type - Vulvar 0.053 0.155 0.877 
Intervention Group Membership -0.086 -1.109 0.269 
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
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Table 46: Final Regression Model for Worries About Sex Life 
Intercept / Predictors β t Sig. 
Intercept 1.825 7.303 <0.001 
Participant Age -0.013 -3.866 <0.001 
Highest Qualification 0.185 2.299 0.023 
IES-R Total 0.013 4.703 <0.001 
Treatment at Royal North Shore 
Hospital  0.234 2.737 0.007 
5.4.2.8.4 Anxiety 
A multiple linear regression model was developed with anxiety score as the 
dependent variable and participant age, marital status, highest qualification, the 
hospitals where the participants are being treated, the type of cancers, and 
membership to the intervention group as independent variables.  
Table 47: Full Regression Model for Anxiety 
Intercept / Predictors β t Sig. 
Intercept 5.895 2.975 0.003 
Participant Age -0.024 -0.904 0.367 
Marital Status -0.840 -1.490 0.138 
Highest Qualification 0.049 0.078 0.938 
Treatment at Royal North Shore Hospital 
(RNSH) 0.310 0.435 0.664 
Treatment at Royal Prince Alfred Hospital 
(RPAH) 1.760 2.034 0.044 
Treatment at Liverpool Hospital 1.800 1.721 0.087 
Treatment at St George Hospital -0.657 -0.417 0.678 
Treatment at Genesis Care, Mater Hospital 0.586 0.514 0.608 
Cancer Type - Cervical -0.018 -0.018 0.986 
Cancer Type - Anal 2.382 2.179 0.031 
Cancer Type - Rectal 0.616 0.715 0.475 
Cancer Type - Vaginal 4.214 2.186 0.030 
Cancer Type - Vulvar -1.616 -0.667 0.506 
Intervention Group Membership -0.544 -0.991 0.323 
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
The results of the analysis indicate that the independent variables input in the model 
account for 16.6% (R2 = .166, F (14, 163) = 2.116, p = 0.014) of variance in the 
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anxiety score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
Table 48: Final Regression Model for Anxiety  
Intercept / Predictors β t Sig. 
Intercept 4.038 0.292 <0.001 
Treatment at Royal Prince Alfred 
Hospital 1.902 0.637 0.003 
Cancer Type - Vaginal 4.212 1.641 0.011 
Cancer Type - Anal 1.957 0.990 0.050 
The final model indicates that being treated at the Royal Prince Alfred hospital, 
vaginal cancer, and anal cancer accounted for a significant proportion of the anxiety 
score, R2 = .115, F (3, 163) = 6.944, p < 0.001. 
Being treated at Royal Prince Alfred hospital, vaginal cancer and anal cancer explain 
approximately 11.5% of the variance in the anxiety score. Being treated at the Royal 
Prince Alfred hospital will translate to 1.902 units increase in the anxiety score when 
all the other independent variables are controlled; presence of vaginal cancer 
translates to a 4.212 units increase in the anxiety score when all the other 
independent variables are controlled; and presence of anal cancer translates to 
1.957 units increase in the anxiety score when all the other independent variables 
are controlled.  
5.4.2.8.5 Depression 
A multiple linear regression model was developed with depression score as the 
dependent variable and participant age, marital status, highest qualification, the 
hospitals where the participants are being treated, the type of cancers, and 
membership to the intervention group as independent variables.  
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Table 49: Full Regression Model for Depression 
Intercept / Predictors β t Sig. 
Intercept 4.488 2.943 0.004 
Participant Age -0.023 -1.133 0.259 
Marital Status -0.322 -0.741 0.460 
Highest Qualification -0.292 -0.607 0.545 
Treatment at Royal North Shore Hospital 
(RNSH) -0.768 -1.400 0.164 
Treatment at Royal Prince Alfred Hospital 
(RPAH) 1.421 2.134 0.034 
Treatment at Liverpool Hospital 0.587 0.729 0.467 
Treatment at St George Hospital -0.938 -0.773 0.441 
Treatment at Genesis Care, Mater Hospital 0.476 0.542 0.589 
Cancer Type - Cervical 1.391 1.733 0.085 
Cancer Type - Anal 0.276 0.328 0.743 
Cancer Type - Rectal -0.007 -0.011 0.991 
Cancer Type - Vaginal 1.328 0.895 0.372 
Cancer Type - Vulvar 0.957 0.514 0.608 
Intervention Group Membership -0.119 -0.281 0.779 
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
The results of the analysis indicate that the independent variables input in the model 
account for 11.6% (R2 = .116, F (14, 163) = 1.397, p = 0.161) of variance in the 
depression score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
Table 50: Final Regression Model for Depression  
Intercept / Predictors β t Sig. 
Intercept 2.709 12.435 <0.001 
Treatment at Royal Prince Alfred 
Hospital 1.439 3.009 0.003 
The final model indicates that being treated at the Royal Prince Alfred hospital 
accounted for a significant proportion of the depression score, R2 = .053, F (1, 163) = 
9.053, p = 0.003. 
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Being treated at Royal Prince Alfred hospital explains approximately 5.3% of the 
variance in the depression score. Being treated at the Royal Prince Alfred hospital 
will translate to 1.439 units increase in the depression score.  
5.4.2.8.6 IES-R 
A multiple linear regression model was developed with IES-R score as the 
dependent variable and participant age, marital status, highest qualification, the 
hospitals where the participants are being treated, the type of cancers, and 
membership to the intervention group as independent variables.  
Table 51: Full Regression Model for IES-R 
Intercept / Predictors β t Sig. 
Intercept 39.335 5.199 <0.001
Participant Age -0.391 -3.867 <0.001
Marital Status -1.168 -0.543 0.588 
Highest Qualification -2.346 -0.983 0.327 
Treatment at Royal North Shore Hospital 
(RNSH) -1.158 -0.426 0.671 
Treatment at Royal Prince Alfred Hospital 
(RPAH) 5.078 1.537 0.126 
Treatment at Liverpool Hospital 3.688 0.923 0.357 
Treatment at St George Hospital -1.513 -0.251 0.802 
Treatment at Genesis Care, Mater Hospital -0.659 -0.151 0.880 
Cancer Type - Cervical 0.489 0.123 0.902 
Cancer Type - Anal 7.557 1.811 0.072 
Cancer Type - Rectal -1.196 -0.364 0.716 
Cancer Type - Vaginal 8.757 1.190 0.236 
Cancer Type - Vulvar -3.430 -0.371 0.711 
Intervention Group Membership -1.093 -0.521 0.603 
Note: Two input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); and Cancer Type - Endometrial 
The results of the analysis indicate that the independent variables input in the model 
account for 19.4% (R2 = .194, F (14, 163) = 2.557, p = 0.003) of variance in the IES-
R score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
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Table 52: Final Regression Model for IES-R 
Intercept / Predictors β t Sig. 
Intercept 37.857 7.120 <0.001
Participant Age -0.398 -4.619 <0.001
Cancer Type - Anal 8.415 2.282 0.024 
The final model indicates that participant age and anal cancer accounted for a 
significant proportion of the IES-R score, R2 = .151, F (2, 163) = 14.316, p < 0.001. 
Participant age and anal cancer explain approximately 15.1% of the variance in the 
IES-R score. One unit increase in age translates to 0.398 units decline in the IES-R 
score when the presence of anal cancer is controlled; and the presence of anal 
cancer translates to 8.415 units increase in the IES-R score when age is controlled.  
5.4.3 Second Follow-up 
5.4.3.1 Rehabilitation Strategies - Second Follow-up 
5.4.3.1.1 Adherence Scale (AS) - Second Follow-up 
The responses from the Adherence Scale are summarised in Table 53, Table 54 and 
Table 55. The trends in responses were very similar to the trends reported at the first 
follow-up; it was observed that out of vaginal dilator, vaginal moisturiser, and PFME, 
a relatively larger proportion of participants reported using a vaginal dilator after 
treatment (N=38, 46.34%), this was followed by the use of vaginal moisturiser (N=15, 
18.29%) and PFME (N=14, 17.07%).   
The summary statistics for the six scores derived from the Adherence scale are 
provided in Table 56. There were no statistically significant differences between the 
control and intervention groups with respect to any of these scores. 
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Table 53: Adherence Scale Responses - Vaginal Dilator Use - Second Follow Up  
Item Category Control Intervention Overall
Prior to treatment did you use a 
cylinder/vibrator 
1= No 24 63.16% 25 56.82% 49 59.76% 
2 =Yes 1 2.63% 2 4.55% 3 3.66% 
9 = Missing 13 34.21% 17 38.64% 30 36.59% 
Have you been given a vaginal dilator 
1= No 4 10.53% 3 6.82% 7 8.54% 
2 =Yes 21 55.26% 24 54.55% 45 54.88% 
9 = Missing 13 34.21% 17 38.64% 30 36.59% 
Since treatment have you used a vaginal 
dilator 
1= No 7 18.42% 6 13.64% 13 15.85% 
2 =Yes 16 42.11% 22 50.00% 38 46.34% 
9 = Missing 15 39.47% 16 36.36% 31 37.80% 
How often do you use a dilator 
1 = More than recommended 1 5.88% 1 4.55% 2 5.13% 
2 = As often as recommended 9 52.94% 7 31.82% 16 41.03% 
3 = Less often than recommended 7 41.18% 14 63.64% 21 53.85% 
Please indicate how much you agree with 
the following statement: I was given 
sufficient explanation on the purpose and 
use of the vaginal dilator as part of my 
post-treatment recovery.  
1 = Strongly agree 9 23.68% 16 36.36% 25 30.49% 
2 = Agree 9 23.68% 7 15.91% 16 19.51%
3 = Neither 0 0.00% 0 0.00% 0 0.00% 
4 = Disagree 1 2.63% 0 0.00% 1 1.22% 
5 = Strongly disagree 1 2.63% 1 2.27% 2 2.44% 
9 = Missing 18 47.37% 20 45.45% 38 46.34% 
Please indicate how much you agree with 
the following statement: I am confident 
using the vaginal dilator. 
1 = Strongly agree 8 21.05% 15 34.09% 23 28.05% 
2 = Agree 8 21.05% 6 13.64% 14 17.07%
3 = Neither 0 0.00% 2 4.55% 2 2.44% 
4 = Disagree 1 2.63% 0 0.00% 1 1.22% 
5 = Strongly disagree 2 5.26% 1 2.27% 3 3.66% 
9 = Missing 19 50.00% 20 45.45% 39 47.56% 
Please indicate how much you agree with 
the following statement: Using the vaginal 
dilator just prior to sexual intercourse 
makes intercourse easier. 
1 = Strongly agree 2 5.26% 1 2.27% 3 3.66% 
2 = Agree 1 2.63% 2 4.55% 3 3.66%
3 = Neither 10 26.32% 14 31.82% 24 29.27% 
4 = Disagree 1 2.63% 0 0.00% 1 1.22% 
5 = Strongly disagree 0 0.00% 1 2.27% 1 1.22% 
9 = Missing 24 63.16% 26 59.09% 50 60.98% 
Please indicate how much you agree with 
the following statement: I would have 
1 = Strongly agree 2 5.26% 1 2.27% 3 3.66% 
2 = Agree 6 15.79% 2 4.55% 8 9.76% 
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Item Category Control Intervention Overall 
liked more opportunity to practice the use 
of vaginal dilator with a nurse. 
3 = Neither 0 0.00% 0 0.00% 0 0.00% 
4 = Disagree 5 13.16% 14 31.82% 19 23.17% 
5 = Strongly disagree 4 10.53% 5 11.36% 9 10.98% 
9 = Missing 21 55.26% 22 50.00% 43 52.44% 
Please indicate how much you agree with 
the following statement: Using the vaginal 
dilator has been helpful. 
1 = Strongly agree 4 10.53% 1 2.27% 5 6.10% 
2 = Agree 4 10.53% 9 20.45% 13 15.85% 
3 = Neither 8 21.05% 13 29.55% 21 25.61% 
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 1 2.63% 0 0.00% 1 1.22% 
9 = Missing 21 55.26% 21 47.73% 42 51.22% 
Please indicate how much you agree with 
the following statement: I have emotional 
difficulties using a vaginal dilator (e.g. 
feeling anxious). 
1 = Strongly agree 0 0.00% 1 2.27% 1 1.22% 
2 = Agree 5 13.16% 3 6.82% 8 9.76% 
3 = Neither 3 7.89% 5 11.36% 8 9.76%
4 = Disagree 3 7.89% 13 29.55% 16 19.51% 
5 = Strongly disagree 6 15.79% 2 4.55% 8 9.76% 
9 = Missing 21 55.26% 20 45.45% 41 50.00% 
Please indicate how much you agree with 
the following statement: I have physical 
difficulties using a vaginal dilator (e.g. it is 
painful). 
1 = Strongly agree 2 5.26% 1 2.27% 3 3.66% 
2 = Agree 3 7.89% 2 4.55% 5 6.10% 
3 = Neither 3 7.89% 1 2.27% 4 4.88%
4 = Disagree 4 10.53% 13 29.55% 17 20.73% 
5 = Strongly disagree 5 13.16% 6 13.64% 11 13.41% 
9 = Missing 21 55.26% 21 47.73% 42 51.22% 
Please indicate how much you agree with 
the following statement: My partner is 
supportive about my dilator use. 
1 = Strongly agree 3 10.34% 5 16.13% 8 13.33% 
2 = Agree 3 10.34% 4 12.90% 7 11.67% 
3 = Neither 3 10.34% 3 9.68% 6 10.00%
4 = Disagree 0 0.00% 0 0.00% 0 0.00% 
5 = Strongly disagree 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 20 68.97% 19 61.29% 39 65.00% 
The above question is not applicable 
because: 
1 = I do not have a partner 7 77.78% 12 92.31% 19 86.36% 
2 = My partner is unaware of my vaginal dilator 
use 2 22.22% 1 7.69% 3 13.64% 
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Table 54: Adherence Scale Responses - Vaginal Moisturiser Use - Second Follow Up  
Item Category Control Intervention Overall
Since treatment have you used a vaginal 
moisturiser 
1= No 17 44.74% 20 45.45% 37 45.12% 
2 =Yes 7 18.42% 8 18.18% 15 18.29% 
9 = Missing 14 36.84% 16 36.36% 30 36.59% 
How often do you use the moisturiser 
1 = More than recommended 3 42.86% 2 25.00% 5 33.33% 
2 = As often as recommended 1 14.29% 0 0.00% 1 6.67% 
3 = Less often than recommended 3 42.86% 6 75.00% 9 60.00% 
Please indicate how much you agree with the 
following statement: I was given sufficient 
explanation on the use of vaginal moisturisers as 
part of my post-treatment recovery. 
1 = Strongly agree 6 15.79% 3 6.82% 9 10.98% 
2 = Agree 6 15.79% 9 20.45% 15 18.29% 
3 = Neither 1 2.63% 1 2.27% 2 2.44% 
4 = Disagree 1 2.63% 2 4.55% 3 3.66% 
5 = Strongly disagree 1 2.63% 2 4.55% 3 3.66% 
9 = Missing 23 60.53% 27 61.36% 50 60.98% 
Please indicate how much you agree with the 
following statement: I am confident using vaginal 
moisturiser. 
1 = Strongly agree 4 10.53% 3 6.82% 7 8.54% 
2 = Agree 5 13.16% 8 18.18% 13 15.85% 
3 = Neither 3 7.89% 3 6.82% 6 7.32% 
4 = Disagree 1 2.63% 1 2.27% 2 2.44% 
5 = Strongly disagree 1 2.63% 0 0.00% 1 1.22% 
9 = Missing 24 63.16% 29 65.91% 53 64.63% 
Please indicate how much you agree with the 
following statement: Using vaginal moisturiser 
has been helpful. 
1 = Strongly agree 2 5.26% 2 4.55% 4 4.88% 
2 = Agree 4 10.53% 6 13.64% 10 12.20% 
3 = Neither 6 15.79% 6 13.64% 12 14.63% 
4 = Disagree 1 2.63% 1 2.27% 2 2.44% 
5 = Strongly disagree 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 25 65.79% 29 65.91% 54 65.85% 
Please indicate how much you agree with the 
following statement: My partner is supportive 
about my vaginal moisturiser use. 
1 = Strongly agree 2 5.88% 3 8.11% 5 7.04% 
2 = Agree 3 8.82% 1 2.70% 4 5.63% 
3 = Neither 5 14.71% 5 13.51% 10 14.08% 
4 = Disagree 1 2.94% 0 0.00% 1 1.41% 
5 = Strongly disagree 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 23 67.65% 28 75.68% 51 71.83% 
The above question is not applicable because: 1 = I do not have a partner 4 100.00% 6 85.71% 10 90.91% 2 = My partner is unaware of my vaginal moisturiser use 0 0.00% 1 14.29% 1 9.09% 
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Table 55: Adherence Scale Responses - Pelvic Floor Muscle Relaxation Exercises Use - Second Follow Up  
Item Category Control Intervention Overall 
Since treatment have you used pelvic floor 
muscle relaxation exercises 
1= No 19 50.00% 20 45.45% 39 47.56% 
2 =Yes 6 15.79% 8 18.18% 14 17.07% 
9 = Missing 13 34.21% 16 36.36% 29 35.37% 
How often (times/week) do you use pelvic 
floor muscle relaxation exercises 
  
1 = One 1 16.67% 2 25.00% 3 21.43% 
2 = Three 1 16.67% 1 12.50% 2 14.29% 
3 = Five 2 33.33% 2 25.00% 4 28.57% 
4 = Seven 2 33.33% 3 37.50% 5 35.71% 
5 = Ten 3 7.89% 2 4.55% 5 6.10% 
9 = Missing 1 2.63% 2 4.55% 3 3.66% 
Please indicate how much you agree with 
the following statement: I was given 
sufficient explanation on the use of pelvic 
floor muscle relaxation exercises as part of 
my post-treatment recovery. 
1 = Strongly agree 2 5.26% 2 4.55% 4 4.88% 
2 = Agree 3 7.89% 3 6.82% 6 7.32% 
3 = Neither 1 2.63% 3 6.82% 4 4.88% 
4 = Disagree 28 73.68% 32 72.73% 60 73.17% 
5 = Strongly disagree 3 7.89% 2 4.55% 5 6.10% 
9 = Missing 4 10.53% 4 9.09% 8 9.76% 
Please indicate how much you agree with 
the following statement: I am confident using 
pelvic floor muscle relaxation exercises. 
1 = Strongly agree 0 0.00% 4 9.09% 4 4.88% 
2 = Agree 2 5.26% 1 2.27% 3 3.66% 
3 = Neither 1 2.63% 1 2.27% 2 2.44% 
4 = Disagree 28 73.68% 32 72.73% 60 73.17% 
5 = Strongly disagree 3 7.89% 2 4.55% 5 6.10% 
9 = Missing 2 5.26% 3 6.82% 5 6.10% 
Please indicate how much you agree with 
the following statement: Using pelvic floor 
muscle relaxation exercises has been 
helpful. 
1 = Strongly agree 3 7.89% 5 11.36% 8 9.76% 
2 = Agree 0 0.00% 0 0.00% 0 0.00% 
3 = Neither 1 2.63% 1 2.27% 2 2.44% 
4 = Disagree 29 76.32% 33 75.00% 62 75.61% 
5 = Strongly disagree 3 8.57% 0 0.00% 3 4.11% 
9 = Missing 2 5.71% 1 2.63% 3 4.11% 
Please indicate how much you agree with 
the following statement: My partner is 
supportive about my use of pelvic floor 
muscle relaxation exercises. 
1 = Strongly agree 1 2.86% 4 10.53% 5 6.85% 
2 = Agree 0 0.00% 0 0.00% 0 0.00% 
3 = Neither 1 2.86% 1 2.63% 2 2.74% 
4 = Disagree 28 80.00% 32 84.21% 60 82.19% 
5 = Strongly disagree 3 100.00% 6 100.00% 9 100.00% 
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Item Category Control Intervention Overall 
9 = Missing 0 0.00% 0 0.00% 0 0.00% 
The above question is not applicable 
because: 
1 = I do not have a partner 19 50.00% 20 45.45% 39 47.56% 
2 = My partner is unaware of my use of pelvic 
floor muscle relaxation exercises 6 15.79% 8 18.18% 14 17.07% 
Table 56: Adherence Scale Scores - Second Follow Up  
 Control Intervention Overall Test 
Statistic df 
p-
value Score Mean/Median SD/IQR Mean/Median SD/IQR Mean/Median SD/IQR
Use and frequency of use of Dilator2 2.00 3.00 2.50 1.75 2.00 2.75 269.0 (U) 52 0.19 
Use and frequency of use of Moisturiser2 0.00 1.00 0.00 1.00 0.00 1.00 330.0 (U) 52 0.89 
Use and frequency of use of PFME2 0.00 0.00 0.00 0.00 0.00 0.00 281.5 (U) 48 0.86 
Vaginal Dilator Aided Recovery1 3.23 0.77 3.32 0.44 3.28 0.58 -0.278 (t) 10.315 0.79 
Vaginal Moisturiser Aided Recovery1 2.82 0.84 2.61 0.85 2.73 0.83 0.546 (t) 17.126 0.59 
PFME Aided Recovery1 2.96 1.10 2.13 0.95 2.58 1.08 1.477 (t) 10.998 0.17 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
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5.4.3.2 Knowledge Scale (KS) - Second Follow-up 
The responses from the knowledge scale are summarised in Table 57. The trends in 
responses to the knowledge scale at the second follow-up were similar to the trends 
observed at the first follow-up. The responses were either clustered at either the 
correct or the incorrect end of the scale. Some of the questions which attracted 
relatively larger proportion of incorrect response were also similar to the first follow-
up and related to sterilisation procedure for dilators (‘Dilators require special 
procedures to keep them hygienically sterilised after each use’), and timing of 
vaginal changes after radiation (‘All vaginal changes from Pelvic Radiation Therapy 
will happen in the first few months after treatment’).  
An independent sample t-test indicated non-significant differences between the 
control and intervention groups (t(39.803)=-1.984, p=0.05) (Table 58). 
5.4.3.3 Feedback Scale (FS) - Second Follow-up 
The responses from the Feedback Scale are summarised in Table 59. The 
responses to the feedback scale at the second follow-up were consistent with the 
trends observed in responses at the first follow-up. The feedback received through 
this scale at the second follow-up was overwhelmingly positive and the general trend 
was for the respondents to be acquiescent since the majority either strongly agreed 
or disagreed with the items.  
Mann-Whitney U test indicated non-significant differences between the control and 
intervention groups for the feedback score (U (37) =151, p=0.54) (Table 60).  
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Table 57: Knowledge Scale Responses - Second Follow Up  
Item Group Incorrect Correct Don't 
Know 
Missing 
The term vaginal stenosis means the narrowing of the vaginal walls  
Control 1 15 5 17 2.63% 39.47% 13.16% 44.74% 
Intervention 1 18 6 19 2.27% 40.91% 13.64% 43.18% 
Overall 2 33 11 36 2.44% 40.24% 13.41% 43.90% 
The use of vaginal dilators is recommended 3-5 times per week     
Control 1 15 5 17 2.63% 39.47% 13.16% 44.74% 
Intervention 1 21 3 19 2.27% 47.73% 6.82% 43.18% 
Overall 2 36 8 36 2.44% 43.90% 9.76% 43.90% 
Dilator’s need to be used for 5-10 minutes at a time                   
Control 3 14 4 17 7.89% 36.84% 10.53% 44.74% 
Intervention 2 20 3 19 4.55% 45.45% 6.82% 43.18% 
Overall 5 34 7 36 6.10% 41.46% 8.54% 43.90% 
Dilators need to be used no longer than for one year after your treatment      
Control 2 12 7 17 5.26% 31.58% 18.42% 44.74% 
Intervention 7 12 6 19 15.91% 27.27% 13.64% 43.18% 
Overall 9 24 13 36 10.98% 29.27% 15.85% 43.90% 
Using vaginal dilators can help in making sexual intercourse less painful                     
Control 1 13 7 17 2.63% 34.21% 18.42% 44.74% 
Intervention 0 21 4 19 0.00% 47.73% 9.09% 43.18% 
Overall 1 34 11 36 1.22% 41.46% 13.41% 43.90% 
It is not important to use vaginal dilators for pelvic examinations by your oncologists                 Control 6 9 5 18 
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Item Group Incorrect Correct Don't 
Know 
Missing 
15.79% 23.68% 13.16% 47.37% 
Intervention 4 15 6 19 9.09% 34.09% 13.64% 43.18% 
Overall 10 24 11 37 12.20% 29.27% 13.41% 45.12% 
Cancer treatment can affect your emotions   
Control 0 21 0 17 0.00% 55.26% 0.00% 44.74% 
Intervention 0 24 1 19 0.00% 54.55% 2.27% 43.18% 
Overall 0 45 1 36 0.00% 54.88% 1.22% 43.90% 
All women receiving Pelvic Radiation Therapy will experience sexual difficulties               
Control 2 13 5 18 5.26% 34.21% 13.16% 47.37% 
Intervention 6 10 9 19 13.64% 22.73% 20.45% 43.18% 
Overall 8 23 14 37 9.76% 28.05% 17.07% 45.12% 
There are family members and health professionals that you can you talk to about your sexual  life if you need 
help after your treatment        
Control 1 19 1 17 2.63% 50.00% 2.63% 44.74% 
Intervention 1 24 0 19 2.27% 54.55% 0.00% 43.18% 
Overall 2 43 1 36 2.44% 52.44% 1.22% 43.90% 
Sexual intercourse cannot spread cancer                        
Control 0 20 1 17 0.00% 52.63% 2.63% 44.74% 
Intervention 2 22 1 19 4.55% 50.00% 2.27% 43.18% 
Overall 2 42 2 36 2.44% 51.22% 2.44% 43.90% 
Pelvic radiation therapy can make you 'radioactive'. Therefore, it is important to be careful that the radiation is 
not transferred to your partner    
Control 4 16 1 17 10.53% 42.11% 2.63% 44.74% 
Intervention 2 23 0 19 4.55% 52.27% 0.00% 43.18% 
Overall 6 39 1 36 
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Item Group Incorrect Correct Don't 
Know 
Missing 
7.32% 47.56% 1.22% 43.90% 
All vaginal changes from Pelvic Radiation Therapy will happen in the first few months after treatment          
Control 6 6 9 17 15.79% 15.79% 23.68% 44.74% 
Intervention 12 7 6 19 27.27% 15.91% 13.64% 43.18% 
Overall 18 13 15 36 21.95% 15.85% 18.29% 43.90% 
Is the use of lubrication necessary when using the dilator    
Control 3 13 5 17 7.89% 34.21% 13.16% 44.74% 
Intervention 1 23 1 19 2.27% 52.27% 2.27% 43.18% 
Overall 4 36 6 36 4.88% 43.90% 7.32% 43.90% 
Dilators require special procedures to keep them hygienically sterilised after each use   
Control 11 6 4 17 28.95% 15.79% 10.53% 44.74% 
Intervention 16 8 1 19 36.36% 18.18% 2.27% 43.18% 
Overall 27 14 5 36 32.93% 17.07% 6.10% 43.90% 
Table 58: Knowledge Scale Score - Second Follow Up  
 Control Intervention Overall Test 
Statistic 
(t) 
df p-value Score Mean SD Mean SD Mean SD 
Knowledge Score 6.65 2.32 8.00 2.20 7.40 2.33 -1.984 39.803 .05 
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Table 59: Feedback Scale Responses - Second Follow Up  
Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
The booklet was easy to read 
Control 1 0 0 13 8 16 2.63% 0.00% 0.00% 34.21% 21.05% 42.11% 
Intervention 0 0 0 11 14 19 0.00% 0.00% 0.00% 25.00% 31.82% 43.18% 
Overall 1 0 0 24 22 35 1.22% 0.00% 0.00% 29.27% 26.83% 42.68% 
The booklet was easy to understand 
Control 1 0 1 12 8 16 2.63% 0.00% 2.63% 31.58% 21.05% 42.11% 
Intervention 0 0 0 12 13 19 0.00% 0.00% 0.00% 27.27% 29.55% 43.18% 
Overall 1 0 1 24 21 35 1.22% 0.00% 1.22% 29.27% 25.61% 42.68% 
The information in booklet was confusing 
Control 10 11 1 0 0 16 26.32% 28.95% 2.63% 0.00% 0.00% 42.11% 
Intervention 11 13 0 0 0 20 25.00% 29.55% 0.00% 0.00% 0.00% 45.45% 
Overall 21 24 1 0 0 36 25.61% 29.27% 1.22% 0.00% 0.00% 43.90% 
The booklet made me anxious 
Control 9 11 1 1 0 16 23.68% 28.95% 2.63% 2.63% 0.00% 42.11% 
Intervention 11 10 0 3 1 19 25.00% 22.73% 0.00% 6.82% 2.27% 43.18% 
Overall 20 21 1 4 1 35 24.39% 25.61% 1.22% 4.88% 1.22% 42.68% 
The booklet was too long 
Control 8 13 1 0 0 16 21.05% 34.21% 2.63% 0.00% 0.00% 42.11% 
Intervention 9 11 1 3 1 19 20.45% 25.00% 2.27% 6.82% 2.27% 43.18% 
Overall 17 24 2 3 1 35 20.73% 29.27% 2.44% 3.66% 1.22% 42.68% 
The booklet was too detailed Control 7 14 1 0 0 16 
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Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
18.42% 36.84% 2.63% 0.00% 0.00% 42.11% 
Intervention 8 11 1 4 1 19 18.18% 25.00% 2.27% 9.09% 2.27% 43.18% 
Overall 15 25 2 4 1 35 18.29% 30.49% 2.44% 4.88% 1.22% 42.68% 
I liked the overall format of the booklet 
Control 1 0 3 9 9 16 2.63% 0.00% 7.89% 23.68% 23.68% 42.11% 
Intervention 1 0 4 11 8 20 2.27% 0.00% 9.09% 25.00% 18.18% 45.45% 
Overall 2 0 7 20 17 36 2.44% 0.00% 8.54% 24.39% 20.73% 43.90% 
I know which options are available to me 
Control 1 0 3 13 5 16 2.63% 0.00% 7.89% 34.21% 13.16% 42.11% 
Intervention 1 0 1 13 9 20 2.27% 0.00% 2.27% 29.55% 20.45% 45.45% 
Overall 2 0 4 26 14 36 2.44% 0.00% 4.88% 31.71% 17.07% 43.90% 
I have acquired new information in dealing with sexual difficulties following 
radiotherapy 
Control 0 3 5 10 3 17 0.00% 7.89% 13.16% 26.32% 7.89% 44.74% 
Intervention 1 2 5 10 3 23 2.27% 4.55% 11.36% 22.73% 6.82% 52.27% 
Overall 1 5 10 20 6 40 1.22% 6.10% 12.20% 24.39% 7.32% 48.78% 
After reading the booklet, I feel confident using vaginal dilators 
Control 1 1 4 10 4 18 2.63% 2.63% 10.53% 26.32% 10.53% 47.37% 
Intervention 1 2 3 11 8 19 2.27% 4.55% 6.82% 25.00% 18.18% 43.18% 
Overall 2 3 7 21 12 37 2.44% 3.66% 8.54% 25.61% 14.63% 45.12% 
The booklet provided additional information to that given to me by health 
professionals to date 
Control 0 4 2 11 5 16 0.00% 10.53% 5.26% 28.95% 13.16% 42.11% 
Intervention 1 5 2 10 7 19 2.27% 11.36% 4.55% 22.73% 15.91% 43.18% 
Overall 1 9 4 21 12 35 
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Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
1.22% 10.98% 4.88% 25.61% 14.63% 42.68% 
I felt uncomfortable with the personal nature of information in the booklet 
Control 3 14 2 1 1 17 7.89% 36.84% 5.26% 2.63% 2.63% 44.74% 
Intervention 11 8 2 1 2 20 25.00% 18.18% 4.55% 2.27% 4.55% 45.45% 
Overall 14 22 4 2 3 37 17.07% 26.83% 4.88% 2.44% 3.66% 45.12% 
The booklet was helpful to me 
Control 0 0 1 12 9 16 0.00% 0.00% 2.63% 31.58% 23.68% 42.11% 
Intervention 1 1 3 12 8 19 2.27% 2.27% 6.82% 27.27% 18.18% 43.18% 
Overall 1 1 4 24 17 35 1.22% 1.22% 4.88% 29.27% 20.73% 42.68% 
The booklet gave me information that I needed 
Control 0 0 2 12 8 16 0.00% 0.00% 5.26% 31.58% 21.05% 42.11% 
Intervention 1 1 2 12 9 19 2.27% 2.27% 4.55% 27.27% 20.45% 43.18% 
Overall 1 1 4 24 17 35 1.22% 1.22% 4.88% 29.27% 20.73% 42.68% 
I know why it is important to use vaginal dilators 
Control 2 0 2 8 9 17 5.26% 0.00% 5.26% 21.05% 23.68% 44.74% 
Intervention 0 1 2 11 11 19 0.00% 2.27% 4.55% 25.00% 25.00% 43.18% 
Overall 2 1 4 19 20 36 2.44% 1.22% 4.88% 23.17% 24.39% 43.90% 
I found it easy to find the information I wanted in the booklet 
Control 0 0 2 14 6 16 0.00% 0.00% 5.26% 36.84% 15.79% 42.11% 
Intervention 1 1 2 11 10 19 2.27% 2.27% 4.55% 25.00% 22.73% 43.18% 
Overall 1 1 4 25 16 35 1.22% 1.22% 4.88% 30.49% 19.51% 42.68% 
I liked the way the booklet looked Control 
0 0 5 13 4 16 
0.00% 0.00% 13.16% 34.21% 10.53% 42.11% 
Intervention 1 1 4 13 6 19 
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Item Group Strongly 
disagree 
Disagree Not sure Agree Strongly 
agree 
Missing 
2.27% 2.27% 9.09% 29.55% 13.64% 43.18% 
Overall 1 1 9 26 10 35 1.22% 1.22% 10.98% 31.71% 12.20% 42.68% 
Table 60: Feedback Scale Score - Second Follow Up  
 Control Intervention Overall Test 
Statistic
(U) 
df p-valueScore Median SD Median SD Median SD 
Feedback 41.00 5.48 43.00 7.95 42.00 6.71 151 37 0.54 
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5.4.3.4 Psychological Status - Second Follow-up 
5.4.3.4.1 Hospital Depression and Anxiety Scale (HADS) - Differences 
between groups at Second follow-up 
Table 61: HADS Scores - Second Follow Up  
 Control Intervention Overall 
Test Statistic  df p-valueScore Mean/ Median 
SD/ 
IQR 
Mean/ 
Median
SD/ 
IQR 
Mean/ 
Median
SD/ 
IQR 
Anxiety1 3.42 3.47 4.61 4.13 4.04 3.84 -1.144 (t) 51.494 0.26 
Depression2 2.00 3.25 1.50 3.75 2.00 3.00 359.000 (U) 54 0.93 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
Independent sample t-test indicated no significant differences between the 
intervention and control groups for anxiety (t(51.494)=-1.144, p=0.26). 
In using the cut-off scores for caseness (normal <8, borderline 8-10, case >11), 
92.3% (N=24) had normal scores, and 7.7% (N=2) were considered caseness for 
anxiety in the control group. In the intervention group, 85.7% (N=24) were normal, 
7.1% (N=2) were borderline and 7.1% (N=2) were considered caseness for anxiety. 
There was no statistical difference between control and intervention group on anxiety 
caseness (χ2=1.929, p=0.38). Overall, for the whole sample, 88.9% (N=48) were 
normal, 3.7% (N=2) were borderline and 7.4% (N=4) were considered caseness for 
anxiety. 
Mann-Whitney U test indicated no significant difference between the intervention and 
control groups for depression (U=359, p=0.93). 
The majority were considered normal according to depression cut-offs. Borderline 
depression was observed in three people each in the control group (11.5%, N=3) 
and intervention group (10.7%, N=3). One person was considered caseness in the 
intervention group (3.6%, N=1), while none fitted the criteria for caseness in the 
control group. Overall, for the whole sample, 87% (N=47) were normal, 11.1% (N=6) 
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were borderline, and one person (1.9%, N=1) was considered caseness for 
depression. 
5.4.3.4.2 Impact of Event Scale Revised (IES-R) - Differences between 
groups at Second follow-up 
Table 62: IES-R Scores - Second Follow Up  
 Control Intervention Overall Test 
Statistic 
(U) 
df p-value Score Median IQR Median IQR Median IQR 
Mean Total IES-R 6.00 20.00 11.00 18.25 8.00 19.00 332.5 54 0.58 
Avoidance 1.00 10.50 5.00 11.25 4.50 11.25 295.5 54 0.23 
Intrusion 2.50 6.00 2.00 5.75 2.00 6.00 344.0 54 0.72 
Hyperarousal 2.00 3.25 1.00 3.00 1.00 3.00 340.0 54 0.66 
Mann-Whitney U test indicated no significant differences between the intervention 
and control groups for IES-R Scores or any of the subscales. 
In using the cut-off scores for caseness (PTSD/psychological distress > 33), all the 
subjects (100%, N=26) had normal scores for mean total IES-R score in the control 
group. In the intervention group 89.3% (N=25) had normal scores, and 10.7% (N=3) 
were considered caseness for mean total IES-R score. There was no statistical 
difference between control and intervention group on mean total IES-R score 
caseness (χ2=2.95, p=0.09). Overall, for the whole sample, 94.4% (N=51) had 
normal scores, and 5.6% (N= 3) were considered caseness for mean total IES-R 
scores.  
Using 15.2 and 17.9 cut-off scores as guidelines for caseness of avoidance and 
intrusion, respectively; the following results were obtained: 
85.2% (N=46) people have lower than cut-off scores for avoidance and the balance 
14.8% (N=8) people have higher than cut-off scores for avoidance. Within the control 
group, 88.5% (N=23) people had lower than cut-off scores for avoidance and the 
balance 11.5% (N=3) had higher than cut-off scores for avoidance. Within the 
intervention group 82.1% (N=23) people had lower than cut-off scores for avoidance, 
and the balance 17.9% (N=5) had higher than cut-off scores for avoidance. There 
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was no statistical difference between control and intervention group (χ2=0.427, 
p=0.51). 
98.1% (N=53) people have lower than cut-off scores for intrusion and one person 
(1.9%, N=1) had higher than cut-off scores for intrusion. Within the control group, 
100% (N=26) of the people had lower than cut-off scores for intrusion. Within the 
intervention group 96.4% (N=27) people had lower than cut-off scores for intrusion, 
and the balance 3.6% (N=1) had higher than cut-off scores for intrusion. There was 
no statistical difference between control and intervention group (χ2=0.946, p=0.33). 
5.4.3.5 Sexual Function - Second Follow-up 
5.4.3.5.1 Sexual Activity Questionnaire (SAQ) – Differences between 
groups at Second follow-up 
The median scores for the various SAQ items were tested for group differences 
using the Mann-Whitney U test and the results indicated that there no significant 
difference between the intervention and control groups for any of the items. 
5.4.3.5.2 Sexual Vaginal Changes Questionnaire (SVQ) - Differences 
between groups at Second follow-up 
Summary statistics for scores were drawn from the SVQ (intimacy, sexual interest, 
worries about sex life, sexual satisfaction, symptoms scale on vaginal changes, 
vaginal bleeding during intercourse, vaginal dimension, and sexual functioning) are 
provided in Table 63. 
The various SVQ items were tested for group differences using appropriate 
parametric or non-parametric techniques and the results indicated that there were no 
significant differences between the intervention and control groups for any of the 
items. 
5.4.3.5.3 The Sexual Functioning After Gynaecological Illness Scale 
(SFAGIS) - Second follow-up 
The responses from the SFAGIS are summarised in Table 64.  
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Table 63: SVQ Scores - Second Follow Up  
 Control Intervention Overall Test Statistic
 df 
p-
valueScore Mean/Median SD/IQR Mean/Median SD/IQR Mean/Median SD/IQR
Intimacy score2 6.00 2.50 5.00 3.75 6.00 2.50 288.000 (U) 53 0.26 
Sexual interest score2 2.00 2.00 1.00 1.00 1.50 1.00 305.500 (U) 52 0.52 
Worries about sex life 
score2 1.00 0.50 1.00 0.50 1.00 0.25 311.500 (U) 50 0.98 
Sexual satisfaction 
score1 3.86 2.03 5.13 1.80 4.53 2.00 -2.201 (t) 40.365 0.03 
Symptoms scale on 
vaginal changes score1 8.33 2.52 13.00 1.41 10.20 3.19 -2.646 (t) 2.998 0.08 
Vaginal bleeding during 
intercourse score1 5.00 1.41 3.75 0.50 4.17 0.98 1.213 (t) 1.127 0.42 
Vaginal  dimension 
score2 1.00 0.50 1.00 1.00 1.00 1.00 25.500 (U) 16 0.44 
Sexual functioning 
score1 8.78 2.39 9.71 1.70 9.19 2.10 -0.915 (t) 13.940 0.38 
1 Parametric statistics including mean and SD apply to this variable 
2 Non-parametric statistics including median and interquartile range (IQR) apply to this variable 
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Table 64: SFAGIS Item Responses - Second Follow Up  
Item Category Control Intervention Overall
1. Because of my illness my 
partner 
1 = This does not concern me because I don't have a partner 6 15.79% 13 29.55% 19 23.17% 
2 = Can catch my illness even if I do not have sexual relations 0 0.00% 0 0.00% 0 0.00% 
3 = Can become sick or hurt if we have sexual relations 0 0.00% 0 0.00% 0 0.00% 
4 = Cannot be harmed provided we do not have sexual relations 1 2.63% 0 0.00% 1 1.22% 
5 = Cannot be harmed if we have sexual relations 13 34.21% 12 27.27% 25 30.49% 
9 = Missing 18 47.37% 19 43.18% 37 45.12% 
2. My doctor told me I could 
have sexual relations 
1 = He/she did not mention it 6 15.79% 9 20.45% 15 18.29% 
2 = Three months or more after end of treatment 5 13.16% 2 4.55% 7 8.54% 
3 = One month after the end of treatment 4 10.53% 3 6.82% 7 8.54%
4 = During and after my treatment 0 0.00% 0 0.00% 0 0.00% 
5 = Whenever my partner and I wanted to have them 6 15.79% 10 22.73% 16 19.51% 
9 = Missing 17 44.74% 20 45.45% 37 45.12% 
3. My doctor talked about 
my sex life 
1 = Not at all 5 13.16% 10 22.73% 15 18.29% 
2 = I do not remember if he/she talked about it 6 15.79% 4 9.09% 10 12.20% 
3 = After the end of my treatment 2 5.26% 2 4.55% 4 4.88%
4 = Before or during my treatment 1 2.63% 2 4.55% 3 3.66% 
5 = Before and after my treatment 8 21.05% 7 15.91% 15 18.29% 
9 = Missing 16 42.11% 19 43.18% 35 42.68% 
4. My partner 
1 = This does not concern me because I do not have a partner 6 15.79% 13 29.55% 19 23.17% 
2 = Is afraid that s/he will “catch” my illness 0 0.00% 0 0.00% 0 0.00% 
3 = Is afraid that my treatment will harm him/her 0 0.00% 0 0.00% 0 0.00%
4 = Does not know very much about my illness or its treatment 1 2.63% 0 0.00% 1 1.22% 
5 = Knows that neither my illness nor its treatment can harm him/her 14 36.84% 12 27.27% 26 31.71% 
9 = Missing 17 44.74% 19 43.18% 36 43.90% 
5. If I had a choice, I would 
like my doctor 
1 = Not to speak to me about sexual matters 2 5.26% 7 15.91% 9 10.98% 
2 = To speak to me about sexual matters 19 50.00% 17 38.64% 36 43.90% 
9 = Missing 17 44.74% 20 45.45% 37 45.12% 
6. If I had a partner, I would 
like my doctor 
1 = To speak to my partner and to myself about sexual matters 9 23.68% 6 13.64% 15 18.29% 
2 = To speak to both my partner and myself together about sexual matters 11 28.95% 12 27.27% 23 28.05% 
3 = To speak only to my partner about sexual matters 0 0.00% 0 0.00% 0 0.00% 
9 = Missing 18 47.37% 26 59.09% 44 53.66% 
7. I would like to receive 
information about sexual 
1 = Not at all 6 15.79% 11 25.00% 17 20.73% 
2 = Prior to the first treatment 9 23.68% 4 9.09% 13 15.85% 
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Item Category Control Intervention Overall 
expectations following 
treatment 
3 = Immediately following the first treatment 0 0.00% 0 0.00% 0 0.00% 
4 = During my first follow-up consultation 1 2.63% 1 2.27% 2 2.44% 
5 = On my request when queries arise 7 18.42% 8 18.18% 15 18.29% 
9 = Missing 15 39.47% 20 45.45% 35 42.68% 
8. I would like to receive 
information about sexual 
expectations following 
treatment from 
1 = Nobody 6 15.79% 12 27.27% 18 21.95% 
2 = Another female 5 13.16% 3 6.82% 8 9.76% 
3 = A female doctor 2 5.26% 1 2.27% 3 3.66% 
4 = Male health worker 0 0.00% 0 0.00% 0 0.00% 
5 = Either a male or female 10 26.32% 8 18.18% 18 21.95% 
9 = Missing 15 39.47% 20 45.45% 35 42.68% 
5.4.3.6 Correlation Analysis 
Correlation matrix using Spearman's Rank Non-Parametric Correlation Coefficients is shown in Appendix 4.2. A number of 
significant correlations were observed at p < 0.05 and p < 0.01. These significant correlations were considered in the subsequent 
multivariate analysis to avoid the problem of multicollinearity. 
5.4.3.7 Analysis of clinical conditions - Baseline and Second Follow Up 
The results from the analysis of psychological status and sexual function scores between the baseline and second follow up phases 
are summarised in Table 65 and Figure 19. 
  
246 
 
 
Table 65: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Overall Sample 
Second Follow Up Baseline p 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 11.1% (6/54) 0.281 (0.124 - 0.636) 24.1% (13/54) 0.159 (0.033 - 0.769) 0.065 
Depression 13.0% (7/54) 0.074 (0.017 - 0.334) 11.1% (6/54) 0.094 (0.027 - 0.322) 1.000 
IES-R Total 5.7% (3/53) - 17.0% (9/53) - 0.146 
Avoidance 16.3% (8/49) 0.195 (0.048 - 0.799) 12.2% (6/49) 0.233 (0.074 - 0.733) 0.727 
Intrusion 2.0% (1/49) 0.021 (0.003 - 0.145) 4.1% (2/49) - 1.000 
Hyperarousal 34.7% (17/49) 0.152 (0.059 - 0.390) 36.7% (18/49) 0.124 (0.041 - 0.375) 1.000 
Presence of Sexual Activity 31.3% (15/48) 0.195 (0.058 - 0.651) 20.8% (10/48) 0.301 (0.144 - 0.629) 0.227 
Partner Unavailability 52.9% (18/34) 0.070 (0.010 - 0.472) 50.0% (17/34) 0.125 (0.034 - 0.462) 1.000 
Self Too Tired 5.9% (2/34) - - - - 
Partner Too Tired - - - - - 
Self Lack of Interest 29.4% (10/34) 0.278 (0.099 - 0.776) 29.4% (10/34) 0.278 (0.099 - 0.776) 1.000 
Partner Lack of Interest 5.9% (2/34) 0.063 (0.006 - 0.672) 5.9% (2/34) 0.063 (0.006 - 0.672) 1.000 
Self Physical Problem 8.8% (3/34) 0.194 (0.057 - 0.652) 17.6% (6/34) 0.107 (0,011 - 0.999) 0.375 
Partner Physical Problem 8.8% (3/34) 0.065 (0.017 - 0.247) 14.7% (5/34) - 0.500 
Intimacy 36.2% (17/47) 0.425 (0.227 - 0.795) 44.7% (21/47) 0.337 (0.141 - 0.804) 0.424 
Sexual interest 50.0% (23/46) 0.167 (0.057 - 0.489) 45.7% (21/46) 0.233 (0.105 - 0.521) 0.727 
Worries about sex life 27.3% (12/44) 0.225 (0.105 - 0.483) 36.4% (16/44) 0.114 (0.029 - 0.458) 0.289 
Sexual satisfaction 47.1% (16/34) 0.593 (0.271 - 1.297) 44.1% (15/34) 0.614 (0.299 - 1.261) 1.000 
Symptoms scale on vaginal changes 50.0% (1/2) - - - - 
Vaginal bleeding during intercourse 50.0% (1/2) - 100.0% (2/2) - - 
Vaginal  dimension 60.0% (3/5) 1.500 (0.181 - 12.459) 40.0% (2/5) 1.333 (0.269 - 6.606) 1.000 
Sexual functioning - - 60.0% (3/5) - - 
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Figure 19: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Overall Sample 
There were no statistically significant differences in the proportion of people with the 
different psychological or sexual function measures in the overall sample between 
the baseline and second follow up. 
The results from the analysis of psychological status and sexual function scores for 
the control group between the baseline and second follow up phases are 
summarised in Table 66 and Figure 20. 
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Table 66: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Control Group 
Second Follow Up Baseline P 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 7.7% (2/26) 0.500 (0.106 - 2.355) 26.9% (7/26) 0.368 (0.026 - 5.126) 0.125 
Depression 11.5% (3/26) 0.065 (0.008 - 0.521) 11.5% (3/26) 0.065 (0.008 - 0.521) 1.000 
IES-R Total - - 15.4% (4/26) - - 
Avoidance 14.3% (3/21) 0.167 (0.014 - 2.006) 9.5% (2/21) 0.211 (0.031 - 1.418) 1.000 
Intrusion - - - - - 
Hyperarousal 38.1% (8/21) 0.205 (0.054 - 0.780) 38.1% (8/21) 0.205 (0.054 - 0.780) 1.000 
Presence of Sexual Activity 36.4% (8/22) 0.143 (0.019 - 1.068) 22.7% (5/22) 0.294 (0.112 - 0.770) 0.375 
Partner Unavailability 44.4% (8/18) - 38.9% (7/18) 0.091 (0.014 - 0.589) 1.000 
Self Too Tired 11.1% (2/18) - - - - 
Partner Too Tired - - - - - 
Self Lack of Interest 27.8% (5/18) 0.256 (0.059 - 1.106) 27.8% (5/18) 0.256 (0.059 - 1.106) 1.000 
Partner Lack of Interest 5.6% (1/18) - - - - 
Self Physical Problem 11.1% (2/18) 0.375 (0.067 - 2.096) 22.2% (4/18) 0.286 (0.023 - 3.620) 0.625 
Partner Physical Problem 11.1% (2/18) 0.063 (0.009 -0.417) 16.7% (3/18) - 1.000 
Intimacy 36.4% (8/22) 0.667 (0.345 - 1.289) 59.1% (13/22) 0.481 (0.124 - 1.868) 0.180 
Sexual interest 52.2% (12/23) 0.327 (0.121 - 0.888) 56.5% (13/23) 0.260 (0.073 - 0.930) 1.000 
Worries about sex life 27.3% (6/22) 0.225 (0.076 - 0.663) 36.4% (8/22) 0.114 (0.016 - 0.814) 0.625 
Sexual satisfaction 35.7% (5/14) 0.833 (0.202 - 3.435) 35.7% (5/14) 0.833 (0.202 - 3.435) 1.000 
Symptoms scale on vaginal changes 50.0% (1/2) - - - - 
Vaginal bleeding during intercourse 100.0% (1/1) - 100.0% (1/1) - - 
Vaginal  dimension 66.7% (2/3) 2.000 (0.500 - 7.997) 66.7% (2/3) 2.000 (0.500 - 7.997) 1.000 
Sexual functioning - - 66.7% (2/3) - - 
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Figure 20: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Control Group 
There were no statistically significant differences in the proportion of people with the 
different psychological or sexual function measures in the control group between the 
baseline and second follow up. 
The results from the analysis of psychological status and sexual function scores for 
the intervention group between the baseline and second follow up phases are 
summarised in Table 67 and Figure 21. 
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Table 67: Prevalence and Relative Risk of Selected Psychological Status and Sexual Function Outcomes - Intervention Group 
Second Follow Up Baseline P 
  Prevalence RR (95% CI) Prevalence RR 
Anxiety 14.3% (4/28) 0.167 (0.050 - 0.553) 21.4% (6/28) 0.091 (0.011 - 0.724) 0.625 
Depression 14.3% (4/28) 0.083 (0.010 - 0.719) 10.7% (3/28) 0.120 (0.025 - 0.566) 1.000 
IES-R Total 11.1% (3/27) - 18.5% (5/27) - 0.727 
Avoidance 17.9% (5/28) 0.217 (0.040 - 1.196) 14.3% (4/28) 0.250 (0.059 - 1.058) 1.000 
Intrusion 3.6% (1/28) 0.037 (0.005 - 0.253) 71.% (2/28) - 1.000 
Hyperarousal 32.1% (9/28) 0.118 (0.031 - 0.448) 35.7% (10/28) 0.069 ( 0.010 - 0.478) 1.000 
Presence of Sexual Activity 26.9% (7/26) 0.246 (0.051 - 1.175) 19.2% (5/26) 0.317 (0.102 - 0.988) 0.688 
Partner Unavailability 62.5% (10/16) 0.185 (0.031 - 1.122) 62.5% (10/16) 0.185 (0.031 - 1.122) 1.000 
Self Too Tired - - - - - 
Partner Too Tired - - - - - 
Self Lack of Interest 31.3% (5/16) 0.303 (0.072 - 1.283) 31.3% (5/16) 0.303 (0.072 - 1.283) 1.000 
Partner Lack of Interest 6.3% (1/16) 0.067 (0.010 - 0.443) 12.5% (2/16) - 1.000 
Self Physical Problem 6.3% (1/16) 0.067 (0.010 - 0.443) 12.5% (2/16) - 1.000 
Partner Physical Problem 6.3% (1/16) 0.067 (0.010 - 0.443) 12.5% (2/16) - 1.000 
Intimacy 36.0% (9/25) 0.188 (0.047 - 0.743) 32.0% (8/25) 0.235 (0.078 - 0.708) 1.000 
Sexual interest 47.8% (11/23) - 34.8% (8/23) 0.200 (0.073 - 0.550) - 
Worries about sex life 27.3% (6/22) 0.225 (0.076 - 0.663) 36.4% (8/22) 0.114 (0.016 - 0.814) 0.625 
Sexual satisfaction 55.0% (11/20) 0.524 (0.188 - 1.462) 50.0% (10/20) 0.571 (0.242 - 1.351) 1.000 
Symptoms scale on vaginal changes - - - - - 
Vaginal bleeding during intercourse - - 100.0% (1/1) - - 
Vaginal  dimension 50.0% (1/2) - - - - 
Sexual functioning - - 50.0% (1/2) - - 
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Figure 21: Prevalence of Selected Psychological Status and Sexual Function 
Outcomes - Intervention Group 
There were no statistically significant differences in the proportion of people with the 
different psychological or sexual function measures in the intervention group 
between the baseline and second follow up. 
5.4.3.8 Multiple Linear Regression - Using Baseline and Second 
Follow-up Phase Data 
Details of the multiple linear regression models with Intimacy, Sexual interest, 
Anxiety, Depression, and IES-R as the dependent variables are shown below.  
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5.4.3.8.1 Intimacy 
A multiple linear regression model was developed with intimacy score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables.  
Table 68: Full Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 6.233 6.423 <0.001
Anxiety 0.060 1.520 0.131 
Depression -0.183 -3.685 <0.001
IES-R Total 0.003 0.294 0.769 
Participant Age -0.020 -1.699 0.092 
Marital Status 0.937 4.040 <0.001
Highest Qualification 0.737 2.642 0.009 
Number of Children 0.067 0.708 0.480 
Language Spoken at Home - English -0.194 -0.875 0.383 
Taking antidepressant or Sedative 0.284 0.673 0.502 
Treatment at Royal North Shore Hospital (RNSH) -0.216 -0.705 0.482 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.277 0.774 0.440 
Treatment at Liverpool Hospital -0.568 -1.157 0.249 
Treatment at St George Hospital 0.976 1.472 0.143 
Treatment at Genesis Care, Mater Hospital -0.112 -0.244 0.807 
Cancer Type - Cervical -0.827 -1.588 0.115 
Cancer Type - Anal -0.688 -1.311 0.192 
Cancer Type - Rectal -0.920 -2.324 0.022
Cancer Type - Vaginal -0.501 -0.606 0.545 
Cancer Type - Vulvar 0.584 0.589 0.557 
Treatment - Surgery 0.681 1.985 0.049 
Treatment - External Pelvic Radio -0.281 -0.658 0.512 
Treatment - Internal Radio 0.114 0.347 0.729 
Treatment - Chemotherapy 1.113 2.851 0.005 
Occupation - Non Professional -0.714 -2.468 0.015 
Occupation - Not Working -0.298 -0.718 0.474 
Intervention Group Membership -0.422 -1.974 0.050 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
253 
The results of the analysis indicate that the independent variables input in the model 
account for 41.7% (R2 = .417, F (26, 163) = 3.762, p < 0.001) of variance in intimacy 
score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
Table 69: Final Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 4.963 18.739 <0.001 
Depression -0.124 -3.132 0.002 
Marital Status 1.041 4.758 <0.001 
Highest Qualification 0.750 3.173 0.002 
Occupation Professional  0.669 2.886 0.004 
Treatment at Liverpool Hospital -0.807 -2.082 0.039 
The final model indicates that depression score, marital status, highest qualification 
attained, occupation status of professional, and being treated at Liverpool hospital 
accounted for a significant proportion of the intimacy score, R2 = .315, F (5, 163) = 
14.511, p < 0.001. 
Depression score, marital status, highest qualifications attained, occupation status of 
professional, and being treated at Liverpool hospital explain approximately 31.5% of 
the variance in the intimacy score. One unit increase in the depression score will 
translate to a 0.124 units decline in the intimacy score when all the other 
independent variables are controlled; being married or in a defacto relationship will 
translate to 1.041 units increase in the intimacy score when all the other independent 
variables are controlled; having attained an education level of year 12 or more will 
translate to 0.75 units increase in the intimacy score when all the other independent 
variables are controlled; bring professionally employed will translate to 0.669 units 
increase in the intimacy score when all other independent variables are controlled; 
and being treated at Liverpool hospital will translate 0.807 units decline in the 
intimacy score when all the other independent variables are controlled.  
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5.4.3.8.2 Sexual Interest 
A multiple linear regression model was developed with sexual interest score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables.  
Table 70: Full Regression Model for Sexual Interest 
Intercept / Predictors β t Sig. 
Intercept 2.534 4.422 <0.001
Anxiety 0.014 0.585 0.560 
Depression -0.059 -2.025 0.045 
IES-R Total -0.001 -0.097 0.923 
Participant Age -0.026 -3.633 <0.001
Marital Status 0.651 4.760 <0.001
Highest Qualification 0.071 0.428 0.669 
Number of Children 0.055 0.978 0.330 
Language Spoken at Home - English 0.137 1.044 0.298 
Taking antidepressant or Sedative 0.381 1.528 0.129 
Treatment at Royal North Shore Hospital (RNSH) -0.137 -0.758 0.450 
Treatment at Royal Prince Alfred Hospital (RPAH) -0.049 -0.231 0.818 
Treatment at Liverpool Hospital -0.840 -2.899 0.004 
Treatment at St George Hospital -0.320 -0.816 0.416 
Treatment at Genesis Care, Mater Hospital -0.159 -0.589 0.557 
Cancer Type - Cervical 0.031 0.100 0.921 
Cancer Type - Anal -0.174 -0.562 0.575 
Cancer Type - Rectal -0.402 -1.721 0.087
Cancer Type - Vaginal -0.700 -1.435 0.154 
Cancer Type - Vulvar 0.089 0.153 0.879 
Treatment - Surgery 0.440 2.171 0.032 
Treatment - External Pelvic Radio 0.491 1.946 0.054 
Treatment - Internal Radio 0.220 1.131 0.260 
Treatment - Chemotherapy -0.105 -0.456 0.649 
Occupation - Non Professional -0.098 -0.575 0.567 
Occupation - Not Working -0.383 -1.567 0.119 
Intervention Group Membership -0.073 -0.577 0.565 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
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The results of the analysis indicate that the independent variables input in the model 
account for 39.9% (R2 = .399, F (26, 163) = 3.499, p < 0.001) of variance in sexual 
interest score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
Table 71: Final Regression Model for Sexual Interest  
Intercept / Predictors β t Sig. 
Intercept 2.744 7.614 <0.001 
Participant Age -0.026 -4.563 <0.001 
Marital Status 0.684 5.372 <0.001 
Treatment- Surgery 0.531 3.659 <0.001 
Treatment at Liverpool Hospital -0.621 -2.780 0.006 
Cancer Type - Rectal -0.385 -2.569 0.011 
The final model indicates that participant age, marital status, treatment using 
surgery, being treated at Liverpool hospital, and rectal cancer accounted for a 
significant proportion of the sexual interest score, R2 = .312, F (5, 163) = 14.351, p < 
0.001. 
Participant age, marital status, treatment using surgery, being treated at Liverpool 
hospital, and rectal cancer explain approximately 31.2% of the variance in the sexual 
interest score. One unit increase in age will translate to 0.026 units decline in the 
sexual interest score when all the other independent variables are controlled; being 
married or in a defacto relationship will translate to 0.684 units increase in the sexual 
interest score when all the other independent variables are controlled; being treated 
using surgery will translate to a 0.531 units increase in the sexual interest score 
when all the other independent variables are controlled; being treated at Liverpool 
hospital will translate to 0.621 units decline in sexual interest score when all the 
other independent variables are controlled; and presence of rectal cancer will 
translate to 0.385 units decline in the sexual interest score when all the other 
independent variables are controlled.  
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5.4.3.8.3 Anxiety 
A multiple linear regression model was developed with anxiety score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables. 
Table 72: Full Regression Model for Anxiety 
Intercept / Predictors β t Sig. 
Intercept 8.877 3.571 <0.001
Participant Age -0.053 -1.668 0.098 
Marital Status -0.890 -1.430 0.155 
Highest Qualification -0.157 -0.207 0.836 
Number of Children -0.166 -0.670 0.504 
Language Spoken at Home - English -0.105 -0.173 0.863 
Taking antidepressant or Sedative -0.066 -0.058 0.954 
Treatment at Royal North Shore Hospital (RNSH) 0.430 0.530 0.597 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.825 0.850 0.397 
Treatment at Liverpool Hospital 0.937 0.705 0.482 
Treatment at St George Hospital -2.747 -1.533 0.128 
Treatment at Genesis Care, Mater Hospital 0.342 0.275 0.784 
Cancer Type - Cervical 1.259 0.901 0.369 
Cancer Type - Anal 2.916 2.070 0.040 
Cancer Type - Rectal 1.501 1.403 0.163 
Cancer Type - Vaginal 4.493 2.026 0.045 
Cancer Type - Vulvar 0.194 0.072 0.943 
Treatment - Surgery -0.740 -0.798 0.426 
Treatment - External Pelvic Radio 0.980 0.856 0.394 
Treatment - Internal Radio 0.124 0.138 0.890 
Treatment - Chemotherapy -1.955 -1.888 0.061 
Occupation - Non Professional 0.384 0.503 0.616 
Occupation - Not Working -1.040 -0.941 0.348 
Intervention Group Membership -0.058 -0.100 0.920 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
257 
The results of the analysis indicate that the independent variables input in the model 
account for 21.5% (R2 = .215, F (23, 163) = 1.665, p = 0.038) of variance in the 
anxiety score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
Table 73: Final Regression Model for Anxiety  
Intercept / Predictors β t Sig. 
Intercept 10.043 6.457 <0.001 
Participant Age -0.072 -2.653 0.009 
Cancer Type - Endometrial -1.371 -2.294 0.023 
The final model indicates that participant age, and endometrial cancer accounted for 
a significant proportion of the anxiety score, R2 = .122, F (2, 163) = 11.184, p < 
0.001. 
Participant age and endometrial cancer explain approximately 12.2% of the variance 
in the anxiety score. One unit increase in age will translate to 0.072 units decline in 
the anxiety score when all the other independent variables are controlled; and 
presence of endometrial cancer will translate to 1.371 units decline in the anxiety 
score when all the other independent variables are controlled. 
5.4.3.8.4 Depression 
A multiple linear regression model was developed with depression score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 16% (R2 = .16, F (23, 163) = 1.157, p = 0.295) of variance in the 
depression score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given in Table 75.    
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Table 74: Full Regression Model for Depression 
Intercept / Predictors β t Sig. 
Intercept 3.959 2.157 0.033 
Participant Age -0.031 -1.320 0.189 
Marital Status -0.796 -1.731 0.086 
Highest Qualification 0.210 0.375 0.708 
Number of Children 0.460 2.515 0.013 
Language Spoken at Home - English -0.283 -0.634 0.527 
Taking antidepressant or Sedative 1.219 1.447 0.150 
Treatment at Royal North Shore Hospital (RNSH) -0.728 -1.218 0.225 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.796 1.112 0.268 
Treatment at Liverpool Hospital 1.144 1.166 0.246 
Treatment at St George Hospital -1.049 -0.793 0.429 
Treatment at Genesis Care, Mater Hospital -0.171 -0.186 0.853 
Cancer Type - Cervical 1.319 1.278 0.203 
Cancer Type - Anal 0.640 0.615 0.539 
Cancer Type - Rectal 0.196 0.248 0.805 
Cancer Type - Vaginal 0.939 0.573 0.568 
Cancer Type - Vulvar 0.229 0.115 0.909 
Treatment - Surgery 0.110 0.160 0.873 
Treatment - External Pelvic Radiotherapy -0.002 -0.003 0.998 
Treatment - Internal Radiotherapy 0.157 0.237 0.813 
Treatment - Chemotherapy 0.520 0.680 0.498 
Occupation - Non Professional -0.672 -1.191 0.236 
Occupation - Not Working -0.930 -1.140 0.256 
Intervention Group Membership -0.166 -0.385 0.701 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
Table 75: Final Regression Model for Depression  
Intercept / Predictors β t Sig. 
Intercept 3.464 11.221 <0.001 
Cancer Type - Endometrial -0.838 -2.099 0.037 
The final model indicates that endometrial cancer accounted for a significant 
proportion of the depression score, R2 = .026, F (1, 163) = 4.405, p = 0.037. 
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Endometrial cancer explains approximately 2.6% of the variance in the depression 
score. Presence of endometrial cancer will translate to 0.838 units decline in the 
depression score.   
5.4.3.8.5 IES-R 
A multiple linear regression model was developed with IES-R score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables.  
Table 76: Full Regression Model for IES-R 
Intercept / Predictors β t Sig. 
Intercept 33.794 4.014 <0.001
Participant Age -0.300 -2.797 0.006 
Marital Status -0.762 -0.361 0.718 
Highest Qualification -1.877 -0.732 0.465 
Number of Children 1.473 1.755 0.081 
Language Spoken at Home - English -1.867 -0.914 0.362 
Taking antidepressant or Sedative 0.547 0.142 0.888 
Treatment at Royal North Shore Hospital (RNSH) -5.330 -1.942 0.054 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.594 0.181 0.857 
Treatment at Liverpool Hospital 0.052 0.012 0.991 
Treatment at St George Hospital -6.085 -1.002 0.318 
Treatment at Genesis Care, Mater Hospital -3.626 -0.862 0.390 
Cancer Type - Cervical -2.672 -0.565 0.573 
Cancer Type - Anal 5.452 1.143 0.255 
Cancer Type - Rectal 0.675 0.186 0.852 
Cancer Type - Vaginal 10.473 1.394 0.166 
Cancer Type - Vulvar -4.587 -0.502 0.616 
Treatment - Surgery -3.975 -1.265 0.208 
Treatment - External Pelvic Radiotherapy 7.467 1.925 0.056 
Treatment - Internal Radio 0.669 0.220 0.826 
Treatment - Chemotherapy 0.770 0.220 0.827 
Occupation - Non Professional -5.424 -2.096 0.038 
Occupation - Not Working -9.260 -2.476 0.014 
Intervention Group Membership 0.085 0.043 0.966 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
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The results of the analysis indicate that the independent variables input in the model 
account for 29.9% (R2 = .299, F (23, 163) = 2.599, p < 0.001) of variance in the IES-
R score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
Table 77: Final Regression Model for IES-R  
Intercept / Predictors β t Sig. 
Intercept 25.125 4.129 <0.001
Participant Age -0.341 -3.658 <0.001
Number of Children 1.569 2.127 0.035 
Treatment at Royal Prince Alfred Hospital 
(RPAH) -5.759 -2.666 0.008 
Occupation - Professional 5.332 2.590 0.011 
Treatment - External Pelvic Radiotherapy 8.287 3.849 <0.001
Cancer Type - Anal 7.644 2.204 0.029 
The final model indicates that participant age, number of children, being treated at 
Royal Prince Alfred hospital, occupation status of professional, treatment using 
external pelvic radiotherapy, and anal cancer accounted for a significant proportion 
of the IES-R score, R2 = .251, F (6, 163) = 8.771, p < 0.001. 
Participant age, number of children, being treated at Royal Prince Alfred hospital, 
occupation status of professional, treatment using external pelvic radiotherapy, and 
anal cancer explain approximately 25.1% of the variance in the IES-R score. One 
unit increase in age will translate to 0.341 units decline in the IES-R score when all 
the other independent variables are controlled; every extra child will translate to an 
increase of 1.569 units in the IES-R score when all the other independent variables 
are controlled; being treated at Royal Prince Alfred hospital will translate to 5.759 
units decline in IES-R score when all the other independent variables are controlled; 
being employed as a professional will translate to 0.5332 units increase in the IES-R 
score when all the other independent variables are controlled; being treated using 
external pelvic radiotherapy will translate to 8.287 units increase in the IES-R score 
when all the other independent variables are controlled; and presence of anal cancer 
will translate to 7.29 units of increase in the IES-R score when all the other 
independent variables are controlled. 
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5.4.3.9 Multiple Linear Regression - Using First Follow-up and 
Second Follow-up Phase Data 
Details of the multiple linear regression models with Use and frequency of use of 
Dilator score, Use and frequency of use of Moisturiser score, Use and frequency of 
use of PFME score, Knowledge score, and Feedback score as the dependent 
variables are shown below.  
5.4.3.9.1 Use and frequency of use of Dilator score 
A multiple linear regression model was developed with Use and frequency of use of 
Dilator score as the dependent variable and anxiety score, depression score, IES-R 
total score, number of children, English language spoken at home, antidepressant 
medication, the hospitals where the participants are being treated, the type of 
cancers, types of treatment, occupation status, and membership to the intervention 
group as independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 41.4% (R2 = .414, F (22, 89) = 2.148, p = 0.009) of variance in Use and 
frequency of use of Dilator score. Many of the independent variables input in this 
model are not significant. Details of the final model with all statistically significant 
independent variables are given in Table 79.  
The final model indicates that intervention group membership, rectal cancer, anal 
cancer and medication accounted for a significant proportion of the Use and 
frequency of use of Dilator score, R2 = .319, F (4, 89) = 9.972, p < 0.001. 
Intervention group membership, rectal cancer, anal cancer and medication explain 
approximately 31.9% of the variance in the Use and frequency of use of Dilator 
score. Association with the intervention group translates to 0.610 units increase in 
the Use and frequency of use of Dilator score when all the other independent 
variables are controlled; presence of rectal cancer translates to a decline in the Use 
and frequency of use of Dilator score by 1.435 units when all the other independent 
variables are controlled; presence of anal cancer translates to a decline in the Use 
and frequency of use of Dilator score by 1.536 units when all the other independent 
variables are controlled; and taking antidepressant medication translates to a decline 
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in the Use and frequency of use of Dilator score by 0.842 units when all the other 
independent variables are controlled.  
Table 78: Full Regression Model for Use and frequency of use of Dilator Score 
Intercept / Predictors β t Sig. 
Intercept 1.602 2.024 0.047 
Anxiety -0.030 -0.632 0.530 
Depression -0.001 -0.010 0.992 
IES-R Total 0.009 0.761 0.450 
Number of Children -0.043 -0.414 0.680 
Language Spoken at Home - English 0.396 1.577 0.120 
Taking antidepressant or Sedative -0.947 -2.140 0.036 
Treatment at Royal North Shore Hospital (RNSH) 0.044 0.112 0.911 
Treatment at Royal Prince Alfred Hospital (RPAH) -0.345 -0.763 0.448 
Treatment at Liverpool Hospital -0.049 -0.089 0.929 
Treatment at St George Hospital 0.357 0.405 0.687 
Treatment at Genesis Care, Mater Hospital 1.069 1.175 0.244 
Cancer Type - Cervical 0.769 1.148 0.255 
Cancer Type - Anal -1.185 -1.522 0.133 
Cancer Type - Rectal -1.337 -2.385 0.020 
Cancer Type - Vaginal 0.843 0.727 0.470 
Treatment - Surgery 0.488 0.961 0.340 
Treatment - External Pelvic Radiotherapy -0.256 -0.540 0.591 
Treatment - Internal Radiotherapy -0.349 -0.783 0.437 
Treatment - Chemotherapy 0.092 0.192 0.849 
Occupation - Professional -0.126 -0.358 0.722 
Occupation - Not Working -0.053 -0.093 0.926 
Intervention Group Membership 0.670 2.402 0.019 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
Table 79: Final Regression Model for Use and frequency of use of Dilator Score  
Intercept / Predictors β t Sig. 
Intercept 1.814 9.780 <0.001 
Intervention Group Membership 0.610 2.582 0.012 
Cancer Type - Rectal -1.435 -4.939 <0.001 
Cancer Type - Anal -1.536 -3.447 0.001 
Medication -0.842 -2.526 0.013 
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5.4.3.9.2 Use and frequency of use of Moisturiser score 
A multiple linear regression model was developed with Use and frequency of use of 
Moisturiser score as the dependent variable and anxiety score, depression score, 
IES-R total score, number of children, English language spoken at home, 
antidepressant medication, the hospitals where the participants are being treated, 
the type of cancers, types of treatment, occupation status, and membership to the 
intervention group as independent variables.  
Table 80: Full Regression Model for Use and frequency of use of Moisturiser Score 
Intercept / Predictors β t Sig. 
Intercept 0.523 0.786 0.434 
Anxiety 0.013 0.312 0.756 
Depression -0.006 -0.108 0.915 
IES-R Total 0.002 0.185 0.854 
Number of Children 0.075 0.790 0.433 
Language Spoken at Home - English -0.125 -0.549 0.585 
Taking antidepressant or Sedative -0.807 -1.913 0.060 
Treatment at Royal North Shore Hospital (RNSH) -0.091 -0.257 0.798 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.729 1.793 0.077 
Treatment at Liverpool Hospital 0.321 0.642 0.523 
Treatment at St George Hospital -0.877 -1.123 0.265 
Treatment at Genesis Care, Mater Hospital 1.830 2.229 0.029 
Cancer Type - Cervical 1.776 3.008 0.004 
Cancer Type - Anal 1.373 2.126 0.037 
Cancer Type - Rectal 0.192 0.408 0.685 
Cancer Type - Vaginal -0.069 -0.067 0.947 
Treatment - Surgery -0.041 -0.091 0.927 
Treatment - External Pelvic Radiotherapy -0.138 -0.329 0.743 
Treatment - Internal Radiotherapy 0.132 0.341 0.734 
Treatment - Chemotherapy -0.735 -1.729 0.088 
Occupation - Professional -0.101 -0.322 0.748 
Occupation - Not Working 0.121 0.232 0.817 
Intervention Group Membership -0.108 -0.437 0.663 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 30.5% (R2 = .305, F (22, 90) = 1.359, p = 0.169) of variance in Use and 
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frequency of use of Moisturiser score. Many of the independent variables input in this 
model are not significant. Details of the final model with all statistically significant 
independent variables are given below.  
Table 81: Final Regression Model for Use and frequency of use of Moisturiser Score 
Intercept / Predictors β t Sig. 
Intercept 0.630 4.187 <0.001 
Cancer Type - Anal 1.321 3.062 0.003 
Cancer Type - Cervical 1.093 2.905 0.005 
Treatment - Chemotherapy -0.523 -2.138 0.035 
The final model indicates that anal cancer, cervical cancer, and chemotherapy 
treatment accounted for a significant proportion of the Use and frequency of use of 
Moisturiser score, R2 = .144, F (3, 90) = 4.874, p = 0.004. 
Anal cancer, cervical cancer and chemotherapy treatment explain approximately 
14.4% of the variance in the Use and frequency of use of Moisturiser score. 
Presence of anal cancer translates to an increase in the Use and frequency of use of 
Moisturiser score by 1.321 units when all the other independent variables are 
controlled; presence of cervical cancer translates to an increase in the Use and 
frequency of use of Moisturiser score by 1.093 units when all the other independent 
variables are controlled; and taking chemotherapy treatment translates to a decline 
in the Use and frequency of use of Moisturiser score by 0.523 units when all the 
other independent variables are controlled. 
5.4.3.9.3 Use and frequency of use of PFME score 
A multiple linear regression model was developed with Use and frequency of use of 
PFME score as the dependent variable and anxiety score, depression score, IES-R 
total score, number of children, English language spoken at home, antidepressant 
medication, the hospitals where the participants are being treated, the type of 
cancers, types of treatment, occupation status, and membership to the intervention 
group as independent variables.  
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Table 82: Full Regression Model for Use and frequency of use of PFME Score 
Intercept / Predictors β t Sig. 
Intercept -0.825 -1.373 0.175 
Anxiety 0.024 0.756 0.453 
Depression -0.058 -1.452 0.152 
IES-R Total -0.004 -0.523 0.603 
Number of Children 0.029 0.410 0.683 
Language Spoken at Home - English 0.014 0.079 0.938 
Taking antidepressant or Sedative -0.273 -0.793 0.431 
Treatment at Royal North Shore Hospital (RNSH) -0.215 -0.812 0.420 
Treatment at Royal Prince Alfred Hospital (RPAH) -0.070 -0.235 0.815 
Treatment at Liverpool Hospital -0.878 -2.312 0.024 
Treatment at St George Hospital 1.155 2.001 0.050 
Treatment at Genesis Care, Mater Hospital -0.408 -0.520 0.605 
Cancer Type - Cervical -0.019 -0.041 0.967 
Cancer Type - Endometrial 0.322 0.915 0.364 
Cancer Type - Anal 0.549 1.268 0.210 
Cancer Type - Vaginal -0.755 -0.958 0.342 
Treatment - Surgery 0.410 1.273 0.208 
Treatment - External Pelvic Radiotherapy 1.160 3.252 0.002 
Treatment - Internal Radiotherapy 0.405 1.312 0.195 
Treatment - Chemotherapy -0.147 -0.452 0.653 
Occupation - Non Professional 0.060 0.257 0.798 
Occupation - Not Working -0.086 -0.220 0.827 
Intervention Group Membership -0.025 -0.134 0.894 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Rectal; and Occupation - Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 37.7% (R2 = .377, F (22, 82) = 1.651, p = 0.065) of variance in Use and 
frequency of use of PFME score. Many of the independent variables input in this 
model are not significant. Details of the final model with all statistically significant 
independent variables are given below.  
Table 83: Final Regression Model for Use and frequency of use of PFME Score  
Intercept / Predictors β t Sig. 
Intercept 0.238 2.866 0.005 
Treatment at St George Hospital 1.763 4.044 <0.001 
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The final model indicates that being treated at St George hospital accounted for a 
significant proportion of the Use and frequency of use of PFME score, R2 = .168, F 
(1, 82) = 16.355, p < 0.001 
Being treated at St George hospital explains approximately 16.8% of the variance in 
the Use and frequency of use of PFME score. Being treated at St George hospital 
translates to an increase in the Use and frequency of use of PFME score by 1.763 
units.  
5.4.3.9.4 Knowledge score 
A multiple linear regression model was developed with Knowledge score as the 
dependent variable and anxiety score, depression score, IES-R total score, number 
of children, English language spoken at home, antidepressant medication, the 
hospitals where the participants are being treated, the type of cancers, types of 
treatment, occupation status, and membership to the intervention group as 
independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 32.9% (R2 = .329, F (22, 68) = 1.023, p = 0.458) of variance in 
Knowledge score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given in Table 85.  
The final model indicates that intervention group membership, and number of 
children accounted for a significant proportion of the Knowledge score, R2 = .171, F 
(2, 68) = 6.826, p = 0.002. 
Intervention group membership and number of children explain approximately 17.1% 
of the variance in the Knowledge score. Association with the intervention group 
translates to 1.793 units increase in the Knowledge score when the number of 
children is controlled; and every extra child translates to an increase the Knowledge 
score by 0.43 units when intervention group membership is controlled. 0.842 units 
when all the other independent variables are controlled.  
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Table 84: Full Regression Model for Knowledge Score 
Intercept / Predictors β t Sig. 
Intercept 4.999 2.103 0.041 
Anxiety 0.141 0.971 0.337 
Depression -0.113 -0.644 0.523 
IES-R Total 0.014 0.439 0.663 
Number of Children 0.348 1.023 0.312 
Language Spoken at Home - English -0.189 -0.252 0.802 
Taking antidepressant or Sedative 0.700 0.579 0.566 
Treatment at Royal North Shore Hospital 
(RNSH) -1.053 -0.889 0.378 
Treatment at Royal Prince Alfred Hospital 
(RPAH) -1.568 -1.254 0.216 
Treatment at Liverpool Hospital -0.545 -0.329 0.744 
Treatment at St George Hospital 1.017 0.436 0.665 
Treatment at Genesis Care, Mater Hospital -2.125 -0.912 0.366 
Cancer Type - Cervical -0.484 -0.265 0.792 
Cancer Type - Endometrial -0.922 -0.661 0.512 
Cancer Type - Anal 0.809 0.509 0.613 
Cancer Type - Vaginal 3.292 0.898 0.374 
Treatment - Surgery 1.071 0.797 0.430 
Treatment - External Pelvic Radio 1.286 0.926 0.359 
Treatment - Internal Radio 0.723 0.636 0.528 
Treatment - Chemotherapy -0.488 -0.357 0.723 
Occupation - Non Professional -0.727 -0.710 0.481 
Occupation - Not Working 0.757 0.572 0.570 
Intervention Group Membership 2.251 2.719 0.009 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Rectal; and Occupation - Professional 
Table 85: Final Regression Model for Knowledge Score  
Intercept / Predictors β t Sig. 
Intercept 5.934 9.649 <0.001 
Intervention Group Membership 1.793 2.843 0.006 
Number of Children 0.443 2.182 0.033 
5.4.3.9.5 Feedback score 
A multiple linear regression model was developed with Feedback score as the 
dependent variable and anxiety score, depression score, IES-R total score, number 
of children, English language spoken at home, antidepressant medication, the 
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hospitals where the participants are being treated, the type of cancers, types of 
treatment, occupation status, and membership to the intervention group as 
independent variables. The individual variable of being treated using external 
radiotherapy and being treated using internal radiotherapy were collapsed into one 
category (‘External Pelvic or Internal Radiotherapy’) as this variable contributed to a 
better model (in terms of R-square) compared to the use of external or internal 
radiotherapy variables in isolation. 
Table 86: Full Regression Model for Feedback Score 
Intercept / Predictors β t Sig. 
Intercept 34.427 7.369 <0.001
Anxiety -0.114 -0.410 0.684 
Depression -0.252 -0.734 0.467 
IES-R Total -0.065 -0.991 0.327 
Number of Children -0.473 -0.724 0.472 
Language Spoken at Home - English 0.695 0.439 0.662 
Taking antidepressant or Sedative 2.437 0.898 0.374 
Treatment at Royal North Shore Hospital (RNSH) -2.257 -0.937 0.354 
Treatment at Royal Prince Alfred Hospital (RPAH) -4.877 -1.917 0.061 
Treatment at Liverpool Hospital 2.340 0.816 0.418 
Treatment at St George Hospital 4.900 1.103 0.276 
Treatment at Genesis Care, Mater Hospital -5.226 -0.683 0.498 
Cancer Type - Cervical 2.103 0.560 0.578 
Cancer Type - Anal 1.716 0.448 0.656 
Cancer Type - Rectal -3.575 -1.166 0.249 
Cancer Type - Vaginal 4.966 0.678 0.501 
Treatment - Surgery 0.912 0.331 0.742 
Treatment - External Pelvic or Internal Radiotherapy 6.958 1.856 0.070 
Treatment - Chemotherapy 1.771 0.573 0.570 
Occupation - Non Professional -1.740 -0.815 0.419 
Occupation - Not Working -0.223 -0.082 0.935 
Intervention Group Membership 4.151 2.442 0.018 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 43% (R2 = .43, F (21, 69) = 1.722, p = 0.060) of variance in Feedback 
score. Many of the independent variables input in this model are not significant. 
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Details of the final model with all statistically significant independent variables are 
given below.  
Table 87: Final Regression Model for Feedback Score 
Intercept / Predictors β t Sig. 
Intercept 33.820 9.798 <0.001
Cancer Type - Rectal -5.459 -3.093 0.003 
Treatment - External Pelvic or Internal Radiotherapy 8.150 2.338 0.022 
The final model indicates that rectal cancer, and treatment using external or internal 
pelvic radiotherapy accounted for a significant proportion of the Feedback score, R2 
= .194, F (2, 69) = 8.069, p = 0.001. 
Rectal cancer and treatment using external or internal pelvic radiotherapy explain 
approximately 19.4% of the variance in the Feedback score. Presence of rectal 
cancer translates to a decline in the Feedback score by 5.459 units when all the 
other independent variables are controlled; and treatment using external or internal 
pelvic radiotherapy translates to an increase of 8.15 units in the Feedback score 
when all the other independent variables are controlled.  
5.4.3.10 Multiple Linear Regression - Using Baseline, First Follow-
up and Second Follow-up Phase Data 
Details of the multiple linear regression models with Intimacy, Sexual interest, 
Anxiety, Depression, and IES-R as the dependent variables are shown below.  
5.4.3.10.1 Intimacy 
A multiple linear regression model was developed with intimacy score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables.  
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Table 88: Full Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 5.411 3.347 0.001 
Anxiety -0.076 -1.266 0.207 
Depression -0.064 -0.782 0.435 
IES-R Total 0.015 0.860 0.391 
Participant Age 0.000 -0.006 0.995 
Marital Status 1.095 2.855 0.005 
Highest Qualification 1.156 2.490 0.014 
Number of Children -0.027 -0.167 0.868 
Language Spoken at Home - English -0.193 -0.508 0.612 
Taking antidepressant or Sedative 0.175 0.259 0.796 
Treatment at Royal North Shore Hospital (RNSH) -0.496 -0.977 0.330 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.277 0.460 0.646 
Treatment at Liverpool Hospital 1.349 1.692 0.092 
Treatment at St George Hospital -0.696 -0.641 0.522 
Treatment at Genesis Care, Mater Hospital 0.049 0.064 0.949 
Cancer Type - Cervical 0.378 0.443 0.658 
Cancer Type - Anal -0.585 -0.670 0.503 
Cancer Type - Rectal -0.575 -0.880 0.380 
Cancer Type - Vaginal 3.091 2.282 0.023 
Cancer Type - Vulvar 0.638 0.402 0.688 
Treatment - Surgery -0.197 -0.351 0.726 
Treatment - External Pelvic Radio -0.664 -0.950 0.343 
Treatment - Internal Radio 0.377 0.685 0.494 
Treatment - Chemotherapy 1.296 1.983 0.049 
Occupation - Non Professional -0.372 -0.766 0.444 
Occupation - Not Working -0.677 -0.958 0.339 
Intervention Group Membership -0.364 -1.033 0.303 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - 
Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 19.6% (R2 = .196, F (26, 245) = 2.051, p = 0.003) of variance in intimacy 
score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
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Table 89: Final Regression Model for Intimacy 
Intercept / Predictors β t Sig. 
Intercept 4.710 13.726 <0.001 
Marital Status 1.291 3.610 <0.001 
Cancer Type - Vaginal 3.258 3.128 0.002 
Highest Qualification 1.120 2.997 0.003 
The final model indicates that marital status, vaginal cancer, and highest qualification 
attained accounted for a significant proportion of the intimacy score, R2 = .121, F (3, 
245) = 11.132, p < 0.001. 
Marital status, vaginal cancer, and highest qualification attained explain 
approximately 12.1% of the variance in the intimacy score. Being married or in a 
defacto relationship will translate to a 1.291 units increase in the intimacy score 
when all the other independent variables are controlled; presence of vaginal cancer 
will translate to 3.258 units increase in the intimacy score when all the other 
independent variables are controlled; and education level of year 12 or more will 
translate to 1.120 units increase in the intimacy score when all the other independent 
variables are controlled.  
5.4.3.10.2 Sexual Interest 
A multiple linear regression model was developed with sexual interest score as the 
dependent variable and anxiety score, depression score, IES-R total score, 
participant age, marital status, highest qualification, number of children, English 
language spoken at home, antidepressant medication, the hospitals where the 
participants are being treated, the type of cancers, types of treatment, occupation 
status, and membership to the intervention group as independent variables. The 
individual variable of being treated using external radiotherapy and being treated 
using internal radiotherapy were collapsed into one category (External Pelvic or 
Internal Radiotherapy) as this variable contributed to a better model (in terms of R-
square) compared to the use of external or internal radiotherapy variables in 
isolation. 
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Table 90: Full Regression Model for Sexual Interest 
Intercept / Predictors β t Sig. 
Intercept 2.498 5.618 <0.001
Anxiety 0.010 0.577 0.565 
Depression -0.062 -2.702 0.007 
IES-R Total 0.001 0.259 0.796 
Participant Age -0.031 -5.219 <0.001
Marital Status 0.603 5.656 <0.001
Highest Qualification 0.163 1.279 0.202 
Number of Children 0.074 1.612 0.108 
Language Spoken at Home - English 0.088 0.823 0.412 
Taking antidepressant or Sedative 0.438 2.361 0.019 
Treatment at Royal North Shore Hospital (RNSH) -0.101 -0.711 0.478 
Treatment at Royal Prince Alfred Hospital (RPAH) -0.011 -0.069 0.945 
Treatment at Liverpool Hospital -0.690 -3.553 <0.001
Treatment at St George Hospital -0.162 -0.545 0.586 
Treatment at Genesis Care, Mater Hospital -0.120 -0.563 0.574 
Cancer Type - Cervical -0.015 -0.062 0.951 
Cancer Type - Anal -0.170 -0.717 0.474 
Cancer Type - Rectal -0.450 -2.511 0.013 
Cancer Type - Vaginal -0.696 -1.839 0.067 
Cancer Type - Vulvar -0.046 -0.103 0.918 
Treatment - Surgery 0.356 2.272 0.024 
Treatment - External Pelvic or Internal Radiotherapy 0.673 3.047 0.003 
Treatment - Chemotherapy -0.096 -0.584 0.560 
Occupation - Professional 0.096 0.707 0.480 
Occupation - Not Working -0.182 -0.862 0.390 
Intervention Group Membership -0.114 -1.156 0.249 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 40.9% (R2 = .409, F (25, 245) = 6.077, p < 0.001) of variance in sexual 
interest score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
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Table 91: Final Regression Model for Sexual Interest  
Intercept / Predictors β t Sig. 
Intercept 2.046 5.590 <0.001
Participant Age -0.027 -5.558 <0.001
Marital Status 0.615 6.064 <0.001
Highest Qualification 0.230 2.036 0.043 
Treatment at Liverpool Hospital -0.554 -3.091 0.002 
Cancer Type - Endometrial 0.413 3.720 <0.001
Medication 0.508 3.003 0.003 
Depression score -0.048 -2.492 0.013 
Treatment - External Pelvic or Internal Radiotherapy 0.608 2.924 0.004 
Treatment - Surgery 0.306 2.407 0.017 
The final model indicates that participant age, marital status, highest qualification, 
being treated at Liverpool hospital, endometrial cancer, taking antidepressant 
medication, depression score, treatment using external or internal pelvic 
radiotherapy, and treatment using surgery accounted for a significant proportion of 
the sexual interest score, R2 = .373, F (9, 245) = 15.589, p < 0.001. 
Participant age, marital status, highest qualification, being treated at Liverpool 
hospital, endometrial cancer, taking antidepressant medication, depression score, 
treatment using external or internal pelvic radiotherapy, and treatment using surgery 
explain approximately 37.3% of the variance in the sexual interest score. One unit 
increase in age will translate to 0.027 units decline in the sexual interest score when 
all the other independent variables are controlled; being married or in a defacto 
relationship will translate to 0.615 units increase in the sexual interest score when all 
the other independent variables are controlled; education level of year 12 or more 
will translate to 0.23 units increase in the intimacy score when all the other 
independent variables are controlled; being treated at Liverpool hospital will translate 
to 0.554 units decline in sexual interest score when all the other independent 
variables are controlled; presence of endometrial cancer will translate to 0.413 units 
of increase in the sexual interest score when all the other independent variables are 
controlled; taking antidepressant medication will translate to 0.508 units increase in 
sexual interest score when all the other independent variables are controlled; one 
unit increase in the depression score will translate to 0.048 units decline in the 
sexual interest score when all other independent variables are controlled; treatment 
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using external or internal radiotherapy will translate to 0.608 units increase in the 
sexual interest score when all the other independent variables are controlled; and 
treatment using surgery will translate to 0.306 units increase in the sexual interest 
score when all the other independent variables are controlled.  
5.4.3.11.3 Anxiety 
A multiple linear regression model was developed with anxiety score as the 
dependent variable and participant age, marital status, highest qualification, number 
of children, English language spoken at home, antidepressant medication, the 
hospitals where the participants are being treated, the type of cancers, types of 
treatment, occupation status, and membership to the intervention group as 
independent variables.  
The results of the analysis indicate that the independent variables input in the model 
account for 18.7% (R2 = .187, F (23, 245) = 2.224, p = 0.002) of variance in the 
anxiety score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given in Table 93.  
The final model indicates that participant age, marital status and anal cancer 
accounted for a significant proportion of the anxiety score, R2 = .105, F (3, 245) = 
9.432, p < 0.001. 
Participant age, marital status, and endometrial cancer explain approximately 10.5% 
of the variance in the anxiety score. One unit increase in age will translate to 0.073 
units decline in the anxiety score when all the other independent variables are 
controlled; being married or in a defacto relationship will translate to 0.016 units 
decline in the anxiety interest score when all the other independent variables are 
controlled; and presence of anal cancer will translate to 2.09 units increase in the 
anxiety score when all the other independent variables are controlled. 
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Table 92: Full Regression Model for Anxiety 
Intercept / Predictors β t Sig. 
Intercept 7.409 4.070 <0.001
Participant Age -0.038 -1.559 0.120 
Marital Status -0.970 -2.058 0.041 
Highest Qualification -0.156 -0.271 0.786 
Number of Children -0.110 -0.564 0.573 
Language Spoken at Home - English -0.159 -0.338 0.736 
Taking antidepressant or Sedative 1.019 1.223 0.223 
Treatment at Royal North Shore Hospital (RNSH) 0.677 1.102 0.272 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.982 1.325 0.187 
Treatment at Liverpool Hospital 1.492 1.515 0.131 
Treatment at St George Hospital -1.841 -1.368 0.173 
Treatment at Genesis Care, Mater Hospital 0.781 0.834 0.405 
Cancer Type - Cervical 1.118 1.068 0.286 
Cancer Type - Anal 3.416 3.221 0.001 
Cancer Type - Rectal 1.499 1.858 0.064 
Cancer Type - Vaginal 4.339 2.616 0.010 
Cancer Type - Vulvar -0.843 -0.427 0.670 
Treatment - Surgery 0.040 0.058 0.954 
Treatment - External Pelvic Radiotherapy 0.516 0.603 0.547 
Treatment - Internal Pelvic Radiotherapy 0.405 0.592 0.554 
Treatment - Chemotherapy -1.473 -1.847 0.066 
Occupation - Professional -0.859 -1.468 0.143 
Occupation - Not Working -1.994 -2.116 0.035 
Intervention Group Membership -0.068 -0.156 0.876 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
Table 93: Final Regression Model for Anxiety  
Intercept / Predictors β t Sig. 
Intercept 9.343 7.672 <0.001
Participant Age -0.073 -3.819 <0.001
Marital Status -1.016 -2.263 0.024 
Cancer Type - Anal 2.090 2.696 0.008 
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5.4.3.12.4 Depression 
A multiple linear regression model was developed with depression score as the 
dependent variable and participant age, marital status, highest qualification, number 
of children, English language spoken at home, antidepressant medication, the 
hospitals where the participants are being treated, the type of cancers, types of 
treatment, occupation status, and membership to the intervention group as 
independent variables.  
Table 94: Full Regression Model for Depression 
Intercept / Predictors β t Sig. 
Intercept 3.723 2.737 0.007 
Participant Age -0.044 -2.418 0.016 
Marital Status -0.625 -1.775 0.077 
Highest Qualification -0.059 -0.137 0.891 
Number of Children 0.482 3.304 0.001 
Language Spoken at Home - English -0.511 -1.452 0.148 
Taking antidepressant or Sedative 1.181 1.897 0.059 
Treatment at Royal North Shore Hospital (RNSH) -0.902 -1.966 0.051 
Treatment at Royal Prince Alfred Hospital (RPAH) 0.910 1.644 0.102 
Treatment at Liverpool Hospital 0.784 1.066 0.288 
Treatment at St George Hospital -0.939 -0.935 0.351 
Treatment at Genesis Care, Mater Hospital -0.183 -0.261 0.794 
Cancer Type - Cervical 1.224 1.566 0.119 
Cancer Type - Anal 0.658 0.830 0.407 
Cancer Type - Rectal 0.207 0.343 0.732 
Cancer Type - Vaginal 0.070 0.057 0.955 
Cancer Type - Vulvar 0.690 0.468 0.640 
Treatment - Surgery 0.385 0.745 0.457 
Treatment - External Pelvic Radiotherapy 0.201 0.314 0.754 
Treatment - Internal Pelvic Radiotherapy 0.551 1.079 0.282 
Treatment - Chemotherapy 0.928 1.558 0.121 
Occupation - Professional 0.430 0.984 0.326 
Occupation - Not Working -0.477 -0.677 0.499 
Intervention Group Membership -0.129 -0.392 0.695 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
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The results of the analysis indicate that the independent variables input in the model 
account for 18.5% (R2 = .185, F (23, 245) = 2.192, p = 0.002) of variance in the 
depression score. Many of the independent variables input in this model are not 
significant. Details of the final model with all statistically significant independent 
variables are given below.  
Table 95: Final Regression Model for Depression   
Intercept / Predictors β t Sig. 
Intercept 3.383 13.535 <0.001 
Medication 1.466 2.646 0.009 
Cancer Type - Endometrial -0.956 -3.067 0.002 
The final model indicates that taking antidepressant medication and endometrial 
cancer accounted for a significant proportion of the depression score, R2 = .066, F (2, 
245) = 8.529, p < 0.001 
Taking antidepressant medication and endometrial cancer explains approximately 
6.6% of the variance in the depression score. Taking antidepressant medication 
translates to 1.466 units increase in the depression score when all the other 
independent variables are controlled; and presence of endometrial cancer will 
translate to 0.956 units decline in the depression score when all the other 
independent variables are controlled. 
5.4.3.13.5 IES-R 
A multiple linear regression model was developed with IES-R score as the 
dependent variable and participant age, marital status, highest qualification, number 
of children, English language spoken at home, antidepressant medication, the 
hospitals where the participants are being treated, the type of cancers, types of 
treatment, occupation status, and membership to the intervention group as 
independent variables.  
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Table 96: Full Regression Model for IES-R 
Intercept / Predictors β t Sig. 
Intercept 33.374 5.200 <0.001
Participant Age -0.410 -4.732 <0.001
Marital Status -0.555 -0.334 0.739 
Highest Qualification -2.956 -1.457 0.146 
Number of Children 1.665 2.417 0.016 
Language Spoken at Home - English -0.284 -0.171 0.865 
Taking antidepressant or Sedative -0.579 -0.197 0.844 
Treatment at Royal North Shore Hospital (RNSH) -5.206 -2.404 0.017 
Treatment at Royal Prince Alfred Hospital (RPAH) -1.289 -0.493 0.622 
Treatment at Liverpool Hospital -0.443 -0.128 0.899 
Treatment at St George Hospital -4.909 -1.035 0.302 
Treatment at Genesis Care, Mater Hospital -3.885 -1.177 0.241 
Cancer Type - Cervical -3.391 -0.919 0.359 
Cancer Type - Anal 6.011 1.607 0.109 
Cancer Type - Rectal 0.482 0.170 0.866 
Cancer Type - Vaginal 4.494 0.768 0.443 
Cancer Type - Vulvar -1.508 -0.217 0.829 
Treatment - Surgery -3.703 -1.517 0.131 
Treatment - External Pelvic Radiotherapy 7.671 2.540 0.012 
Treatment - Internal Pelvic Radiotherapy 1.710 0.710 0.479 
Treatment - Chemotherapy 1.504 0.535 0.593 
Occupation - Professional 5.480 2.656 0.008 
Occupation - Not Working -3.170 -0.954 0.341 
Intervention Group Membership -0.558 -0.361 0.719 
Note: Three input variable excluded due to multicollinearity: Treatment at Royal Hospital for Women 
(RHW) / Prince of Wales Hospital (POWH); Cancer Type - Endometrial; and Occupation - Non-
Professional 
The results of the analysis indicate that the independent variables input in the model 
account for 29.5% (R2 = .295, F (23, 245) = 4.042, p < 0.001) of variance in the IES-
R score. Many of the independent variables input in this model are not significant. 
Details of the final model with all statistically significant independent variables are 
given below.  
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Table 97: Final Regression Model for IES-R  
Intercept / Predictors β t Sig. 
Intercept 29.669 5.972 <0.001
Participant Age -0.420 -5.427 <0.001
Number of Children 1.642 2.705 0.007 
Occupation - Professional 4.748 2.861 0.005 
Treatment at Royal North Shore Hospital (RNSH) -4.446 -2.570 0.011 
Treatment - External Pelvic Radiotherapy 6.967 4.025 <0.001
Cancer Type - Anal 8.085 2.921 0.004 
The final model indicates that participant age, number of children, being employed 
as a professional, being treated at Royal North Shore hospital, treatment using 
external pelvic radiotherapy, and anal cancer accounted for a significant proportion 
of the IES-R score, R2 = .255, F (6, 245) = 13.65, p < 0.001. 
Participant age, number of children, being employed as a professional, being treated 
at Royal North Shore hospital, treatment using external pelvic radiotherapy, and anal 
cancer explain approximately 25.5% of the variance in the IES-R score. One unit 
increase in age will translate to 0.420 units decline in the IES-R score when all the 
other independent variables are controlled; every extra child will translate to 1.642 
units increase in the IES-R score when all  the other independent variables are 
controlled; being professional employed will translate to 4.748 units increase in the 
IES-R score the other independent variables are controlled; being treated at the 
Royal North Shore hospital will translate to 4.446 units decline in the IES-R score 
when all the other independent variables are controlled; treatment using external 
pelvic radiotherapy will translate to 6.967 units increase in the IES-R score when all 
the other independent variables are controlled; and presence of anal cancer will 
translate to 8.085 units of increase in the IES-R score when all the other 
independent variables are controlled.  
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CHAPTER 6 - Overall discussion of 
the information booklet randomised 
controlled trial findings 
6.1 Introduction 
This study evaluated an information booklet aimed to improve women’s knowledge 
and use of strategies to improve their adjustment to the psychosexual impacts of 
pelvic radiotherapy (PRT) for gynaecological cancer or anorectal cancer. The booklet 
provided basic information on PRT, in addition to information about female 
reproductive anatomy, sexual and physical side effects and psychosexual sequelae 
after PRT. It provided information about dilator use and where to access support and 
care, as well as debunking myths to alleviate concerns post PRT. Moreover, the 
booklet had prompt questions to normalise difficulties, give women permission to 
raise any concerns or difficulties they had and facilitate communication. It was hoped 
that, particularly for women who prefer anonymity and confidentiality with regards to 
discussing their sexual concerns, this would be a non-threatening and supportive 
resource which encouraged them to address sexual problems while, through 
improved dilator use, allowing for optimal cancer surveillance.  
Overall, the RCT findings showed that women in the study who received the study 
developed booklet had higher levels of knowledge, including information about PRT 
physical and psychosexual side-effects and rehabilitation options, than those in the 
control group who received a general radiotherapy booklet. Booklet knowledge was 
associated with greater frequency and use of vaginal dilators, and indeed the 
intervention group used vaginal dilators more frequently than the control group. 
Therefore, it appears that the psychoeducational booklet is successful in educating 
women about post PRT physical and psychosexual side effects and rehabilitation 
options following pelvic radiation therapy, and it promotes the use of a dilator as a 
rehabilitation technique.  
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Low levels of PRT-related psychological distress/PTSD symptomatology, and 
anxiety and depression were found in the sample at all-time points (baseline, 3 and 6 
month follow-up), and the study booklet was not found to be associated with these 
outcomes. See Table 98 below for the current study findings and comparisons with 
other studies, both for prevalence and intervention impact. 
Though low levels of sexual activity, sexual dysfunction and sexual dissatisfaction 
were found in the sample at all-time points (baseline, 3 and 6 month follow-up) the 
study booklet was not found to improve activity, reduce dysfunction or improve 
satisfaction. A surprisingly high proportion of women did not have a current partner 
(over 40%) which may partially explain these results. Post–treatment decline in 
sexual activity, function and satisfaction was seen from baseline to 3 and 6 month 
follow-up. There was significant levels of sexuality related missing/non-response 
data which may have led to underestimated sexual effects results (Bell et al., 2013).  
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Table 98: Comparisons of current findings with those of other studies for posttraumatic stress/psychological distress, anxiety, 
depression, and sexual activity, function and satisfaction 
Current Study Other studies/Norms 
Posttraumatic stress / psychological distress  
Gynaecological cancer 
Prevalence at baseline: 
 clinical posttraumatic 
stress/psychological 
distress: 17.1% 
(n=13) 
 Intervention effect: 
None 
 clinical 
posttraumatic 
stress/psychological 
distress: 15.6% - 
29% 
Prevalence: 
1. 15.6% in clinical range for probable diagnosis of PTSD (Urbaniec 
et al., 2011). 
 
2. About 15 (19%) indicative of PTSD, about 29% survived in the 
advanced stage of the disease (Hodgkinson et al., 2007) 
 
Intervention effect:  
3. Haggmark et al., (2001) similarly found no differences between 
groups on any of the outcomes measured including satisfaction with 
the information, anxiety, subjective distress, subjective distress and 
QOL in an Australian study assessing provision of information about 
radiation. 
Vaginal and vulvar cancer 
 
Prevalence at baseline: 
 clinical posttraumatic 
stress/psychological 
distress: 66.7% (n=2) 
 Intervention effect: 
None 
 No data found 
Prevalence: 
1. No data found 
 
Intervention effect:  
2. No study found 
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Anorectal cancer 
Prevalence at baseline: 
 clinical posttraumatic 
stress/psychological 
distress: 28.6% (n=6) 
 Intervention effect: 
None 
 No data found 
 
Prevalence: 
1. No data found 
 
 
Intervention effect:  
2. Haggmark et al. (2001) similarly found no differences between 
groups on any of the outcomes measured like satisfaction with 
information, subjective distress, anxiety, depression and QOL in an 
Australian study assessing provision of information about radiation. 
Patients received any one of: standard information plus group, 
repeated individual information, standard information plus brochure 
or standard information only 
Anxiety 
Prevalence % (n); 
Intervention impact 
Prevalence: % Range Detailed findings re prevalence and impact of intervention 
Gynaecological cancer 
Prevalence at Baseline: 
 clinical anxiety: 9.8% 
(n=8)  
 borderline anxiety: 
17.1% (n=14) 
 Intervention effect: 
None 
 clinical anxiety:  
14% - 28.9%  
 borderline anxiety: 
14.6% -14.6% 
 
Prevalence: 
1.  28.9% of women reported clinical anxiety as measured by SAI 
(Urbaniec et al., 2011). 
 
2. Almost 1/3 (29%) had clinical level anxiety; unmet need was fear 
of recurrence was most frequently reported (24%). Hodgkinson et al., 
2007). 
 
Intervention effect: 
3. The relaxation and counselling intervention and baseline scores 
were significant predictors of outcome; this intervention was 
associated with reduction in anxiety scores (P=0.001) (Petersen & 
Quinlivan, 2002). 
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Vaginal and vulvar cancer 
Prevalence at Baseline:  
 clinical anxiety: 
33.3% (n=1)  
 borderline anxiety: 
33.3% (n=1) 
 Intervention effect: 
None 
 clinical anxiety:  
20.5% 
Prevalence: 
1. Cross sectional sample – With sufficient data,15 out of 73 patients 
with scores above 11 were identified as cases, for longitudinal samples 
– preoperative HADS-A was  9 in 45% of cases and post-operative 
HADS-A was 5 in 25% of cases (Janda et al., 2005). 
 
 
 
 
Intervention effect: 
2. No intervention studies identified 
Anorectal cancer 
Prevalence at Baseline:  
 clinical anxiety: 13% 
(n=3)  
 borderline anxiety: 
26.1% (n=6) 
 Intervention effect: 
None 
 clinical anxiety:  
18.4% - 18.4%  
Prevalence: 
1. HADS-A score of 8 or above was observed in 18.4% of patients 
(n=14) at the time of 1. Of these, 57.14% (n=8) consisting of 10.53% of 
the total sample recorded HADS-D score of 8 or higher at time 1. 
 
Intervention effect: 
2. In patients undergoing surgery for rectal cancer, statistically 
significant difference in anxiety between the groups at Time 3 was 
observed for the group provided with an RCT containing tailored 
information pack (O’Connor et al., 2014). 
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Depressive symptomatology  
Gynaecological cancer 
Prevalence at Baseline:  
 clinical depression: 
1.2% (n=1)  
 borderline 
depression: 9.8% 
(n=8) 
 Intervention effect: 
None 
 
 clinical depression:  
2.2% - 5.5%  
 borderline 
depression: 4.5% -
17.8% 
 
Prevalence: 
1. 11.1% mild depression, 6.7% moderate depression, 2.2% severe 
depression (Urbaniec et al., 2011). 
 
2. In Australia, a ‘definite case’ of depression on the HADS was 
observed in 11 survivors (5.5%) which matched the community 
prevalence rates (5.5%), 9 (4.5%) ‘possible case’ of depression 
(Hodgkinson et al, 2007). 
 
Intervention effect:  
3. Mcpherson et al. (2001) found interventions (including written 
material, telephone help-lines, teaching, educational programmes 
and audiovisual aids) had positive effects on patient outcomes e.g. 
knowledge and recall, managing symptoms, satisfaction, health 
service utilisation and affective states over and above standard care. 
However, they found that in the majority of studies the interventions 
had little effect on psychological indicators 
Vaginal and vulvar cancer 
 
Prevalence at Baseline:  
 clinical depression: 
33.3% (n=1) 
 Intervention effect: 
None 
 
 clinical depression:  
3.9% - 15% 
Prevalence: 
1. Cross sectional sample – 3 out of 71 (3.9%) cases. Longitudinal 
sample – preoperative HADS-D = 3 (15% of cases) and 
postoperative HADS-D =1 (5% of cases) (Janda et al., 2005). 
 
 
Intervention effect:  
2. No study found 
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Anorectal cancer 
Prevalence at Baseline:  
 clinical depression: 
4.3% (n=1)  
 borderline 
depression: 13% 
(n=3) 
 Intervention effect: 
None 
 clinical depression:  
18.4% - 18.4% 
Prevalence: 
1. HADS-A scores in 18.4% (n=14) patients were 8 or higher at time 
1. Out of these, 57.14% (n=8) or 10.53% of the total sample, also 
showed an HADS-D score of 8 or above at time 1 (O’Connor et al., 
2014). 
 
Intervention effect:  
2. No differences were found in depression between the intervention 
and control group in a RCT when a tailored information pack was 
used for patients undergoing rectal cancer surgery (O’Connor et al., 
2014). 
HADS     
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Sexual function and satisfaction  
Gynaecological cancer 
Prevalence at baseline  
 Sexual activity 
engagement: 19.5% 
(n=16)  
 Majority of this 
cohort indicated 
satisfaction with their 
sex life, little or no 
vaginal dryness, little 
or no vaginal 
dryness pain or 
bleeding during 
sexual intercourse, 
often or always 
reaching orgasm, 
and feeling quite a 
bit or very much 
relaxation after 
intercourse. 
 Intervention effect: 
None 
 Sexual activity 
engagement:  
15% - 40.5% 
 
Prevalence: 
1. Lasting unfavourable vaginal changes and sexual dysfunction 2 
years post RT, slight changes over time. About 85% reported low or 
no sexual interest, 35% reported lack of lubrication ranging from  
moderate to severe, 30% were dissatisfied with sexual life and 45% 
never or only occasionally could complete sexual intercourse. 
Although 63% of those sexually active before having cancer 
remained sexually active after treatment, the frequency was reduced 
significantly (Jensen et al., 2003). 
 
2. Sexual morbidity co-varied with worsened depressive symptoms, 
body change stress, and psychological QOL over and above 
negative effects of older age, poorer performance status, and greater 
fatigue (Levin et al., 2010). 
 
3. Compared with cervical cancer survivors (CCSs) treated by 
surgery alone, more significant specific problems were noticed in 
QOL of CCSs having radiotherapy like more significantly such as 
sexual dysfunction (p=0.01).  Adjuvant radiotherapy significantly 
affected QOL (Le Borgne et al., 2013). 
 
4. Brand’s review of retrospective chart for 179 patients affected by 
vaginal stenosis done after pelvic and vaginal radiation treatment for 
cervical cancer showed in 38% of patients. The risk increased for 
over 50 years.  About 85% of them expressed low or no sexual 
interest, about 35% reported lack of lubrication ranging from 
moderate to severe, 55% had mild to severe dyspareunia, 50% had 
problems of decreased vaginal dimension and 45% reported sexual 
intercourses which were never or only occasionally complete 
(Krychman & Millheiser, 2013). 
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5. 51.5% and 59.5% were not sexually active due to lack of a partner 
(37%), lack of interest (21% in control group, 40%, p<0.05), own 
physical problems (31.9%, p<0.05) and physical problems suffered 
by partner (21%, p<0.05 GC group) (Harter et al., 2013). 
 
6. Area of least concern sexual functioning, relationships with others 
and employment (Virtue et al., 2014). 
 
Intervention effect:  
7. Randomised controlled trial of an internet-based intervention for 
cancer associated female sexual dysfunction found that the 
counselled group had significant improvement on sexuality 
measures. 
Vaginal and vulvar 
cancer 
Vaginal and vulvar cancer 
- Prevalence (Range) Vaginal and vulvar cancer – Prevalence 
Prevalence at baseline: 
 Sexual activity 
engagement: 0% 
 Intervention effect: 
None 
 Sexual activity 
engagement:           
16.9% - 16.9% 
Prevalence: 
1. Interference of physical health condition of significantly higher 
proportion of survivors (16.9%) affected their having sex all or most 
of the time. Only in 4.1% of the population-based comparison group, 
such problem was noted. Among survivors, sexual problems were 
significantly higher (Lindau et al., 2007). 
 
2. Majority of women had no or only short-term disruption to 
sexuality and body image in the case of early-stage post- vulvar 
cancer conservative treatment. Sexuality adversely affected by 
surgery, decreased frequency of sexual intercourse, decreased 
desire and arousal, increased prevalence of sexual dysfunction 
contrast to healthy cohort. For some women, sexual satisfaction was 
closely related with intimacy and relationship status than with 
physical arousal (Barlow et al., 2014). 
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Intervention effect:  
3. No study found 
Anorectal cancer 
 
Prevalence at baseline 
 Sexual activity 
engagement: 23.8% 
(n=5) 
 Intervention effect: 
None 
 Sexual activity 
engagement: 0% - 
60% 
 
1. Rise in general sexual dysfunction (SD), dyspareunia and vaginal 
dryness were 61.5, 59.1 and 56.6 per cent respectively. In 62%, new 
general SD or worsening of pre-existent SD reported after rectal 
cancer treatment.  Preoperative radiotherapy only significant risk 
factor (Lange et al., 2009). 
 
2. Radiotherapy or chemo-radiation was acceptable with overall QOL 
scores but had poor sexual functioning scores recording 55% with 
difficulty in their sex lives (Das et al., 2010). 
 
3.  Risk of sexual disorders after rectal resection considerable 
variation 40% to 100%, correlated with type of surgery and patient 
age. Dyspareunia common adverse occurrence (Rauch et al., 2004). 
 
Intervention effect:  
4. A manualised sexual health intervention for sexually active female 
rectal and anal cancer survivors assessing psychological correlate 
with sexual dysfunction.  Sexual dysfunction was significantly 
correlated with psychological wellbeing which included 
sexual/relationship satisfaction (Philip et al., 2013). 
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6.2 Primary and Secondary Outcomes  
Each primary and secondary outcome is discussed separately below.  
6.2.1 Primary Outcome: Adherence to rehabilitation strategies  
The primary outcome of interest in this prospective longitudinal RCT of the study 
developed information booklet related to adherence to recommended rehabilitation 
strategies after PRT. It was hypothesised that patients who received the study 
booklet would report greater and more consistent use of vaginal dilators, vaginal 
moisturiser/lubricant and Pelvic Floor Muscle exercises (PFME). The only hypothesis 
supported was greater and more frequent adherence to vaginal dilator use, which 
will be discussed below. 
6.2.1.1 Dilator use 
Dilator use is particularly important to reduce vaginal stenosis in women after PRT. 
In this study at 3 month follow up 48% (n=12) of women felt there vagina was smaller 
since they were diagnosed with cancer, at 6 months 42% (n=8) reported this. Other 
studies have found even higher rates of stenosis in similar populations (1.2% -88%) 
(Miles et al., 2010; Lancaster, 2004; Jeffries et al., 2006). Dilator use may be 
important for all women undergoing PRT (which is discussed with each cancer in the 
study see Chapter 2). Furthermore the link between degree and severity of vaginal 
stenosis and sexual dysfunction is well documented (Flay & Matthews, 1995; 
Bergmark et al., 1999); furthermore stenosis hampers pelvic exams to detect 
recurrence (Decruze et al., 1999; Flay & Matthews, 1995). 
Women in this study who received the booklet reported greater use of dilators than 
the control group at both follow-ups. They also reported less emotional difficulties 
(e.g. feeling anxious) and physical difficulties (e.g. pain) in using dilators at 6 months 
follow-up (but not at 3 months). The positive finding that the booklet impacted on 
dilator use is consistent with other RCTs which found that psychoeducation 
interventions can impact the use of vaginal dilators in gynaecological patients. For 
instance, Jeffries et al. (2006), undertook a prospective, longitudinal RCT of a group 
psychoeducational intervention to improve compliance with vaginal dilation after PRT 
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in cervical and endometrial cancer patients (n=42). In that study treatment was found 
to significantly improve compliance with dilator use, however between group 
differences had vanished at 6 months, and at 12 months only five women were using 
a dilator once a week (Jeffries et al., 2006). In contrast, compliance with dilators in 
the current study remained high at 6 months follow-up, at around 45%, with group 
differences persisting. Jeffries et al. (2006) ascribed the success of their intervention 
to the inclusion of motivational and behavior change elements consistent with the 
information-motivation-behavioural skills model (Fischer & Fischer, 1998, cited in 
Brotto et al., 2010). The current study booklet similarly addressed motivation and 
self-efficacy, which may have contributed to its success, particularly in the longer 
term.  
Robinson et al. (1999) also used psychoeducation with the view to increasing vaginal 
dilation in their RCT. Women with gynaecological cancer (n=36) were randomised to 
two hour and a half sessions or written information and brief counselling in the 
control arm. It was found that the treatment significantly improved dilator compliance 
in younger women only.  
The current study is the only trial of a written resource that does not require staff 
input. Furthermore, as opposed to finite interventions, women could have this 
resource to refer to as and when it is needed in an ongoing manner. Hence, it 
appears to be a feasible and cost-effective option for routine use in the radiation 
oncology setting to encourage dilator use. However, women might need the booklet 
to be supplementary to individual and/or group psychotherapeutic intervention and/or 
specialist nurse/doctor intervention to target different issues.   
The current study rates of adherence to dilator use at 3 and 6 month follow-up 
respectively in the sample were (45%) (n=37) and 46% (n=38).  This appears to be 
significantly higher than adherence rates reported in many other descriptive and 
interventional studies and it is notable that adherence was maintained at 6 months. 
In contrast, Brand et al. (2012) followed 60 gynaecological cancer patients who had 
all undergone radiation treatment at an Australian hospital for 12-months and found 
that 35% were adhering at least 2 to 3 times per week. Even lower rates of 6-12% 
have been reported in other studies (Schover et al., 1989; Jeffries et al., 2006).  Law 
et al. (2013) found in a sample of rectal, cervical and endometrial cancer patients 
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post PRT, that adherence declined over 12 months. It was highest in the first quarter 
(58%), but down to 25% by the fourth quarter. Thus timing of assessment may 
explain some of these disparities.  
Punt (2011) found higher compliance rates of 89.2% (66/74) at 6 months, however 
their study included only a one-off assessment. According to the author this high rate 
may be as a function of intervention by clinicians at the centre where the study was 
conducted (Punt, 2011). Furthermore, there was also a low response rate in Punt’s 
study (45.7%), similarly to the current study. If non-responders were non-adherers, 
the rates of compliance would have been similar to those reported in other studies 
such as Jeffries et al. (2006) and Robinson et al. (1999).  
As our intervention did not increase adherence in all women, further consideration of 
barriers to vaginal dilator use appears to be indicated. Some women in the current 
study were not provided with dilators. Juraskova (2003) found a third of early stage 
endometrial and cervical cancer patients in their study noted some extent of vaginal 
stenosis, however many of these women were still not provided with or using 
dilators. Thus lack of clinician recommendation and support may be a significant 
barrier.  In the current study many women either did not have a partner and/or were 
sexually inactive and this may have been another disincentive to maintaining vaginal 
patency. Baseline interest in sex may also impact motivation to use dilators. 
Friedman et al. (2011) found that women with endometrial cancer who were more 
interested in their sex life were more likely to adhere to using dilators in their study. 
We found that in general, women who had rectal and anal cancer used a vaginal 
dilator less often than those with other diagnoses. This finding is consistent with 
Goodman et al. (2013), in their prospective vaginal dilator post PRT study for 
gastrointestinal (GI) cancer (including rectal and anal cancer), where they evaluated 
the incidence of vaginal stenosis and adherence and efficacy of using dilators. They 
found that rectal cancer patients and sexually inactive women were less prone (p < 
.05) to adhere to vaginal dilator use. Similarly, Law et al. (2013) found that rectal 
cancer patients were less prone to adhere to dilator use than anal and endometrial 
patients. 
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Rectal and anal patients can be dealing with significant uncertainty regarding 
surgical outcomes, such as the possibility of having a temporary or permanent 
stoma; both anal and rectal cancer patients can also be offered adjuvant 
chemotherapy and radiation therapy (Carter et al., 2013; Philip et al., 2013). Peeters 
et al. (2005) found that neoadjuvant radiotherapy in rectal cancer patients can cause 
long-term functional problems, such as higher incontinence day and night including 
anal blood and mucous loss, and chemoradiation has been found to worsen these 
effects (Braendengen et al., 2011; Horisberger et al., 2014). Furthermore, aggressive 
and other multimodality treatment in rectal cancer patients with ongoing high levels 
of fatigue, perineal pain, radiating pain in the legs, walking difficulties, and sexual 
dysfunction and urologic and bowel voiding dysfunction (Mannaerts et al., 2001; 
2002) can reduce motivation to take up vaginal rehabilitation options such as 
dilators.  
Anxiety and depression related to the cancer, its treatment and the side effects 
(including physical and sexual morbidity) can also understandably reduce motivation 
towards rehabilitation (Rehse & Pukrop, 2003; Philip et al., 2013). Reports that 
psychological morbidity impacts adherence to the frequency and use of dilators are 
common in the literature (Bonner et al., 2012). Similarly, we found that women who 
were on anti-depressant medication were less likely to adhere to dilator use. Anti-
depressant medication is associated with psychological morbidity, and this could 
explain the reduced likelihood of adherence to dilator use amongst this group of 
women. Thus a wide range of factors impact adherence to dilator use, which could 
be usefully targeted in interventions designed to influence this behaviour.   
6.2.1.2 Adherence to vaginal lubricant and moisturiser use 
Improving vaginal dryness and discomfort is important to enhance sexual interest, 
perceptions of arousal and ability to achieve orgasm. Vaginal lubricants administered 
regularly and in the correct manner have been found to inhibit post sexual 
intercourse irritation and mucosal tears which are also implicated in vaginal urinary 
tract infections (Carter et al., 2011). There is growing clinician and patient recognition 
of the benefits of these products particularly for menopausal women (Carter et al., 
2010, 2013). A significant number of women with gynaecological and anorectal 
cancer experience PRT-, chemotherapy- and/or surgery-induced premature 
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menopause. Furthermore, women commonly experience lack of lubrication post PRT 
which can be as a result of treatment induced menopausal symptoms (Jensen et al., 
2004b; Schover, 2005; Sekse et al., 2010; 2013; Stilos et al., 2008; Bodurka & Sun, 
2006). Thus need for moisturiser / lubricant would have been expected to be high in 
this population.  
In the current study the hypothesis that women given the intervention information 
booklet would use vaginal moisturiser/lubricant more frequently than the control 
group was not supported. At 3 month follow-up most women had not used a 
moisturiser/lubricant since their treatment in both groups respectively (n=20; 53%) 
(n=24; 55%).  
Why did the booklet not influence this behaviour, despite influencing dilator use? 
There was a significant amount of missing data in this area of the questionnaire 
(women may have been reluctant to answer sensitive questions) thus making it less 
likely to find an effect. Furthermore, the booklet focused more on dilator use, with 
considerably more material on this than on moisturiser/lubricant use, and this may 
have influenced responses.  
No patients in the current study either strongly agreed or disagreed that they had 
been given sufficient explanation on using these rehabilitation aids as part of their 
post treatment recovery at 3 and 6 months follow up. Most women in both groups 
neither agreed nor disagreed that using a vaginal moisturiser/lubricant was helpful, 
but most women either agreed, or strongly agreed that they felt confident using a 
moisturiser/lubricant. Thus it is not clear that they lacked sufficient instruction.  
The study was able to cast some light on predictors of vaginal lubricant/moisturiser 
use. The final multiple regression model suggested that women with anal and 
cervical cancer used more vaginal lubricant/moisturiser, while those being treated 
with chemotherapy used it less. Women may have been still contending with 
chemotherapy side effects at 6 months follow-up, explaining the latter relationship.  
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6.2.1.3 Adherence to pelvic floor muscle exercises (PFME) 
PRT is associated with numerous long-term side effects on pelvic organs (such as 
the sexual organs, bladder and bowel) and therefore pelvic floor muscle exercises 
(PFME) are recommended to increase control.  
In the current study the hypothesis that having the intervention information booklet 
would increase adherence to PFME at 3 and 6 month follow-up after PRT was not 
supported.  There was an increase from 40% overall of women using PFME since 
their treatment at 3 month to 52% at 6 month follow-up, but with no difference 
between groups and with half of women still not using this strategy.  
Most women in both groups respectively disagreed that they had been given 
sufficient information on PFME as part of their post-treatment recovery and similarly 
disagreed to feeling confident or finding PFME helpful at 6 months follow up. 
Similarly the majority of women disagreed that their partners were supportive about 
their use of PFME at 6 months. Thus partners were not supporting women to take up 
this strategy. The booklet appeared not to have provided sufficient information about 
PFME, or about skills in utilising PFME, and this could be an avenue for future 
revision. 
Hazewinkel et al. (2010a) qualitatively explored gynaecological cancer patients’ 
reasons for not seeking medical assistance for severe pelvic floor difficulties in 
(n=15). The following reasons were cited: symptoms were bearable in light of their 
cancer diagnosis, and not having knowledge about possible intervention. Some 
women (n=7) were prepared to present for treatment if given the opportunity and 
eleven women noted that intervention should be improved especially with timely 
referral to pelvic floor specialists and oncology nurses.   
6.2.2 Secondary Outcomes 
It was hypothesised that at each follow-up, women who received the intervention 
would report greater knowledge, including of PRT physical and psychosexual side-
effects and rehabilitation options, more positive feedback about the intervention 
booklet, improved psychological status, and improved sexual 
activity/function/satisfaction than those in the control group. The only hypothesis 
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supported here was greater knowledge at 3 and 6 months follow-up. The secondary 
outcome findings will be discussed below. 
6.2.2.1 Knowledge  
At 3 and 6 months follow-up more women who received the intervention 
demonstrated good knowledge of when, how, and for how long to use dilators; the 
prevalence and significance of vaginal stenosis; that using dilators may allow for less 
painful intercourse; the importance of using dilators for pelvic examinations; and 
lubricant being necessary for dilator use. At 6 months follow-up more women who 
received the intervention also correctly answered that they are not radioactive and 
cannot spread the radiation to their partner when having intercourse. Hence the 
study booklet appears to have facilitated the debunking of some myths following 
PRT. This is important, because higher levels of knowledge were associated with 
greater and more frequent use of vaginal dilators as described in Chapter 5. 
A relatively large proportion of patients in both groups had incorrect knowledge about 
the sterilisation procedure of dilators and of the timing of vaginal changes after 
radiation, which did not improve over time. While this information was in the booklet 
it may not have been clear enough, suggesting an area for potential revision. 
O’Connor et al. (2014) note that as a coping strategy some women can ignore or 
avoid information, though most want to know as much as they can about their 
treatment. It is possible that this was not an area of interest for the women in the 
study, although we cannot confirm that from the data. 
In the final multiple regression model higher levels of knowledge were found in 
women who had more children. Speculatively, this may be due to women with more 
children having a greater sense of responsibility in obtaining information.  
Other studies have demonstrated that booklets can increase knowledge. Boundaki et 
al. (2004) evaluated the impact of a patient information leaflet in improving 
knowledge, reducing distress and increasing intention to have a mouth screen in oral 
cancer patients, showing it provided some beneficial outcomes on each outcome at 
follow-up. Similarly, Hack et al. (2007) reported that a video and pamphlet 
intervention increased knowledge such as about aspects such as treatment efficacy 
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and differing expert views in oral cancer patients. The meta-analysis of psycho-
educational intervention by Devine & Westlake (1995) also observed significant 
impact of written material on knowledge among cancer patients. McPherson et al. 
(2001) did find that age, gender and preference for receiving information influenced 
how helpful booklets can be in increasing knowledge, highlighting that sensitivity 
needs to be applied in information provision in the oncology setting.     
6.2.2.2 Feedback (booklet acceptability) 
In the current study no significant association between intervention group 
membership and booklet feedback was found. The feedback received was mostly 
positive about both booklets. This may have been because the control booklet 
contained too much useful and relevant material and therefore did not act effectively 
as a control. Moreover, social desirability bias (Thompson & Phua, 2005 cited in 
“Social Desirability Bias”, 2014) may have impacted responses. Alternatively, the 
timing of the intervention booklet provision may not have been ideal (although it was 
recommended in the pilot study), with women still experiencing too many side effects 
from recent treatment. Arguably, the information may have been more relevant and 
desired once the diagnosis and completing treatment was less front of mind. Dunn et 
al. (2004) contend that further research is needed in this area to evaluate how to 
produce materials that are most useful and appreciated by patients.  
6.2.2.3 Psychological status 
6.2.2.3.1 PRT-related Psychological distress/Posttraumatic stress 
No differences were observed between groups in terms of posttraumatic stress with 
regards to PRT (women were asked to answer the IES-R in relation to their radiation 
and over the last 7 days). At baseline the majority of women were found to have non-
clinical or below average levels of PRT-related psychological distress/posttraumatic 
stress, avoidance, and intrusion on the IES-R. Overall 83%, 94% and 94% were non-
clinical cases at baseline, 3 months and 6 months respectively. This reduction in 
PRT from baseline is consistent with the literature (Philip et al., 2013). Thus there 
appeared to be a ceiling effect on these variables, making it very difficult to detect 
improvement.   
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Haggmark et al. (2001) similarly found no differences between groups on any of the 
outcomes measured (satisfaction with information, anxiety, depression, subjective 
distress and QOL) in an Australian study assessing provision of information about 
radiation, suggesting that this is a setting where change in psychosocial outcomes is 
difficult to achieve through information provision. 
In the final multiple regression model, younger women, those with more children, 
those who had anal cancer and those who had external pelvic radiotherapy (EBRT) 
treatment had higher levels of radiation-related psychological distress/PTSD 
symptomatology. Youth and having young dependents has been associated with 
greater distress in many studies (Pilger et al., (2012)). As noted above, rectal and 
anal cancer can also have a greater impact on QOL than other cancer. Furthermore, 
talking about rectal and anal cancer has been described by women as feeling taboo 
(see current study pilot chapter) and difficult to discuss; this may lead to less social 
support since women may not feel comfortable and supported in talking about it. In 
Nout et al.’s (2009) study, endometrial cancer patients who had EBRT had 
significantly higher rates of diarrhoea and bowel symptoms resulting in higher 
restriction such as staying close to a toilet, which affected daily activities and social 
functioning. Hence women who had EBRT in the current study may have had greater 
symptomatology, resulting in higher levels of psychological distress.   
6.2.2.3.2 Anxiety 
The intervention booklet also did not impact on general anxiety. In the current study, 
at baseline the majority of women were found to have non-clinical or below average 
levels of anxiety, with 73.2% with non-clinical levels, 17.1% borderline and 9.8% 
considered clinically anxious. At 3 months, overall 87.2% were non-clinical cases, 
8.5% borderline/probable cases and 4.3% clinical cases. At 6 months overall 88.9% 
were non-cases, 3.7% were borderline/probable cases and 7.4% were considered 
clinically anxious. Thus again a ceiling effect appeared to be evident. The current 
study’s rates of anxiety are similar to, though slightly lower than, those found in 
Hodgkinson et al.’s (2007) study of gynaecological cancer survivors (14%) and in 
Stafford and Judd’s (2011) study of gynaecological cancer patients (15%). In a 
similar pelvic radiation population to the current study, Mackenzie et al. (2013) found 
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15% likely cases of anxiety, 11.5% possible cases and 7.8% probable cases. Thus 
anxiety rates in our study appear to be characteristic of this population.  
As noted above, Haggmark et al. (2001), and Dunn et al. (2004) in Australian 
radiation information provision studies, found no differences between groups on any 
of the outcomes measured, including anxiety, reinforcing the difficulty of impacting 
anxiety through information. Similarly, Husson et al. (2010) and Elf & Wikblad, (2001) 
did not find information provision reduced anxiety.  
One intervention study which randomised rectal cancer patients to receive packs 
tailored to patient need and preferred information, or standard care (O’Connor et al., 
2014) did find an impact on anxiety, suggesting that tailored information packs might 
impact anxiety levels. This may be a useful concept to explore in future studies.  
In this study, women with anal and vaginal cancer, those seen at Royal Prince Alfred 
Hospital, younger women and single women had higher levels of anxiety. As noted 
above, anal cancer impacts heavily on QOL, while younger women are known to 
experience greater psychological morbidity with a cancer diagnosis. Similarly, 
women’s partner support is known to be a robust predictor of improved mood and 
QOL (Helgeson & Cohen, 1996 cited in Scott & Halford, 2004). Royal Prince Alfred 
Hospital, being a tertiary centre, may have more complex cases presenting which 
may explain higher levels of anxiety. 
6.2.2.3.3 Depression 
The intervention booklet also did not impact on depression. In the current study, the 
majority of women at baseline were considered non-clinical depression cases, with 
89% non-clinical levels, 9.8% borderline and 1.2% considered clinically depressed. 
Overall, at 3 months follow-up for the whole sample, 95.7% were non-clinical cases, 
2.1% were borderline and 2.1% were considered a case for depression. Overall, at 6 
months follow-up, 87% were non-clinical cases, 11.1% were borderline, and 1.9% 
was considered cases for depression. Thus again there was a ceiling effect. The 
current study rates of depression appear to be similar to those reported in a number 
of studies in similar populations. For example, both Hodgkinson et al. (2007) and 
Stafford and Judd (2011) reported that about 6% of their samples of gynaecological 
cancer patients had clinical depression. O’Connor et al. (2014) found that 10.53% of 
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rectal cancer patients had clinical depression while Mackenzie et al. (2013) and 
Adams et al. (2014) respectively, found the likely presence of depression in 5.7%  of 
PRT patients (including, besides other cancers, cervix, uterine, rectal and bladder) 
patients). Janda et al. (2005) examined vulvar cancer surgical patients and found 
clinical depression in 15% of women preoperatively and in 5% of women 
postoperatively.   
Mcpherson et al. (2001) noticed positive patient outcomes for interventions which 
included written material, telephone help-lines, teaching, educational programmes 
and audio-visual aids. These positive effects on patient outcomes reflected in 
knowledge and recall, managing symptoms, satisfaction, health service utilisation 
and affective states above and beyond the usual care provision. However, in  most 
of the studies, these interventions had practically no effect on psychological 
indicators correspondingly to this current study and others quoted. It does appear 
that additional components above and beyond information are required to impact 
anxiety and depression. 
In the current study, women taking anti-depressant medication and being treated at 
Royal Prince Alfred hospital had higher levels of depression. As noted above, Royal 
Prince Alfred treats complex cases as a tertiary institution which may explain this 
finding.  
6.2.2.3.4 Conclusions on psychological status 
Stafford & Judd (2011) concluded that women are most susceptible to psychological 
difficulties at diagnosis. This improves significantly over time. Furthermore, they note 
that their rates are lower than those in larger scale studies in the literature, as was 
the case in the current study. Though reasons for this are uncertain, they suggest 
this may be as a result of a well-resourced multidisciplinary team providing good 
care and alerting patients to the diverse psychosocial support available to them. This 
was potentially the case in the current study too.  
6.2.3.4 Sexual activity/function/satisfaction 
In the current study, the hypothesis that the intervention information booklet would 
improve sexual activity/function/satisfaction at the follow-up of 3 and 6 months was 
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not supported. Significant amounts of missing data in sections of the questionnaire 
dealing with vaginal changes and sexually-related issues made assessment of these 
outcomes difficult. There was also attrition during the follow-up periods, which further 
reduced the number of cases available for investigation. Across the sample, there 
were also low levels of sexual activity and many women reported not having a 
current partner. Furthermore, it is prudent to bear in mind that pretreatment baseline 
scores may not be an accurate measure of baseline vaginal health and sexual 
function since, especially in advanced genital tract cancers, these might be 
adversely affected by the tumour and is hence not a true pre-diagnosis score 
(Jensen et al., 2003). Thus methodological issues may be partially responsible for 
the non-significant result.  
At baseline (no differences between the groups) most women in the sample overall 
were not sexually active (n=61; 74%), with only 20% of women (n=16) engaging in 
sexual relations, (the remainder did not respond). At 3 and 6 months follow-up 55% 
(n=45) and 44% (n=36) of women respectively where not engaging in sexual activity, 
while 17% (n=14) and 18% (n=15) were engaging in sexual activity, however the 
missing/ non-response data increased significantly from baseline from 6% - 38%. 
Similarly, at all assessment points, most women were interested in close physical 
contact in the form of a kiss or a cuddle. But about two-thirds of women were ‘not at 
all’ or ‘had little interest’ in sexual relations across the study. 
Low sexual activity in our sample is not surprising. Increasing age and lack of partner 
are strongly related to sexual inactivity (Rosen et al., 2009) and sexuality is not 
important for all women (Matulonis et al., 2008; Carmack Taylor et al., 2004). More 
than half of women over 50 years of age are sexually inactive according to Schick et 
al. (2010), who examined sexual health of women over 50 years in the USA.  
Thus sexual dysfunction can be pre-morbid and unrelated to the cancer and its 
treatment (Friedman et al., 2011). However, women treated for cancers anywhere in 
the pelvic region may experience cancer and treatment-related physical and 
psychosexual side effects that make resuming sexual activity physically painful 
and/or difficult (Lindau et al., 2007). Women in the current study were asked to 
respond about how their pelvic cancer had impacted their sexual activity. At baseline 
overall 20% (n=12) of women reported they were not sexually active due to cancer-
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related physical problems making sexual relations difficult or uncomfortable, 
decreasing to 13% (n=6) and 14% (n=5) at follow-up of 3 and 6 months respectively. 
Many women reported greater vaginal dryness (27% (n=4), 48% (n=12) and 53% 
(n=10) at baseline, 3 and 6 month follow-up respectively), with similar numbers 
reporting that the size of their vagina had decreased. About 2/3 of women reported 
more pain during intercourse since having cancer, over the study period. 
Furthermore, about a third of women in this study reported sexual dissatisfaction 
over all time periods, and a quarter were unhappy with their appearance. Thus 
physical morbidity interfering with sexual satisfaction was certainly reported in this 
sample, although the numbers were relatively low (due to missing data and high 
level of sexual inactivity), possibly obscuring effects.   
Similarly, Schover et al. (2013), in an RCT of an intervention to improve sexual 
function in women post breast and gynaecological cancer treatment noted that 74% 
at baseline reported not currently engaging in a sexual relationship, with 20% 
reporting sexual problems. Many of these women (40%) were not in a relationship or 
intimate relationship. They cited lack of interest, physical problems and being too 
tired as some of the reasons for sexual inactivity. Sexual interest is one of the 
greatest areas of sexuality affected post-PRT. For instance, in a longitudinal study, 
Jensen et al. (2003) on sexual function and vaginal changes in post-PRT for cervical 
cancer, found that 85% of women had little or no sexual interest. Bergmark et al. 
(1999; 2002) found significant distress for women with regards to their lack of sexual 
interest. HRT (unless inadvisable) might benefit women with regards to increased 
interest (Jensen et al., 2003) if it is related to treatment-related menopause. 
In the final multiple regression model in the current study, it was found that women 
who were married or in a defacto relationship, relatively more educated, had vaginal 
cancer and were professionally employed had higher levels of intimacy. While it is 
clear why being in a relationship would facilitate sexual activity, the positive 
association between education and professional employment and sexual activity is 
harder to explain. Education has been positively associated with post-radiotherapy 
HRQOL as have income level and employment status (Sau et al., 2013). But the 
association between such variables and greater intimacy is hard to explain. Perhaps 
those with greater education are more able to access information and support 
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regarding sexuality. Further, there is little research in post-treatment psychosexual 
functioning in vaginal cancer to draw upon, to enable comparison and explanation. 
Further research is needed to explicate these associations.  
In the current study women with higher levels of depression had lower levels of 
intimacy. With regards to depression this finding is consistent with the literature 
(O’Connor et al., 2014; Brotto et al., 2008; Rehse & Pukrop, 2003). This finding 
suggests that interventions to improve sexual functioning may need to address wider 
psychosocial issues to be effective, and this may further explain the limited impact of 
the intervention booklet in this study, as it did not directly address depression. A 
similar study that relied on written material (Robinson et al., 1994) utilising a brief 
bibliotherapeutic intervention in cervical and endometrial cancer patients (n= 83) 
improved knowledge (p>0.0001) and mood (p>0.001) but had no effects on sexual 
problems, communication and body image. 
Other studies which have reported significant intervention effects on sexuality have 
been more intensive and included psychosocial elements. For example, Capone et 
al. (1980) undertook an intervention study in a gynaecological cohort of an in hospital 
crisis counselling versus standard care in cervical cancer patients (n=97). At 3 
months women in the intervention group had better self-concept and sexual 
functioning, with sexual functioning differences maintained at 6 and 12 months.  
Similarly, Schover et al. (2013) examined the efficacy of an internet-based 
intervention on cancer-associated female sexual dysfunction in localised breast and 
gynaecological cancer patients. This longitudinal RCT (baseline, post-treatment, 3 
and 6 month follow-up) compared a self-help intervention versus the same plus three 
counselling sessions. They found the counselled group improved to a significantly 
greater degree on the sexuality measures although there were no differences 
between groups in emotional distress and QOL.  
6.2.3.4.1 Patient-doctor communication/information needs related to 
sexuality 
About ¼ of women in the current study reported that their doctor did not talk about 
their sex lives at all, while a further 15% noted that their clinician spoke about their 
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sex life only after the end of their treatment. Only seven women in each group 
reported that their doctor discussed sexuality both before and after their treatment. In 
contrast, over half the women would have liked their doctor to speak to them about 
sexual matters, and did not mind if this came from a male or female doctor (although 
some preferred a woman). About ¼ of women did not want to receive sexual 
information from anyone, and this finding does highlight the need for sensitive 
negotiation around this topic.  
Schover et al. (2013) contend that less than 20% of women with sexual difficulties 
present for professional intervention, though distress is high as seen on sexual 
health questionnaires. Of further concern is the limited number of gynaecologists and 
mental health clinicians who have expertise in managing these physical and sexual 
difficulties (Goldfarb et al., 2013). The issue of unmet needs for information about 
sexuality will be discussed in the study concluding chapter (Chapter 7). 
6.3 Strengths and limitations of this study 
6.3.1 Limitations 
6.3.1.1 Sample size and response rate 
A significant limitation of the current study was the small sample, which has 
implications for the generalisability of the findings. Some of the target cancers (e.g. 
anal and vaginal cancer) are relatively rare. At the time of recruitment, many women 
may still have been struggling with adjusting to the diagnosis and undergoing 
treatment of their cancer; therefore they may have been disinclined to complete a 
lengthy baseline questionnaire. In addition, the sexual focus of the study might not 
have been a priority for women at this time, when issues relating to mortality and 
treatment concerns and acute effects could be front of mind, debilitating and/or 
distressing. Many women who initially agreed to participate dropped out of the study 
before completing baseline questionnaires. Stafford and Judd (2011) suggest that 
women who self-select into QOL studies may have greater or lesser distress and 
sexual morbidity or significant unmet needs, deciding to participate or not on this 
basis. Hence selection bias was a potential limitation in the current study, though not 
possible to assess. 
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There was also significant loss to follow-up at 3 and 6 months. Repeated attempts 
were made to contact women and duplicate questionnaires were sent within 
allocated time frames for doing so. Women may have dropped out for non-cancer or 
treatment related reasons. Some women may have moved house. Furthermore, 
women might have dropped out due to dealing with treatment complications, acute 
and late side effects and cancer related-difficulties. Some women may have been 
deceased.  
Analysis of the withdrawers/non-responders from the study on some known clinical 
and demographic characteristics did not show any differences between the control 
group and the intervention group rendering it less likely that the results may not be 
generalisable.  
However, despite the small sample size the internal validity of the study appears to 
be intact. Initial sample size calculations indicated that 132 women were required 
(Section 5.3.4). The final sample size of 82, despite being smaller than the initial 
estimated sample size requirements, was large enough to detect a medium level 
effect size (i.e. f2 of 0.15), a statistical power of 0.80 and Type 1 error rate of 0.01 in 
the regression model, which was crucial to the primary outcomes of this study. Post-
hoc sample size calculations for the model which had the most number of predictors 
(i.e. the model which uses first follow-up and second follow-up phase data and has 
Frequency of use of Dilator Score as the dependent variable had 4 predictors) 
indicated that a sample size of 59 people (or 118 in stacked regression) would be 
sufficient to detect medium level effect size (i.e. f2 of 0.15), a statistical power of 0.80 
and Type 1 error rate of 0.01.  
Furthermore, as noted above, the study did not find any significant differences 
between the final sample and the decliners; and there were no differences between 
the control and the intervention groups in terms of the demographic and clinical 
characteristics at baseline. A lack of any systemic difference makes it less likely that 
participants were different from non-participants in a non-random manner. To make 
sure that the results are not because of chance (Type II error), the groups were 
assessed using multiple assessment techniques and common findings were 
reported. This reduces the chance of accepting a statistically significant finding that 
is due only to chance. According to (Cohen, 1988) the R-square statistic associated 
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with a multiple linear regression model can be used as a measure of effect size. The 
two most important multiple linear regression models in this study established the 
significant impact of the intervention on the use of dilator and knowledge of 
rehabilitation options. These models were deemed to have a large (R-square = 
.414), and medium-to-large (R-square = .171) effect size, respectively.  
Frequently non-response rates of 15% - 30% are often found in focused, 
psychological difficulties intervention RCT’s (Schover et al., 2013). Having fewer 
questionnaires, utilised interactively with short-term goal initiatives, and allowing 
participants to track their own progress on self-report outcomes are some ideas to 
enhance questionnaire/study completion (Schover et al., 2013), and this should be 
considered in future studies.  
6.3.1.2 Missing data 
As Bell et al. (2013) note, though the effects of cancer can severely impact sexual 
wellbeing for women, many are not keen to respond to questions related to sex 
leading to missing data on surveys, as corroborated by Cheung et al. (2006; cited in 
Bell et al., 2013). Immigrants as opposed to Anglo-Australians may be even less 
inclined to discuss sexual matters (Bell et al., 2013). They found that missing data 
rates were extensive (65%) with immigrants (Arabic, Greek and Chinese women) not 
responding to a greater degree than Anglo-Australian women, however, women, 
older and more advanced disease respondents also had a higher probability of not-
responding to items. Bell et al. (2013) suggest this is usually informatively missing 
data, which may bias results, leading to the underestimation of sexual morbidity and 
overestimation of QOL (Bell et al., 2013). In the current study women were asked not 
to miss sexual questions and rather were asked to respond though these were 
sensitive questions, which is in line with Bell et al.’s recommendation to avoid this 
complication. Despite this, there was a large amount of missing/non-response data 
on the sexual/vaginal changes questions/scales. This could be explained by the non-
response related issues identified in the previous section such as sexual focus of the 
study and the timing of assessments (e.g. post diagnosis and pre-treatment), and 
also completion of lengthy questionnaires. Further research is required to identify 
strategies to minimise missing data in this context. 
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6.3.1.3 Control condition 
The general ‘Cancer Council Understanding Radiotherapy’ booklet may have been 
too strong a control since it is a comprehensive supportive care resource. It was 
included to control for added attention, in a way that matched the format (booklet) 
but not the effective content (related to sexuality) of the intervention. However both 
resources may have impacted on psychological status and sexual function, 
explaining why no differences were found between the two groups.  
6.3.1.4 Generalisability 
The findings of the current study cannot be generalised to non-English speakers 
since most women in the study were of Anglo-Saxon descent. Hence the 
generalisability of the results to other culturally and linguistically diverse groups 
(CALD) is uncertain given potentially different post-treatment psychosexual 
adjustment patterns in these groups. Those with cognitive deficits might be a 
vulnerable cohort for sexual dysfunction, but were also excluded since assessing the 
booklet required literacy.  
The NSW hospitals included in the study might provide different services to other 
states in Australia and overseas, limiting the generalisability of the findings.  
6.3.1.5 Differing study methodologies 
The results of the current study and others are difficult to compare since numerous 
methods are used across studies to assess, analyse and report sexual function. 
Different stages, survival prognosis and mixed treatment modality also limit finding 
generalisation and comparison. In the current study including multiple treatment 
modalities was a limitation, however for most women undergoing treatment for pelvic 
cancers this is the norm. The sample would have been too small if radiation-only 
patients were included, 80% of women in the current study underwent combined 
treatments. Women would have been treated with different radiation treatment 
volumes and internal and external radiotherapy this could also not be assessed due 
to small numbers. However, Jensen et al. (2003) contend that interventions should 
trace these consequences in the development of applicable resources to alleviate 
side effects. Similarly Nesser (2011) argued that mixed modality treatments and 
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different radiation volumes need to be taken into account when evaluating 
interventions. Our small numbers made controlling for multiple confounders difficult.  
6.3.2 Strengths 
The current study included women with anal and rectal cancer. Little focus and 
attention has been paid to this patient cohort though they have known informational, 
psychological and psychosexual unmet needs.  
The study used a rigorous approach to developing and piloting the intervention prior 
to evaluation with input from multiple stakeholders as well as being based on the 
empirical literature. 
The study appears to be contributing a novel finding in that a written psychosexual 
resource improved knowledge and vaginal dilation post PRT. Combining the study 
resource with interactional care from clinicians may further increase adherence and 
decrease barriers to use and possibly improve psychological and sexual outcomes 
for women post PRT. The booklet could also aid clinicians in identifying couples that 
would benefit from post PRT psychosexual counselling (Jensen et al., 2003). 
However, further research to improve outcomes appears to be indicated. 
6.4 Future Research Directions 
Further research creating low literacy resources for CALD populations in this area 
appears to be indicated and would arguably be beneficial for all women regardless of 
their background. Translating the booklet into different languages could make it more 
accessible too.  
Moreover, as Schover et al. (2013) found, attrition in cancer-related sexual function 
studies requires attention to improve this; future research in this area would 
significantly enhance this field of endeavour. 
The optimal timing for provision of sexually related information and support requires 
further investigation. Longitudinal data would shed more light on psychological and 
psychosexual effects for women and is recommended for further research.  
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6.5 Summary 
This study-developed booklet on psychosexual adjustment after PRT was associated 
with higher levels of knowledge and use of dilators, when controlling for demographic 
and/or clinical characteristics. Therefore, the psychoeducational booklet appears to 
be successful in providing knowledge about physical and psychosexual side-effects 
and rehabilitation options following pelvic radiation therapy, and it promotes the use 
of dilator as a rehabilitation technique. Given its failure to impact sexual outcomes, 
psychological wellbeing and quality of life, further research is required to examine 
whether altering the booklet or combining it with other interventions such as 
counselling would result in more comprehensive effects. Further, research regarding 
whether routine implementation of such an intervention is possible would be useful.  
In future research, strategies to encourage women to participate in studies and take 
up such booklets are required, as well as to avoid missing data on sexual outcome 
measures.  
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CHAPTER 7 - Overall study 
conclusions 
7.1 Introduction 
The information booklet in the current study was developed, piloted and trialled 
because research about and resources for women’s psychosexual adjustment post 
PRT have been identified as an area that requires development and assessment in 
order to optimally intervene to improve recovery and reduce distress. Despite many 
calls for interventions in the literature in this area, few, if any, specific resources such 
as the study psychosexual information booklet appear to have been developed for 
women who have had PRT. Thus this study was undertaken with a view to ultimately 
providing a much needed, novel resource (Juraskova et al., 2003; Lancaster, 2004; 
Schover, 2007; Katz, 2009; Wolf, 2006, Carter et al., 2013).  
Furthermore, the psychosexual adjustment of women treated with PRT for anal and 
rectal cancer has received little attention, even though vaginal and psychosexual 
changes post treatment side effects parallel the gynaecological cancer setting. Even 
in the gynaecological setting subgroups of women have received little research 
attention (Marijnen et al., 2005; Das et al., 2010; Peeters et al., 2005; Birgisson et 
al., 2007; Donovan et al., 2010; Wolf, 2006; Bentzen et al., 2013; Incrocci & Jensen, 
2013). For instance, women post PRT with endometrial, vaginal and vulvar cancer 
have received little attention (Incrocci & Jensen, 2013; Lian et al., 2008; Tran et al., 
2007; Hazewinkel et al., 2012; Aerts et al., 2014).  
In the gynaecological cancer setting, radiation-induced effects contribute to the 
development of sexual dysfunction in a reported 49-79% of affected women (Munro 
et al., 1996). Many studies have reported major changes to levels of sexual 
desire/activity, inability to achieve orgasm, and decreased overall satisfaction with 
sexual life in the months and years following radiotherapy (Frumovitz et al., 2005; 
Jensen et al., 2004b; Juraskova, 2003; Lindau et al., 2007). Considering that 
upwards of 40% of gynaecological cancer patients report chronic post-treatment 
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sexual difficulties, there is a real potential for sexual and relationship dysfunction to 
persist when other areas of adjustment such as mental health have normalised 
(Katz, 2005; 2009; Schover, 2005; Wolf, 2006; White, 2008).  
Lange et al. (2009) found that 62% of women with rectal cancers noted new or 
aggravated sexual problems post PRT treatment whilst rates of sexual activity 
steadily diminished over time to 18% two years post treatment. Gervaz et al. (2008) 
suggest that sexual function in rectal patients does not improve but stabilises over 
time ranging from 6 months to 2 years. Poor sexual function scores post PRT, were 
found in 55% of women with anal cancer (Das et al.’s (2010), although little is known 
about sexual dysfunction for women with rectal and anal cancer with further research 
needed in this area (Ho et al., 2011; Incrocci & Jensen, 2013).  
Given the high rates of reported sexual dysfunction and the relative dearth of 
research in key patient sub-groups, the pilot study (Phase II) aimed to (i) explore 
women’s views about sexuality and their rehabilitation informational needs following 
PRT; (ii) investigate the feasibility and acceptability of providing women undergoing 
PRT with an information booklet about radiation-induced side effects potentially 
affecting recovery and especially sexual functioning/vaginal changes (developed in 
Phase I of the study), and (iii) assess the acceptability of a measurement protocol 
that would be used in a later randomised controlled trial (RCT) of the booklet (Phase 
III).  
The pilot highlighted many challenges to quality of life and informational needs faced 
by women after PRT, particularly those associated with sexual rehabilitation. Overall, 
the pilot findings provided support for the provision of psychoeducational resources 
to better support women in physical and psychosexual rehabilitation following 
radiotherapy for gynaecological and anorectal cancer. The pilot results suggested 
women would welcome, appreciate and highly value a resource such as the study 
booklet as a facet of their post treatment care and recovery. It appeared that the 
booklet would facilitate self care and being able to play a role in their rehabilitation, 
which women expressed would give them some welcome control at a time when 
they feel quite out of control.  
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It’s known that less than 20% of women with sexual difficulties present for 
professional intervention, though distress is high as seen on sexual health 
questionnaires (Schover et al., 2013). Patients can feel embarrassed, reluctant; think 
their issues are inconsequential and/or that they are ungrateful for their care if they 
ask about sexuality-related issues, all of which can serve as barriers to raising their 
concerns (Falk & Dizon, 2013). They may also be oblivious to treatment options 
being available and hence not raise issues. The booklet appeared to be a valuable 
resource for women who prefer confidentiality and anonymity.  
Of further concern is that a limited amount of gynaecologists and mental health 
clinicians have expertise in managing these physical and sexual difficulties (Goldfarb 
et al., 2013) and having a resource such as the study booklet may be helpful in 
reducing this barrier to discussing these problems with women. Anecdotally, and a 
potential area for further research, clinicians in the pilot and trial expressed a strong 
need and wish to have the booklet on hand with immediate effect. The researcher 
accidentally left the trial booklet at a large tertiary radiation centre not involved in the 
trial, returning to find it bookmarked in many sections by a clinician who had found it. 
Finally, the pilot confirmed that women hold a number of myths about treatment side 
effects and sexuality, as reported in the literature (Dunn et al., 2004). The study 
booklet debunked myths and effects of the treatment were brought in to the open, 
validated and normalised to reduce ‘the sounds of silence’ with regards to the 
psychosexual effects of PRT (Katz, 2005, p. 238). Dunn et al. (2004) contend that 
this would be especially of consequence in the radiation oncology setting where 
negative unqualified health beliefs may preside during treatment.  
The booklet was revised based on the feedback from the study participants, as well 
as the findings of a current Cochrane Review (Johnson & Miles, 2010) regarding 
vaginal dilator use. Given the high levels of acceptability of the pilot booklet, the 
effectiveness was then prospectively evaluated in a multicentre RCT. 
The aims of the RCT were to assess whether the psychosexual information booklet 
would improve adherence to the recommended rehabilitation strategies, improve 
knowledge, lower levels of PRT-related psychological distress, anxiety and 
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depression and improve sexual activity, function and satisfaction post PRT for 
women with gynaecological and anorectal cancer. 
The RCT findings showed that the study-developed booklet was associated with 
higher levels of knowledge and use of vaginal dilators, when controlling for 
demographic and/or clinical characteristics. Therefore, the psychoeducational 
booklet appears to be successful in providing knowledge about physical and 
psychosexual side-effects and rehabilitation options following pelvic radiation 
therapy, and it promotes the use of dilator as a rehabilitation technique. Given that 
women in the pilot recognised dilator use as a difficult area for them, with many 
patient-clinician and patient-related barriers, this represents an important outcome. 
However, the study booklet failed to improve sexual activity/function/satisfaction or to 
lower levels of PRT-related psychological distress or anxiety and depression. Given 
the complexity of these issues, it appears that it is a challenging task to improve 
quality of life, and reduce psychological and sexual/psychosexual morbidity post 
PRT/treatment for gynaecological and anorectal cancer with ongoing work in this 
area required.  
7.2 Advantages of mixed methods 
Despite the negative findings regarding the impact of the booklet on sexual and 
psychological outcomes, qualitative data from the pilot did show that women found 
the information helpful and felt that it reduced their distress. Qualitative data provide 
important insights into the direct impact of the intervention as perceived by 
recipients. Healthcare services can only procure funding if efficacy outcomes are 
found, with RCT’s remaining the gold standard in evidence-based medicine. 
However, it is not uncommon for quantitative intervention studies to fail to detect an 
effect on complex phenomenon such as psychological wellbeing, due to the 
multiplicity of influences on such outcomes. Of concern, this can result in educational 
resources that are seen as effective and positive by recipients and clinicians being 
inappropriately dispensed with (Celemajer, 2001 cited in Dunn et al., 2004). Bredart 
et al. (2002, cited in Dunn et al., 2004) contend that RCTs should form just one 
element of an iterative process of assessing the merit of psychosocial resources, 
utilising both quantitative and qualitative approaches. Thus a combination of 
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methods is often required to reveal the full impact of an intervention. The current 
study, by utilising mixed methods, was able to elicit both quantitative and qualitative 
data which can be weighed up together in coming to a final conclusion about the 
benefits of the intervention (Dunn et al., 2004).  
7.3 Limitations of the study 
The small sample size in the current study pilot and trial limit the generalisability of 
the findings and for this reason the results need to be interpreted with caution. Harter 
et al. (2013) note that low response rates are often found in research about 
sexuality, with the participation rate in posted sexual surveys frequently being only 
between 15-50%. There were significant amounts of missing/non-response physical 
and psychosexual data in the RCT suggesting that women are reluctant to answer 
sexuality-related questionnaires. Women self-selected in to the pilot and trial hence 
they may have had greater or less distress and/or side effects in agreeing to 
participate. Further research to assess selection bias appears to be indicated.  
On the basis of the pilot, the booklet was provided to women in the RCT very early in 
the treatment trajectory with concomitant requirements for questionnaire completion 
at this time. Some women declined participation in the study because they felt 
overwhelmed at this time. Again, a tailored approach to the timing of provision of 
information may be required. Tailoring may particularly be required when providing 
information to women with diverse cancers, although the booklet was designed to 
address general issues of relevance to all such women.  
7.4 Strengths of the study 
A strength of the pilot and RCT studies was the inclusion of cancers in women for 
whom sexuality interventions are rarely studied, such as anal and rectal cancer. Due 
to limitations in the literature, a staged approach to the research was adopted, with 
the initial pilot study used to confirm the issues for all patient subgroups and ensure 
that the booklet optimally addressed their needs. Recruitment was pursued 
vigorously, and despite a relatively small sample size in the RCT this still represents 
a relatively large study in this field.  
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Measures were carefully selected and where suitable measures were unavailable, 
they were carefully developed for the study on the basis of the literature and pilot 
study results, with rigorous psychometric evaluation on the basis of which 
appropriate scoring methods were developed. These purpose-designed scales (of 
Adherence,  Knowledge and Feedback Scales) may be useful for researchers in the 
future. Finally, the RCT design allowed a rigorous evaluation of the booklet, and 
demographic and clinical variables were controlled for in the analysis.  
7.5 Lessons learned 
Evaluating complex interventions in this setting is a challenging area given 
multifaceted physical changes, psychological and psychosexual difficulties for 
women. However, perhaps revising ways of intervening should be considered since 
positive effects of interventions have been found. As noted above, the timing of 
providing the booklet might have affected the outcomes since this was a difficult time 
for women, post diagnosis and pre-treatment, with much to contend with. Follow-up 
at 12-18 months (and more longitudinally) might yield important information with 
regards to late radiation physical and psychosexual side effects and psychological 
morbidity, and later benefits from the booklet.  
The booklet may have been more effective if combined with effective specialist 
psychosocial or sexual intervention, at least in some women. Mcpherson et al. 
(2001) found that non-specialist interventions (including written material, telephone 
help-lines, teaching, educational programmes and audiovisual aids) had positive 
effects on patient outcomes such as knowledge (as found in the current study) and 
recall, managing symptoms, satisfaction, health service utilisation and affective 
states above and beyond the usual care provision. However, they found that in the 
majority of studies, as in the current study, the interventions had little effect on 
sexual outcomes or psychological indicators. Studies with structured educational 
groups yielded better results for more general psychosocial outcomes (e.g Fawzy et 
al., 2001) though these can be expensive to run (Dunn et al., 2004). 
It is not completely clear which psychological interventions would be the best 
candidates for a combined approach.  Moderate support has been shown for the 
feasibility and the effectiveness of a targeted psychological intervention for sexual 
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dysfunction, although with high attrition rates, placebo responses were evident and 
barriers impacted patients seeking out psychosexual interventions (Brotto et al., 
2010). Sexual morbidity was improved with some psychosexual interventions 
(Maughan & Clarke, 2001; Brotto et al., 2008), and not for others such as Scott et al. 
(2004).  As many patients do not wish to attend groups a resource like the current 
study booklet could provide information specifically about sexuality, in a manner that 
might be preferable for many women, which could also complement more general 
issues addressed in a group.  
7.6 Clinical Implications 
In summary, the study booklet appears to be useful for women in the gynaecological 
and anorectal cancer post PRT setting. The booklet improved knowledge and 
vaginal dilator use in the trial and women in the pilot found it to be helpful, useful and 
that it reduced distress. It is a cost-effective intervention and potentially could reach 
many women if published in hardcopy or online. Women could have the option to 
read the booklet in privacy or, if desired, it could facilitate discussion of their 
concerns with clinicians and/or partners, family and friends. The effects of the 
booklet may be improved by combining it with clinician-led and/or psychotherapeutic 
individual or group intervention. Cancer nurse specialists have driven the need for 
resource development such as the study booklet to a large degree and should be 
included in the process (O’Connor et al., 2014).  
The clinical and psychosexual significance for women in implementing rehabilitation 
strategies is potentially far-reaching with regards to facilitating the detection of new 
and/or recurrent cancer (with dilator use), and to improving sexual and broader 
relationship outcomes for women, which in turn, could affect their physical and 
emotional wellbeing. However, a recent review highlighted that there is a lack of 
evidence and controversy on the efficacy of dilator use which may alter dilator 
provision practices in the future. Further research is being undertaken in this area, 
for example, Law et al. (2013) are assessing vaginal stenosis and vaginal dilator use 
in gynaecological and anorectal cancer patients. 
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7.7 Future research 
As noted in the trial summary, since the booklet failed to impact sexual outcomes 
and psychological wellbeing, further research is required to assess if modifying the 
booklet, or combining it with other interventions such as counselling, would result in 
more holistic effects. Further, research regarding whether routine implementation of 
such an intervention is possible, is required. The accessibility and uptake of 
psychosexual interventions, whether online or in hardcopy, also requires further 
exploration. 
Assessing a bigger sample, examining individual pelvic cancers and individual 
treatment effects would further enhance physical changes and psychosexual 
research in the area of psychoeducational information development and provision in 
the oncology setting.  
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Invitation letter 
 
Dear 
 
We would like to invite you to participate in a study exploring ways to improve communication about post-
radiation rehabilitation for women who will have/have had pelvic-radiation therapy for cervical, endometrial or 
colorectal cancer. We have developed a booklet which provides information about pelvic-radiation therapy, 
side-effects of this treatment, and post-treatment rehabilitation options, including the use of vaginal dilators. 
We would like to obtain your feedback on the content and format of the information booklet and whether you 
feel such a booklet would be useful for women in a similar situation. 
 
This is a collaborative project between the Centre for Medical Psychology and Evidence-based Decision-
making (CeMPED), School of Psychology, University of Sydney and the Sydney Cancer Centre at the Royal 
Prince Alfred Hospital (RPAH). 
 
Enclosed in this package are: Participant Information Sheet and Consent Form, an information booklet, a 
study questionnaire and a pre-paid self-addressed envelope. 
 
The participation in the study involves reading the booklet, completing the questionnaire and participating in a 
short telephone interview. The questionnaire and interview will help us to determine whether the information 
booklet is helpful and useful for women who have undergone pelvic radiotherapy. Ultimately we hope to 
improve the well-being and quality of life of future patients who will such a situation. 
 
Participation in this study is voluntary, you are not obliged to participate, and if you do, you can withdraw from 
the study at any time without any repercussions. Although most people find an opportunity to review their 
experiences helpful, this research will ultimately benefit future patients. 
 
If you agree to participate in this study, please return your completed questionnaire together with the signed 
consent form in the reply paid envelope provided. If you do not wish to participate in the study, please dispose 
of this study package in whichever way you wish. 
 
If you have any questions, please contact Dr Ilona Juraskova (Principal Researcher) or Ms Fran Lubotzky 
(Associate Researcher) at any time on (02) 9036 5275. 
 
Thank you for considering this invitation. 
 
Kind regards, 
 
Professor Jonathan Carter 
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A pilot of an information booklet to improve communication about post pelvic-radiotherapy 
adjustment for women with gynaecological or colorectal cancer 
 
 
 
INFORMATION FOR PARTICIPANTS 
 
 
Introduction 
 
You are invited to take part in a research study into ways to improve communication about post-radiation 
adjustment for women treated with pelvic-radiation therapy for cervical, endometrial or colorectal cancer. We 
have developed an information booklet about pelvic-radiation therapy, the side-effects of the treatment and 
post-treatment rehabilitation options. We would like to obtain your feedback on the information, the format 
and the usefulness of the booklet.  
 
The study is being conducted by: 
 
 Dr Ilona Juraskova  (NSW Cancer Institute Research Fellow, Centre for Medical Psychology and 
Evidence-based Decision-making (CeMPED), School of Psychology, 
University of Sydney) 
 
 Prof Phyllis Butow   (NHMRC Senior Research Fellow; Director (CeMPED), University of Sydney) 
 Prof Jonathan Carter   (Head, Sydney Gynaecologic Oncology Group, Royal Prince Alfred Hospital) 
 Ms Kath Nattress   (Clinical Nurse Consultant, Sydney Gynaecology Oncology Group, RPAH) 
 Ms Fran Lubotzky   (Ph.D. student, School of Psychology, University of Sydney) 
 
Study Procedures 
 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You will be 
provided with an information booklet to read. After you have read the booklet you will then be asked to 
complete a questionnaire. The questionnaire will seek information about you (e.g. your age, medical history), 
general questions about how you feel, general questions about sexual activity, questions about the 
information in the booklet and feedback on the booklet (e.g. was the information relevant). Completing the 
questionnaire will take about 20 minutes. Within a week of receiving your questionnaire, our research 
coordinator (Fran Lubotzky) will contact you by phone to obtain verbal feedback on the content and format of 
the booklet. The telephone interview will take approximate 15-20 minutes.  
 
Risks 
 
Whilst it is unlikely, some participants may find the contents of the questionnaire or the interview unsettling. If 
you find any of the items in the questionnaire or the interview in any way distressing, or would like help with 
any questions, please contact the researchers on (02) 9036 5275 and discuss your concerns. We can also 
refer you to a psychologist if you feel this would be of assistance. 
 
Benefits 
 
While we intend that this research study furthers medical and psychological knowledge and may improve 
post-treatment rehabilitation for women undergoing pelvic-radiation therapy in the future, participation in the 
study may not be of direct benefit to you. However, you may gain some benefit from the information in the 
booklet. 
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Costs 
 
Participation in this study will not cost you anything, nor will you be paid.   
 
 
Voluntary Participation 
 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you do take part, you can 
withdraw at any time without having to give a reason.  Whatever your decision, please be assured that it will 
not affect your medical treatment or your relationship with the medical staff who are caring for you.   
 
 
Confidentiality 
 
All the information collected from you for the study will be treated confidentially, and only the researchers 
named above will have access to it.  The study results may be presented at a conference or in a scientific 
publication, but individual participants will not be identifiable in such a presentation. 
 
 
Further Information 
 
When you have read this information, Fran Lubotzky will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact Dr Ilona 
Juraskova (principal investigator) or Fran Lubotzky (research coordinator) on (02) 9036 5275. 
 
This information sheet is for you to keep. 
 
 
Ethics Approval and Complaints 
 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney South West Area 
Health Service.  Any person with concerns or complaints about the conduct of this study should contact the 
Executive Officer on 02 9515 6766 and quote protocol number X08-0234. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 2 
Version 3, RPAH, 15
th
 March 2010 
Page 1 of 8 
Version 3, RPAH, 15
th
 March 2010 
1 
 
A pilot of an information booklet to improve communication about post-radiotherapy adjustment 
for women with gynaecological or colorectal cancer 
 
 
 
Interview script 
 
 
INTRODUCTION 
 
Thank you for agreeing to take part in this interview.  The main aim of this study is to explore 
ways about how to improve communication about adjustment following pelvic-radiation therapy 
for cervical, endometrial or colorectal cancer.  As you know, we have developed an information 
booklet which describes pelvic-radiation therapy, the side-effects of the treatment and post-
treatment rehabilitation options. We would like to obtain your feedback on the information, the 
format and the usefulness of the booklet.  
 
I have in front of me a series of questions that I would like to ask you about the booklet.  
Everybody in the study is asked the same questions.   
 
If any of the questions are unclear, it is my job to help you understand the content of these 
questions. So, please do not hesitate to ask me to repeat a question or provide further 
explanation of what is meant by that question. 
 
The whole interview should probably take approximately 20 minutes of your time. 
  
Please let me know if any questions are upsetting to you, or if you would prefer not to answer 
any question.  We can stop the interview or take a break at any time. 
 
 
INTERVIEW QUESTIONS  
Question 1: Initial Response 
 
A) What were your first impressions of this booklet? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
B) What did you like about it?  What was the best part? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
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C) What did you dislike about it? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
D) Overall do you think a booklet like this is useful for a woman to use if they are undergoing 
pelvic-radiation treatment for cervical, endometrial or colorectal cancer? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
 
Question 2: Layout 
 
A) Do you have any comments about the ‘look’ or ‘design’ of the booklet, e.g., the colours; the 
size of the writing; anything about the way it is presented? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
B) Do you have any comments about the diagrams? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
C) What did you think about the length of the booklet?  Was it: 
 Too long                 1              
 The right length      2                                           
 Too short                3        
 
 
D) Was there: 
Too much information                         1              
The right amount of information         2 
Not enough information                      3             
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Question 4: Timing     
 
A) Based on your experience, when do you feel would be the best time to receive the booklet? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
__________________________________________________________________________ 
 
B) Would it have been helpful if a member of your treatment team went through some of the 
pages with you before you took the booklet home?  If so, which ones? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Question 5: Now we will go over specific sections 
 
A) Was the introduction of the booklet clear in describing the purpose of the booklet?  
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
 B) What was informative in the description of the types of pelvic-radiation therapy? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
C) Was the section called “understanding your body” helpful? If yes, what was helpful about it? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
D) How was the information on the side-effects of pelvic-radiation treatment useful? 
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___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
E) Which parts of the information about sexuality during and after pelvic-radiation treatment 
were helpful? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
F) Have you experienced any sexual difficulties after pelvic-radiation therapy? If you answered 
‘yes’ how has the booklet been helpful to you? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
G) What did you think of the section about the myths about cancer, treatment and sexuality in 
the booklet (e.g. that cancer can be spread through sexual intercourse)? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
H) What were the recommended practical strategies on how to maximise vaginal health 
following pelvic-radiation therapy in the booklet? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
I) Which of the recommended strategies have you implemented as a consequence of having 
the booklet? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
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___________________________________________________________________________
___________________________________________________________________________ 
 
J) Were the strategies easy to understand? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
K) Why do you think is it important to use vaginal dilators? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
L) What did you think about the information on the psychological/emotional affects of pelvic-
radiation therapy? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
M) How was the ‘further contacts’ section useful to you? 
Would you access any of these websites, if so which ones would you access? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
N) How did you like the ‘asking questions’ section of the booklet helpful? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
 
 
O) Are there any questions that you think should be included in the ‘asking questions’ section? 
 
Page 6 of 8 
Version 3, RPAH, 15
th
 March 2010 
6 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
P) Did you find the diary/self-rating feedback option useful, if yes, how was it useful? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Q) Was the vignette of interest to you and if so what was of interest to you? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Question 6 
 
A) Are there any topics or questions that you feel were not covered in the booklet that should 
be included? 
Yes     1             
No      2 
 
B) If yes, please tell us what you think should be added. 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Are there any topics or information that you think should not have been included in the 
booklet? 
 
Yes            1  
No             2 
 
C) If yes, please tell us what you think should be removed  
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
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___________________________________________________________________________
___________________________________________________________________________ 
 
 Question 7   
 
Did anyone else read through the booklet? (please say which apply)   
 
Yes       Spouse/Partner   1             
             Child                      2 
                    Other family        3             
             Friend                   4 
             Other                     5 
 
 
If anyone else read the booklet, was it helpful to them?   
 
Very helpful                       1              
A bit helpful                       2 
Not helpful                         3             
Not sure                            4 
 
 
Did the booklet make it easier to talk about what you are experiencing/have experienced? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
 
Did the booklet help to discuss your rehabilitation options with anyone, if so how? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Question 8 
 
Do you have any other comments that you would like to make? 
 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Reconfirm confidentiality / anonymity 
THANK YOU VERY MUCH FOR YOUR TIME TODAY 
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Letter of Invitation / Instructions 
 
Dear 
 
We would like to invite you to take part in a research study aiming to improve communication about 
post-radiation adjustment for women treated with pelvic-radiation therapy for cervical, endometrial 
or anorectal cancer. We have developed an information booklet “Recovering after Pelvic Radiation 
therapy: A guide for women” about pelvic-radiation therapy, the side-effects of the treatment and 
post-treatment rehabilitation options. The aim of this study is to investigate whether this booklet 
improves information about the treatment side effects and the use of rehabilitation strategies, when 
compared to standard care. 
 
This is a collaborative project between the Centre for Medical Psychology and Evidence-based 
Decision-making (CeMPED), School of Psychology, The University of Sydney and Sydney Cancer 
Centre, Royal Prince Alfred Hospital. 
 
Enclosed in this package is an Information Sheet that explains the study in more detail. Please 
read the Information Sheet and make sure you understand the contents before you decide whether 
or not to participate. 
 
If you decide you would like to participate in the study, please follow the steps below: 
 
1. Sign the enclosed consent form 
 
2. Fill out the enclosed questionnaire 
 
3. Return both the signed consent form and the completed questionnaire in the reply paid 
envelope provided. 
 
If you do not wish to participate in the study, please dispose of this study package in whichever 
way you wish. 
  
 
If you have any questions, please contact Fran Lubotzky (research co-ordinator) on 0405 808 080 
or Dr Ilona Juraskova (Principal Researcher) on (02) 9036 5275. 
 
Thank you for considering this invitation. 
 
Kind regards, 
 
Dr Ilona Juraskova 
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A randomised controlled trial of an information booklet  
to improve communication about post-radiotherapy adjustment  
for women with gynaecological or anorectal cancer  
 
 
 
PARTICIPANT CONSENT FORM 
 
 
 
I, ...................................................................................................................................... [name]  
 
of 
 
..............................................................................................................................…….[address]  
 
have read and understood the Information for Participants on the above named research study. 
 
I have been made aware of the procedures involved in the study, including any known or expected 
inconvenience, risk, discomfort or potential side effect and of their implications as far as they are currently 
known by the researchers. 
 
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
 
 
NAME:    ........................................................................................................... 
 
 
SIGNATURE:   ........................................................................................................... 
 
 
DATE:    ........................................................................................................... 
 
 
NAME OF WITNESS:  ........................................................................................................... 
 
 
SIGNATURE OF WITNESS: ........................................................................................................... 
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th
 May 2010  
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st
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A Randomised Controlled Trial of an Information Booklet  
to improve communication about post-radiotherapy adjustment  
for women with gynaecological or anorectal cancer. 
 
FACSIMILE COVER SHEET:  If patient AGREES to participate 
 
 
 
 
 
 
Date:   
 
From (sender’s name and hospital): 
 
Number of Pages (including cover):   
 
MESSAGE 
Participant’s Name:       
 
Date of Birth:   
 
Study ID# (as per package #):  _ _ _ _ _ _  
 
Pelvic–radiation treatment start date: __________________________________________  
  
Pelvic-radiation treatment end date: ____________________________________________ 
 
Address: 
 
 
Phone Number: Home:            
       Mobile:  
      Office:  
Attention: Dr Ilona Juraskova 
Address: CeMPED, The School of Psychology 
Phone: (02) 9036 5275 
Fax: (02) 9036 5292 
 
North Sydney Central Coast Area Health Service – Royal North Shore Hospital 
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to improve communication about post-radiotherapy adjustment  
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PARTICIPANT INFORMATION 
 
 
Introduction 
 
You are invited to take part in a research study aiming to improve communication about post-radiation 
adjustment for women treated with pelvic radiation therapy for cervical, endometrial or anorectal cancer. We 
have developed an information booklet about pelvic-radiation therapy, the side-effects of the treatment and 
post-treatment rehabilitation options. The goal of this study is to investigate whether this booklet improves 
women’s understanding of the treatment side effects and improves the knowledge about, and the use of, 
rehabilitation strategies for these side effects, when compared with the Cancer Council NSW booklet 
“Understanding Radiotherapy”. 
 
The study is being conducted by: 
 
 Dr Ilona Juraskova  (NSW Cancer Institute Research Fellow, Centre for Medical Psychology and 
Evidence-based Decision-making (CeMPED), School of Psychology, The 
University of Sydney) 
 
 Prof Phyllis Butow   (NHMRC Senior Research Fellow; Director (CeMPED), The University of 
Sydney) 
 Professor Chris Milross   (Head of Department Radiation Oncology Dept, Sydney Cancer Centre, Royal   
                                         Prince Alfred Hospital) 
 Dr Susan Carroll              (Radiation Oncologist, Sydney Cancer Centre, Royal Prince Alfred Hospital) 
 Ms Kathryn Nattress  (Clinical Nurse Consultant, Sydney Gynaecology Oncology Group, RPAH) 
 Professor Caroline Hunt  (Director of Clinical Training, School of Psychology, The University of Sydney) 
 Ms Fran Lubotzky   (Ph.D. student, School of Psychology, The University of Sydney) 
 
 
This study is being conducted at various hospitals in Australia. 
 
Study Procedures 
 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form, complete the 
enclosed study questionnaire and post both documents back to the researchers in the reply-paid envelope 
provided. The questionnaire asks general questions about your emotional, physical, and sexual wellbeing. 
 Within a week of receiving this study package, the researchers will call you to explain the study in more 
detail and clarify the study procedures.  
 Two weeks before the end of your radiation treatment the researchers will post you one of two study 
booklets; either the “Recovering after pelvic radiation” (study) booklet or the Cancer Council NSW 
“Understanding Radiotherapy” (control) booklet. Which booklet you receive will be decided at random 
(by a computer). Reading the booklet will take approximate 30 minutes of your time. Within a week 
after receiving the booklet the researchers will contact you to answer any questions that you may have 
regarding the information in the booklet.  
 At 3, 6 and 12 months after the radiation treatment you will be asked to complete follow-up 
questionnaires which will be posted to you with prepaid addressed envelopes. The questionnaire will 
ask questions about your emotional, physical, and sexual wellbeing, as well as the side effects of 
treatment and the use of post-radiation rehabilitation strategies. Completing each questionnaire will 
take approximately 20 minutes. 
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Risks 
 
Whilst it is unlikely, some participants may find the content of the questionnaires unsettling or that it raises 
new issues. If you find any information in the booklet or questionnaires in any way distressing, or would like 
help with any questions or to discuss anything further, please contact the researchers on (02) 9036 5275 to 
discuss your concerns. We can also refer you to a psychologist if you feel this would be of assistance. 
 
 
Benefits 
 
While we intend for this research study to contribute to improving future communication about treatment side 
effects and strategies to minimise them, we cannot promise any benefit to you personally from participating 
in this research. However, you may gain some benefit from the information in the booklet and some 
questions may promote discussions with your partner or health professionals, which may be helpful. 
           
 
Costs 
 
Participation in this study will not cost you anything, nor will you be paid.   
 
 
Voluntary Participation 
 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you do take part, you can 
withdraw at any time without having to give a reason.  Whatever your decision, please be assured that it will 
not affect your medical treatment or your relationship with the medical staff who are caring for you.   
 
 
Confidentiality 
 
All the information collected from you for the study will be treated confidentially, and only the researchers 
named above will have access to it.  The study results may be presented at a conference or in a scientific 
publication, but individual participants will not be identifiable in such a presentation. 
 
 
Further Information 
 
If you would like to know more at any stage, please feel free to contact Fran Lubotzky (research coordinator) 
on 0405 808 080 or Dr Ilona Juraskova (principal investigator) on (02) 9036 5275. 
 
This information sheet is for you to keep. 
 
 
Ethics Approval and Complaints 
 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney South West Area 
Health Service.  Any person with concerns or complaints about the conduct of this study should contact the 
Executive Officer on 02 9515 6766 and quote protocol number [X10-0161]. 
 
 
 
 
Randomised Controlled Trial of an Information Booklet – Recovering after Pelvic Radiation 
Therapy 
Script for follow-up calls to patients by researcher team  
 
“An Information Booklet has been developed by The University of Sydney to improve 
communication about post-radiation adjustment for women treated for gynaecological or 
anorectal cancer with pelvic-radiation therapy. The study will be introduced to you by your 
radiation oncologist or nurse at your first radiation therapy appointment. You will be asked if 
you would like to participate in the study and if you provide your verbal consent you will be 
given a study package to take home with you. In the study package you will find an 
invitation to the study, information about the study, a written consent form and a 
questionnaire to take home, complete and post back (with a prepaid self-addressed 
envelope) to researchers from The University of Sydney within one month. Within a week of 
receiving this study package the researchers will call you to explain the study in more detail 
and clarify the study procedures. 
Two weeks before the end of your treatment the researchers from The University of Sydney 
will send you a package containing one of two booklets – either a new Information Booklet, 
or a standard Cancer Council “Understanding Radiotherapy” booklet. Which one you receive 
is done at random, so you have an equal chance of receiving either booklet. 
Additional questionnaires will be posted to you at 3, 6 and 12 months to complete, and 
returned by prepaid self-addressed envelope to the researchers at The University of Sydney.  
Would you be interested in being involved with this study? Your participation is voluntary 
and if you decide not to participate, this will not affect your treatment here or anywhere 
else. Even if you decide to participate but later change your mind, you can withdraw at 
anytime without giving a reason, this will not affect your care in any way at any time. Do you 
think you would be interested in taking part?” 
 
Randomised Controlled Trial of an Information Booklet – Recovering after Pelvic Radiation 
Therapy 
Script for call to patients by researcher team after booklet received 
 
“As you are aware an Information Booklet has been developed by The University of Sydney 
to improve communication about post-radiation adjustment for women treated for 
gynaecological or anorectal cancer with pelvic-radiation therapy. The study will be 
introduced to you by your radiation oncologist or nurse at your first radiation therapy 
appointment. You will be asked if you would like to participate in the study and if you 
provide your verbal consent you will be given a study package to take home with you. In the 
study package you will find an invitation to the study, information about the study, a written 
consent form and a questionnaire to take home, complete and post back (with a prepaid 
self-addressed envelope) to researchers from The University of Sydney within one month.  
 
I am calling to see if you have any questions or would like me to clarify any details of the 
study? I am also calling to remind you to please complete the questionnaire and return it by 
self-addressed reply paid envelope to us. 
 
MASTER,  Questionnaire Reminder Letter, Version 1, 13th February, 2012 
 
 
 
 
 
Dear  
 
Re: Randomised controlled trial of an information booklet to improve communication about post-
radiotherapy adjustment for women with gynaecological or anorectal cancer 
 
Thank you for agreeing to participate in our above study. 
We are writing to you as a friendly reminder because we do not appear to have received your first 
questionnaire for the above study.  This questionnaire was enclosed in a large envelope your doctor 
gave you on the day you were introduced to the study. 
We realise there is a lot going on in your life at the moment, however we would appreciate it if you 
would complete and return this questionnaire as soon as possible.  This is because it is necessary for 
us to compare your emotional and physical wellbeing before and after your treatment so we can 
improve communication about post-treatment recovery after pelvic radiation therapy.  We have 
enclosed another copy in case you can’t find yours. 
Please be assured that your questionnaires are completely confidential.  Your healthcare team will 
not see them and your personal details are not made available to anyone.   Furthermore, your 
participation in this study is entirely voluntary and you can withdraw at any time. 
If you have any questions, please do not hesitate to contact me on 0405 808 080.  We appreciate 
your participation in our study. 
Yours sincerely 
 
 
Fran Lubotzky 
 
Research Coordinator 
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Date:   
 
From (sender’s name and hospital): 
 
Number of Pages (including cover):   
 
MESSAGE 
 
Date 
Decliner’s 
Initials 
Date of 
Birth 
Reason for Declining (if known) 
    
    
    
    
    
    
    
    
 
 
 
Attention: Dr Ilona Juraskova 
Address: CeMPED, The School of Psychology 
Phone: (02) 9036 5275 
Fax: (02) 9036 5292 
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Changes made to the information booklet for the RCT (chapter V onwards) based on 
women’s feedback in relation to pilot aims i) and ii) 
What Why Women’s comments 
Introduction, 
included 
gynaecological 
anal, rectal and 
bladder cancer  
In pilot booklet had 
worded: 
gynaecological, 
rectal and colon 
cancer 
 n/a 
Changed wording 
in ‘Why we 
developed this 
booklet’ p5 
To emphasise 
pelvic health and 
examinations and 
reduce emphasis on 
sexual health 
Q1 B2 - Is there too much of a sexual emphasis in 
this booklet? 
Yes, only because I didn't have those issues.  
Huge emphasis on myths and sexuality meant it 
was all about sexuality.  
 
Were there any aspects of the booklet that you 
feel could be improved? 
Maybe more emphasis on other side effects.  
Seems whole booklet focused on sexuality.   
 
I felt, as an older woman and alone, that 
sexuality dominates the booklet (though 
important) but my general well being and care 
was paramount in my mind. 
 
I found the following information in the booklet 
upsetting 
I felt somewhat alienated by the dominance of 
sexuality - uterine cancer and good health is a 
woman's primary concern I feel 
 
Included anal and 
bladder cancers in 
‘why we 
developed this 
booklet p5 
Include and 
‘alienated’ group 
Q1 C - What did you dislike about it? 
anal not written there.  NNB - fix!! 
Q1 B - What did you like about it? What was the 
best part?  
I suppose the best part was having a written tool 
to refer to at different parts of the journey.  
Different sections at different times.  There's 
nothing an anal cancer - no booklets.  I love 
getting things to read.  Your booklet only written 
material related to my experience – it was a 
reference point 
 
Were there any aspects of the booklet that you 
feel could be improved? 
Include anal cancer as a pelvic cancer 
 
Deleted recovery 
diary 
Considered 
redundant 
Q5 P - Did you find the diary/self-rating feedback 
option useful, if yes, how was it useful? 
Haven't used it.  Depends on the person.  Don't 
think it hurts  to put it there 
 
I didn't know if I'd use it unless there was an 
issue but not for me 
 
personally no, not a very good diary person 
 
I haven’t used it 
 
I probably wouldn't have used them.  Younger, 
two young children, no time to myself during the 
treatment 
 
No, I wrote it down in my own diary 
 
would not use - n=14 
 
 
Changed vulva 
diagram from 
Cancer Council 
one to line 
illustration 
Less confronting Q1 B3 - Were the diagrams too sexual in nature? 
No - quite confronting did not like the graphics 
Q5 C - Was the section called "understanding 
your body" helpful? If yes, what was helpful 
about it? 
Diagram quite confronting.  Layout on page 
could be looked at to soften it a bit... Almost 
coming off page into my eyeball. 
Rewrote myths 
section – myth and 
fact sections, 
HPV*  
for clarity and to 
give more updated 
information 
Q5 G - What do you think of the section about 
the myths about cancer, treatment and sexuality 
in the booklet (e.g. that cancer can be spread 
through sexual intercourse)? 
change the heading and the section - because 
say myths only 
 
 Good to have the section positive / negative - 
more general 
Rewrote strategies 
to enhance vaginal 
health p22 to put 
vaginal health first 
To emphasise 
pelvic health and 
examinations and 
reduce emphasis on 
sexual health 
Q1 B2 - Is there too much of a sexual emphasis in 
this booklet? 
The honest answer is yes.  Quite confronting to 
read re the mechanics of sexual nature. 
Inserted 2  extra 
‘case studies’ – 
anal, endometrial 
To refer to three 
different cancers 
and a range of ages 
Q2 B - Do you have any comments about the 
diagrams? 
more variety with case studies 
 
Liked that.  Could be useful to have that for anal, 
rectal inclusiveness - alienatory - anal cancer - 
don't feel you are quite so alienated.  Not a 
cancer you can talk about.   
 
Question 6 A Are there any topics or questions 
that you feel were not covered in the booklet 
that should be 1: yes, 2: no 
 I consciously thought I would like to have read 
more people’s experiences maybe 2 to3.  
Inserted 
Lymphoedema 
website info in 
contacts list 
Patient request – a 
significant side 
effect of PRT 
Were there any aspects of the booklet that you 
feel could be improved? 
The Lymphoedema Association will provide 
anyone with a list of specially qualified 
practitioners to help reduce the symptoms.   
 
Q1 C - What did you dislike about it? 
only thing got a bit upset about Lymphoedema 
reoccurrence - in all the stages at no point was 
Lymphoedema discussed 
maybe don’t want to scare patients, sense of 
anger possibly 
 
didn't know what Lymphoedema was and 
couldn’t understand it, had to write a letter 
Reference list – 
deleted 2005 Best 
Practice Guidelines 
Too old and due to 
new review 
Cochrane Review 
(2010), no current 
guidelines at the 
time. 
 
 
Deletions from 
glossary – 
oophorectomy, 
premature 
menopause, 
progesterone, 
testosterone, 
vaginismus, 
vulvectomy, 
vulvodynia, womb 
Not relevant or 
information not 
included in booklet 
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4. 5.
If you are reading this booklet, you have undergone (or will undergo) pelvic 
radiation therapy for gynaecological, anal, rectal or bladder cancer.
From previous research we know that many patients would appreciate 
receiving information from their health professionals about sexual issues 
that	could	possibly	arise	post-treatment.	However,	some	women	may	
feel uncomfortable and therefore reluctant, to ask questions about this 
topic. This booklet provides a summary of relevant information as well as 
a list of questions that you might like to ask your doctor or a member of 
your healthcare team (see page 48).  Ways to address these issues are also 
recommended. 
This booklet has been designed, and has important information, for all women, 
with or without a partner. If you have a partner, we encourage you to share 
this booklet with them (or others close to you). They may find the information 
helpful in understanding what you are experiencing and this may help you to 
discuss these experiences together.  If you are unfamiliar with any of the terms 
used in this booklet, please consult the glossary (page 42). 
Why we developed this booklet
This booklet and you1
Your diagnosis and treatment can have an impact on how 
you feel, how your body functions and on your pelvic health 
and sexual wellbeing. This booklet suggests ways that 
may reduce the impact of the cancer and its treatment on 
your pelvic health.  The booklet also provides information 
on radiation treatment side effects and recommended 
rehabilitation options which may help follow-up pelvic 
examinations to be performed more comfortably.
“Knowing what was going on helped me greatly.  
I believe knowledge is power.”
6. 7.
2 Understanding your body
Below are some diagrams and information about the female anatomy to help 
you understand the parts of your body likely to be affected by pelvic radiation 
therapy and the possible side effects of that treatment. 
The female reproductive system
Reproduced with permission by Cancer Council Victoria.  
From the booklet ‘Sexuality and Cancer’, 2007, p. 9.  
Illustrations by Con Stamatis.
A woman’s sex organs consist of the outer lips or labia majora, found 
under the mons pubis, which is the fatty tissue under the pubic hair. 
When parted these lips show somewhat thinner, inner lips, called the 
labia minora. Both labia join at the top to cover a tiny knob of tissue 
sensitive to touch, called the clitoris. Together these external organs are 
called the vulva. 
Below the clitoris is the urethra, through which urine is passed.  Below 
the urethra is the vaginal opening.  Inside a woman’s body is the 
vagina, the cervix, uterus (womb), two Fallopian tubes, and two ovaries. 
The vagina is lined with a mucous membrane (skin) and muscle that 
stretches to accommodate a penis, and stretches even more during 
childbirth.
 The Vulva
Illustration by Margaret Carew.
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3 Pelvic radiation therapy
Pelvic	cancers	include:	rectal	cancer;	anal	cancer;	colon	cancer;	cervical	cancer;	
uterine	(endometrial)	cancer;	vaginal	cancer;	vulva	cancer;	and	bladder	cancer.
Radiotherapy uses x-rays and other forms of radiation to kill or injure cancer 
cells so they cannot multiply.  For some types of cancer, radiotherapy is the 
only	treatment	given.		However,	it	is	more	often	used	in		combination	with	
other forms of treatment, such as surgery and/or chemotherapy (anti-cancer 
drug treatment).  Your treatment is carefully planned so that as little damage as 
possible is done to your normal tissue. 
 
Radiotherapy	can	be	given	in	two	ways:	externally	or	internally.
External pelvic radiation therapy is given externally via a machine placed a 
particular distance from the body and cancer site. The machine directs radiation 
into the cancer mass and surrounding tissue.
Internal pelvic radiation therapy (brachytherapy) is commonly used for 
cervical and endometrial cancer. Radioactive material is placed in thin tubes 
and inserted into the body on or near the cancer site. Internal therapy can be 
given	in	two	ways:
 1) the tubes are inserted into the body and left to emit a continuous 
low dose treatment for up to 30 hours, or
 2) more commonly, the tubes are inserted several times for several 
high-dose rate treatments over a much shorter length of time. 
Your healthcare team will discuss with you what to expect from your particular 
radiotherapy treatment process.
This booklet will discuss some side effects of pelvic radiotherapy that may affect 
your post-treatment pelvic/vaginal health and your sexual life. The degree and 
extent of such side effects will depend upon the type and stage of your cancer, 
the area of the body included within the radiation field and the total dose of 
radiation used. 
Radiotherapy may lead to acute and/or late effects, due to damaged tissue 
and the formation of scar tissue. One of the areas more commonly affected 
following pelvic radiation treatment is the vagina. (The general, acute and late 
effects of pelvic radiation treatment are discussed after this section.) 
Vagina
During radiation therapy to the pelvic area, the muscles and lining of the vagina 
may become tender and sore due to inflammation, and this soreness can last 
for a few weeks after treatment has finished.  The mucous membrane lining the 
vaginal walls may also be damaged and as it heals it may stick together, causing 
adhesions that partially close the opening in the vagina.  A damaged mucous 
membrane can prevent adequate lubrication, which can make the vagina 
feel dry and itchy and make sexual penetration without the use of a synthetic 
lubricant uncomfortable.  As the deeper vaginal tissue heals, inflexible scar 
tissue can form.  This tissue is more fibrous and bulky than the normal tissue in 
the vagina and more rigid, not allowing the vagina to stretch as it needs to do 
during sexual intercourse.  This rigidity and inability to stretch is called stenosis. 
Because of these changes, the vagina may feel as if it is narrower and shorter.  
Your treatment team will try to limit the damage caused by radiation as much 
as possible, but nonetheless some damage may occur.  Some tissues take much 
longer to heal than others, so some of the side effects may be there for a long 
time. Most side effects can be improved with appropriate care and techniques. 
Your healthcare team may be able to suggest ways to reduce these side effects.  
For example, you may be advised to use vaginal lubricants, moisturisers or 
dilators or continue to have regular intercourse.  If recommended for you, the 
regular use of a dilator (once the acute inflammatory phase has settled - no 
earlier than 6 weeks after treatment has ended) may help prevent the lining 
of the vagina from sticking together.  Scar tissue can be gently stretched so it 
does not tighten and shorten the vagina.  This makes vaginal examination at 
follow-ups easier to perform.  This booklet provides information on the use 
of dilators (see page 20).
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troublesome depending on the type, dose and length of the radiotherapy 
treatment.
Late effects and long-term implications of treatment
Radiotherapy to the pelvic area can sometimes lead to long-term side 
effects, with some occurring later on (for example, up to 1 year or more post-
treatment).	However,	improvements	in	treatment	planning	and	the	way	in	
which the radiotherapy is given have made these late effects much less likely.
Bowel and bladder problems   In some people the bowel or the bladder 
may be permanently affected by the radiotherapy. If this happens, then 
more frequent and looser bowel motions and bleeding may occur.  Speak 
to a member of your treatment team who can suggest treatment if you are 
experiencing these side effects.
Fertility problems   Radiotherapy to the pelvic area for cancer of the rectum, 
bladder or cervix can stop the production of female hormones in the ovaries. 
Radiotherapy to the pelvic area for anal, rectal, gynaecological or bladder 
cancer can affect sexual organs and functioning.  This is likely to have a 
permanent effect on your ability to have children (fertility).  It is best for you 
(and your partner if you have one at present) to talk about these issues with 
your doctor. If you still wish to have children, speak with your doctor before you 
start radiotherapy. 
Women who hope to have children or to have added to their family may feel 
deeply upset about a possible loss of fertility. These feelings are understandable 
and it can help to talk to a specialist nurse or counsellor who can provide 
support and offer resources to help you (and your partner if you have one at 
present) cope.
Menopause   When the ovaries remain within, or close to, the radiation field, 
pre-menopausal women may experience early menopause as damaged ovaries 
cannot produce oestrogen and the lessening of oestrogen contributes to the 
cessation of monthly periods.  Some menopausal symptoms, such as vaginal 
dryness, hot flushes and mood swings, may occur. Post-menopausal	women 
will have already dealt with these symptoms.
General side effects
Radiotherapy for cancer can cause a range of both acute and late effects, 
depending on the type of radiotherapy received (e.g. brachytherapy, external 
beam radiotherapy). The most common effects occur during or soon after the 
treatment. Side effects happen because radiotherapy can cause damage to 
healthy cells as well as cancer cells. Some effects of radiotherapy may affect 
how you feel about yourself as a woman.  These will be discussed below 
and	throughout	the	rest	of	the	booklet.		Please	speak	to	a	member	of	your	
healthcare team, a counsellor, or see the contacts section of this booklet if you 
would	like	to	talk	to	someone	about	any	difficulties	you	may	be	having.
Acute effects
Diarrhoea   Radiotherapy may irritate the bowel and cause diarrhoea and 
abdominal cramps. Diarrhoea may persist for several months following 
treatment. If there is a problem, let a member of your healthcare team know 
because effective treatment can be prescribed.
Hair loss   Radiotherapy can cause hair loss in the area being treated. This 
may be permanent.
Other effects   You may have slight bleeding or discharge from the vagina 
once the radiotherapy treatment has ended. If this continues or becomes 
heavy, it is important to let your doctor or nurse know. A heavier and offensive 
smelling discharge may mean you have an infection which requires treatment.
Pain	may	be	experienced	due	to	inflammation	of	the	tissue	and	skin	in	the	
irradiated area. Most women will notice their skin becomes red, itchy and dry 
initially. Your treatment team can provide you with advice as to how to care for 
your skin during treatment.
Radiotherapy to the pelvic area can also cause tiredness and a burning 
sensation when passing urine (cystitis). These side effects can be mild or 
4 Pelvic radiation therapy  side effects
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The diagnosis of cancer and its treatments can have a dramatic effect on a 
person’s sexual identity.  It may challenge many beliefs, sexual behaviours and 
issues of intimacy, and cause you to confront issues of survival and mortality. 
At the moment, sexual activity may be the last thing on your mind as you 
consider various treatment options and cope with any anxiety surrounding a 
cancer	diagnosis.	However,	as	you	start	to	feel	better	following	the	treatment,	
your life may return to a more familiar pattern.  This may include recommencing 
your sexual life. You may find it helpful to discuss your sexual life with your 
healthcare team so that any known sexual doubts can be addressed, and any 
problems, real or anticipated, can be dealt with.  Desire, patience and practice, 
together with a willingness to investigate, and a sense of humour, will really help. 
Women treated for cancers anywhere in the pelvic region may experience 
treatment side effects that make resuming sexual activity physically painful  
and/or	difficult.		It is normal to be anxious about becoming sexually active 
again after treatment for any pelvic cancer.
In addition to the physical changes, having cancer can also affect you 
emotionally and psychologically. For instance, you may feel anxious and worn 
out by your illness, your treatment, and your prognosis. Your mood may go up 
and down, and you may feel you have lost your femininity (identity as a woman), 
your body image and/or control over your body.  
All these emotions may affect your sense of being sexually desirable and 
sexually competent, and your willingness to resume an intimacy with  
your partner.
Being aware of ways pelvic radiation therapy may affect your post-treatment 
sexual ability may help you make some adjustments to your usual practices. 
Expert professional help is always available. If you feel comfortable, speak to a 
member of your healthcare team and/or see the ‘contacts’ section on pages 38-
39 of this booklet.  
 Common sexual problems after pelvic radiation therapy
5 Sexuality during and after  pelvic radiation therapyTalk to your doctor about what you can expect from your specific radiation treatments. In some cases, certain side effects may be preventable. 
Ask your doctor about your options.
If you would like more information, the Cancer Council’s booklet 
“Understanding Radiotherapy” describes ways to manage the side effects of 
radiotherapy. Also see the contacts sections of this booklet (pages 38–39)  
and/or speak to a member of your treatment team if you have any concerns 
about your treatment and effects which may or may not occur.
“Your strongest resource is you.”
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Since internal tissue is often more fragile than our surface skin, it may split and 
ulcerate more easily, leaving the way open for infection to enter the body. 
External radiation may cause some slight discolouration and pigment changes 
on the skin at the site of the radiation. The skin may first look and feel sunburnt, 
but this will gradually fade to a tanned look, returning to its normal colour 
within 6 to 12 months.  It is advisable to avoid soaps, perfumes, creams, sun, 
scratching and synthetic fibres in order to minimise pain, irritation and further 
discomfort.
Loss of desire for sex   Loss of libido, as it is often called, may occur for any 
number of physical or psychological reasons. Many women find the need for 
intimacy intensifies when they are under stress. There may well be physical 
reasons that sexual activity is uncomfortable and these can be addressed. 
Embarrassment, particularly for those women following treatment for anal, 
rectal and bladder cancers, at having a bag to gather their urine and/or 
faeces may take a while to overcome. Becoming menopausal at an early age, 
and the loss of fertility, can have a significant psychological impact on your 
sexual relationships and how you feel about yourself as a woman.  Talking 
to a member of your healthcare team or counsellor can be helpful if you are 
experiencing	any	difficulties	with	your	body	image	and/or	sexual	relationship	
(see pages 38-40 for support contacts in this booklet).
Although it may be difficult or different at first, it is still possible to have a 
satisfying sex life after radiation treatment. If you are experiencing worrisome 
concerns, discussing these difficulties with a member of your healthcare team or 
a counsellor may be helpful.
Difficulty reaching orgasm   This may occur if there has been damage to the 
extensive nerve network that serves the clitoris, since clitoral stimulation is seen 
as an important precursor to orgasm for many women.  Many women find 
difficulty	reaching	orgasm.		This	can	be	for	a	number	of	reasons,	including	fear	
and anxiety, nerve damage as a result of surgery and radiation, and fatigue due 
to treatment (see pages 8-10).
Pain during intercourse   This is known as dyspareunia, and may result from 
abdominal or other bodily pain, vaginal soreness, hypersensitivity and/or 
rigidity of vaginal walls, preventing the vagina’s stretching and lubrication. 
Often an involuntary tightening and spasm fear response to the mere thought 
A selection of sexual problems that might occur following radiation treatment 
is listed below. Later in the booklet there are tips and advice on overcoming 
some	of	difficulties	you	may	be	experiencing	(see	pages	20–29).	
Vaginal Dryness   Cancer treatments may cause a variety of changes that lead 
to vaginal dryness which, if left untreated, can lead to small tears in the lining 
of the vagina, bleeding, ulceration and an increased risk of infection. These 
conditions can lead to pain during sexual intercourse. Extra lubrication may 
make intercourse more comfortable (see page 27).
Reduced vaginal flexibility and size   Vaginal rigidity and scar tissue may lead to 
a feeling that the vagina is shorter or less flexible since the vagina will have lost 
the ability to soften and stretch to the degree that it previously had. The vaginal 
dilators provided for you to use as part of your post-treatment rehabilitation are 
intended to help maintain as much softness and flexibility in the vaginal tissue 
as possible.
Pain   Following radiotherapy, the vagina may feel tender and sensitive. 
Apprehension and fear that it may hurt when touching, rubbing or when 
penetration takes place, may cause an involuntary tightening of the pelvic floor 
muscles and increase any pain already felt (see pages 28-29).
Lymphoedema (swelling of legs)   When the lymph nodes have been damaged 
as a result of surgery and radiation, the lymphatic system may not carry all 
the	fluid	away	as	efficiently	as		before.		Swelling	is	caused	by	a	build-up	of	
lymphatic fluid, which is a colourless liquid that normally surrounds our cells 
and has its own circulatory system.  Those who have had both surgery to 
remove the lymph nodes and external beam radiotherapy are most at risk.  
Many women with lymphoedema find that this impacts on how they feel 
about their bodies and sexuality.  Compression stockings and massage may 
help with the swelling, however, these require a referral from your doctor. 
Feeling swollen may impact on your feelings of comfort with your body 
sexually;	speaking to a member of your healthcare team or a counsellor may 
help with your concerns.
Damage to the skin in the radiation field   Damage to the internal tissues during 
brachytherapy (internal radiation) can cause soreness, redness and swelling.  
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Myth: Sexual intercourse will cause or spread your cancer, or make it return 
following successful treatment.
Current understanding:  Sexual intercourse will NOT cause or spread 
your cancer, nor will it make your cancer return following successful 
treatment.*
Myth: You can transmit your cancer to your partner through sexual intercourse.
Current understanding:  You CANNOT transmit your cancer to your partner 
through sexual intercourse.*
Myth: You are ‘radioactive’ following your treatment, hence you can harm  
your partner.
Current understanding:  You are not ‘radioactive’ following your treatment. 
It is safe to engage in sexual activity as soon as there is a mutual desire 
and ability to do so, and there are no contra-indications.
Myth: Sex and/or masturbation will make cancer worse.
Current understanding:  Sex and/or masturbation will not make cancer 
worse.
Myth: I’ll never enjoy sex again.
Current understanding:  Most women are able to resume a healthy 
sexual life after their treatment.  Although the vagina may be smaller or 
narrower after your pelvic radiation treatment there are things you can 
do that can help, including using vaginal dilators so that you can still 
enjoy sexual intercourse.
Myth: You need to have intercourse to keep your vagina open.
Current understanding:  For some women, the use of a dilator may be 
recommended to keep the vagina open.  If you feel comfortable to, you 
may choose to engage in sexual intercourse.  Some women may prefer to 
use a vibrator or finger.  However, do not feel obliged to engage in sexual 
activities in order to keep the vagina open.
*	Many	women	have	concerns	about	the	HPV	and	its	link	to	cervical	and	anal	cancer.		 
Your healthcare team will be happy to discuss any concerns you may have in more detail.
of	penetration	can	occur.	Insufficient	preparation	for	sexual	penetration,	both	
physical and psychological, can make this worse. Some women find that sperm 
stings after radiation therapy and have found that using condoms helps reduce 
the sting and reduces friction during penetration. Finding more comfortable 
sexual positions, using extra lubrication, being gentle and patient may all help 
if pain is experienced during sexual intercourse. To help reduce pain and vaginal 
tightness some women have found it helpful to use vaginal dilators just before 
sexual intercourse.
Some of these effects will be temporary whilst others may seem more 
permanent. You can receive expert professional advice from your specialist 
nurse or doctor to help you manage, relieve and control some of these 
conditions.  This, in turn, can make a big difference to your health, your quality 
of life and your intimate relationships. 
Not all women experience these side effects. Some women experience 
very few side effects, whilst others seem to be affected by several of them. 
It is important to consult with your doctor and your healthcare team about 
initiating and/or continuing sexual intercourse during radiotherapy. Each 
person is unique in their treatment and responses to that treatment. It may, or 
may not, be appropriate to continue any sexual activity you normally engage in 
while you undergo your treatment.  You and your partner can discuss this with 
your doctor.
 
 “Sometimes it can seem difficult to discuss, but intimate 
relationships are often affected by cancer ...” 
Many women and their partners have fears and concerns about how the 
cancer and/or treatment will affect their sexual life. On the following page we 
dispel some of the common myths.
Myths about cancer, treatment and sexuality 
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“Cancer affects 
so many parts of 
people’s lives, yet 
we often don’t 
talk about things 
that are very 
important to us. 
When asked, 
many people 
admit that 
the cancer has 
affected their 
relationships and 
sex life – yet they 
usually don’t talk 
about it unless 
asked... 
It is important to 
know about any 
concerns that 
you have about 
issues like this, as 
there are quite 
a few ways of 
helping.”
6 Coping with sexual difficulties  following pelvic radiation therapy
An intimate relationship with a partner may help you to feel loved and 
supported as you go through your cancer treatment. The loving support 
of family and friends is just as important. Restoring sexual activity may 
take time, particularly if there are continuing side effects from your 
cancer treatments. Where possible, it is recommended to prevent or 
minimise these side effects even if you have no intention of being sexually 
active now or in the immediate future.
Listed below are some tips on how to anticipate, cope with and  
get	help	for	common	sexual	difficulties	that	you	and	your	partner	 
may be experiencing.
Knowing what sexual side effects could occur before you begin your 
cancer treatment can help you be more prepared to deal with them 
as you go through treatment. If you experience side effects, find out 
from a qualified health professional as much as you can about what 
may be causing them and methods to manage them. This will help you 
feel more in control of the situation and be aware of all the treatment 
options available to you. 
It may also just simply take time for you to regain your sexual function 
after cancer treatment. While that can be frustrating it is good to 
remember that if you had a positive and satisfying sex life before cancer 
you’ll likely resume that after your treatment. A rewarding intimacy with 
your partner is not dependant on sexual intercourse. 
“My healing journey is my responsibility.” 
What can you do to regain your sexual life?
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What are vaginal dilators?
Most cancer centres provide vaginal dilators, or will give you information about 
where to access dilators, as part of your post-treatment care. 
Vaginal dilators are rehabilitation devices specifically thought to prevent or 
reduce narrowing of the vagina (vaginal stenosis), which is a condition which 
affects a significant number of women following radiation treatment for cancer 
in the pelvic area. Dilators are used to gently stretch both the muscles around 
the entrance to the vagina and the tissues inside the vagina.
Some centres provide packs which can include up to four vaginal dilators, 
which are smooth, white tubes rounded at the end (see picture on previous 
page). They conveniently graduate in size and length depending on the 
appropriateness of their size and the stage you are in your treatment with 
dilators.  The smallest dilator is about the diameter of a tampon. The largest 
dilator represents the size of the average erect penis, which is helpful for re-
commencement of sexual activity.  If you receive only one dilator, it will be the 
size of the largest one.
Why is it important to use vaginal dilators?
Your healthcare team may recommend that you use vaginal dilators no earlier 
than six weeks after your treatment has ended, once the acute inflammatory 
phase has subsided. If left untreated, vaginal changes can develop over time 
(up to five years post-treatment) and impact on your pelvic health and sexual 
function. The walls of the vagina can thicken and harden with scar tissue, thus 
making the passage seem narrower. This may cause considerable distress to 
you and your partner, or the partner you may have in the future. 
 
If recommended for you, using dilators may allow for more comfortable 
pelvic exams and the detection of cancer recurrence. Dilator use may 
lessen the effect of vaginal scarring, maximise the vagina’s flexibility and 
prevent the walls from thickening and sticking together.
 
Your healthcare team may recommend using vaginal 
dilators which are thought to prevent or reduce vaginal 
narrowing (stenosis) after pelvic radiation treatment.
 
Example of four different size dilators, a brush to clean the dilators and a lubricant. 
Picture	by	Juraskova
Vaginal dilators
7
Practical strategies to enhance 
vaginal health following pelvic 
radiation therapy
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How often should I be using the dilator?
The majority of centres will recommend that you start using your vaginal 
dilators no earlier than six weeks after you’ve completed your treatment, 
once the acute inflammatory phase has settled.  Most women will be seen for 
follow-up at this point.
The recommended frequency of using dilators is at least three-five times 
per week.  Daily use of vaginal dilators may be recommended for women 
who have a tendency to form scar tissue and if stenosis/narrowing is evident/
noticed. This may change after recommendation by your doctor.
How long should a woman continue dilation for after the  
initial period?
It may be recommended by your health care team that dilators are used for an 
ongoing time period at least 3-5 times per week in order to avoid narrowing 
of the vagina. This is to aid future pelvic examinations to assess changes such 
as cancer recurrence and to maintain your vaginal health and sexual life.  For 
the longer term, it is not necessary to use them as frequently, particularly if you 
have resumed sexual intercourse.  You should talk to your specialist nurse for 
further advice.
How to use vaginal dilators 
•	 Find a private and comfortable time and place where you can relax and 
use the dilator. 
•	 At first you may benefit from using a mirror in order to see the vulva 
and vaginal opening (see diagrams on pages 6 & 7). 
•	Locate the labia and clitoris as well as the opening to your vagina. 
•	Having	a	bath	before	using	a	dilator	may	make	you	feel	more	relaxed.
•	There are various positions in which to use the dilator. You can:
 º  Lie down on your back on a lounge or a bed with your knees 
slightly apart and bent, or 
Although you may not have the desire for sexual relations during your 
treatment and for quite some time after the treatment ends, you may 
feel differently in the future and wish to have a sexual relationship again. 
By using vaginal dilators you will give yourself the option to engage 
in sexual relations at a later stage should you wish to.  Regardless of 
whether or not you wish to resume sexual activity in the future, vaginal 
dilators should be used to make pelvic examinations more comfortable.  
Many women find that using dilators daily helps establish a routine.
Discussing the use of vaginal dilators also gives you the opportunity to 
discuss sexual problems and fears linked with pelvic radiation therapy 
and/or cancer with your healthcare team. 
“Well I’d been told right at the beginning by the nurse  
who took me through the actual treatment that I would  
need to use a dilator and why. So um, I was not  
particularly concerned…”
For most women, vaginal examinations will be a necessary 
part of your follow-up care so your doctor can check 
for cancer recurrence. Using dilators may make it easier 
for you to be examined more comfortably and assist 
your doctor in monitoring your recovery. Using a range 
of dilators, going gradually up in size, can help to keep 
the vagina open and able to stretch to a level that is 
comfortable for you so any changes such as cancer 
recurrence can be seen and assessed easily. Dilators can 
also make it easier for you to start or continue sexual 
relations after your pelvic radiation treatment.
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•	 The dilator should be removed slowly, withdrawing it by rotating 
it in clockwise and anticlockwise movements as you are able until it 
is out. 
•	 Slight vaginal skin loss and blood spotting is not uncommon when 
using dilators. If you experience any discomfort, bleeding or signs of 
infection, ask for advice from your healthcare team.   
 
Please	be	aware	that	it	is	not unusual for there to be symptoms, such 
as bleeding or discomfort, following a period of not having sexual 
intercourse and/or not using a dilator. 
•	Douching (rinsing of the vagina) is not advised at any time. 
•	 If comfortable, your partner may also be encouraged to be 
involved with dilator use.  Whilst this is recommended, it may be 
more useful for you to do it yourself for the first few times so you are 
familiar with how it feels and you have total control of the procedure.
•	 Some women have found it helpful, for reducing pain and vaginal 
tightness, to use vaginal dilators just before sexual intercourse. 
 
How to look after dilators 
•	 Dilators do not need any special treatment but they do need to 
be particularly clean, especially if there are areas of broken skin in 
the vagina into which you can introduce infection.  As soon as you 
withdraw the dilator, it is advisable to wash it and clean it and keep it in 
a clean bag or case.
•	 The dilators can be cleaned with soap and water, making sure they are 
rinsed thoroughly. They may also be sterilized by boiling or soaking in a 
sterilizing agent such as is used to sterilize babies’ bottles. They should 
be rinsed and warmed before using again. 
 º  Stand with a leg raised on the side of the bed, on a chair or bath, 
or in the shower to insert the dilator. 
•	 Make sure you have the appropriate size dilator and lubricant handy. 
Wash your hands. Locate the labia and clitoris and feel down to the 
opening of your vagina. Gently explore the opening with a lubricated 
finger (make sure nails are short).  Warm the dilator by running it under 
hot water then drying it. Lubricate all around the dilator and vaginal 
opening. 
•	 Anticipating that an activity may be painful can cause muscles to tense 
involuntarily, as self-protection. So it is helpful to take a few slow deep 
breaths and allow yourself to relax before beginning the insertion.  
(See	Pelvic	Floor	Muscle	exercises	on	pages	28-29,	which	help	with	
relaxing the muscles and ease dilator use).
•	 Insert the dilator slowly and gently, feeling the way the vagina tilts 
as you go.  Insert the dilator as deeply as is comfortable, without 
strongly forcing it.  Hold	the	dilator	handle	using	the	thumb	and	
forefinger to limit the force.  The first few times you use a dilator, it may 
be too uncomfortable to insert it completely. Do not worry or become 
discouraged, as it may take some time before you are able to insert even 
the smallest dilator completely. Consistent use will usually overcome this.
•	 Once the dilator is inside the vagina, move it in a forward and 
backward motion, then in a left to right motion. If possible, gently rotate 
the dilator using the handle. 
•	 If you are offered a range of dilator sizes, it is usual to start with 
the smallest size.  You should progress to the largest as it becomes 
comfortable to do so.
•	 If you have problems moving your hands or other physical restrictions, 
information will be tailored to your individual needs as you may find it 
difficult	to	rotate	the	dilator.	
•	 Each time the dilator is used it should be in the vagina for at least 5 
minutes. Although this doesn’t seem like much each time, it will require 
planning and consistency. You may find it helpful to make it part of a 
regular routine, for instance, after brushing your teeth or showering.
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•	Forgetting to use dilators. To help you remember to use your dilators, 
you could complete a diary to document your use.
 
•	 Vaginal lubricants (water-based, with no perfumes or colourings -  
e.g. Sylk, Wetstuff ). These seem to be the best lubricants available on 
the market since they don’t evaporate as fast as some other lubricants 
(e.g. KY jelly). Extra lubrication will make dilator use and intercourse 
much more comfortable.
•	 Vaginal moisturisers Many women prefer to use moisturisers, which are 
inserted into the vagina and are less sticky in consistency. An example 
of	such	moisturisers	is	REPLENS,	which	can	be	bought	at	pharmacies	
and some supermarkets. Vaginal moisturisers can be inserted with a 
special applicator, up to three times per week, and not only at times of 
having sexual intercourse. It is beneficial to use vaginal moisturisers and 
lubricants at the same time. This puts water into the vaginal tissues 
and keeps them moist, which is helpful for vaginal dilator use and 
sexual intercourse.  Many women find it more comfortable to buy 
vaginal moisturisers and lubricants online.
•	 If you are still experiencing lubrication problems speak to your 
doctor who may have other lubrication options for you.
•	 If you feel comfortable to do so, vibrators may be used in conjunction 
with, or instead of, dilators. They should be cleaned and maintained the 
same way as a dilator.
Potential difficulties with dilator use and how to overcome them
Common	reasons	for	insufficient	use	of	vaginal	dilators	are:	
•	 Having insufficient information regarding dilator use.  This is why 
this booklet has been developed, so that you have the information at 
your finger-tips.
•	 Some women have been brought up to see any sexual self-
exploration or touching as wrong, dirty or sinful.		However,	dilators	
are not a sexual device.  They are part of rehabilitation.  It may help to 
talk to a member of your healthcare team to help you overcome any 
difficulties.		Remember,	using	a	dilator	is	recommended	for	maintaining	
pelvic health following radiotherapy.
•	 Modesty.  Although it may feel immodest or like masturbation, using 
dilators	may	allow	adequate	future	pelvic	examinations	and	Pap	smears	
and make sexual intercourse more comfortable.
•	 Having been told about using dilators after vaginal narrowing 
(stenosis) is established. Dilators are recommended to reduce 
narrowing.  It is much easier to help stretch the vagina before the 
vagina becomes narrow than to fix it afterwards.
•	 Experiencing anxiety about using vaginal dilators. This can be 
normal.	Hopefully	with	time,	you	will	become	more	familiar	with	using	
the dilator. It will feel more comfortable and simply become another 
part of your post-treatment rehabilitation programme.
•	 Experiencing a fear of damaging the vagina.  The phase for 
potentially causing harm is during and just after pelvic radiation 
treatment, during the acute inflammmatory phase. This is why it is not 
recommended to use dilators earlier than six weeks following the end 
of treatment, until this  inflammation has settled.
If you need any further advice or to raise any concerns, 
please ask a member of your treatment team with whom 
you feel most comfortable (also see contacts at the end of 
this booklet – pages 38-39).
 Sylk  Wetstuff     Replens
Lubricants
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 R = Relax
Let	the	PFM	release,	fully	feeling	the	relief	of	letting	go.
“Contract-Hold-Relax”
Can you let go/relax a little further each repetition?
•		Another	benefit	of	PFM	Relaxation	Exercises	is	that	they	increase	blood	
flow to the pelvic area, which enhances lubrication.
 
 
Some women have found it effective to “work” the pelvic floor muscles while 
they are taking a shower. They put a foot up on the side of the tub, use a little 
bit of lubrication (which is slipperier than water) on their fingers, and again 
locate the vaginal opening and massage it gently. Squeezing an inserted finger 
or two can help gain control of the pelvic floor muscles. 
Joining	a	Yoga	class	is	an	excellent	way	to	practice	strengthening	pelvic	floor	
muscles and to learn relaxation techniques.
  
 Muscles in your body can tense or spasm when you experience pain or antici-
pate that something will be painful such as inserting a vaginal dilator or having 
intercourse.	This	can	cause	your	Pelvic	Floor	Muscles	(PFM)	to	“switch	on”	and	
contract tightly as a protective response. There are a number of strategies that 
help to keep the Pelvic Floor Muscles relaxed and these are described below. 
•		If	you	clench	your	jaw	closed,	your	PFM	may	clench	also,	so try keeping 
your mouth open during insertion of the dilators,	so	that	your	PFM	are	
more inclined to open.
•	 If your hands are gripping the examination table, bed, or each other, 
your	PFM	may	be	gripping	closed	also	-	try keeping your hands soft and 
relaxed so that your PFM are soft and relaxed.
•	 Breathing – if you hold your breath, your diaphragm will be rigid 
and	this	can	cause	the	same	with	your	PFM.	To help the PFM relax, try 
exhaling with a wide opened mouth, sighing ‘haaaa’.
•	 Anything going into the vagina should go in slowly, in stages, 
approximately 1 cm at a time, coinciding with each breath out (i.e. with 
you	letting	go	of	your	PFM).
•		If	this	is	still	difficult,	the	PFM	contract-hold-relax	exercises	(described	
below) may also be used for penetration/dilation in stages, with each 
“relax” of the contract-hold-relax exercise.
•	 The PFM Relaxation Exercises – these exercises are described on 
the	following	page.		These	are	NOT	to	strengthen	your	muscles	but	to	
teach you to relax them.
 C = Contract as if stopping the flow when urinating 
 Do a medium squeeze. 
 
 H = Hold 
 Even hold for 10 seconds.
Pelvic Floor Muscle (PFM) Relaxation Exercises
Other Exercises
31.
Anne (29) has been through pelvic radiation 
therapy for Cervical Cancer
I am a 29 year old cervical cancer patient. I have had 
chemo-radiation treatment for early stage cervical cancer. 
My treatment ended six months ago. I found having sex 
very painful at first and I was frightened to have sex. 
Often my partner cannot get his penis in very far so we 
often haven’t been able to complete our lovemaking. I 
get tense and anxious about having sex and was very 
tired after the treatment. I have been having hot flushes 
which have woken me up in the night. 
I feel so different since I had the treatment, even though 
I have the support of my family, I am finding it so hard to 
come to terms with not being able to have children. I use 
dilators three times a week, at first I found them painful 
to use. Now I am using Replens vaginal moisturiser and 
Sylk at the time of using the dilators. It has become less 
painful to use dilators now and I am able to use the larger 
ones. Occasionally I use the dilators with my partner. We 
use the dilator together, in the bath, before we have sex 
and it helps me to know what I will be able to take when 
we do have sex.
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8 Psychological/emotional effects of pelvic radiation therapy
In	addition	to	sexual	difficulties,	women	at	various	stages	of	cancer	diagnosis	
and treatment may also experience anxiety, depression, remorse, guilt, 
uncertainty, alienation, loss of self-esteem, and changes in body image. Further 
psychological	difficulties,	such	as	post-traumatic	stress,	loss	or	mourning,	
and	sexual	relationship	difficulties	have	been	experienced	after	diagnosis	or	
treatment. 
There	are	many	ways	to	cope	with	the	emotional	difficulties	of	pelvic	radiation	
therapy experienced or post-treatment. Some women strive to maintain an 
optimistic attitude, some find acceptance of the situation helps and others find 
strength in their faith.  Many women speak of trying to appreciate every day 
and continuing to live as normally as possible. 
However, it is not unusual to find these feelings overwhelming.  Having 
someone to talk to can make a significant difference to your well-being rather 
than suffering alone or feeling that you cannot talk about the feelings that may 
be troubling you. Please see pages 35-39.
“Apart from the physical effects of cancer, we’re aware of the 
emotional toll cancer and its treatment can take on you  
and your family…” 
“Pleasure, laughing and love help me to stay well  
and look forward”
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Georgina (44) has been through pelvic 
radiation therapy for Anal Cancer
The doctor told me before I started radiotherapy that the 
treatment would put me into the menopause and that 
because of the effect the radiotherapy has on the vagina 
that I might find sex uncomfortable or even painful. Sex 
has always been a very positive and good part of my 
relationship with my partner and I was concerned that 
things might change and was very keen to do anything 
that might help. I started using the dilators about six 
weeks after finishing my radiotherapy and tried to use 
them every day. I found it easier that way as I just made 
them part of my daily routine. 
It’s now almost a year since I finished treatment. 
Although I was quite anxious about having sex again and 
it definitely was uncomfortable when we tried for the first 
few times things have improved. At my six month follow 
up my doctor explained that as I was having regular 
intercourse I didn’t need to use the dilators any more as 
sex serves the same purpose.
Mary (78) has been through pelvic radiation 
therapy for Endometrial Cancer
Well I have to say I was a little surprised when they told 
me the nurse wanted to speak to me about using vaginal 
dilators after I’d finished my brachytherapy treatment. 
Edward died three years ago but he’d been ill for a long 
time before that so we hadn’t made love for a good 
number of years. Not that it affected our relationship, 
we were still very close and happy. So I couldn’t quite 
understand why I needed to use the dilators as I couldn’t 
ever imagine that I’d have that sort of relationship again. 
The nurse explained that it was still important I 
use the dilators to try and prevent the vagina from 
getting narrower and shorter. I now understand an 
important part of my follow-up is the doctor doing a 
vaginal examination to check for signs of the cancer 
coming back.  It also makes the examination a lot more 
comfortable too! I perhaps don’t use them as often as I 
should but try to use them at least twice a week. I find 
it’s most comfortable if I use them after I’ve been in the 
bath when I’m a little more relaxed. I was given a pack of 
different sizes and I still don’t use the biggest size as it 
was just too uncomfortable.
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9 Where can you get information  and support
You may want to: 
Talk with your healthcare team  
You may be embarrassed to talk about the sexual side effects you’re 
experiencing. It may be helpful to write down questions (see question prompt 
list at the end of this booklet – pages 48-50). In addition, your doctor may be 
embarrassed or hesitant to instigate conversations about sex. If this is the 
case, ask to be referred to a specialist or seek support from other members of 
your healthcare team, such as nurses and counsellors. It may be easier for you 
to introduce sexual topics you would like to discuss with your doctor and/
or healthcare team as you talk about the use of the dilators you are given and 
report your progress using them. 
Talk with your partner
Let your partner know what you’re experiencing and how he or she can help 
you cope. For instance, you might find that using a lubricant eases your vaginal 
dryness or changing positions helps you avoid pain during sex. Together you 
can find solutions to ease the way back into a fulfilling sex life.   
If you are not currently sexually active in your relationship or with a partner 
you may wish to talk to close family and friends about your hopes and fears (in 
addition, please see contacts on pages 38-39 in this booklet for those you can 
talk to about any concerns that you may have).    
Our sexual and emotional lives are usually private and 
not openly discussed. Due to this it may be difficult to talk 
about these problems and you may feel uncomfortable 
talking about them with your partner, family members 
or friends. You may be more comfortable talking to a 
member of your healthcare team, such as your specialist 
nurse, psychologist or social worker. Services are available 
- you don’t have to cope alone. 
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Explore other ways of being intimate
Intercourse isn’t the only option for closeness with your partner. Consider 
spending more time together talking, cuddling or caressing. Connecting 
in other ways might help make you feel more comfortable and less 
anxious about the sexual side effects you’re experiencing. Massage and 
going on dates together, for example, are some other ways of enhancing 
intimacy. Having baths and/or showers together can enhance intimacy.
Talk with other cancer survivors
Your healthcare team might be able to steer you to a support group in 
your city/town. Another option is to connect with other cancer survivors 
online, which provides a degree of anonymity if you are uncomfortable 
talking about these issues face to face. 
If you would prefer to talk to someone else
Please see the contact list below. For example, the Cancer Council 
Helpline	is	a	confidential	service	where	you	can	talk	about	your	concerns	
and	needs	with	specialist	cancer	nurses.	The	Cancer	Council	Helpline	
can send you written information and put you in touch with appropriate 
services in your area such as a counsellor or someone who has been 
through a similar experience to you.
There are many helpful books, articles, videos and websites, which will 
provide you with information, understanding and support (see pages  
38-40). However, it is better to access only those sites recommended 
by your doctor or healthcare team since there can be misleading 
information on some sites.
If possible, try to get as much support as you can from your 
partner, family and friends. Information for carers of people who are 
experiencing, or who have experienced, cancer are also available on 
these websites and helplines.
“Rebuilding your body image is an important part of your 
emotional and sexual healing. How you feel about your body and 
yourself as a woman affects your confidence, your own sense of 
attractiveness and your sexual desire. Massage, touch, relaxation 
techniques, gentle exercise and programs such as Look Good…Feel 
Better (call 1800 650 960 or visit www.lgfb.org.au) can help put you 
back in touch with your body, raise your self-esteem and improve 
your overall sense of wellbeing.” 
“The support of my husband, daughters, extended family and my 
community, as well as my puppies, has helped me through  
the journey.” 
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Australian Association of Stomal Therapy Nurses  
www.stomaltherapy.com
Continence Foundation of Australia  
www.continence.org.au
Lymphoedema website 
www.nbocc.org.au/lymphoedema
National Public Toilet Map  
www.toiletmap.gov.au
The Wellness Community – this is an international non-profit organization that 
provides free online support, education and hope to people with cancer.  
www.thewellnesscommunity.org
Online support – chat rooms can be helpful and also a good resource for those 
who can’t get to groups/counselling etc. 
e.g. Carers Australia 
www.carersaustralia.com.au
Look Good…Feel Better 
www.lgfb.org.au   1800 650 960 
 
If you need help at anytime during the day or night call the Lifeline  
24-hour telephone counselling service on 13 11 14
International websites:
Macmillan Cancer Support (UK) 
www.macmillan.org.uk
National Cancer Institute (US) 
www.cancer.gov 
Their	cancer	and	sexuality	link: 
www.cancer.gov/search/results/aspx
10 Contacts & resources
The Cancer Council Helpline – Monday to Friday, 9am to 5pm,  
for	the	cost	of	a	local	call:	13 11 20
As	well	as	English,	the	Helpline	is	offered	in	the	following	languages:
Cantonese and Mandarin  1300 300 935
Greek  1300 301 449
Italian  1300 301 431
Arabic  1300 301 625
For languages not on this list call 13 14 50 for the Translating and 
Interpreting Service.
Although the first two websites below are for health professionals,  they both 
provide a significant amount of information on cancer, its treatment and 
managing a wide range of side effects.
The Psychosexual Care of Women affected by Gynaecological Cancers:  
A learning resource for health care professionals 
www.cancerlearning.gov.au
Sydney Gynaecological Oncology Group – Sydney Cancer Centre 
www.gynaecancer.org.au
The Cancer Council Australia  
www.cancer.org.au 
Australian Society of Gynaecological Oncologists (ASGO)  
www.asgo.net.au 
Cancer Council NSW (CCNSW)  
www.nswcc.org.au 
Gynaecological Cancer Support 
www.gynaecancersupport.org.au
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A few good books and booklets:
Below are a few recommended books and booklets.  There are many to 
choose from, so these are just a few suggested titles.
Understanding Bowel Cancer: A Guide for people with Cancer, their 
Families and Friends 
Cancer	Council,	NSW,		2011
Sexuality and Cancer – For People with Cancer, their Family and Friends 
Victoria Cancer Council, 2007 
This booklet is available online – www.cancervic.org.au
Understanding Sexuality and Cancer 
NSW	Cancer	Council,	2006 
(Ph.	13	11	20)
Overcoming Loss of Libido 
E.	Kelly,	Health	Books.
Living and Loving Together 
Dr	B.	Montogomery,	Penguin
Understanding Radiotherapy 
	The	Cancer	Council	NSW,	2007 
(Ph.	13	11	20)
Becoming Orgasmic 
J.	Heiman	&	J.	Lopiccolo,	Simon	Schuster
Chicken Soup for the Unsinkable Soul: 101 Inspirational Stories of 
Overcoming Life’s Challenges 
Jack	Canfield,	Mark	Victor	Hansen	&	Heather	McNamara	1999 
Health	Communication	Inc
The Cancer Council NSW provides a range of booklets which you can 
also access online.  These can be posted to you free of charge.
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Hysterectomy: The surgical removal of the uterus and cervix.
Labia Majora: The outer lips of the vagina. 
Labia Minora: The inner lips of the vagina. These join at the top to cover the 
clitoris with a fatty hood. 
Libido: Sex drive.
Lymphoedema: Swelling caused by a build-up of lymph fluid. This happens 
when lymphatic vessels and lymph nodes do not drain properly after 
treatment.
Medical oncologist: A doctor who specialises in diagnosing and treating 
cancer using chemotherapy, hormonal therapy, and biological therapy. 
Menopause: The time when women stop having their periods. The average 
age for menopause is 52 years. 
Mons Pubis: The area of fatty tissue covered with pubic hair. 
Oestrogen: The main female sex hormone produced mostly by the ovaries in 
pre-menopausal women and by the aramotase enzyme in post-menopausal 
women. 
Oncologist: A doctor who specialises in the treatment of cancer. 
Orgasm: Sexual climax. 
Ovary: The main female reproductive organ. There are two small, almond 
shaped ovaries found on either side of the uterus, close to the end of 
the Fallopian tubes. They also produce the sex hormones – oestrogen, 
progesterone and testosterone. 
12 Glossary of terms
Body image:	How	you	feel	about	your	body,	how	you	think	it	looks	and	
how you present it to others. 
Brachytherapy: A type of radiotherapy treatment that implants 
radioactive material sealed in needles or seeds into or near the tumour. 
Cancer: A group of diseases in which malignant cells grow out of control 
and may spread to other parts of the body. 
Cervix: The end of the uterus that forms a canal and extends to the 
vagina. 
Chemotherapy: The use of cytotoxic drugs, which kill or slow cell 
growth, to treat cancer. 
Climax: The peak of sexual response. 
Clitoris: The main sexual pleasure organ for women. It is made up of 
erectile tissue with rich sensory nerve endings. 
Diagnosis: Process	of	identifying	a	disease	from	symptoms	and	tests.	
Fallopian tubes: The two, finger-like tubes that extend from the uterus 
to the ovaries. The Fallopian tubes carry fertilised eggs from the ovary to 
the uterus. 
Follow-up: Monitoring a person’s health over time after treatment. 
Gynaecological oncologist: A doctor who specialises in the 
comprehensive and surgical management of women with 
gynaecological cancer.
Hormone:	A	substance	that	affects	how	other	organs	work.	Hormones	
control development, growth and reproduction. They are distributed 
around the body through the bloodstream. 
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Pelvic cancers: Bladder cancer, rectal cancer, colon cancer, vaginal 
cancer, cervical cancer, uterine (endometrial) cancer, and ovarian cancer 
among others.
Post-menopausal: The period in a woman’s life after the menopause. 
Quality of life: An individual’s overall sense of well-being. This can often 
be related to a person’s health perceptions and their ability to function. 
Radiation oncologist: A doctor who specialises in treating cancer with 
radiotherapy.
Radiotherapy: The use of radiation, usually x-rays or gamma rays, 
to kill cancer cells or injure them so they cannot grow and multiply. 
Radiotherapy treatment can also harm normal cells, but they are able to 
repair themselves. 
Self-esteem:	How	you	feel	about	yourself.	
Side effect: Unintended effects of a drug or treatment. 
Treatment-induced menopause: Menopause that is treatment- 
induced occurs before natural menopause.
Uterus: Also called the womb. It is a hollow, muscular organ shaped like 
an upside-down pear and located between the bladder and the bowel. 
Vagina: A muscular canal about eight to 10 centimetres long, that 
extends from the entrance of the uterus to the vulva. 
Vulva: The outer sex organs. They include the mons pubis, labia majora, 
labia minora and the clitoris.
“When you have gone so far that you can’t  
manage one more step, then you’ve gone just  
half the distance that you’re capable of. “
- Greenland proverb 
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Support Contact  
(e.g. psychologist, social worker etc.)
Name  
Phone 
Email  
Medical Oncologist
Name  
Phone 
Email  
13 Useful healthcare team contacts
Specialist Nurse or Cancer  
Nurse Coordinator
Name  
Phone 
Email  
Radiation Oncology Nurse
Name  
Phone 
Email  
Radiation Oncologist
Name  
Phone 
Email  
Gynaecological Oncologist or  
Colorectal Surgeon
Name  
Phone 
Email  
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Sexual health questions
 Will my sex life be affected?
	 How	soon	can	I	be	involved	in	sexual	activity?
	 How	will	this	treatment	affect	my	hormones?
 When will I feel like having sex again?
 Is it safe to have sex if I am having radiotherapy treatment?
 What sort of problems may we experience during intercourse?
 It hurt when we had intercourse, why?
  I understand treatment can cause shortening/narrowing of the vagina. 
Who can I talk to about it?
 I am finding it uncomfortable to have sex. Who can I talk to about this?
  What changes are likely to be temporary and what changes are likely  
to be permanent?
 It hurts when I have sex. Is this normal?
  Can I get information about finding a sexual counsellor or therapist?
14 Asking questions can help
List of questions you may want to ask your treating team:
Below is a list of some questions that you may want to ask your 
healthcare team.  Space has been provided after the questions for you to 
write which questions you may want to ask or to write any of your own 
that are not listed here. 
General cancer and/or treatment questions
  What are the common side effects of treatment that I could 
experience?
 Is there anything that can be done to treat these side effects?
	 	How	could	my	lifestyle	be	affected	(e.g.	daily	activities,	 
sexual life)?
 Can you give me any advice on how to cope better?
  Is there someone I can talk to who has been through  
this treatment?
  Are there any services/support groups to help me and my 
partner/family deal with this illness?
 Who do I contact if I experience any problems?
 Will the treatment affect my fertility?
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Vaginal dilator questions
	 	I	am	experiencing	difficulties	using	my	vaginal	dilators.	Who	can	
I talk to about this?
  I am experiencing pain when I use the dilators. Who can I talk to 
about this?
 My vagina seems dry. What do you recommend?
  Which lubricant should I use? Is there someone I can talk to 
about this?
Other questions and notes for medical appointments
You can use this section to jot down additional questions you want to 
ask at your next appointment and leave space to record the answers.
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Appendix 3 - Questionnaires 
Appendix 3.1 - Pilot Questionnaire 
Hospital Anxiety and Depression scale 
Impact of Events Scale - Revised 
Sexual Activity Questionnaire 
Female Sexual Function Index (Satisfaction Subscale) 
Sexual Function After Gynaecological Illness Scale 
Knowledge Scale 
Feedback Scale 
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Questionnaire  
 
CONFIDENTIALITY: 
 
We would like to ask you to complete the following questionnaire.  All the information will be 
treated as strictly confidential and your identity will never be revealed in any reports.  None of 
the clinicians treating you will see the answers.  The completed questionnaires will be kept 
separately from any information that could identify you and will be kept securely under lock 
and key.  There is no need for you to write your name on this questionnaire.  
 
 
INSTRUCTIONS: 
 
There are no right or wrong answers, and we ask you simply to tick those answers that most 
apply to you.  Some of the questions may not be relevant to you.  However, it is important for 
the study that, if at all possible, you answer all the questions.   
 
 
When you have completed the questionnaire, please return it to the 
researchers in the replied-paid envelope provided. 
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Section A: DEMOGRAPHICS AND MEDICAL HISTORY 
 
The first section of the questionnaire asks some general background and health questions which 
will be helpful to us in analysing the data.  It will not be used for identification. 
 
 
1.   What is your current age? 
 
  Age: _______ years  
 
 
 
2. What was your age at the time of your gynaecological cancer diagnosis? 
 
   Age: _______ years 
 
 
 
3. What is your present marital status? 
 
1 Single 
2 Married: Length of relationship: _______ years 
3 In a relationship, not living together: Length of relationship: _______ years 
4 De facto (not married but living together): Length of relationship: _______ years 
5 Separated/Divorced 
6 Widowed 
 
 
4. What is your sexual orientation? 
 
1 Heterosexual 
2 Homosexual 
3 Bisexual 
4 I prefer not to answer this question 



5. Do you have children?   
   
    0 No.  Please go to question 6.   
 1 Yes.  Number of children: _______  
 
 
 
6. What is the highest qualification you have obtained? 
 
1 Year 10 or below 
2 Year 12 – HSC  
3 TAFE certificate/diploma, Business College 
4 Bachelors degree 
5 Postgraduate diploma/degree 
 Other (please specify): ____________________ 
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7. What is your current employment status? 
        (Please tick the box that best describes your employment status) 
 
1 Full-time employed   7 Part-time student 
2 Part-time employed   8 Permanently unable to work 
3 Unemployed    9 Temporarily unable to work 
4 Self-employed   10 Retired 
5 Homemaker     Other (please specify): ____________________ 
6 Full-time student 
 
 
8. What is your occupation (if not currently working or retired, specify past occupation)? 
 
       ______________________________________ 
 
 
 
9. Do you speak a language other than English at home? 
 
1 No, only English 
2 Yes, Italian  
3 Yes, Greek 
4 Yes, Chinese 
5 Yes, Arabic 
 Other (please specify): ____________________ 
 
 
10. Are you currently taking any anti-depressant or sedative medication(s)? 
  
    0 No.  Please go to question 11.   
 1 Yes.  Please specify the name of medication(s): __________________________ 
 
 
11.  What form(s) of treatment for gynaecological or colorectal cancer did you undergo? (you may 
tick more than one box where applicable)__please state which cancer you were treated 
for__________________________________________________________________________ 
 
1 Surgery 
2 External pelvic radiotherapy 
3 Internal radiotherapy (Brachytherapy) 
4 Chemotherapy 
5 Other (please specify) ___________________ 
 
 
12. Were you provided with a vaginal dilator? 
 
   0 No.  Please go to question 13.   
 1 If Yes, when? __________________________ 
 
 Do you feel you were given adequate information about the dilator’s use?  
   0 No  
   1 Yes 
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HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
Section B: GENERAL QUESTIONS ABOUT HOW YOU FEEL  
 
This section is designed to help us know how you feel.  Please read each item below, and place a 
tick in the box opposite the reply which comes closest to how you have been feeling in the past 
week. Don’t take too long over your replies; your immediate reaction to each item will probably be 
more accurate than a long thought out response. 
 
a. I feel tense or ‘wound up’:   
 0 Most of the time 
 1 A lot of the time 
 2 From time to time, occasionally 
 3 Not at all 
 
b. I still enjoy the things I used to enjoy: 
 0 Definitely as much 
 1 Not quite so much 
 2 Only a little 
 3 Hardly at all 
 
c. I get a sort of frightened feeling as if something awful is about to happen: 
 0 Very definitively and quite badly 
 1 Yes, but not too badly 
 2 A little, but it doesn’t worry me 
 3 Not at all 
 
d. I can laugh and see the funny side of things: 
 0 As much as I always could 
 1 Not quite so much 
 2 Definitely not so much now 
 3 Not at all 
 
e. Worrying thoughts go through my mind: 
 0 A great deal of the time 
 1 A lot of the time 
 2 From time to time but not too often 
 3 Only occasionally 
 
f. I feel cheerful: 
 0 Not at all 
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 1 Not often 
 2 Sometimes 
 3 Most of the time 
g. I can sit at ease and feel relaxed: 
 0 Definitely 
 1 Usually 
 2 Not often 
 3 Not at al 
h. I feel as if I am slowed down: 
 0 Nearly all the time 
 1 Very often 
 2 Sometimes 
 3 Not at all 
i. I get a sort of frightened feeling like butterflies in my stomach: 
 0 Not at all 
 1 Occasionally 
 2 Quite often 
 3 Very often 
j. I have lost interest in my appearance: 
 0 Definitely 
 1 I don’t take so much care as I should 
 2 I may not take quite as much care 
 3 I take just as much care as ever 
k. I feel restless as if I have to be on the move: 
 0 Very much indeed 
 1 Quite a lot 
 2 Not very much 
 3 Not at all 
l. I look forward with enjoyment to things 
 0 As much as I ever did 
 1 Rather less than I used to 
 2 Definitely less than I used to 
 3 Hardly at all 
m. I get sudden feelings of panic: 
 0 Very often indeed 
 1 Quite often 
 2 Not very often 
 3 Not at all 
n. I can enjoy a good book or radio or TV program: 
 0 Often 
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 1 Sometimes 
 2 Not often 
 3 Very seldom 
 
IMPACT OF EVENT SCALE-REVISED 
The following is a list of difficulties people sometimes have after stressful life events such as 
undergoing radiotherapy. Please read each item and then indicate how distressing each has been 
for you during the past 7 days with respect to having radiation treatment. Please tick the box 
which indicates how much you were distressed or bothered by these difficulties. 
 
                                                                                    Not        A      Mode-     Quite   Extremely 
                                                                                 At all     little     rately      a bit  
                                                                                                Bit                                     
 
1. Any reminder brought back feelings about it.                                                    
 
 
2. I had trouble staying asleep.                                                
 
3. Other things kept making me think about it.                                              
 
4. I felt irritable and angry.                                                 
  
5. I avoided letting myself get upset when I                
    thought about it or was reminded of it.                                              
 
6. I thought about it when I didn’t mean to.                                               
 
 
7. I felt as if it hadn’t happened or wasn’t real.                                              
 
 
8. I stayed away from reminders about it.                                               
 
 
9. Pictures about it popped into my mind.                                               
 
 
10. I was jumpy and easily startled.                                                
              
 
11. I tried not to think about it.                                                
 
                         
12. I was aware that I still had a lot of feelings           
      about it.                                                  
 
13. My feelings about it were kind of numb.                                               
 
    
14. I found myself acting or feeling like I was             
      back at that time.                                                 
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15. I had trouble falling asleep.                                                
 
                                             
16. I had waves of strong feelings about it.                                               
 
17. I tried to remove it from my memory.                                              
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                                                                                  Not         A       Mode-     Quite      Extremely 
                                                                                 At all     little     rately      a bit  
                                                                                                bit                                        
 
18. I had trouble concentrating.                                                   
 
 
19. Reminders of it caused me to have physical         
      reactions, such as sweating, trouble breathing, 
      nauseas, or a pounding heart.                                                  
 
 
20. I had dreams about it.                                                    
  
                
21. I felt watchful and on guard.                                                   
           
 
22. I tried not to talk about it.                                                    
 
 
SEXUAL ACTIVITY QUESTIONNAIRE 
 
Section C: GENERAL QUESTIONS ABOUT SEXUAL ACTIVITY  
 
Some women with gynaecological or anorectal cancer notice changes which may affect them 
sexually.  Although the following questions are sensitive and personal, they are important in 
determining how gynaecological or anorectal cancer and its treatment affect this part of your life.  
Please be assured that your responses to these questions will remain strictly confidential. 
   
         Yes  No 
1. Are you currently married or having an     1  0 
intimate relationship with someone? 
 
2. Have you changed your sexual partner     1  0 
in the last 6 months? 
 
3. Do you engage in sexual activity with     1  0 
anyone at the moment?    If ‘Yes’ please  If ‘No’ please  
       go to question 5 answer question 4 
           
4. (If answered ‘No’ to question 3 above):  I am not sexually active at the moment because: 
(please tick as many of the below items as apply) 
  
  a) I do not have a partner at the moment 
  b) I am too tired 
  c) My partner is too tired 
  d) I am not interested in sex 
  e) My partner in not interested in sex 
  f) I have a physical problem which makes sexual relations difficult or uncomfortable 
  g) My partner has a physical problem which makes sexual relations difficult or uncomfortable 
  h) Other (please describe): ____________________________________________________ 
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      If you answered “No” to Question 3 and have answered Question 4 above please go to  
         page 9 and continue to complete the questionnaire. 
   Please complete this section if you are sexually active (i.e. you have answered ‘Yes’ to Question 1 above).   
Please read each of the following questions carefully and tick the box that best describes your 
sexual feelings and experiences during the past month. 
 
5. During the past month:                 Very       Somewhat A little  Not at all 
         much 
 
a) Was ‘having sex’ an important part      3        2          1            0 
of your life this month? 
 
b) Did you enjoy sexual activity this month?       3        2          1            0 
 
 
c) In general, were you too tired to have sex?    3                2          1            0 
 
      Very  Somewhat A little  Not at all 
      much 
 
d) Did you desire to have sex with your       3        2          1            0 
partner(s) this month? 
 
e) During sexual relations, how frequently      3        2          1            0 
did you notice dryness of your vagina  
this month? 
 
f) Did you feel pain or discomfort during      3        2          1            0 
penetration this month?  
 
g) In general, did you feel satisfied after      3        2          1            0 
sexual activity this month? 
    5 times     3-4      1-2  Not at all 
    or more    times   times 
 
h) How often did you engage in sexual      3        2          1            0 
activity this month?    
    Much  Somewhat   About Less than 
    more  more    the same usual 
 
i) How did this frequency of sexual    3        2          1            0 
activity compare with what it is usual 
for you? 
    Very   Somewhat  A little Not at all 
    much   
 
j) Were you satisfied with the frequency   3        2          1            0 
of sexual activity this month? 
 
 
k) Any other comments? _____________________________________________________ 
 
  _________________________________________________________________________ 
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FEMALE SEXUAL FUNCTION INDEX (SATISFACTION SUBSCALE) 
 
Over the past 4 weeks, how satisfied have you been with the amount of emotional 
closeness during sexual activity between you and your partner? 
 
 No sexual activity  
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied 
 Moderately dissatisfied 
 Very dissatisfied 
 
 
Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? 
 
 No sexual relationship  
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied 
 Moderately dissatisfied 
 Very dissatisfied 
 
 
Over the past 4 weeks, how satisfied have you been with your overall sexual life? 
 
 Very satisfied 
  Moderately satisfied 
  About equally satisfied and dissatisfied 
  Moderately dissatisfied 
  Very dissatisfied 
 
 
SEXUAL FUNCTION AFTER GYNAECOLOGICAL ILLNESS SCALE 
Please tick one box for each of the questions below 
 
I am afraid to have sexual relations  
 
       Very often 
       Sometimes 
       A little bit 
       I do not know because I never thought about it. 
 
 
Because of my illness my partner 
 
      This does not concern me because I don’t have a partner 
      Can catch my illness even if I do not have sexual relations 
      Can become sick or hurt if we have sexual relations 
      Cannot be harmed provided we do not have sexual relations 
      Cannot be harmed if we have sexual relations 
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The person who makes the first move toward the other to have sexual relations is 
 
  This does not concern me because I do not have a partner 
  Neither my partner nor myself – we do not have sexual relations 
  My partner 
  Myself 
  Either my partner or myself 
 
 
Since the end of my treatment 
 
  I have not had a partner 
  I touch my partner a little bit 
  My partner and I sometimes hold and kiss each other 
  My partner and I often hold and kiss each other 
  My partner and I have had much touching or “heavy petting” 
 
 
I have an orgasm (climax) during sexual relations 
 
  Never 
  Rarely 
  Sometimes 
  Often 
  Nearly always or always 
 
 
After my treatment my vagina 
 
  Became completely closed 
  Became smaller or tighter 
  Perhaps changed in size – I am not sure 
  Became larger or looser 
  Does not seem to have changed size compared to before treatment 
 
 
Since the end of my treatment, I have had reduced sensation in my genitals 
 
  Not at all 
  A little bit 
  Somewhat 
  Quite a bit 
  A lot 
 
Since the end of my treatment 
 
  I have not felt any sexual excitement or “turn on” 
  I have had a little sexual excitement but no vaginal “wetness” during sexual relations 
  I have been sexually excited but do not know if my vagina has been “wet” or “dry” 
  I have had some vaginal “wetness” but less than before treatment 
  I have had vaginal “wetness” when I am sexually excited 
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     My doctor told me I could have sexual relations 
 
       He/she did not mention it 
       Three months or more after the end of my treatment 
       One month after the end of my treatment 
       During and after my treatment 
       Whenever my partner and I wanted to have them 
 
      
      My doctor talked about my sex life 
     
        Not at all 
        I do not remember if he/she talked about it 
        After the end of my treatment 
        Before or during my treatment 
        Before and after my treatment 
 
 
     Since the end of my treatment 
 
       I am completely “turned off” or disgusted by sexual relations 
       I not have an interest in sexual relations 
       I can “take” or “leave” having sexual relations – I am indifferent 
       I have little interest in having sexual relations 
       I am strongly interested in having sexual relations 
 
 
      My partner 
 
      This does not concern me because I do not have a partner 
       Is afraid that s/he will “catch” my illness 
       Is afraid that my treatment (such as medications and radiotherapy) will harm him/her 
       Does not know very much about my illness or its treatment 
       Knows that neither my illness nor its treatment can harm him/her 
  
       Since the end of my treatment 
 
       I have not had sexual relations but I have had vaginal bleeding 
       I have not had sexual relations and I have not had vaginal bleeding 
       I always have a little vaginal bleeding after sexual relations 
       I sometimes have a little vaginal bleeding after sexual relations 
       I have had sexual relations and no vaginal bleeding 
    
        
       When I have had sexual relations after treatment my vagina was  
 
          This does not concern me because I have not had sexual relations 
         Completely dry 
         I do not know if my vagina was wet or dry 
         A little dry 
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         Normally wet 
 
 
        
       If I had a choice, I would like my doctor 
 
         Not to speak to me about sexual matters 
         To speak to me about sexual matters 
 
 
        If I had a partner, I would like my doctor 
 
          To speak to my partner and to myself about sexual matters 
          To speak to both my partner and myself together about sexual matters 
           To speak only to my partner about sexual matters  
 
 
 
       I would like to receive sexual information from 
 
         Nobody – I do not want any information 
         Another female (doctor, nurse, social worker, psychologist) 
         A female doctor only 
         A male health worker (doctor, nurse, social worker, psychologist) 
         Either a male or a female health worker 
 
 
       I would like to receive information about sexual expectations following treatment 
 
         Not at all 
         Prior to the first treatment 
         Immediately following the first treatment 
         During my first follow-up consultation 
         On my request when queries arise 
         All of the above 
 
      I received a vaginal dilator 
 
        Not at all  
        More than three months after the end of my treatment 
       Two to three months after the end of my treatment 
        One month after the end of my treatment 
        Just after my radiation treatment 
 
 
       I was given sufficient explanation on the use of a dilator 
  
         Yes 
         No 
         Not applicable 
     
 
       I use the vaginal dilator 
 
         Not at all because it was not given or prescribed to me 
         Not at all even though it was given or prescribed to me 
         Less often than I should 
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         As often as the doctor or nurse told me to use it 
         More often than I was told to use it 
          
KNOWLEDGE SCALE   
 Section D: KNOWLEDGE QUESTIONS  
Below are a number of statements about the information provided in the booklet. Please show 
whether you think they are true or false by ticking the box beside each statement.  
 
                                                                           True                    False             Don’t know 
  
The term vaginal stenosis means the narrowing  
 of the vaginal walls                            
 
 
The use of vaginal dilators is recommended                  
 3-5 times per week                              
 
Dilator’s need to be used for 5-10 minutes                    
at a time                            
 
 
Dilators need to be used no longer than for      
one year after your treatment                             
 
 
 
Using vaginal dilators can help in making                   
sexual intercourse less painful                              
 
 
It is not important to use vaginal dilators for               
pelvic examinations by your oncologists                               
 
 
Cancer treatment can affect your emotions                                            
 
All women receiving Pelvic Radiation Therapy          
will experience sexual difficulties                               
 
 
There are people to talk to about your sexual                   
   life if you need help after your treatment                              
 
 
Sexual intercourse can spread cancer                                                     
 
 
Pelvic radiation therapy can make you ‘radioactive”.       
   Therefore, it is important to be careful that this is not  
transferred to your partner                              
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   A side-effect of Pelvic Radiation Therapy in  
   pre-menopausal women  is that they will  
   undergo premature (early) menopause                             
 
Section 4: KNOWLEDGE QUESTIONS (Continued) 
Continued below are a number of statements about the information provided in the booklet. Please 
show whether you think they are true or false by ticking the box beside each statement.  
 
                                                                                True               False             Don’t know 
 
All vaginal changes from Pelvic Radiation Therapy  
   will happen in the first few months after treatment                              
 
 
It is advised that you use a lubricant when using  
the dilator                                         
 
 
Dilators require special procedures to keep them  
   hygienically sterilised after each use                               
 
 
 
 
Nearly there … only 4 pages to go 
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FEEDBACK SCALE 
SECTION E: FEEDBACK ON THE BOOKLET 
We are interested in gaining your feedback about the way in which the information is provided in the 
booklet and also about its format.  Please indicate the level to which you agree or disagree with the 
following statements by circling the number, which most appropriately fits your response.  
 
 
            The Information Booklet 
 
Strongly 
disagree 
 
Disagree 
 
Not Sure 
 
Agree 
 
Strongly 
agree 
The booklet was easy to read 1 2 3 4 5 
The booklet was easy to understand 
 
1 
 
2 
 
3 
 
4 
 
5 
The information in booklet was confusing  1 2 3 4 5 
The booklet made me anxious  1 2 3 4 5 
The booklet was too long  1 2 3 4 5 
The booklet was too detailed  1 2 3 4 5 
I liked the overall format of the booklet 1 2 3 4 5 
 
I know which options are available to me 
1 2 3 4 5 
 
I have acquired new information in dealing 
with sexual difficulties following 
radiotherapy 
1 2 3 4 5 
 
After reading the booklet, I feel confident 
using vaginal dilators 
1 2 3 4 5 
The booklet provided additional information 
to that provided to me by health 
professionals to date 
1 2 3 4 5 
 
I felt uncomfortable with the personal nature 
of information in the booklet  
1 2 3 4 5 
 
Given the personal nature of this issue, I 
felt the research team has handled my care 
in an appropriate and sensitive manner 
 
1 2 3 4 5 
 
The booklet was helpful to me 
1 2 3 4 5 
 
The booklet gave me information that I 
needed 
1 2 3 4 5 
 
The booklet gave me information that I did 
not have 
1 2 3 4 5 
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            The Information Booklet 
 
Strongly 
disagree 
 
Disagree 
 
Not Sure 
 
Agree 
 
Strongly 
agree 
 
 
I know why it is important to use vaginal 
dilators 
1 2 3 4 5 
 
 
I found it easy to find the information I 
wanted in the booklet 
1 2 3 4 5 
 
I liked the way the booklet looked 
 
 
1 2 3 4 5 
 
 
 
GENERAL COMMENTS 
 
 Do you have any general comments about the booklet? 
 
_______________________________________________________________________________________ 
 
 
 
_______________________________________________________________________________________
 
 
 
 
 
 
 
 
Were there any aspects of the booklet that you feel could be improved? (If yes- in your 
view, how could that be achieved?) 
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I found the following information of no importance to me (please specify why): 
 
 
 
 
 
 
 
 
I found the following information in the booklet upsetting: 
 
 
 
 
 
 
 
 
I found the following information in the booklet offensive (please specify why): 
 
 
 
 
 
 
 
 
I found the following information helpful: 
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Additional comments 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You have now come to the end of this questionnaire. 
We greatly appreciate the time and effort you gave in helping us with our study. 
Please post this questionnaire using the enclosed reply paid envelope. 
 
 
 
 
viii 
Appendix 3.2 - RCT Baseline Questionnaire 
Hospital Anxiety and Depression scale 
Impact of Events Scale - Revised 
Sexual Activity Questionnaire 
Sexual Vaginal Changes Questionnaire 
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Version 3, Master Baseline Questionnaire, 21st February 2011 
Site Specific Master Baseline Questionnaire, RNSH, Version 1, 21st March 2011 
1 
North Sydney Central Coast Health 
Service – Royal North Shore 
Hospital – Logo to be inserted 
 
 
Date issued 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIALITY: 
 
We would like to ask you to complete the following questionnaire.  All the information will be 
treated as strictly confidential and your identity will never be revealed in any reports.  None 
of the clinicians treating you will see the answers.  The completed questionnaires will be 
kept separately from any information that could identify you and will be kept securely under 
lock and key.  There is no need for you to write your name on this questionnaire.  
 
 
INSTRUCTIONS: 
 
There are no right or wrong answers, and we ask you simply to tick those answers that most 
apply to you.  Some of the questions may not be relevant to you.  However, it is important 
for the study that, if at all possible, you answer all the questions.   
 
 
When you have completed the questionnaire, please return it to the researchers in the replied-
paid envelope provided.  
Thank you very much for your help with this study. 
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Version 3, Master Baseline Questionnaire, 21st February 2011 
Site Specific Master Baseline Questionnaire, RNSH, Version 1, 21st March 2011 
2 
 
SECTION 1 
 
The first section of the questionnaire asks some general background and health questions which will 
be helpful to us in analysing the data.  It will not be used for identification. Please tick () the 
statement that best describes you. 
 
 
1.   What is your current age? 
 
  Age: _______ years  
 
 
 
2. What was your age at the time of your gynaecological or colorectal cancer diagnosis? 
 
   Age: _______ years 
 
 
 
3. What is your present relationship status?  
 
    Single 
 Married or (De facto, not married but living together)  
 In a relationship, not living together  
 Separated/Divorced 
 Widowed 
 
 Q3a.  What is the length of this relationship or separation: _____years 
 
 
 
4. What is your sexual orientation? 
 
 Heterosexual 
 Homosexual  
 Bisexual 
 I prefer not to answer this question 
 
 
 
5. Do you have children?   
   
     No.  Please go to question 6.   
   Yes.  Number of children: _______  
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6. What is the highest qualification you have obtained? 
 
 Year 10 or below 
 Year 12 – HSC  
 TAFE certificate/diploma, Business College 
 Bachelors degree 
 Postgraduate diploma/degree 
 Other (please specify): ____________________ 
 
7. What is your occupation (if not currently working or retired, specify past occupation)? 
 
 __________________________________ 
 
 
8. Do you speak a language other than English at home?  
 
 No, only English 
 Yes, Italian  
 Yes, Greek 
 Yes, Chinese 
 Yes, Arabic 
 Other (please specify): ____________________ 
 
 
9. Are you currently taking any anti-depressant or sedative medication(s)?  
 
     No.  Please go to question 11.   
   Yes.  Please specify the name of medication(s): __________________________ 
 
 
10.  What form(s) of treatment for gynaecological or colorectal cancer did you undergo? (you may 
tick more than one box where applicable)  
 
 Surgery 
 External pelvic radiotherapy 
 Internal radiotherapy (Brachytherapy) 
 Chemotherapy 
 Other (please specify) ___________________ 
 
11. Please state which type of cancer you were treated for: _____________________________________ 
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SECTION 2 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
Emotions play an important part in most illnesses and these questions are included to see how you 
have been feeling recently. Please read each item and tick () the box opposite the reply that is 
closest to how you have felt in the previous week. 
 
 I feel tense or wound up     I still enjoy the things I used to 
enjoy 
  
Most of the time     Definitely as much   
A lot of the time    Not quite so much   
From time to time, occasionally     Only a little    
Not at all    Hardly at all   
          
I get a sort of frightened feeling as if 
something awful is about to happen: 
    I can laugh and see the funny side 
of things: 
  
Very definitely and quite badly     As much as I always could   
Yes, but not too badly     Not quite so much now   
A little, but it doesn’t worry me      Definitely not so much now   
Not at all    Not at all  
          
Worrying thoughts go through my mind:      I feel cheerful:   
A great deal of the time     Not at all   
A lot of the time    Not often   
From time to time but not too often      Sometimes   
Only occasionally     Most of the time  
          
I can sit and feel relaxed:     I feel as if I am slowed down:   
Definitely     Nearly all the time   
Usually     Very often   
Not often      Sometimes   
Not at all     Not at all  
          
I get a sort of frightened feeling like 
‘butterflies’ in the stomach:  
    I have lost interest in my 
appearance:  
  
Not at all     Definitely   
Occasionally     I don’t take as much care as I should   
Quite often      I may not take quite as much care  
Very often     I take just as much care as ever   
     
I feel restless as if I have to be on the 
move:     
I look forward with enjoyment to 
things: 
  
Very much indeed    Most of the time   
Quite a lot     A lot of the time  
Not very much      From time to time, occasionally   
Not at all     Not at all  
     
I get sudden feelings of panic:  
    
I can enjoy a good book or radio or 
TV programme: 
  
Very often indeed    Often  
Quite often     Sometimes  
Not very often      Not often    
Not at all    Very seldomly   
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SECTION 3 
IMAPCT OF EVENT SCALE REVISED 
 
The following is a list of difficulties people sometimes have after stressful life events such as undergoing 
radiotherapy. Please read each item and then indicate how distressing each has been for you during the past 
7 days with respect to having radiation treatment. Please tick () box which indicates how much you were 
distressed or bothered by these difficulties. 
 
                                                                               Not        A        Mode-     Quite   Extremely 
                                                                              At all     little     rately      a bit  
                                                                                             Bit                                     
1. Any reminder brought back  
feelings about it.                                                                              
2. I had trouble staying asleep.                                               
3. Other things kept making me  
think about it.                                                                                                  
 
4. I felt irritable and angry.                                                            
  
5. I avoided letting myself get upset when I                
    thought about it or was reminded of it.                                             
6. I thought about it when I didn’t mean to.                                              
7. I felt as if it hadn’t happened  
or wasn’t real.                                                                                                  
8. I stayed away from reminders about it.                                              
9. Pictures about it popped into my mind.                                              
10. I was jumpy and easily startled.                                               
              
11. I tried not to think about it.                                               
                         
12. I was aware that I still had a lot of feelings           
      about it.                                                 
 
13. My feelings about it were kind of numb.                                              
14. I found myself acting or feeling like I was             
      back at that time.                                                
15. I had trouble falling asleep.                                               
                                     
16. I had waves of strong feelings about it.                                              
17. I tried to remove it from my memory.                                                                                                                             
18. I had trouble concentrating.                                               
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                                                                               Not        A         Mode-     Quite   Extremely 
                                                                              At all     little     rately      a bit  
                                                                                             Bit                                     
 
19. Reminders of it caused me to have  
physical reactions, such as sweating,  
trouble breathing, nauseas, or a pounding  
heart.                                                     
20. I had dreams about it.                                                   
  
                
21. I felt watchful and on guard.                                                  
           
22. I tried not to talk about it.                                                   
 
 
SECTION 4 
 
SEXUAL ACTIVTY SCALE (SUBSCALE)  
 
Some women with gynaecological or anorectal cancer notice changes which may affect them sexually.  
Although the following questions are sensitive and personal, they are important in determining how 
gynaecological or anorectal cancer and its treatment affect this part of your life.  Please be assured that your 
responses to these questions will remain strictly confidential. Please tick () one statement per question. 
   
         Yes  No 
1. Are you currently married or having an        
intimate relationship with someone? 
 
2. Have you changed your sexual partner        
in the last 6 months? 
 
3. Do you engage in sexual activity with        
anyone at the moment?     If ‘Yes’ please   If ‘No’ please  
       go to Section 5  answer question 4 
           
 
 
4. (If answered ‘No’ to question 3 above):  I am not sexually active at the moment because: 
(please tick as many of the below items as apply) 
  
  I do not have a partner at the moment 
  I am too tired 
  My partner is too tired 
  I am not interested in sex 
  My partner in not interested in sex 
  I have a physical problem which makes sexual relations difficult or uncomfortable 
  My partner has a physical problem which makes sexual relations difficult or uncomfortable 
  Other (please describe): ____________________________________________________ 
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SECTION 5 
SEXUAL-VAGINAL CHANGES QUESTIONNAIRE 
Physical contact and sexual relations can be an important part of many people’s lives. People who suffer from illnesses 
involving their pelvic region may experience changes in their sex life. The questions below refer to this. The information 
you provide will remain strictly confidential. 
 
SVQ PART 1: Please answer all the questions yourself by ticking the box that that best applies to you.  
During the PAST MONTH: 
 Not at all A little Quite a bit Very much 
1. Have you been interested in close physical contact (a 
kiss and a cuddle)? 
1 2 3 4 
2. Have you had close physical contact with your family 
and close friends? 
1 2 3 4 
3. Have you had any interest in sexual relations? 1 2 3 4 
4. Do you have a partner?  1   Yes 2   No  (if no, please go to Question 8) 
5. Has your partner wanted to have sexual relations? 
Not at all A little Quite a bit Very much 
1 2 3 4 
6. Have you had sexual relations? 
(if you answered no to this question, please continue to 
Question 8). 
No 
Yes,  
1-2 times 
a month 
Yes,  
3-4 times 
a month 
Yes,  
1-2 times 
a week 
Yes,  
More than 
twice a 
week 
1 2 3 4 5 
7. Did your partner have difficulty achieving an erection? 
Not at all A little Quite a bit Very much 
1 2 3 4 
8. Has your sex life/lack of sex life made you worry? 1 2 3 4 
 
For the following questions, please circle the number between 1 and 7 that best applies to you.  
During the PAST MONTH: 
9. How satisfied or dissatisfied have you been with your sex life/lack of sex life? 
Very dissatisfied      Very satisfied 
1 2 3 4 5 6 
7 
 
 
 
 
10.  How satisfied or dissatisfied have you been with your appearance? 
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Very dissatisfied      Very satisfied 
1 2 3 4 5 6 7 
 
• If you HAVE been sexually active during the past month, please go on to PART 2 (this page). 
 
• If you HAVE NOT been sexually active during the past month, please go on to PART 3 (the next page – pg. 9). 
 
SVQ PART 2 :  
The following questions apply to you only if you HAVE BEEN sexually active during the past month. Please answer all 
the questions yourself by ticking the box that best applies to you.  
During the PAST MONTH: 
 Not at all A little Quite a bit Very much 
11. Did it feel that your vagina was dry during 
intercourse? 
1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
12. Have you had any pain during intercourse? 1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
13. Have you experienced bleeding during intercourse? 1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
14. Did you feel that intercourse was bothersome 
because your vagina felt too small? 1 2 3 4 
 Never Occasionally Often Always  
15.  Were you able to complete sexual intercourse? 1 2 3 4 
16.  Have you reached orgasm? 1 2 3 4 
 Not at all A little Quite a bit Very much 
17.  Did you feel relaxed after having sex? 1 2 3 4 
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SVQ PART 3:  
The following questions are about your experience of any changes in your feelings and/or your sex life today compared to 
before you were diagnosed with cancer.  
Please answer all the questions yourself by ticking the box that best applies to you.  
During the PAST MONTH: 
CH1. Has your interest in close physical contact changed since you 
were diagnosed with cancer? 
I am less 
interested now 
It is unchanged 
I am more 
interested now 
1 2 3 
CH2. How much close physical contact do you have with your 
family and close friends compared to before you were diagnosed 
with cancer? 
I have less than 
before 
It is unchanged 
I have more 
than before 
1 2 3 
CH3. Has your interest in sexual relations changed since you were 
diagnosed with cancer? 
I am less 
interested now 
It is unchanged 
I am more 
interested now 
1 2 3 
 
 
The following questions apply to you only if YOU HAVE A PARTNER: 
During the PAST MONTH: 
CH4. Has your partner’s interest in sexual relations changed since 
you were diagnosed with cancer? 
S/he is less 
interested now 
It is unchanged 
S/he is more 
interested now 
1 2 3 
 
The following questions apply to you only if you are SEXUALLY ACTIVE: 
CH5. Has the dryness of your vagina changed compared to before 
you were diagnosed with cancer? 
It is less dry 
now 
It is unchanged It is drier now 
1 2 3 
CH6. Do you feel that the size of your vagina has changed since you 
were diagnosed with cancer? 
It is smaller now It is unchanged It is larger now 
1 2 3 
 
The following question applies to you only if you have experienced any PAIN DURING INTERCOURSE: 
CH7. Has the pain you experience during intercourse changed since 
you were diagnosed with cancer? 
I have less pain 
now 
It is unchanged 
I have more 
pain now 
1 2 3 
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GENERAL COMMENTS 
  
Any Additional Comments that you would like to add? 
 
  
  
 
 
 
 
 
 
 
      
  
  
 
 
 
 
  
  
 
 
 
 
 
 
 
      
  
  
 
 
 
 
 
 
 
 
You have now come to the end of this questionnaire. 
We greatly appreciate the time and effort you gave in helping us with our study. 
Please post this questionnaire (together with signed consent form)  
using the enclosed reply paid envelope. 
ix 
Appendix 3.3 - RCT Follow-up 3 and 6 Months 
Questionnaires 
Hospital Anxiety and Depression scale 
Impact of Events Scale - Revised 
Sexual Activity Questionnaire 
Sexual Function After Gynaecological Illness Scale 
Sexual Vaginal Changes Questionnaire 
Adherence Scale 
Knowledge Scale 
Feedback Scale 
   
 
        Please continue on next page 
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Information Booklet study 
Follow up Questionnaire 
 
CONFIDENTIALITY: 
 
We would like to ask you to complete the following questionnaire.  All the information will be 
treated as strictly confidential and your identity will never be revealed in any reports.  None of 
the clinicians treating you will see the answers.  The completed questionnaires will be kept 
separately from any information that could identify you and will be kept securely under lock 
and key.  There is no need for you to write your name on this questionnaire.  
 
 
INSTRUCTIONS: 
 
There are no right or wrong answers, and we ask you simply to tick those answers that most 
apply to you.  Some of the questions may not be relevant to you.  However, it is important for 
the study that, if at all possible, you answer all the questions.   
 
 
When you have completed the questionnaire, please return it to the researchers in the replied-
paid envelope provided. 
Thank you very much for your help with this study. 
 
 
        Please continue on next page 
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SECTION 1 
 
The first section of the questionnaire asks some general background and health questions which will 
be helpful to us in analysing the data.  It will not be used for identification. Please tick () the 
statement that best describes you. 
 
 
1.   What is your current age? 
 
  Age: _______ years  
 
 
 
2. What was your age at the time of your gynaecological or anorectal cancer diagnosis? 
 
   Age: _______ years 
 
 
 
3. What is your present relationship status?  
 
    Single 
 Married or (De facto, not married but living together)  
 In a relationship, not living together  
 Separated/Divorced 
 Widowed 
 
 Q3a.  What is the length of this relationship or separation: _____years 
 
 
 
4. What is your sexual orientation? 
 
 Heterosexual 
 Homosexual  
 Bisexual 
 I prefer not to answer this question 
 
 
 
5. Do you have children?   
   
     No.  Please go to question 6.   
   Yes.  Number of children: _______  
 
 
Version 3, Master Follow Up Questionnaire (Control), 21
st
 February 2011 
Site Specific Master Follow Up Questionnaire (Control) RNSH, Version 1, 21
st
 March 
2011 
 
 
3 
 
 
 
6. What is the highest qualification you have obtained? 
 
 Year 10 or below 
 Year 12 – HSC  
 TAFE certificate/diploma, Business College 
 Bachelors degree 
 Postgraduate diploma/degree 
 Other (please specify): ____________________ 
 
7. What is your occupation (if not currently working or retired, specify past occupation)? 
 
 __________________________________ 
 
 
8. Do you speak a language other than English at home?  
 
 No, only English 
 Yes, Italian  
 Yes, Greek 
 Yes, Chinese 
 Yes, Arabic 
 Other (please specify): ____________________ 
 
 
9. Are you currently taking any anti-depressant or sedative medication(s)?  
 
     No.  Please go to question 11.   
   Yes.  Please specify the name of medication(s): __________________________ 
 
 
10.  What form(s) of treatment for gynaecological or anorectal cancer did you undergo? (you 
may tick more than one box where applicable)  
 
 Surgery 
 External pelvic radiotherapy 
 Internal radiotherapy (Brachytherapy) 
 Chemotherapy 
 Other (please specify) ___________________ 
 
11. Please state which type of cancer you were treated for: _____________________________________ 
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SECTION 2 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
Emotions play an important part in most illnesses and these questions are included to see how 
you have been feeling recently. Please read each item and tick () the box opposite the reply 
that is closest to how you have felt in the previous week. 
 
 
 
 
 
I feel tense or wound up     I still enjoy the things I used to 
enjoy 
  
Most of the time     Definitely as much   
A lot of the time    Not quite so much   
From time to time, occasionally     Only a little    
Not at all    Hardly at all   
          
I get a sort of frightened feeling as if 
something awful is about to happen: 
    I can laugh and see the funny side 
of things: 
  
Very definitely and quite badly     As much as I always could   
Yes, but not too badly     Not quite so much now   
A little, but it doesn’t worry me      Definitely not so much now   
Not at all    Not at all  
          
Worrying thoughts go through my mind:      I feel cheerful:   
A great deal of the time     Not at all   
A lot of the time    Not often   
From time to time but not too often      Sometimes   
Only occasionally     Most of the time  
          
I can sit and feel relaxed:     I feel as if I am slowed down:   
Definitely     Nearly all the time   
Usually     Very often   
Not often      Sometimes   
Not at all     Not at all  
          
I get a sort of frightened feeling like 
‘butterflies’ in the stomach:  
    I have lost interest in my 
appearance:  
  
Not at all     Definitely   
Occasionally     I don’t take as much care as I should   
Quite often      I may not take quite as much care  
Very often     I take just as much care as ever   
     
I feel restless as if I have to be on the 
move:     
I look forward with enjoyment to 
things: 
  
Very much indeed    Most of the time   
Quite a lot     A lot of the time  
Not very much      From time to time, occasionally   
Not at all     Not at all  
     
I get sudden feelings of panic:  
    
I can enjoy a good book or radio or 
TV programme: 
  
Very often indeed    Often  
Quite often     Sometimes  
Not very often      Not often    
Not at all    Very seldomly   
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SECTION 3 
IMPACT OF EVENT SCALE-REVISED 
 
The following is a list of difficulties people sometimes have after stressful life events such as 
undergoing radiotherapy. Please read each item and then indicate how distressing each has been for 
you during the past 7 days with respect to having radiation treatment. Please tick () box which 
indicates how much you were distressed or bothered by these difficulties. 
 
                                                                               Not        A        Mode-     Quite   Extremely 
                                                                              At all     little     rately      a bit  
                                                                                             Bit                                     
1. Any reminder brought back  
feelings about it.                                                                              
2. I had trouble staying asleep.                                               
3. Other things kept making me  
think about it.                                                                                                  
 
4. I felt irritable and angry.                                                            
  
5. I avoided letting myself get upset when I                
    thought about it or was reminded of it.                                             
6. I thought about it when I didn’t mean to.                                              
7. I felt as if it hadn’t happened  
or wasn’t real.                                                                                                  
8. I stayed away from reminders about it.                                              
9. Pictures about it popped into my mind.                                              
10. I was jumpy and easily startled.                                               
              
11. I tried not to think about it.                                               
                         
12. I was aware that I still had a lot of feelings           
      about it.                                                 
 
13. My feelings about it were kind of numb.                                              
14. I found myself acting or feeling like I was             
      back at that time.                                                
15. I had trouble falling asleep.                                               
                                     
16. I had waves of strong feelings about it.                                              
17. I tried to remove it from my memory.                                                                                                                             
18. I had trouble concentrating.                                               
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                                                                               Not        A         Mode-     Quite   Extremely 
                                                                              At all     little     rately      a bit  
                                                                                             Bit                                     
 
19. Reminders of it caused me to have  
physical reactions, such as sweating,  
trouble breathing, nauseas, or a pounding  
heart.                                                     
20. I had dreams about it.                                                   
  
                
21. I felt watchful and on guard.                                                  
           
22. I tried not to talk about it.                                                   
 
 
SECTION 4 
SEXAUL ACTIVTY SCALE (SUBSCALE) 
 
Some women with gynaecological or anorectal cancer notice changes which may affect them 
sexually.  Although the following questions are sensitive and personal, they are important in 
determining how gynaecological or anorectal cancer and its treatment affect this part of your life.  
Please be assured that your responses to these questions will remain strictly confidential. 
   
         Yes  No 
1. Are you currently married or having an        
intimate relationship with someone? 
 
2. Have you changed your sexual partner        
in the last 6 months? 
 
3. Do you engage in sexual activity with        
anyone at the moment?     If ‘Yes’ please   If ‘No’ please  
       go to Section 5  answer question 4 
           
 
4. (If answered ‘No’ to question 3 above):  I am not sexually active at the moment because: 
(please tick as many of the below items as apply) 
  
  I do not have a partner at the moment 
  I am too tired 
  My partner is too tired 
  I am not interested in sex 
  My partner in not interested in sex 
  I have a physical problem which makes sexual relations difficult or uncomfortable 
  My partner has a physical problem which makes sexual relations difficult or uncomfortable 
  Other (please describe): ____________________________________________________ 
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SECTION 5 
SEXUAL FUNCTION AFTER GYNAECOLOGICAL ILLNESS SCALE 
Please tick () one response for each statement below: 
 
1. Because of my illness my partner 
 
  This does not concern me because I don’t have a partner 
  Can catch my illness even if I do not have sexual relations 
  Can become sick or hurt if we have sexual relations 
  Cannot be harmed provided we do not have sexual relations 
  Cannot be harmed if we have sexual relations 
 
2. My doctor told me I could have sexual relations 
 
  He/she did not mention it 
  Three months or more after the end of my treatment 
  One month after the end of my treatment 
  During and after my treatment 
  Whenever my partner and I wanted to have them 
 
3. My doctor talked about my sex life 
 
  Not at all 
  I do not remember if he/she talked about it 
  After the end of my treatment 
  Before or during my treatment 
  Before and after my treatment 
 
4. My partner 
 
  This does not concern me because I do not have a partner 
  Is afraid that s/he will “catch” my illness 
  Is afraid that my treatment (such as medications and radiotherapy) will harm him/her 
  Does not know very much about my illness or its treatment 
  Knows that neither my illness nor its treatment can harm him/her 
 
5. If I had a choice, I would like my doctor 
 
  Not to speak to me about sexual relations 
  To speak to me about sexual matters 
 
6. If I had a partner, I would like my doctor 
 
  To speak to my partner and to myself about sexual matters 
  To speak to both my partner and myself together about sexual matters 
  To speak only to my partner about sexual matters 
 
7. I would like to receive information about sexual expectations following treatment 
 
  Not at all 
  Prior to the first treatment 
  Immediately following the first treatment 
  During my first follow-up consultation 
  On my request when queries arise 
 
8. I would like to receive information about sexual expectations following treatment from 
 
  Nobody – I do not want any information 
  Another female (doctor, nurse, social worker, psychologist) 
  A female doctor only 
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  A male health worker (doctor, nurse, social worker, psychologist) 
  Either a male or a female health worker 
SECTION 6 
SEXUAL-VAGINAL CHANGES QUESTIONNAIRE  
Physical contact and sexual relations can be an important part of many people’s lives. People who suffer from 
illnesses involving their pelvic region may experience changes in their sex life. The questions below refer to this. 
The information you provide will remain strictly confidential. 
 
SVQ PART 1: Please answer all the questions yourself by ticking the box that that best applies to you.  
During the PAST MONTH: 
 Not at all A little Quite a bit Very much 
1. Have you been interested in close physical contact 
(a kiss and a cuddle)? 
1 2 3 4 
2. Have you had close physical contact with your 
family and close friends? 
1 2 3 4 
3. Have you had any interest in sexual relations? 1 2 3 4 
4. Do you have a partner?  1   Yes 2   No  (if no, please go to Question 8) 
5. Has your partner wanted to have sexual relations? 
Not at all A little Quite a bit Very much 
1 2 3 4 
6. Have you had sexual relations? 
(if you answered no to this question, please continue to 
Question 8). 
No 
Yes,  
1-2 times 
a month 
Yes,  
3-4 times 
a month 
Yes,  
1-2 times 
a week 
Yes,  
More 
than 
twice a 
week 
1 2 3 4 5 
7. Did your partner have difficulty achieving an 
erection? 
Not at all A little Quite a bit Very much 
1 2 3 4 
8. Has your sex life/lack of sex life made you worry? 1 2 3 4 
 
For the following questions, please circle the number between 1 and 7 that best applies to you.  
During the PAST MONTH: 
9. How satisfied or dissatisfied have you been with your sex life/lack of sex life? 
Very dissatisfied      Very satisfied 
1 2 3 4 5 6 7 
10.  How satisfied or dissatisfied have you been with your appearance? 
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Very dissatisfied      Very satisfied 
1 2 3 4 5 6 7 
 
• If you HAVE been sexually active during the past month, please go on to PART 2 (this page). 
 
• If you HAVE NOT been sexually active during the past month, please go on to PART 3 (the next page – pg10) 
 
SVQ PART 2 :  
The following questions apply to you only if you HAVE BEEN sexually active during the past month. Please 
answer all the questions yourself by ticking the box that best applies to you.  
During the PAST MONTH: 
 Not at all A little Quite a bit Very much 
11. Did it feel that your vagina was dry during 
intercourse? 
1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
12. Have you had any pain during intercourse? 1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
13. Have you experienced bleeding during 
intercourse? 
1 2 3 4 
 If yes, has it bothered you? 1 2 3 4 
14. Did you feel that intercourse was bothersome 
because your vagina felt too small? 1 2 3 4 
 Never Occasionally Often Always  
15.  Were you able to complete sexual intercourse? 1 2 3 4 
16.  Have you reached orgasm? 1 2 3 4 
 Not at all A little Quite a bit Very much 
17.  Did you feel relaxed after having sex? 1 2 3 4 
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SVQ PART 3:  
The following questions are about your experience of any changes in your feelings and/or your sex life today 
compared to before you were diagnosed with cancer.  
Please answer all the questions yourself by ticking the box that best applies to you.  
 
During the PAST MONTH: 
CH1. Has your interest in close physical contact changed since 
you were diagnosed with cancer? 
I am less 
interested now 
It is unchanged 
I am more 
interested now 
1 2 3 
CH2. How much close physical contact do you have with your 
family and close friends compared to before you were diagnosed 
with cancer? 
I have less 
than before 
It is unchanged 
I have more 
than before 
1 2 3 
CH3. Has your interest in sexual relations changed since you 
were diagnosed with cancer? 
I am less 
interested now 
It is unchanged 
I am more 
interested now 
1 2 3 
 
 
The following questions apply to you only if YOU HAVE A PARTNER: 
During the PAST MONTH: 
CH4. Has your partner’s interest in sexual relations changed 
since you were diagnosed with cancer? 
S/he is less 
interested now 
It is unchanged 
S/he is more 
interested now 
1 2 3 
 
The following questions apply to you only if you are SEXUALLY ACTIVE: 
CH5. Has the dryness of your vagina changed compared to 
before you were diagnosed with cancer? 
It is less dry 
now 
It is unchanged It is drier now 
1 2 3 
CH6. Do you feel that the size of your vagina has changed since 
you were diagnosed with cancer? 
It is smaller 
now 
It is unchanged It is larger now 
1 2 3 
 
The following question applies to you only if you have experienced any PAIN DURING INTERCOURSE: 
CH7. Has the pain you experience during intercourse changed 
since you were diagnosed with cancer? 
I have less pain 
now 
It is unchanged 
I have more 
pain now 
1 2 3 
 
Please keep going. You are over halfway!  
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Section 7 
ADHERENCE SCALE 
In this section we would like to know about your use of the vaginal dilators, vaginal 
moisturisers, vaginal lubricants, and pelvic floor muscle relaxation exercises as part of your 
post-treatment recovery. 
We would also like to know how you feel this has helped or not helped with your sexual 
functioning. 
  
  
  
  
Part A: Vaginal Dilators 
Please answer the following questions by placing a tick in the appropriate box: 
1. Prior to radiation treatment, did you 
use a cylinder/vibrator as part of 
your sexual life? 
   No    Yes 
2. Have you been given vaginal 
dilator? 
   No    Yes 
3. Since radiation treatment, have you 
used a vaginal dilator? 
  No (If no, please 
continue to question 2a) 
  Yes (If yes, please 
proceed to question 2b) 
a) If no, what was your reason for 
not using a vaginal dilator? 
(Then proceed to PART B →) 
  
  
  
b) If yes, how often do you use a 
vaginal dilator? 
   More often than recommended 
          Please specify how many times/week: _____ 
   As often as recommended  (i.e. 3-5 
times/week) 
   Less often than recommended 
       Please specify how many times/week: _____ 
4. Please explain why you use a vaginal 
dilator: 
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Please indicate how much you agree 
with the following statements: 
Strongly 
agree 
Agree 
Neither 
agree or 
disagree 
Disagree 
Strongly 
disagree 
5. I was given sufficient explanation 
on the purpose and use of the 
vaginal dilator as part of my post-
treatment recovery. 
     
6. I am confident using the vaginal 
dilator. 
     
7. Using the vaginal dilator just prior 
to sexual intercourse makes 
intercourse easier. 
     
8. I would have liked more 
opportunity to practice the use of 
vaginal dilator with a nurse. 
     
9. Using the vaginal dilator has been 
helpful. 
     
10. I have emotional difficulties using 
a vaginal dilator (e.g. feeling 
anxious). 
     
11. I have physical difficulties using a 
vaginal dilator (e.g. it is painful). 
     
12. My partner is supportive about my 
dilator use. 
     
OR this question is not 
applicable because: 
 I do not have a 
partner 
  My partner is unaware of       
         my vaginal dilator use 
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Part B: Vaginal moisturisers 
Vaginal moisturiser is a cream that is applied to the inside of the vagina (such as Replens or 
Ovestin). Please note that vaginal moisturiser is different to vaginal lubricant (i.e. a gel that is 
applied to the opening of the vagina to lubricate the vagina such as KY jelly, Sylk, or Pjur 
Original). 
Please answer the following questions by placing a tick in the appropriate box: 
13. Since radiation treatment, have you 
used vaginal moisturiser? 
   No 
(If no, please continue 
to question 12a) 
   Yes 
(If yes, please proceed to 
question 12b) 
a) If no, what was your reason for 
not using vaginal moisturiser? 
(Then proceed to PART C →) 
  
  
  
b) If yes, how often do you use a 
vaginal moisturiser? 
   Most of the time 
   A lot of the time 
   From time to time / occasionally 
 
Please indicate how much you 
agree with the following 
statements: 
Strongly 
agree 
Agree 
Neither 
agree or 
disagree 
Disagree 
Strongly 
disagree 
14. I was given sufficient 
explanation on the use of vaginal 
moisturisers as part of my post-
treatment recovery. 
     
15. I am confident using vaginal 
moisturiser. 
     
16. Using vaginal moisturiser has 
been helpful. 
     
17. My partner is supportive about 
my vaginal moisturiser use. 
     
OR this question is not 
applicable because: 
 I do not have a partner   My partner is unaware of  
        my moisturiser use 
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Part C: Pelvic floor muscle relaxation exercises 
Please answer the following questions by placing a tick in the appropriate box: 
18. Since radiation treatment, have 
you used pelvic floor muscle 
relaxation exercises? 
  No 
(If no, please continue to 
question 23a) 
   Yes 
(If yes, please proceed to 
question 23b) 
a) If no, what was your reason for 
not using pelvic floor muscle 
relaxation exercises? 
 (Then proceed to THE END 
→)  
  
  
  
b) If yes, how often do you use 
pelvic floor muscle relaxation 
exercises:  
______________ times/week 
 
Please indicate how much you agree 
with the following statements: 
Strongly 
agree 
Agree 
Neither 
agree or 
disagree 
Disagree 
Strongly 
disagree 
19. I was given sufficient explanation 
on the use of pelvic floor muscle 
relaxation exercises as part of my 
post-treatment recovery. 
     
20. I am confident using pelvic floor 
muscle relaxation exercises. 
     
21. Using pelvic floor muscle 
relaxation exercises has been 
helpful. 
     
22. My partner is supportive about my 
use of pelvic floor muscle 
relaxation exercises. 
     
OR this question is not 
applicable because: 
  I do not have a partner   My partner is unaware 
of 
        my use of pelvic floor 
        muscle relaxation 
        exercises 
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SECTION 8 
KNOWLEDGE SCALE 
Below are a number of statements about the information provided in the booklet. Please show whether 
you think they are true or false by ticking the box beside each statement.  
 
  
                                                                                             True         False   Don’t know 
The term vaginal stenosis means the narrowing 
of the vaginal walls  
  
   
The use of vaginal dilators is recommended                  
 3-5 times per week        
   
Dilator’s need to be used for 5-10 minutes                    
at a time  
   
Dilators need to be used no longer than for      
one year after your treatment      
   
Using vaginal dilators can help in making                   
sexual intercourse less painful    
   
It is not important to use vaginal dilators for               
pelvic examinations by your oncologists    
   
Cancer treatment can affect your emotions      
All women receiving Pelvic Radiation Therapy          
will experience sexual difficulties      
   
There are family members and health 
professionals that you can talk to about your 
sexual  life if you need help after your treatment        
   
Sexual intercourse cannot spread cancer                      
  
   
Pelvic radiation therapy can make you 
‘radioactive”. Therefore, it is important to be  
careful that the radiation is not transferred to 
your partner       
   
   A side-effect of Pelvic Radiation Therapy in  
   pre-menopausal women  is that they will  
   undergo premature (early) menopause    
   
All vaginal changes from Pelvic Radiation 
Therapy will happen in the first few months after 
treatment          
   
Is the use of lubrication necessary when using 
the dilator    
   
Dilators require special procedures to keep them 
hygienically sterilised after each use   
   
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SECTION 9 
FEEDBACK SCALE 
We are interested in gaining your feedback about the way in which the information is provided in the 
booklet and also about its format.  Please indicate the level to which you agree or disagree with the 
following statements by circling the number, which most appropriately fits your response.  
 
 
The Information Booklet 
 
Strongly 
disagree 
 
Disagree 
 
Not Sure 
 
Agree 
 
Strongly 
agree 
The booklet was easy to read 1 2 3 4 5 
The booklet was easy to understand 
 
1 
 
2 
 
3 
 
4 
 
5 
The information in booklet was confusing 1 2 3 4 5 
The booklet made me anxious 1 2 3 4 5 
The booklet was too long 1 2 3 4 5 
The booklet was too detailed 1 2 3 4 5 
I liked the overall format of the booklet 1 2 3 4 5 
 
I know which options are available to me 
1 2 3 4 5 
 
I have acquired new information in dealing with 
sexual difficulties following radiotherapy 
1 2 3 4 5 
 
After reading the booklet, I feel confident using 
vaginal dilators 
1 2 3 4 5 
The booklet provided additional information to 
that given to me by health professionals to date 
1 2 3 4 5 
 
I felt uncomfortable with the personal nature of 
information in the booklet 
1 2 3 4 5 
 
The booklet was helpful to me 
1 2 3 4 5 
 
The booklet gave me information that I needed 
1 2 3 4 5 
 
I know why it is important to use vaginal 
dilators 
1 2 3 4 5 
 
I found it easy to find the information I wanted 
in the booklet 
1 2 3 4 5 
 
I liked the way the booklet looked 
 
1 2 3 4 5 
 
Version 3, Master Follow Up Questionnaire (Control), 21
st
 February 2011 
Site Specific Master Follow Up Questionnaire (Control) RNSH, Version 1, 21
st
 March 
2011 
 
 
17 
 
GENERAL COMMENTS  
Any Additional Comments that you would like to add? 
 
  
  
 
 
 
 
 
 
 
      
  
  
 
 
 
 
  
  
 
 
 
 
 
 
 
      
  
  
 
 
 
 
 
 
 
 
You have now come to the end of this questionnaire. 
We greatly appreciate the time and effort you gave in helping us with our study. 
Please post this questionnaire using the enclosed reply paid envelope. 
 
x 
Appendix 4 - Quantitative Analysis 
Tables 
Missing Value Analysis Tables 
Correlation Analysis Matrices 
Table 1: Missing value summary by measure 
 
Variable N Missing 
Missing 
Percentage 
Use and frequency of use of Dilator 112 134 54% 
Use and frequency of use of Moisturiser 113 133 54% 
Use and frequency of use of PFME 103 143 58% 
Vaginal Dilator Aided Recovery Score 44 202 82% 
Vaginal Moisturiser Aided Recovery 
Score 
39 207 84% 
PFME Aided Recovery Score 24 222 90% 
Knowledge Score 88 158 64% 
Feedback Score 88 158 64% 
Anxiety 197 49 20% 
Depression 198 48 20% 
Avoidance 193 53 22% 
Intrusion 193 53 22% 
Hyperarousal 193 53 22% 
IES-R Total 193 53 22% 
Partner Unavailability 147 99 40% 
Self Too Tired 147 99 40% 
Partner Too Tired 147 99 40% 
Self Lack Of Interest 147 99 40% 
Partner Lack Of Interest 147 99 40% 
Self Physical Problem 147 99 40% 
Partner Physical Problems 147 99 40% 
Intimacy 185 61 25% 
Sexual Interest 185 61 25% 
Worries About Sex Life 177 69 28% 
Variable N Missing 
Missing 
Percentage 
Sexual Satisfaction 155 91 37% 
Symptoms Scale On Vaginal Changes 16 230 93% 
Vaginal Bleeding During Intercourse 18 228 93% 
Vaginal Dimension 42 204 83% 
Sexual Functioning 43 203 83% 
 
  
Table 2: Multiple Linear Regression - Using Baseline and Second Follow-up Phase Data - Missing Values in the Dependent and 
Independent Variables 
 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Partner Unavailability Dependent 108 56 34% No 
Self Too Tired Dependent 108 56 34% No 
Partner Too Tired Dependent 108 56 34% No 
Self Lack of Interest Dependent 108 56 34% No 
Partner Lack of Interest Dependent 108 56 34% No 
Self Physical Problem Dependent 108 56 34% No 
Partner Physical Problem Dependent 108 56 34% No 
Intimacy Dependent 132 32 20% Yes 
Sexual interest Dependent 133 31 19% Yes 
Worries about sex life Dependent 127 37 23% Yes 
Sexual satisfaction Dependent 110 54 33% No 
Symptoms scale on vaginal changes Dependent 11 153 93% No 
Vaginal bleeding during intercourse Dependent 12 152 93% No 
Vaginal  dimension Dependent 26 138 84% No 
Sexual functioning Dependent 27 137 84% No 
Anxiety Dependent/Independent 143 21 13% Yes 
Depression Dependent/Independent 144 20 12% Yes 
IES-R Total Dependent/Independent 139 25 15% Yes 
Participant Age Independent 145 19 12% Yes 
Length of Relationship Independent 80 84 51% No 
Marital Status Independent 145 19 12% Yes 
Highest Qualification Independent 145 19 12% Yes 
Number of Children Independent 117 47 29% No 
Language Spoken at Home - English Independent 118 46 28% No 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Taking antidepressant or Sedative Independent 117 47 29% No 
Treatment at Royal Hospital for Women (RHW) / 
Prince of Wales Hospital (POWH) 
Independent 164 0 0% Yes 
Treatment at Royal North Shore Hospital (RNSH) Independent 164 0 0% Yes 
Treatment at Royal Prince Alfred Hospital (RPAH) Independent 164 0 0% Yes 
Treatment at Liverpool Hospital Independent 164 0 0% Yes 
Treatment at St George Hospital Independent 164 0 0% Yes 
Treatment at Genesis Care, Mater Hospital Independent 164 0 0% Yes 
Cancer Type - Cervical Independent 164 0 0% Yes 
Cancer Type - Endometrial Independent 164 0 0% Yes 
Cancer Type - Anal Independent 164 0 0% Yes 
Cancer Type - Rectal Independent 164 0 0% Yes 
Cancer Type - Vaginal Independent 164 0 0% Yes 
Cancer Type - Vulvar Independent 164 0 0% Yes 
Treatment - Surgery Independent 117 47 29% No 
Treatment - External Pelvic Radio Independent 117 47 29% No 
Treatment - Internal Radio Independent 117 47 29% No 
Treatment - Chemotherapy Independent 117 47 29% No 
Occupation - Professional Independent 114 50 30% No 
Occupation - Non-Professional Independent 114 50 30% No 
Occupation - Not Working Independent 114 50 30% No 
Group Membership Independent 164 0 0% Yes 
 
 
Table 3: Multiple Linear Regression - Using First Follow-up and Second Follow-up Phase Data - Missing Values in the Dependent 
and Independent Variables 
 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Partner Unavailability Dependent 101 63 38% No 
Self Too Tired Dependent 101 63 38% No 
Partner Too Tired Dependent 101 63 38% No 
Self Lack of Interest Dependent 101 63 38% No 
Partner Lack of Interest Dependent 101 63 38% No 
Self Physical Problem Dependent 101 63 38% No 
Partner Physical Problem Dependent 101 63 38% No 
Intimacy Dependent 126 38 23% Yes 
Sexual interest Dependent 125 39 24% Yes 
Worries about sex life Dependent 120 44 27% No 
Sexual satisfaction Dependent 103 61 37% No 
Symptoms scale on vaginal changes Dependent 10 154 94% No 
Vaginal bleeding during intercourse Dependent 11 153 93% No 
Vaginal  dimension Dependent 27 137 84% No 
Sexual functioning Dependent 27 137 84% No 
Anxiety Dependent/Independent 136 28 17% Yes 
Depression Dependent/Independent 136 28 17% Yes 
IES-R Total Dependent/Independent 130 34 21% Yes 
Participant Age Independent 137 27 16% Yes 
Length of Relationship Independent 91 73 45% No 
Marital Status Independent 137 27 16% Yes 
Highest Qualification Independent 136 28 17% Yes 
Number of Children Independent 136 28 17% Yes 
Language Spoken at Home - English Independent 136 28 17% Yes 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Taking antidepressant or Sedative Independent 132 32 20% Yes 
Treatment at Royal Hospital for Women (RHW) / 
Prince of Wales Hospital (POWH) 
Independent 164 0 0% Yes 
Treatment at Royal North Shore Hospital (RNSH) Independent 164 0 0% Yes 
Treatment at Royal Prince Alfred Hospital (RPAH) Independent 164 0 0% Yes 
Treatment at Liverpool Hospital Independent 164 0 0% Yes 
Treatment at St George Hospital Independent 164 0 0% Yes 
Treatment at Genesis Care, Mater Hospital Independent 164 0 0% Yes 
Cancer Type - Cervical Independent 164 0 0% Yes 
Cancer Type - Endometrial Independent 164 0 0% Yes 
Cancer Type - Anal Independent 164 0 0% Yes 
Cancer Type - Rectal Independent 164 0 0% Yes 
Cancer Type - Vaginal Independent 164 0 0% Yes 
Cancer Type - Vulvar Independent 164 0 0% Yes 
Treatment - Surgery Independent 134 30 18% Yes 
Treatment - External Pelvic Radiotherapy Independent 134 30 18% Yes 
Treatment - Internal Radiotherapy Independent 134 30 18% Yes 
Treatment - Chemotherapy Independent 134 30 18% Yes 
Occupation - Professional Independent 133 31 19% Yes 
Occupation - Non-Professional Independent 133 31 19% Yes 
Occupation - Not Working Independent 133 31 19% Yes 
Group Membership Independent 164 0 0% Yes 
 
  
Table 4: Multiple Linear Regression - Using First Follow-up and Second Follow-up Phase Data - Missing Values in the Dependent 
and Independent Variables 
 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Use and frequency of use of Dilator Dependent 112 52 32% Yes 
Use and frequency of use of Moisturiser Dependent 113 51 31% Yes 
Use and frequency of use of PFME Dependent 103 61 37% Yes 
Vaginal Dilator Aided Recovery Score Dependent 44 120 73% No 
Vaginal Moisturiser Aided Recovery Score Dependent 39 125 76% No 
PFME Aided Recovery Score Dependent 24 140 85% No 
Knowledge Score Dependent 88 76 46% Yes 
Feedback Score Dependent 88 76 46% Yes 
Anxiety Independent 115 49 30% Yes 
Depression Independent 116 48 29% Yes 
IES-R Total Independent 117 47 29% Yes 
Participant Age Independent 118 46 28% No 
Length of Relationship Independent 97 67 41% No 
Marital Status Independent 118 46 28% No 
Highest Qualification Independent 117 47 29% No 
Number of Children Independent 145 19 12% Yes 
Language Spoken at Home - English Independent 144 20 12% Yes 
Taking antidepressant or Sedative Independent 141 23 14% Yes 
Treatment at Royal Hospital for Women (RHW) 
/Prince of Wales Hospital (POWH) 
Independent 164 0 0% Yes 
Treatment at Royal North Shore Hospital 
(RNSH) 
Independent 164 0 0% Yes 
Treatment at Royal Prince Alfred Hospital 
(RPAH) 
Independent 164 0 0% Yes 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Treatment at Liverpool Hospital Independent 164 0 0% Yes 
Treatment at St George Hospital Independent 164 0 0% Yes 
Treatment at Genesis Care, Mater Hospital Independent 164 0 0% Yes 
Cancer Type - Cervical Independent 164 0 0% Yes 
Cancer Type - Endometrial Independent 164 0 0% Yes 
Cancer Type - Anal Independent 164 0 0% Yes 
Cancer Type - Rectal Independent 164 0 0% Yes 
Cancer Type - Vaginal Independent 164 0 0% Yes 
Cancer Type - Vulvar Independent 164 0 0% Yes 
Treatment - Surgery Independent 143 21 13% Yes 
Treatment - External Pelvic Radiotherapy Independent 143 21 13% Yes 
Treatment - Internal Radiotherapy Independent 143 21 13% Yes 
Treatment - Chemotherapy Independent 143 21 13% Yes 
Occupation - Professional Independent 141 23 14% Yes 
Occupation - Non-Professional Independent 141 23 14% Yes 
Occupation - Not Working Independent 141 23 14% Yes 
Group Membership Independent 164 0 0% Yes 
 
  
Table 5: Multiple Linear Regression - Using Baseline, First Follow-up and Second Follow-up Phase Data - Missing Values in the 
Dependent and Independent Variables 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Partner Unavailability Dependent 147 99 40% No 
Self Too Tired Dependent 147 99 40% No 
Partner Too Tired Dependent 147 99 40% No 
Self Lack of Interest Dependent 147 99 40% No 
Partner Lack of Interest Dependent 147 99 40% No 
Self Physical Problem Dependent 147 99 40% No 
Partner Physical Problem Dependent 147 99 40% No 
Intimacy Dependent 185 61 25% Yes 
Sexual interest Dependent 185 61 25% Yes 
Worries about sex life Dependent 177 69 28% No 
Sexual satisfaction Dependent 155 91 37% No 
Symptoms scale on vaginal changes Dependent 16 230 93% No 
Vaginal bleeding during intercourse Dependent 18 228 93% No 
Vaginal  dimension Dependent 42 204 83% No 
Sexual functioning Dependent 43 203 83% No 
Anxiety Dependent/Independent 197 49 20% Yes 
Depression Dependent/Independent 198 48 20% Yes 
IES-R Total Dependent/Independent 193 53 22% Yes 
Participant Age Independent 200 46 19% Yes 
Length of Relationship Independent 134 112 46% No 
Marital Status Independent 200 46 19% Yes 
Highest Qualification Independent 199 47 19% Yes 
Number of Children Independent 199 47 19% Yes 
Variable Type N Missing 
Missing 
Percentage 
Included in 
Modelling 
Language Spoken at Home - English Independent 199 47 19% Yes 
Taking antidepressant or Sedative Independent 195 51 21% Yes 
Treatment at Royal Hospital for Women (RHW) / 
Prince of Wales Hospital (POWH) 
Independent 246 0 0% Yes 
Treatment at Royal North Shore Hospital (RNSH) Independent 246 0 0% Yes 
Treatment at Royal Prince Alfred Hospital (RPAH) Independent 246 0 0% Yes 
Treatment at Liverpool Hospital Independent 246 0 0% Yes 
Treatment at St George Hospital Independent 246 0 0% Yes 
Treatment at Genesis Care, Mater Hospital Independent 246 0 0% Yes 
Cancer Type - Cervical Independent 246 0 0% Yes 
Cancer Type - Endometrial Independent 246 0 0% Yes 
Cancer Type - Anal Independent 246 0 0% Yes 
Cancer Type - Rectal Independent 246 0 0% Yes 
Cancer Type - Vaginal Independent 246 0 0% Yes 
Cancer Type - Vulvar Independent 246 0 0% Yes 
Treatment - Surgery Independent 197 49 20% Yes 
Treatment - External Pelvic Radiotherapy Independent 197 49 20% Yes 
Treatment - Internal Radiotherapy Independent 197 49 20% Yes 
Treatment - Chemotherapy Independent 197 49 20% Yes 
Occupation - Professional Independent 194 52 21% Yes 
Occupation - Non-Professional Independent 194 52 21% Yes 
Occupation - Not Working Independent 194 52 21% Yes 
Group Membership Independent 246 0 0% Yes 
 
Table 1: Correlation Matrix - Baseline 
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Depression .342*                                   
Avoidance .513* .246*                                 
Intrusion .631* .413* .748*                               
Hyperarousal .569* .540* .600* .817*                             
Partner Unavailability -.096 -.153 -.088 -.020 -.022                           
Self Too Tired -.032 .076 -.119 -.116 -.004 -.116                         
Self Lack of Interest -.125 -.053 -.090 .063 .058 -.239 .217                       
Partner Lack of Interest .008 -.013 -.075 .037 .050 -.205 -.029 .211                     
Self Physical Problem .021 .200 .142 .077 .178 -.388* .249 -.032 -.116                   
Partner Physical Problems .245 .283* .086 .078 .157 -.349* -.049 -.117 .137 -.080                 
Intimacy -.013 -.169 .082 .006 -.077 -.329* -.200 -.320* -.182 .177 .071               
Sexual Interest .004 -.197 .164 .106 -.091 -.235 -.095 -.094 -.135 -.074 -.030 .536*             
Worries About Sex Life .324* .210 .318* .375* .228 -.052 .163 -.025 -.142 .284* -.144 .088 .215           
Sexual Satisfaction -.328* -.326* -.117 -.259 -.246 .367* -.098 -.192 -.173 -.349* .034 .120 .126 -.556*         
Symptoms Scale On Vaginal Changes .154 .649 .103 -.154 .263     -1.000*   1.000*   .406 -.973* -.229 -.553       
Vaginal Bleeding During Intercourse .616 .105 .154 -.359 0.000     -.866   .866   -.379 -.918* -.541 -.462 .949     
Vaginal Dimension .465 .356 .483 .490 .409     0.000   0.000   -.131 -.524 .367 -.562 .649 .433   
Sexual Functioning -.029 -.464 -.134 -.172 -.279     0.000   0.000   -.063 -.061 -.034 .282 -.158 -.132 -.517 
Note: * Significant Correlation between Factors (p < .05) 
Table 2: Correlation Matrix - First Follow Up 
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Anxiety -.104                                                         
Depression -.135 .337*                                                       
IES-R Total -.407* .330* .141                                                     
Avoidance -.384* .312* .075 .945*                                                   
Intrusion -.374* .410* .178 .890* .749*                                                 
Hyperarousal -.344* .380* .343* .829* .699* .762*                                               
Partner Unavailability -.012 .134 .127 -.056 -.030 -.042 -.065                                             
Self Too Tired -.129 .075 .217 -.013 .027 -.051 .028 -.242                                           
Partner Too Tired -.112     .057 .160 -.183 0.000 -.137 -.039                                         
Self Lack of Interest -.080 -.130 .076 .248 .247 .217 .281 -.358* .192 -.104                                       
Partner Lack of Interest .121 -.270 -.379* -.052 -.009 -.163 -.027 -.421* -.121 .325* .293*                                     
Self Physical Problem -.187 .009 .053 .216 .266 .137 .182 -.388* .378* .352* .222 .125                                   
Partner Physical Problem .094 -.043 .244 .184 .139 .160 .272 -.388* -.112 -.063 .093 .125 -.011                                 
Intimacy score -.024 -.152 .028 -.024 .049 -.098 -.093 -.219 -.011 .086 .041 .068 .018 .191                               
Sexual interest score -.189 -.161 -.137 -.012 .101 -.156 -.154 .009 -.159 .322* -.422* .029 -.088 .149 .429*                             
Worries about sex life score -.438* .264 -.045 .472* .496* .392* .288* .183 .114 .272 -.217 -.082 .093 -.225 -.016 .351*                           
Sexual satisfaction score .392* -.279 -.286 -.271 -.228 -.207 -.284* -.039 -.028 -.255 .258 .056 -.077 -.274 .121 -.050 -.429*                         
Symptoms scale on vaginal ch. -.334 -.433 -.763 -.091 -.030 -.092 -.277               .094 -.161 .127 -.131                       
Vaginal bleeding during interco. .060 -.906* -.548 -.359 0.000 -.422 -.620               -.407 -.671 -.411 .461 .258                     
Vaginal  dimension score -.657* .300 -.250 .609* .683* .618* .309               -.250 -.141 .779* -.411 .613 -.098                   
Sexual functioning score .113 -.226 .007 -.508* -.496 -.445 -.361               .289 .428 -.333 .971* -.031 .313 -.465                 
Vaginal Dilator Aided Recovery -.160 .035 .174 -.072 -.020 -.116 .034 .155 -.349 .039 .145 -.049 .276 .269 .237 .356 .163 -.065 .205 -.229 .049 .192               
Vaginal Moisturiser Aided Recov. .048 .032 -.211 .278 .279 .351 .110   -.571 -.410 .072 .307 -.036 .077 .317 .104 .201 .111 -1.00* -.272 .262 -.212 .074             
PFME Aided Recovery .668* -.386 -.101 -.193 -.182 -.077 -.173         0.000 -.258 .258 .021 -.261 -.612* .516 -.500 .258 -.898* .705 -.184 .179           
Use and frequency of use of Dila. .094 .106 -.128 -.015 .065 -.050 -.121 .176 -.264 .226 -.226 -.077 .076 -.016 .084 .263* .170 -.003 -.220 -.900* .130 -.090 .410* -.142 -.411         
Use and frequency of use of Moi. -.015 .204 .163 .144 .147 .158 .088 -.103 -.121 -.085 .189 .006 .341* .238 .228 .089 .031 .067 .164 -.285 .303 -.068 .301 .567* -.020 .120       
Use and frequency of use of PF. .103 -.120 -.335* -.038 .008 -.087 -.096 .052 -.113 .413* .003 .152 .013 -.166 -.009 .077 .115 .173   .342 -.172 .358 -.381 -.053 .539 .218 -.022     
Knowledge Score -.061 -.006 -.221 -.055 -.030 -.003 -.337* .128 -.327   -.347 -.321 .031 -.169 -.026 .342* .002 .094 -.079 .874* -.046 .188 .311 .173 -.462 .381* -.076 .062   
Feedback Score .159 .076 -.120 -.004 .022 -.023 -.031 -.033 -.397* -.098 .151 .054 -.169 .137 .164 .152 -.052 .226 -.125 -.344 .173 -.094 .404 .227 -.869* .327* .195 .053 .383* 
Note: * Significant Correlation between Scores (p < .05) 
  
Table 3: Correlation Matrix - Second Follow Up 
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Anxiety -.302* 
                            
Depression -.043 .494* 
                           
IES-R Total -.326* .686* .354* 
                          
Avoidance -.298* .570* .252 .949* 
                         
Intrusion -.412* .734* .415* .843* .688* 
                        
Hyperarousal -.202 .660* .395* .806* .675* .730* 
                       
Partner Unavailability -.242 .131 .054 -.060 -.033 .005 .095 
                      
Self Too Tired -.212 .291 .312 .312 .290 .289 .273 -.227 
                     
Partner Too Tired -.231 -.247 -.147 -.218 -.191 -.198 -.172 -.158 -.038 
                    
Self Lack of Interest -.030 .099 .254 .209 .119 .242 .084 -.269 .113 -.102 
                   
Partner Lack of Interest .233 -.354* -.042 .016 .058 -.194 -.247 -.227 -.054 -.038 .371* 
                  
Self Physical Problem -.195 .199 .066 .240 .167 .204 .304 -.374* .606* .423* .101 -.089 
                 
Partner Physical Problem .137 -.220 -.192 -.164 -.140 -.004 -.191 -.281 -.067 -.047 .247 -.067 -.111 
                
Intimacy score -.180 -.353* -.342* -.075 -.035 -.097 -.098 -.222 .096 .239 -.233 .096 .145 .190 
               
Sexual interest score -.166 -.153 -.150 -.155 -.121 -.154 -.097 -.230 .036 .169 -.357* -.170 -.008 .131 .529* 
              
Worries about sex life 
score 
-.404* .495* .300* .418* .408* .387* .356* .118 .188 -.097 -.257 -.139 -.014 -.173 .027 .226 
             
Sexual satisfaction score .333* -.131 -.131 -.189 -.196 -.175 -.329* -.049 -.227 -.172 .107 .317 -.141 .023 -.045 -.152 -.400* 
            
Symptoms scale on vaginal 
changes score 
-.900* .359 -.205 .300 .462 .462 .051 
       
-.354 -.791 .527 -.564 
           
Vaginal bleeding during 
intercourse score 
.169 -.257 0.000 .338 .429 .257 .359 
       
-.577 -.365 .456 -.600 -.258 
          
Vaginal  dimension score -.448 .086 -.344 .342 .408 .235 .052 
       
-.342 -.230 .048 -.172 .580 .354 
         
Sexual functioning score .174 -.459 -.457 -.572* -.559* -.507* -.478 -.133 -.399 
   
-.399 
 
.749* .676* -.727* .585* -.316 -.456 -.378 
        
Vaginal Dilator Aided 
Recovery 
-.043 -.076 .160 -.197 -.249 -.038 -.076 -.138 .276 .069 .322 
 
-.218 .470 .347 .464* -.020 -.263 .316 .344 -.739* .533 
       
Vaginal Moisturiser Aided 
Recovery 
.133 .341 -.062 .406 .287 .255 .159 -.088 .308 -.396 .567 
 
.129 -.056 -.359 -.388 .017 .178 0.000 .500 .319 -.207 .054 
      
PFME Aided Recovery .045 -.359 -.464 -.256 -.354 .093 -.083 -.131 
  
.621 
 
-.207 .655 .679* .387 -.106 .276 -.500 .866 -.710 .543 .718* .068 
     
Use and frequency of use 
of Dilator 
.064 .104 -.066 -.136 -.154 -.069 -.102 .323* -.016 -.016 -.316 -.319 .190 -.221 .005 .142 -.015 .148 -.158 -.456 0.000 .247 .126 -.025 .002 
    
Use and frequency of use 
of Moisturiser 
-.023 .205 -.041 .111 .085 .179 .047 -.224 .160 -.097 .301 -.139 .262 .075 -.107 -.036 .068 .128 .866 .577 .669* -.280 -.285 .758* -.310 -.032 
   
Use and frequency of use 
of PFME 
.242 -.045 -.165 -.086 -.124 -.128 -.083 -.067 -.115 -.080 .105 -.115 .011 .081 .051 .068 -.268 .394* 
  
-.327 .567 .376 .170 .834* .199 .034 
  
Knowledge Score .218 .286 .116 .166 .116 .126 .181 .004 .145 -.228 .370* .259 .044 -.037 -.367* -.203 -.105 -.025 .821 .257 .306 -.056 .436 .235 -.174 .199 .152 .306 
 
Feedback Score -.045 -.177 -.211 -.138 -.071 -.101 -.148 -.036 .187 .013 .157 
 
.136 .415* .010 .030 -.075 -.030 .316 .344 .809* -.414 .038 .065 .160 .194 .146 .003 .120 
Note: * Significant Correlation between Scores (p < .05) 
